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1. Introduction 
  
1.1 General background  
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines) aimed to combat the problem of 
driving under the influence of psychoactive substances by providing a solid scientific base for 
European policy makers. It brought together experienced organisations in Europe to assemble a co-
ordinated set of data resources and measures. DRUID is an integrated European research project 
which consisted of different sub-projects (Work Packages) that were aimed at different topics such as 
the prevalence and risk of psychoactive substances, enforcement, classification of medicines, 
rehabilitation of offenders and withdrawal of driving licenses (www.druid-project.eu). 
 
The main objective of WP2 of DRUID was to assess the situation in Europe regarding the prevalence 
and risk of the use of illicit drugs, alcohol and psychoactive medicinal drugs by drivers. 
 
The prevalence of drug driving was estimated by means of roadside surveys and the prevalence of 
drugs in injury accidents was estimated by means of hospital surveys of seriously injured and/or killed 
drivers. Accident risk estimates for drug driving were assessed by relating the prevalence of drugs 
among the general driving population to the prevalence among seriously injured and/or killed drivers, 
by relating medication records to accident data and by relating substance use among accident-
involved drivers to accident culpability. 
 
1.2 Part 1 and 2 of the report 
Part 1 of the report presents the general results of the roadside surveys, based on the thirteen country 
reports that were written by all partners. Part 1 describes the general results and common trends, and 
focuses on both similarities as well as difference between countries  This second part includes the 
report from each of the participating countries with more detailed descriptions of the method, results 
and representativeness of the individual national studies.  
 
Each of the following chapters contains the edited report of one country. The national reports were 
written by the partners according to a template, leaving room for individual countries to include their 
own specific findings. A general check on the consistency of the reports was performed by the editors, 
ensuring that all requested information was included, and the reports were made comparable in length 
and layout; this whole process was conducted in consultation with the partners.  
 
Each of the country reports contains the following sections:  
 
1. Description of the roadside driver sample 
2. Roadside data collection and analysis (description of methods) 
3. Non-response 
4. Results (based on a set of example tables, including confidence intervals) 
5. Discussion of results 
6.  Acknowledgements 
7. References  
 
1.3 Participating countries in the roadside survey 
Roadside surveys were carried out in thirteen European countries. These countries are presented in 
table 1.1 and figure 1.1. 
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Table 1.1. Participating countries 
 1. Belgium (BE) 
 2. Czech Republic (CZ) 
 3. Denmark (DK) 
 4. Spain (ES) 
 5. Finland (FI) 
 6. Hungary (HU) 
 7. Italy (IT) 
 8. Lithuania (LT) 
 9. Netherlands (NL) 
10. Norway (NO) 
11. Poland (PL) 
12. Portugal (PT) 
13. Sweden (SE) 
 
All participating countries are members of the European Union (EU) except for Norway, which is 
associated with the European Union as a member of the European Economic Area (EEA). 
 
 
Figure 1.1 Participating countries 
 
 3 
1.4 Method 
Detailed information on the general design of the study, substances, data collection and analysis can 
be found in Part 1, Chapter 2 of Deliverable 2.2.3. Here we summarize the main aspects. Each 
country report also provides more specific information.  
 
1.4.1 Study design 
A cross-sectional roadside survey was conducted to determine the prevalence of psychoactive 
substances among the general driving population in thirteen European countries. In order to be able to 
compare the thirteen different studies, guidelines for a uniform design were developed for all 
participating countries (see Annex 1 in Part 1). 
 
1.4.2 Substances 
In total 23 substances have been included in the core substance list at the beginning of the project. 
The list of core substances was based on discussions between all partners. These core substances 
should at least be included in the sample analysis. Furthermore, the analysis for additional substances 
was permitted as well. Some countries have included the results from their additional substances in 
their country reports. See Annex 2 in Part 1 for details about the core and additional substances. 
 
For each substance an analytical cut-off has been prepared based on the lowest limit of quantitation 
(LOQ). This is the concentration at which quantitative results can be reported with a high degree of 
95% confidence. For the analysis of the data, equivalent cut-offs, and not the LOQ's, are used for the 
core substances. The equivalent cut-offs in saliva are chosen in a way that they will on average result 
in the same number of positives for a substance as it would be the case when the analysis would have 
been in blood. The reason for this is that for many substances the concentrations in oral fluid are much 
higher than in blood, while for other compounds the concentrations are lower (Gjerde et al., 2010; 
Wille et al., 2009). This means that if oral fluid samples were used to collect information on recent drug 
use, the prevalence of the substances is likely to have higher prevalence results than that it would 
have been the case if blood was used as a sampling matrix. Therefore, equivalent cut-offs have been 
used for substances in oral fluid, which are the equivalent of the LOQ's in blood. However, for the core 
substances diazepam, flunitrazepam and zolpidem, as well as for 7-amino-flunitrazepam, which is a 
metabolite of flunitrazepam, the equivalent cut-offs for oral fluid were below the LOQ. Therefore, the 
equivalent cut-off in blood has been determined. Table 1.2 provides an overview of the initial and the 
equivalent cut-offs for all core substances. 
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Table 1.2. Recommended equivalent cut-offs for DRUID core substances 
Substance Cut-off in 
whole blood 
(ng/mL) 
Cut-off in 
oral fluid 
(ng/mL) 
Recommended 
equivalent cut-off in 
oral fluid (ng/mL) 
Recommended 
equivalent cut-off in 
whole blood (ng/mL) 
6-AM 10 5 161 10 
Alprazolam 10 1 3.5 10 
Amphetamine 20 25 360 20 
Benzoylecgonine 50 10 95 50 
Clonazepam 10 1 1.7 10 
Cocaine 10 10 170 10 
Codeine 10 20 94 10 
Diazepam 20 5 5.02 140 
Flunitrazepam 2 1 1.02 5.31 
Lorazepam 10 1 1.1 10 
MDA 20 25 2201 20 
MDEA 20 25 2703 20 
MDMA 20 25 2701 20 
Methadone 10 20 22 10 
Methamphetamine 20 25 410 20 
Morphine 10 20 95 10 
Nordiazepam 20 1 1.1 20 
Oxazepam 50 5 13 50 
THC 1 1 27 1.0 
Zolpidem 20 10 102 37 
Zopiclone 10 10 251 10 
Tramadol 50 50 480 50 
7-amino-clonazepam 10 1 3.11 10 
7-amino-flunitrazepam 2 1 1.02 8.51 
1 data based on less than 10 individual cases 
2 recommended cut-off in oral fluid lower than the original DRUID cut-off in oral fluid, therefore the cut-
off in blood has been raised 
3 no positive cases, cut-off MDEA used for MDMA 
1.4.3 Data collection  
Information like gender and age was collected for each subject, as well as a saliva and/or a blood 
sample, for more information on the items of the data collection see Annex 1 (in Part 1).  
Prevalence of alcohol and drugs was calculated on the basis on the various designs of blood and/or 
saliva sampling in the driving populations in the partner states. In case of two samples – both blood 
and saliva, the value of blood was leading.  
Three out of thirteen countries have collected both blood and saliva samples: Belgium, Italy and the 
Netherlands. In Lithuania only blood was collected and in all other participating countries only saliva 
samples were collected.  
All countries have used a StatSure Saliva Sampler device for saliva collection, except for the 
Netherlands, where saliva was collected by means of ordinary spit cups. The Statsure Saliva Sampler 
is a saliva collection device, which the partners agreed upon to use at the beginning of the project. By 
the time this decision was made, the roadside survey in the Netherlands already had been started. 
After consultation with the partners the partners from the Netherlands decided not to restart their 
collection of samples, but to continue the roadside survey with the ordinary spit cups. Blood samples 
were collected in Belgium, Italy, the Netherlands and Lithuania. All four countries used glass tubes for 
the collection containing sodium fluoride and potassium oxalate.  
Extraction of the substances was based on liquid-liquid (LLE) or solid phase (SPE), chromatographic 
separation was performed by gas chromatography (GC) or Liquid chromatography (LC), detection was 
done by mass spectrometry.  
Annex 2 (in Part 1) provides a detailed overview of the toxicological methods that were used by the 
partners. 
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1.4.4 Preparation of the data 
In each database a number of columns were included with if-then statements to determine to which 
substance group a record belonged. The if-then statements were based on the distribution of 
substances and the equivalent cut-offs for substance concentrations.  
Records were removed from the databases of the thirteen countries in case data for one or more total 
substance groups were missing or if samples were not analysed at all. Finally, underaged drivers 
(aged 17 years and younger) were removed as well from the databases. Table 1.3 presents the total 
number of included samples per country. The 'cleaned' databases from the 13 countries contained 
between 1264 and 9236 records. In total almost 50.000 records were included.  
 
Table 1.3. Participating countries and the number of samples included per country 
Participating countries Number of included samples 
 1. Belgium (BE) 2949 
 2. Czech Republic (CZ) 2037 
 3. Denmark (DK) 3002 
 4. Spain (ES) 3174 
 5. Finland (FI) 3841 
 6. Hungary (HU) 2738 
 7. Italy (IT) 1310 
 8. Lithuania (LT) 1264 
 9. Netherlands (NL) 9236 
10. Norway (NO) 4822 
11. Poland (PL) 4005 
12. Portugal (PT) 3965 
13. Sweden (SE) 6199 
      Total 48542 
 
The weight factors in the final analysis are based on the 'clean' version of the national databases. 
 
1.4.5 Analysis  
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
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2 Country report Belgium 
 
Authors: Trudy Van der Linden, Sara-Ann Legrand, Peter Silverans, Alain Verstraete  
 
2.1 Description of the roadside driver sample 
2.1.1 Introduction; description of main deviations and 
justification/reasons 
The roadside survey in Belgium complies with the general guidelines mentioned in Annex 1 of the 
summary report. 
 
The objective for the Belgium roadside survey was to study the prevalence of drug and alcohol use 
among drivers in 5 regions that correspond to the catchment areas of the hospitals 1selected in the 
Belgium hospital study (deliverable 2.2.5). The drivers included in the roadside survey will be used as 
control population in a case-control study of non-fatal accidents. Because no traffic volume data are 
available for those 5 regions separately, for the international database those 5 catchment areas were 
combined into 3 regions (Flanders, Brussels and Wallonia).  
 
For road type a slightly different categorisation than urban and rural was used, because this distinction 
is not made in Belgium. Road type was classified into speed limit <90 km/h and ≥90km/h. 
 
For type of vehicle there were 7 categories: personal car, motorcycle, small van, moped, truck/bus, 
bicycle and other. According to the guidelines (annex 1) only drivers of cars and van were included in 
the analyses.   
 
Volunteers were also asked about the results of the alcohol test (safe, alarm, positive or no breath 
test), whether a drug test was performed, whether their license was withdrawn and whether the police 
made other comments. The last questions of the questionnaire were self-reporting about the use of 
medication and recreational drugs.  
 
It was decided not to include following optional factors:  
- time of driver’s participation (only date and time of the session is listed) 
- nationality of driver 
- valid license 
- driving experience 
- clinical signs of impairment: we decided to use self-reported drug use and time of consumption 
 
2.1.2 Geographic distribution of drivers over the country 
The geographical distribution of the roadside sessions was performed systematically: an equal number 
of sessions was scheduled in the catchment area of each hospital participating in DRUID task 2.2.b. 
In Belgium, federal police forces organise all activities on highways. In the original planning, 20% of 
sessions were scheduled with their collaboration. The remaining 80% of sessions were organised in 
collaboration with the regional police forces. These are subdivided in police zones covering several 
municipalities and/or cities. For practical reasons, it was decided to include 9 police zones for each 
catchment area. These were selected according to information from the emergency services. The nine 
police zones from which most accidents were transported to the participating hospitals in the years 
before the DRUID road side study started. 
. 
 
                                                 
1 Ghent University Hospital, Regional Hospital of Namur, University Hospital Sart Tilman (Liège), Leuven 
University Hospital and Brussels University Hospital. 
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Figure 2.1: Belgian catchment areas and regions 
 
For prevalence calculations, these data were converted into the three administrative regions in 
Belgium (Brussels, Flanders and Wallonia) since the distribution of vehicle kilometers is only available 
per region. The catchment areas of two hospitals are situated in Flanders (Ghent and Louvain), two in 
Wallonia (Liège and Namur) and one catchment area is situated partly in Flanders and partly in 
Brussels. 
 
Overall, only 3.7 % of drivers were sampled in Brussels, while 57.2% were sampled in Flanders and 
39.3% in Wallonia. This is almost identical to the known distribution of vehicle kilometers per region in 
Belgium. (Table 2.1) 
 
Table 2.1. Geographic distribution of drivers over the country 
Region Distribution of drivers Distribution of vehicle 
kilometers by region2 
Brussels 
Flanders 
Wallonia 
 
Total  
110 (3.7%) 
1681 (57.2%) 
1158 (39.3%) 
 
2949 (100%) 
3.98% 
57.44% 
38.58% 
 
100% 
 
 
2.1.3 Distribution of drivers by road type 
Table 2.2 provides an overview of the distribution of drivers by road type. 
Table 2.2. Distribution of drivers by road type 
Road type 
 
Distribution of 
drivers 
Distribution of vehicle kilometers 
by road type3 
Other roads (≤ 90 km/h) 
Highway (> 90 km/h) 
 
Total  
2593 (87.9%) 
356 (12.1%) 
 
2949 (100%) 
65.15% 
34.86% 
 
100% 
 
                                                 
2 and 2 Federale overheidsdienst mobiliteit en vervoer (2008). Directoraat-generaal Mobiliteit en Verkeersveiligheid Directie 
Mobiliteit. Opmeting van de in 2007 jaarlijks afgelegde kilometers. Nr. 43. September 2008. Retrieved January 18 2009 from 
http://www.mobilit.fgov.be/data/mobil/brochkmsit07Nl.pdf  
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The road type in this report differs from the international description. ‘Urban’ and ‘rural’ was not used, 
but instead a division of road types based on maximum speed: ‘highway’ and ‘other roads’ was made. 
87.9% of the drivers were sampled on ‘other roads’ (≤90 km/h) and 12.1% on the ‘highway’ (>90 km/h) 
(see also the short introduction in chapter 1.1 above). 
 
2.1.4 Distribution of drivers by season 
An overview of the distribution of drivers by quarter of the year can be found in table 2.3. 
 
Table 2.3. Distribution of drivers by quarter of the year 
Quarter of the year 
 
Distribution of drivers 
n % 
                     First 
                     Second 
                     Third 
                     Fourth 
          Total  
842 28.5 
776 26.3 
693 23.6 
638 21.6 
2949  
 
 
2.1.5 Distribution of drivers by day of the week and time of the day 
Table 2.4. Distribution of drivers by day of the week and time of the day 
Time period 
 
Distribution of 
drivers 
Distribution of Belgian traffic flow over DRUID 
time periods4 
Week 04:00-9:59 
Week 10:00-15:59 
Week 16:00-21:59 
Week 22:00-3:59 
Weekend 04:00-9:59 
Weekend 10:00-15:59 
Weekend 16:00-21:59 
Weekend 22:00-3:59 
 
Total 
278 (9.4%) 
765 (25.9%) 
632 (21.4%) 
95 (3.2%) 
171 (5.8%) 
228 (7.7%) 
521 (17.7%) 
259 (8.8%) 
 
2949 (100%) 
18.7% 
25.15% 
25.15% 
5.8% 
6.3% 
8.18% 
8.18% 
2.54% 
 
100% 
 
Most of the drivers were sampled during the week, between 10:00-15:59 (25.9%). For comparison we 
also give the distribution of the Belgian traffic flow over the 8 DRUID time periods (table 2.4). Table 2.4 
shows that the findings are similar to the calculations based on figures provided by the Flemish 
department ‘roads and traffic’ (2007). Differences can be found in the time periods 1, 3, 7 and 8 with 
oversampling between 16:00-3:59 in weekends. Weighing factors adjusted these data. 
The various time periods have been fully covered. There were no systematic lunch breaks at defined 
times. 
 
                                                 
4 Source: own calculations based on Vlaamse Overheid-Agentschap wegen en verkeer. Verkeerstelling 2007. 
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2.1.6 Distribution of drivers by gender and age 
Tables 2.5, 2.6 and 2.7 give an overview of the distribution of drivers by gender and age 
groups 
Table 2.5. Distribution of drivers by gender and age 
 Gender Total 
  male female unknown 
Age groups unknown 19 (1.0%) 1 (0.1%) 0 20 (0.7%) 
  18-24 208 (10.5%) 127 (13.2%) 1 336 (11.4%) 
  25-34 381 (19.2%) 230 (23.8%) 0 611 (20.7%) 
  35-49 730 (36.8%) 367 (38.0%) 0 1097 (37.2%) 
  50+ 645 (32.5%) 240 (24.9%) 0 885 (30.0%) 
Total 1983(100%) 965(100%) 1 2949 (100%) 
 
67.2% (1989) of the drivers were male and 32.7% (967) female (see also table 6). 57.9% of the drivers 
can be placed in the age groups 25-34 (20.7%) and 35-49 (37.2%). This is almost identical to the 
known distribution of drivers by age groups in Belgium. (Table 7) To make this comparison, the DRUID 
age data were recoded into the same age categories used in this study. There is a minor difference in 
the 55+ category. 
 
Table 2.6. Distribution of drivers by gender 
  Belgian roadside survey 
of drinking and driving 
2007 
DRUID Respondents  
Gender Male 7853 (67%) 1983 (67.2%) 
  Female 3867(33%) 965 (32.7%) 
  Unknown   1 (0.03%) 
Total 11721 2957 
 
Table 2.7: Distribution of drivers by age groups 
  Belgian roadside survey of 
drinking and driving 20075 
DRUID Respondents 
 
Age groups <25 y 12% 13.1% 
 26-39 y 31% 31.6% 
 40-54 y 35% 35.9% 
 55+ 22% 18.7% 
 unknown  0.7% 
Total 100% 100% 
   
Druid Age groups 18-24  11.4% 
 25-34  20.7% 
 35-49  37.2% 
 50+  30.0% 
 unknown  0.7% 
Total   100% 
                                                 
5 Cf. http://bivvweb.ipower.be/Observ/FR/Rapport%20ROI%202007%20FR.pdf 
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Figure 2.2. Histogram:  age and gender distribution of respondents 
 
2.2 Roadside data collection and analysis  
 
2.2.1 Ethical approval 
The protocol was submitted to the ethics committee of Ghent University Hospital. Approval was 
obtained on 18/07/2008. (Belgian registration number B67020073143) 
2.2.2 Setup of the sampling 
The research procedure consisted of two independent phases: the first phase was an aselect alcohol 
control performed by the police force (the respondents were selected at random by police officers). 
The police officers were asked not to pay attention to: external signs of impairment, age, gender,..., 
but to stop drivers at random and to test all stopped drivers. The stopped drivers were, after the police 
procedure, asked if they wanted to cooperate in the DRUID-research. If they refused, a refusal form 
with demographical data of the person was completed to be able to calculate a response rate. The 
second phase was the DRUID research itself, which took place in a mobile home purchased for the 
DRUID project. The drivers were informed about the objective and the content of the research, asked 
to fill in a questionnaire, to give a saliva sample and a blood sample taken by a nurse. Drivers who did 
not want to participate in the study, where asked to only fill in the questionnaire. If they refused, a 
refusal form was filled in to be able to calculate a response rate. Respondents who participated in the 
study were given a compensation in form of a gift voucher of € 20.  
 2.2.3 Body fluid collection: blood, oral fluid or both; method of oral fluid 
collection 
Each volunteer was asked to provide a blood sample (5mL tube with potassium oxalate) and an oral 
fluid sample collected with the Statsure Saliva Sampler. The vast majority of participants were willing 
to provide both samples: 93.13 % gave both while 6.73% only gave an oral fluid sample (table 2.8).  
 
Table 2.8. Number of oral fluid and whole blood samples taken from participants 
  blood sample taken 
  Yes No 
Oral fluid sample taken Yes 2750 (93.13%) 199 (6.73%) 
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2.2.4 Toxicological analysis of body fluids 
The following methods were used: 
- enzymatic method for ethanol analysis on saliva and whole blood samples on a Roche cobas 
Integra 400. 
- liquid-liquid extraction followed by UPLC-MS/MS analysis for saliva samples 
- solid phase extraction followed by UPLC-MS/MS analysis for all substances except 
cannabinoids in whole blood samples 
- ELISA for qualitative analysis of cannabinoids in whole blood (IDS Elisa One-Step Cannabis 
(Cat No. TH-96-CE-U) 
- liquid-liquid extraction followed by GC-MS analysis for cannabinoids in whole blood. 
All blood samples of volunteers for whom saliva samples where positive for cannabinoids, as well as 
400 negatives were analysed) with ELISA. Only one saliva-negative was found positive for 
cannabinoids in blood (THC: 3.0 ng/mL and THCOOH 12.6 ng/ml).  
Whole blood samples that were positive with ELISA were analysed by GC-MS after extraction using 
liquid-liquid extraction. 
Detailed information on the toxicological analyses can be found in D2.2.5, part2 annex 3 of the Belgian 
Country Report, p 215 - 221. 
 
2.2.5 Method of BAC quantification 
Both oral fluid and whole blood were analysed for ethanol. For comparability with other country reports 
(which mainly use oral fluid), results for ethanol presented are based on oral fluid and converted using 
the following formula: 
 
Calculated blood ethanol (g/L) = measured ethanol in oral fluid (g/L) x 1.22  
2.2.6 Interviews  
The following data were recorded: 
- per roadside session:  
o date and time of day 
o maximum speed allowed at location 
o weather and road conditions 
o total number of drivers stopped by police (including total data on alcohol and drug 
controls) 
- from each participating driver (answers on a questionnaire) 
o type of vehicle 
o gender 
o age 
o education level 
o result of breathalyser test, drug control or other observations by police 
o self-reported drug, alcohol and medicine use 
- from each refusing driver (filled in by a police officer) 
o type of vehicle 
o gender 
o age 
o result of breathalyser test, drug control or other observations by police 
 
2.2.7 Statistical analysis 
In order to calculate frequencies to describe the distribution of drivers (by age groups, gender, road 
type,...) we made our statistical analysis with the software programme SPSS version 15 (renamed in 
PASW). Mann-Whitney, Chi-square, Fisher Exact tests and Confidence intervals (95%) for difference 
in proportions were used to determine differences in distribution. Percentages of positive findings and 
concentration ranges were calculated using Microsoft Office Excel 2007. 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
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Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
2.3 Non-response  
 
As non-response increases, the potential for a biased sample increases. This means that the obtained 
responses of a probability sample may no longer be representative of the larger population. A strategy 
for addressing non-response is to compare date on respondents and non-respondents (refusals).  
 
2.3.1 Size and nature of non-response 
 
2.3.1.1 Age and Gender 
Table 2.9.  Non-response distribution of drivers by gender and age  
Gender 
  
  
Participation 
Refusals Participation 
Male Age groups unknown 19 (0.8%) 19 (1.0%) 
    18-24 223 (10.0%) 208 (10.5%) 
    25-34 552 (24.7%) 381 (19.2%) 
    35-49 858 (38.4%) 730 (36.8%) 
    50+ 584 (26.1%) 645 (32.5%) 
  Total 2236 (100%) 1983 (100%) 
Female Age groups unknown 28 (3.1%) 1 (0.1%) 
    18-24 75 (8.3%) 127 (13.2%) 
    25-34 238 (26.4%) 230 (23.8%) 
    35-49 369 (40.9%) 367 (38.0%) 
    50+ 193 (21.4%) 240 (24.9%) 
  Total 903 (100%) 965 (100%) 
Unknown Age groups unknown 4 (6.0%) 0 
    18-24 7 (10.4%) 1 (100%) 
    25-34 14 (20.9%) 0 
    35-49 28 (41.8%) 0 
    50+ 14 (20.9%) 0 
  Total 67 (100%) 1 (100%) 
 
67.2% (1983) of the drivers (respondents) were male and 32.7% (965) female (see also table 2.6). 
69.7% of the drivers who refused to participate were male and 28.2% female (chi-square, p =0.0016). 
We can conclude that there is a significant difference in gender between the group of respondents 
(volunteers) and the group of refusals (non-response). Males were underrepresented and females 
overrepresented in the respondents,.7 
 
64.2% of the drivers who refused to participate in the DRUID-research can be placed in the age group 
25-34 (25.1%) and the age group 35-49 (39.1%).  
There was a significant (p < 0.001)8 difference in distribution by age groups between the refusers and 
participants. The age group 18-24 was overrepresented in the female respondent group. A possible 
                                                 
6 Chi square and p-value were calculated based on the database leaving out the ‘unknown’ gender data 
7 Confidence intervals for difference in proportions were calculated for every gender / age group between the group of refusals 
and the group of volunteers.  
8 Mann –Whitney and p-value were calculated based on the database leaving out the ‘unknown’ data.  
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explanation could be that the gift card of 20 euro was a more attractive incentive for this group. The 
age group 25-34 was underrepresented and the 50+ age group overrepresented. This can possibly be 
explained by the fact that part of them, being retired and less under time pressure to go to work, were 
more inclined to participate. There was no significant difference for the age group 35-49.7 
The magnitude of these differences was very small, and mainly significant due to the large sample 
sizes. 
 
2.3.1.2 Type of vehicle 
Table 2.10. Distribution of drivers by type of vehicle non-response 
  Participation 
Refusals Respondents 
Type of vehicle Personal car 2961 (92.4%) 2778 (94.2%) 
  Van 245 (7.6%) 171 (5.8%) 
Total 3206 (100%) 2949 (100%) 
 
In the non-response group, 92.4% was driving a personal car; in the group of respondents, this was 
94.2%. There was a significant difference (p= 0.004) in the distribution between volunteers and 
refusals. People driving a van refused more to participate. This is probably explained by the fact that 
drivers of vans are more likely to be driving for work, and less inclined to participate because of 
pressure to complete their assignments on time. 
 
2.3.1.3 Breath alcohol results 
Table 2.11. Distribution of drivers by BAC non-response (excluding the unknowns) 
  Participation 
  Refusals Respondents 
BAC safe 2949(98.2%) 2257 (98.1%) 
  alarm 18(0.6%) 21 (0.9%) 
  positive 35 (1.2%) 22 (1.0%) 
Total 3002(100%) 2300 (100%) 
 
Looking at the BAC categories, we can find an almost identical distribution of BAC (Table 2.11) 
between the group of volunteers and refusals (p= 0.321). Thus there is no significant difference in 
distribution of drivers by BAC between the refusals (non response) and the respondents (volunteers). 
 
2.3.1.4 Druid Time Periods 
Table 2.12. Distribution of drivers by time period, non-response 
  Participation 
Refusals Respondents 
Time period Week 4:00-9:59 357(11.1%) 278 (9.4%) 
  Week 10:00-15:59 700 (21.8%) 765 (25.9%) 
  Week 16:00-21:59 548 (17.1%) 632 (21.4%) 
  Week 22:00-3:59 66 (2.1%) 95 (3.2%) 
  Weekend 4:00-9:59 341 (10.6%) 171 (5.8%) 
  Weekend 10:00-15:59 322 (10.0%) 228 (7.7%) 
  Weekend 16:00-21:59 584 (18.2%) 521 (17.7%) 
  Weekend 22:00-3:59 288(9.0%) 259 (8.8%) 
Total 3206(100%) 2949(100%) 
 
For the distribution of drivers by time period, there is also a significant difference; (p < 0.001).  
By calculating confidence intervals for the difference in proportions for each time period separately, the 
following non-response data were found:  
- in time period 4:00-9:59 (week and weekend) and from 10:00-16:00 in weekends more people 
refused than participated 
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- on weekdays from 10:00 to 3:59 there were more volunteers than refusals 
- on weekend days from 16:00 to 3:59 there was no significant difference between respondents and 
refusals. 
The magnitude of these differences was very small, and mainly significant due to the large sample 
sizes. 
 
2.3.2 Possible confounding effect of non-response 
The differences in distribution of drivers between the group of respondents and non-responders can 
have an effect on the prevalence.  
In general it is known that males are more often positive for psychoactive substances. In this study 
there was an oversampling of females and males were underrepresented. This could indicate an 
underestimation of the obtained prevalence. 
The age groups 18-24 and 50+ are both slightly overrepresented. An increased use of medicines in 
the age group 50+ or increased use of recreational drugs in the group 18-24 years could have had an 
effect on the prevalence. Thus the resulting prevalence estimate could be an overestimation. 
There were more respondents during weekdays and less during weekend-days compared to refusers. 
We expect higher prevalence on weekend-days, so there might be an underestimation of the 
prevalence estimates. 
In general the differences between the compared groups of refusers and respondents were very small 
and mainly became significant due to the very large sample sizes.  
 
None of the characteristics associated with the response rate seemed to have major effects. However, 
we cannot entirely exclude the possibility of a remaining bias in the prevalence estimates. This bias 
may be due to a possible correlation between drug use and willingness to participate in the study that 
is in itself uncorrelated with the variables taken into account in the non-response analysis. Since drug 
using participants might as well be more willing to participate (in order to show a positive "nothing to 
hide" attitude towards the police, for instance) then less willing to participate (fear of being caught, 
willing to hide drug use, ...) we have no idea of the direction of such a possible bias. But this remaining 
degree of incertitude has to be taken into account in the interpretation of the prevalence estimates. 
 
2.4 Results 
2.4.1 Adjusted general substance group distribution 
In all the results presented below (except for figure 2.3), the prevalence estimates are for the named 
drug only. If the drug is used in combination with alcohol, or in combination with another drug, the 
prevalence is not included in the drug-only estimate but only in the drug- drug and drug-alcohol 
estimates at the bottom of the table. Hence the prevalence estimates need to be read as a drug-only 
prevalence estimate. The total prevalence of each drug (alone and in combination) is higher than the 
drug-only estimate. (see fig 2.3) 
 
Table 2.13. Substance group distribution (n= 2949) 
Type Group Prevalence (%) Confidence Intervals 
None 89.35 88.18-90.41 
Alcohol Alcohol 6.42 5.59-7.36 
Illicit Drugs Amphetamines 0  
 Cocaine  0.20 0.09-0.43 
 THC  0.35 0.19-0.64 
 Illicit opiates 0.09 0.03-0.28 
Medicinal drugs Benzodiazepines 2.01 1.57-2.59 
 Z-drugs 0.22 0.10-0.47 
 Opiates and opioids 0.75 0.50-1.13 
Various 
combinations 
Drug-alcohol 0.31 0.16-0.58 
 Drug-drug 0.30 0.16-0.58 
Total 100  
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10.7% of drivers were found positive for one or more (il)licit substances. The highest prevalence was 
found for alcohol only (6.42%). Almost 3% of the sampled subjects were positive for medicinal drugs 
only: benzodiazepines (2.01%) and medicinal opioids (0.75%) being the most common drugs 
detected. 0.6% of respondents had used an illicit drug with the highest prevalence for THC (0.35%). 
 
 
 
Figure 2.3. Distribution of drugs alone and combined 
In figure 2.3 the total distribution of all substance groups is shown, taking into account both the drug 
alone or in combination (not mutually exclusive). In 6.8% of the samples alcohol (> 0.1 g/L) was found, 
benzodiazepines in 2.3%. Except for cocaine, all other groups have a higher prevalence for single use 
compared to combined use. 
 
In general 6.8% of the respondents was found positive for alcohol (alone or in combination). Of these, 
65.4% had a BAC between 0.1 g/l (= DRUID cut-off) and 0.5 g/l (= the legal cut-off in Belgium) and 
8.2% had a BAC at or above 1.2 g/l. 
In the general population the prevalence of driving with a BAC > 0.5 g/L is 2.4%.  
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2.4.2 Adjusted distribution of substance groups age and gender 
Table 2.14. Distribution of substance groups by gender and age (male: n= 1957; female: n= 971), 
Prevalence + Confidence Intervals 
Gender  
Substances 
Age groups Total 
 18-24 25-34 35-49 50+ 
 % CI % CI % CI % CI % CI 
Male  
None 84.08 78.13-
88.65 
89.64 86.11-
92.36 
 90.90 88.62-
92.77 
86.05 83.21-
88.48 
88.28 86.78- 
89.62 
Alcohol 7.08 4.20-11.71  7.51 5.23-10.66  6.24 4.71-8.21 8.92 6.98-11.33 7.47 6.39-8.72 
Cocaine  0.97 0.25-3.68  0.58 0.17-2.02  0.15 0.03-0.78  0.04 0-0.66 0.29 0.13-0.65 
THC  3.91 1.93-7.76  0.64 0.19-2.11  0.06 0.01-0.64 0 0-0.57 0.51 0.28-0.93 
Illicit opiates 0.63 0.12-3.15  0.29 0.05-1.55 0 0-0.52 0 0-0.57 0.11 0.03-0.39 
Benzo-
diazepines 
0 0-2.03  0.25 0.04-1.49  1.90 1.14-3.17  3.02 1.96-4.61 1.78 1.28-2.46 
Z-drugs 0 0-2.03 0 0-1.03 0 0-0.52 0.54 0.20-1.45 0.18 0.07-0.49 
Medicinal opioids  0.63 0.12-3.15 0 0-1.03  0.61 0.25-1.49  0.32 0.09-1.12 0.51 0.28-0.93 
Drug-alcohol  1.33 0.41-4.22  0.37 0.08-1.69 0.13 0.02-0.75  0.59 0.23-1.52 0.44 0.23-0.85 
Drug-drug 1.36 0.42-4.27  0.72 0.23-2.23 0 0-0.52  0.51 0.18-1.40 0.43 0.22-0.83 
Total male 100  100  100  100  100  
Female  
None 93.08 86.75-
96.51 
93.63 89.88-
96.05 
91.80 88.54-
94.19 
88.22 83.57-
91.68 
91.52 89.60-
93.11 
Alcohol 5.77 2.73-11.80 5.32 3.15-8.85 3.10 1.76-5.42 4.31 2.40-7.64 4.28 3.17-5.74 
Cocaine 0 0-3.37 0 0-1.52 0 0-1.04 0 0-1.55 0 0-0.39 
THC  0.26 0.02-3.86 0 0-1.52 0 0-1.04 0 0-1.55 0.03 0-0.45 
Illicit opiates 0 0-3.37 0 0-1.52 0.13 0.01-1.27 0 0-1.55 0.05 0-0.48 
Benzodiazepines 0 0-3.37 1.05 0.33-3.25 2.70 1.47-4.91 4.82 2.77-8.27 2.50 1.69-3.69 
Z-drugs 0 0-3.37 0 0-1.52 0.53 0.14-1.94 0.40 0.07-2.26 0.30 0.10-0.89 
Medicinal opioids 0.88 0.15-4.92 0 0-1.52 1.66 0.77-3.56 2.06 0.89-4.72 1.25 0.72-2.16 
Drug-alcohol 0 0-3.37 0 0-1.52 0.08 0.01-1.19 0 0-1.55 0.03 0-0.45 
Drug-drug 0 0-3.37 0 0-1.52 0 0-1.04 0.19 0.02-1.90 0.05 0-0.48 
Total female 100  100  100  100  100  
Total  
None 87.45 83.19-
90.75 
91.25 88.76-
93.23 
91.20 89.39-
92.73 
86.63 84.27-
88.69 
89.35 88.18-
90.41 
Alcohol 6.58 4.28-10.00 6.62 4.92-8.87 5.20 4.04-6.67 7.68 6.12-9.60 6.42 5.59-7.36 
Cocaine 0.61 0.16-2.33 0.35 0.10-1.21 0.10 0.02-0.52 0.03 0-0.48 0.20 0.09-0.43 
THC  2.55 1.27-5.04 0.38 0.11-1.23 0.04 0-0.43 0 0-0.42 0.35 0.19-0.64 
Illicit opiates 0.40 0.08-1.99 0.17 0.03-0.93 0.04 0-0.43 0 0-0.42 0.09 0.03-0.28 
Benzo-
diazepines 
0 0-1.28 0.57 0.21-1.55 2.17 1.46-3.21 3.50 2.49-4.91 2.01 1.57-2.59 
Z-drugs 0 0-1.28 0 0-0.62 0.18 0.05-0.65 0.50 0.21-1.22 0.22 0.10-0.47 
Medicinal opioids 0.72 0.21-2.50 0 0-0.62 0.96 0.53-1.73 0.79 0.39-1.61 0.75 0.50-1.13 
Drug-alcohol 0.83 0.26-2.67 0.22 0.05-1.01 0.11 0.02-0.55 0.43 0.17-1.11 0.31 0.16-0.58 
Drug-drug 0.85 0.27-2.70 0.43 0.14-1.33 0 0.-0.35 0.42 0.16-1.10 0.30 0.16-0.58 
Total 100  100  100  100  100  
 
In general a significant difference was found for gender (p= 0.001) and age groups (p= 0.004). More 
males were positive for one or more substances compared to females and more positive subjects 
were found in the age groups 18-24 and 50+.  
Alcohol alone was found significantly more frequently in males (7.47%) than in females (4.28%) (p= 
0.001). This was also the case for THC (p= 0.036) which was found more often in the age group 18-24 
(2.55%) compared to the other age categories (ranging 0.04-0.38%). In females THC was only found 
in drivers between 18 and 24 years old. This trend was also seen in the injured drivers study (see 
D2.2.5). Benzodiazepines were found equally in both genders (p= 0.201) and more in the age group 
50+ (3.5%), while none were observed in drivers between 18 and 24 years old (p < 0.001). Z-drugs 
were only found in drivers older than 35, no difference was found regarding gender (p= 0.691). 
Medicinal opioids were found more often in females (p= 0.031). 
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2.4.3 Adjusted distribution of substance groups by day of the week and 
time of the day 
Table 2.15. Distribution of substance groups by day of the week and time of the day (n= 2949), Prevalence 
+ Confidence Intervals 
 Substances Time periods Total 
 Weekdays 
04:00-21:59 
Weeknights 
22:00-03:59 
Weekend-days 
04:00-21:59 
Weekend-nights 
22:00-03:59 
 % CI % CI % CI % CI % CI 
None 91.81 90.54-
92.92 
76.84 69.97-
82.53 86.28 
83.47-
88.69 
78.38 67.80-
86.19 
89.35 88.18-
90.41 
Alcohol 3.99 3.22-
4.93 
21.05 15.61-
27.76 8.94 
7.00-
11.34 
16.60 9.85-
26.61 
6.42 5.59-7.36 
Cocaine  0.11 0.03-
0.37 
1.05 0.27-
3.98 0.23 
0.05-
0.98 
0.39 0.03-5.59 0.20 0.09-0.43 
THC  0.20 0.08-
0.51 
0 0-2.20 0.76 0.33-1.76 
1.54 0.30-7.51 0.35 0.19-0.64 
Illicit opiates 0.06 0.01-
0.29 
0 0-2.20 0.23 0.05-0.97 
0 0-4.88 0.09 0.03-0.28 
Benzodiazepines 2.12 1.58-
2.84 
1.05 0.27-
3.98 2.03 
1.21-
3.41 
1.16 0.19-6.90 2.01 1.57-2.59 
Z-drugs 0.3 0.14-
0.65 
0 0-2.20 0.07 0.01-0.70 
0 0-4.88 0.22 0.10-0.47 
Medicinal 
opioids 
0.98 0.63-
1.50 
0 0-2.20 0.30 0.08-1.08 
0.39 0.03-5.59 0.75 0.50-1.13 
Drug-alcohol 0.14 0.05-
0.43 
0 0-2.20 0.78 0.34-1.79 
1.16 0.19-6.90 0.31 0.16 
Drug-drug 0.31 0.14-
0.66 
0 0-2.20 0.37 0.11-1.19 
0.39 0.03-5.59 0.30 0.16-0.58 
Total 100  100  100  100  100  
 
In general a significant difference was found between the time periods (p< 0.001). More positives were 
found on weeknights compared to week-days and more during weekend nights compared to weekend 
day. Comparing day and night, fewer positive cases occurred during the day (p< 0.001). More 
respondents sampled during the weekend tested positive compared to cases sampled during 
weekdays (p< 0.001). 
 
 
A significant difference was found for alcohol alone (≥ 0.1 g/L) between day and night (p < 0.001), 
more drivers tested positive during nights with percentages of 21.05 during the week and 16.6 during 
the weekend. For the distribution of alcohol by week versus weekend a significant difference was seen 
between with a higher percentage during the weekend. (p < 0.001) 
For THC alone the highest percentage was found during weekend-nights (1.54%); no cases were 
found during weeknights. More positive cases were found during the weekend compared to weekdays 
(p = 0.020) and no difference was seen when comparing day and night (p= 0.582) 
Comparing week and weekend no significant difference in the distribution of cocaine (p=0.646), illicit 
opiates (p= 0.440), benzodiazepines (p= 0.880), Z-drugs (p=0.347) and medicinal opioids (p=0.081) 
were found.  
Comparing day and night no significant differences in the distribution of cocaine (p=0.083) and  
benzodiazepines (p=0.480) were found. Z-drugs were found more often during the night. For medicinal 
opiates and drug-drug combinations only one person was found positive during a weekend-night. 
The highest percentage for alcohol-drug combinations was found during weekend-nights, none during 
weeknights. 
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2.4.4 Adjusted general distribution of alcohol alone by BAC categories 
Table 2.16. Distribution of alcohol alone by BAC categories (n=189) 
Alcohol alone Prevalence (%) Confidence intervals 
BAC 0.1 - 0.49 g/L 4.27 3.59-5.06 
BAC 0.5 - 0.79 g/L 1.33 0.97-1.81 
BAC 0.8 - 1.19 g/L 0.42 0.24-0.72 
BAC ≥ 1.2 g/L 0.41 0.23-0.71 
Sum 6.42 5.59-7.36 
 
The highest prevalence was found for the BAC-category 0.1-0.49 g/L (4.27%). The distribution was 
found equal for the groups 0.8-1.19 g/L and ≥1.2 g/L.  2.16% of the general driving population in 
Belgium is positive for alcohol only with a BAC > 0.5 g/L. 
2.4.5 Adjusted distribution of BAC categories by gender and age 
Table 2.17. Distribution of alcohol alone by BAC category and gender and age (n=189), Prevalence + 
Confidence Intervals 
Gender  Alcohol 
alone 
BAC g/L 
  
Age groups 
Total 
 
18-24 25-34 35-49 50+ 
 % CI % CI % CI % CI % CI 
Male 0.1 - 0.49  4.40 2.26-
8.39 
4.46 2.78-
7.09 
4.60 3.31-
6.36 
5.83 4.29-
7.88 
5.00 4.13-
6.05 
  0.5 - 0.79  0.99 0.26-
3.71 
2.13 1.08-
4.18 
0.76 0.34-
1.69 
1.85 1.07-
3.19 
1.40 0.97-
2.02 
  0.8 - 1.19  0.52 0.09-
2.96 
0.32 0.06-
1.60 
0.76 0.34-
1.69 
0.54 0.20-
1.45 
0.57 0.32-
1.02 
  ≥ 1.2  1.17 0.34-
3.99 
0.59 0.17-
2.03 
0.12 0.02-
0.73 
0.70 0.29-
1.67 
0.50 0.27-
0.92 
Sum male 7.08 4.20-
11.71 
7.51 5.23-
10.66 
6.24 4.71-
8.21 
8.92 6.98-
11.33 
7.47 6.39-
8.72 
Female 0.1 - 0.49  4.26 1.79-
9.82 
2.85 1.40-
5.74 
1.92 0.93-
3.90 
3.30 1.68-
6.35 
2.77 1.91-
4.00 
  0.5 - 0.79  0.53 0.06-
4.33 
2.47 1.15-
5.24 
0.89 0.32-
2.48 
0.62 0.14-
2.62 
1.19 0.67-
2.08 
  0.8 - 1.19  - - - - - - 0.40 0.07-
2.26 
0.10 0.02-
0.58 
  ≥ 1.2  0.99 0.18-
5.09 
- - 0.30 0.06-
1.57 
- - 0.22 0.06-
0.77 
Sum female 5.77 2.73-
11.80 
5.32 3.15-
8.85 
3.10 1.76-
5.42 
4.31 2.40-
7.64 
4.28 3.17-
5.74 
Total 0.1 - 0.49  4.34 2.54-
7.30 
3.81 2.56-
5.63 
3.71 2.75-
5.00 
5.15 3.89-
6.78 
4.27 3.59-
5.06 
  0.5 - 0.79  0.82 0.25-
2.65 
2.27 1.36-
3.77 
0.80 0.42-
1.52 
1.52 0.91-
2.54 
1.33 0.97-
1.81 
  0.8 - 1.19  0.33 0.06-
1.87 
0.19 0.04-
0.96 
0.51 0.23-
1.13 
0.50 0.21-
1.21 
0.42 0.24-
0.72 
  ≥ 1.2  1.10 0.39-
3.07 
0.35 0.10-
1.22 
0.18 0.05-
0.65 
0.51 0.21-
1.22 
0.41 0.23-
0.71 
Sum total 6.58 4.28-
10.00 
6.62 4.92-
8.87 
5.20 4.04-
6.67 
7.68 6.12-
9.60 
6.42 5.59-
7.36 
 
The BAC-category 0.1-0.49 g/L was more present in the male subgroup (5.00%) compared to the 
females (2.77%). The other BAC-categories were equally distributed over the gender categories. 2.5% 
and 1.5% of respectively males and females in the general driving population in Belgium is positive for 
alcohol only with a BAC > 0.5 g/L. 
 
For the age groups, all BAC-categories were equally distributed, except that there were more BAC 
≥1.2 g/L in the age group 18-24. 
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2.4.6 Adjusted distribution of BAC categories by day of the week and 
time of the day 
Table2.18. Distribution of alcohol alone by BAC category and time period (n=189), prevalence and 
confidence intervals 
Alcohol 
alone 
BAC g/L 
Time periods Total 
 Weekdays 
04:00-21:59 
Weeknights 
22:00-03:59 
Weekend-days 
04:00-21:59 
Weekend-nights 
22:00-03:59 
 % CI % CI % CI % CI % CI 
0.1 - 0.49 2.73 2.10-3.53 14.74 10.20-20.82 5.84 4.30-7.88 8.11 3.79-16.52 4.27 3.59-5.06 
0.5 - 0.79 0.95 0.61-1.48 4.21 2.07-8.36 1.27 0.66-2.44 5.41 2.13-13.03 1.33 0.97-1.81 
0.8 - 1.19 0.26 0.11-0.59 2.11 0.78-5.53 0.35 0.10-1.16 1.54 0.30-7.51 0.42 0.24-0.72 
≥ 1.2 0.05 0.01-0.28 - - 1.48 0.80-2.71 1.54 0.30-7.51 0.41 0.23-0.71 
Sum 3.99 3.22-4.93 21.05 15.61-27.76 8.94 7.00-11.34 16.60 9.85-26.61 6.42 5.59-7.36 
 
The BAC-category 0.1-0.49 g/L was found less on weekdays compared to the other time periods. The 
categories 0.5-0.79 and 0.8-1.19 g/L were more prevalent at night compared to daytime. The category 
≥ 1.2 g/L was not found on weeknights and was more prevalent in weekend compared to weekdays 
(p= 0.001). On weekdays, 1.3% of the general driving population in Belgium is positive for alcohol only 
with a BAC > 0.5 g/L, on weeknights 6.32%. In the weekend this percentage increases to 3.1% on 
weekend-days and 8.49% on weekend-nights. 
 
Although the data are not completely comparable due to the fact that only the "alcohol alone" 
prevalence was taken into account in these analyses, it is interesting to compare these results with the 
most recent Belgian drink driving road side survey, which took place in 2009. Based on a sample of 
more than 12000 subjects tested in October and November 2009, it was estimated that 13% of the 
drivers on weekend-nights tested above 0.5 g/L. On weeknights the prevalence was 6.7%, around 
1.5% on weekdays and around 2.2% on weekend days. Taking the confidence intervals into account 
the DRUID results seem roughly comparable to the roadside survey results, although the prevalence 
on weeknights seems somewhat underestimated and the prevalence on weekend-days seems 
somewhat overestimated in the DRUID study compared to the road side survey. These differences 
might be related to methodological differences (e.g. the DUI road side survey only took place in 2 
months of the year, whereas the DRUID sample covered the entire year, the DRUID estimates do not 
take drug-alcohol combinations into account in the present analyses, only breath test results were 
taken into account in the DUI road side survey whereas the DRUID results for alcohol are based on 
saliva etc...). 
2.4.7 Adjusted distribution of additional substances 
Table 2.19. Distribution of additional substances (n= 2949), prevalence and confidence intervals 
Substance Prevalence (%) Confidence Intervals 
Amitryptiline 0.19 0.088 – 0.43 
Bromazepam 0.52 0.31 – 0.85 
Buprenorphine 0  
Citalopram 1.52 1.13 – 2.02 
Mirtazapine 0.23 0.11 – 0.48 
Trazodone 1.17 0.84 – 1.63 
 
 
Table 2.19 shows that citalopram (1.52%) and trazodone (1.17%) were the most common additional 
findings, all other additional substance have significantly lower prevalence. 
These findings are in line with the sales figures of medicines in Belgium: citalopram is a frequently 
prescribed antidepressant9. 
 
                                                 
9 http://www.riziv.fgov.be/drug/nl/statistics-scientific-information/pharmanet/info-spot/2010-09-08/index.htm 
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2.4.8 Distribution of positives according to the Belgian Law 
Out of the 2949 respondents, 86 (2.9%) had a BAC above the Belgian legal level.  
 
Out of the 2750 respondents for which a blood was available, 38 concentrations were above the 
Belgian cut-off for illicit substances (ethanol not included) mentioned in the Belgian law. (see table 
2.20). Taking into account the number of respondents positive for more than one illicit substance 
(except ethanol), 28 respondents would be punishable for driving under the influence of illicit drugs.  
 
Table 2.20. Number of positives according to Belgian Law based on results of blood samples (n=2750) 
Substance Cut-off Belgian Law (ng/mL) blood 
analysis 
Positive according to Belgian 
Law (n) 
Ethanol* 0.5 g/L 86 
THC 1 13 
Amphetamine 25 0 
MDMA 25 0 
Morphine 10 5 
6-acetyl-morphine 10 1 
Cocaine 25 7 
Benzoylecgonine 25 12 
* The figures listed in this table for ethanol are calculated BAC based on oral fluid for all respondents (n=2949) 
 
Out of the 199 respondents for which only a saliva sample was available, 26 saliva concentrations 
were above the Belgian cut-off for illicit substances mentioned in the Belgian law (see table 2.21). 
Taking into account the number of respondents positive for more than one illicit substance, 15 
respondents would be punishable for driving under the influence of illicit drugs. 
 
Table 2.21. Number of positives according to Belgian Law based on results of saliva samples (n=199) 
Substance Cut-off Belgian Law (ng/ml) saliva 
analysis 
Positive according to Belgian 
Law (n) 
THC 10 7 
Amphetamine 25 0 
MDMA 25 1 
Morphine 5 3 
6-acetyl-morphine 5 2 
Cocaine 10 7 
Benzoylecgonine 10 6 
 
Adding up the number of positives in blood and in oral fluid (table 20 and 21) and taking into account 
the number of respondents positive for more than one illicit substance, we can conclude that, of all our 
respondents, 43 (1.5%) would be punishable for use of illicit drugs and 2.9% for alcohol according to 
the Belgian law. 
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Table 2.22. Comparison number of positives in blood and oral fluid according to Belgian Law 
Substance Number of 
cases taken 
into conside-
ration 
Cut-off 
Belgian Law 
(ng/ml) oral 
fluid analysis 
Positive in 
oral fluid 
according to 
Belgian Law 
(n) 
Cut-off 
Belgian Law 
(ng/ml) 
blood 
analysis 
Positive in 
blood 
according to 
Belgian Law 
(n) 
THC 2750 10 40 1 13 
Amphetamine 2750 25 2 25 0 
MDMA 2750 25 0 25 0 
Morphine 2750 5 12 10 5 
6-acetylmorphine 2750 5 3 10 1 
Cocaine 2750 10 25 25 7 
Benzoylecgonine 2750 10 24 25 12 
 
When comparing the number of positives in blood to the number of positives in oral fluid according to 
the Belgian Law, out of the 2750 respondents for which a blood and a saliva sample was available, 38 
blood concentrations and 106 oral fluid concentrations were above the Belgian cut-off (see table 22). 
Taking into account the number of respondents positive for more than one illicit substance, 28 
respondents would be punishable according to the cut-off in blood, 71 respondents according to the 
cut-off in oral fluid. 
These figures show that the Belgian Law is stricter for results of oral fluid samples than for blood.  
 
2.5 Discussion  
2.5.1 Representativeness 
Compared to the whole Belgian driving population, the selection of subjects was very representative 
for the whole population of drivers in Belgium. This is illustrated by the good correspondence between 
the study data and the data from the Flemish department ‘roads and traffic’ regarding gender, regional 
and road type distribution.  
 
The distribution of drivers by gender and by age group are almost identical to the known distribution of 
drivers in Belgium (see table 2.6 and 2.7)10. There is also an equal distribution of the traffic flow over 
the time periods (table 2.4). 
 
Based on these figures and the available data, we can conclude that there are no indications that our 
sample is not representative for the whole population (of drivers) in Belgium. 
 
2.5.2 Effects of non-response 
Comparing volunteers and refusers, significant differences were observed for distribution of drivers by 
gender, age groups and time period. In the next paragraph some possible confounding effects are 
mentioned. Due to the low percentage for some drugs, not all substance groups are discussed. 
 
Since males were slightly underrepresented11 and there was a difference seen in positives between 
males and females, gender could be a confounding effect indicating an underestimation of the found 
prevalence.  
Benzodiazepines were more found in the age group 50+, which was also overrepresented12, indicating 
a possible overestimation of the prevalence of benzodiazepines. 
                                                 
10 Dupont, 2009. Belgian roadside survey of drinking and driving 2007:  
http://bivvweb.ipower.be/observ/NL/rapportrijdenonderinvloed2007.pdf 
11 Confidence interval for difference in proportion between male participants (67.3%) and male refusers (71.2%): 
(0.0158;0.0622) 
12 Confidence interval for difference in proportion between participants aged 50+ (30.2%) and refusers aged 50+ (25.1%): 
(0.0285;0.0735) 
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Non-response was higher on weekend-days, indicating a possible underestimation of the prevalence 
of alcohol. In contrast an overestimation could be made because non-response was lower on 
weekdays and –nights. 
Since THC was detected mostly during weekend-nights and this time period was not under- or 
oversampled, no confounding effect of time period was presumed. 
 
2.5.3 Highlights 
The following substances (alone and in combination) were found in decreasing frequency: alcohol 
(6.8%), benzodiazepines (2.3%), medicinal opioids (1.0%), THC (0.5%), cocaine (0.4%), Z-drugs 
(0.3%) and illicit opiates (0.2%). 
Approximately 5% of alcohol positive cases were positive for a drug-alcohol combination. Cases 
positive for alcohol only were more common in male drivers. The second most prevalent group was 
the one positive for benzodiazepines only (2%), with positive cases more common in the 
subpopulation aged 50 and over and none in drivers between 18 and 24. THC was found more in the 
age group 18-24, none in females of 25 and older. This trend was also seen in the injured drivers 
study (see D2.2.5). 
Alcohol alone was found more during nights compared to daytime and more during weekend-days 
compared to weekdays. Drivers positive for cannabis only were found more often during weekend-
night, and no positive cases found during weeknights. Alcohol-drug combinations were most found 
during the weekend. 
The BAC-category 0.1-0.49 g/L was more present in the male subgroup (5.00%) compared to the 
females (2.77%). For age groups, all BAC-categories were equally distributed, except for BAC ≥1.2 
g/L, which had a higher percentage in the age group 18-24. 
On weekdays, 1.3% of the general driving population in Belgium is positive for alcohol only with a BAC 
> 0.5 g/L, on week nights 6.32%. In the weekend this percentage increases to 3.1% on weekend-days 
and 8.49% on weekend-nights. 
Most positives have low blood concentrations. Comparing blood and oral fluid, higher concentrations 
are found in oral fluid samples. Implementing the new equivalent DRUID-cut-offs made it more 
feasible to compare the Belgian results, based on blood, with the results of the other that are based on 
oral fluid.  
More than 80% of findings for benzodiazepines and Z-drugs were sub-therapeutic concentrations. For 
antidepressants approximately 50% of the concentrations were therapeutic and 50% were lower than 
therapeutic. For opioids almost 62% were in therapeutic range. In general only 3 concentrations (2 
alprazolam, 1 codeine) were above therapeutic range. 
According to the Belgian law, of all our respondents, 43 (1.5%) would be punishable for driving under 
the influence of illicit drugs and 86 (2.9%) for driving under the influence of alcohol. 
When comparing the number of positives in blood to the number of positives in oral fluid using the cut-
offs mentioned in the Belgian Law, out of the 2750 respondents for which a blood and a saliva sample 
was available, 28 (1.0 %) respondents would be punishable according to the cut-off in blood, 71 
(2.6%) respondents according to the cut-off in oral fluid, which illustrates that more people will be 
found positive with the saliva cut-offs than with the blood cut-offs.  
The comparison of the number of positive subjects among the volunteers who gave blood and saliva, 
and the volunteers who refused to give a blood sample shows that there was a much higher 
percentage of positives (in saliva) among the latter (7.5% versus 2.6%, p= 0.0005). This suggests a 
possible bias in those who have refused to give a blood sample. One can suppose that people 
thinking that they could test positive might have been more likely to refuse to give a blood sample. 
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3 Country report Czech Republic 
 
Authors: Aleš Zaoral, Jan Weinberger, Petr Zámečnik, Darina Havlíčková, Transport Research 
Centre (CDV). 
 
Toxicological analyses: Alain Verstraete, manager of the toxicological laboratory of the University 
Hospital Gent (Belgium). 
 
3.1 Description of roadside driver sample 
The roadside survey in the Czech Republic complies with general guidelines mentioned in Annex 1 of 
the general part of the report. The compliance of the working method has been approved by the 
Ethical committee of teaching hospital in Brno. The research was carried out and facilitated thanks to 
cooperation between Directorate Traffic police Services and Centrum dopravního výzkumu – 
Transport Research Centre (CDV).  
 
3.1.1 Study objectives and research design  
The project DRUID is the international project incorporated into seventh frame program. The objective 
of the project is to gain more insight into the prevalence of psychoactive substances among the driving 
population. 
The roadside survey in the Czech Republic started with pilot data collection (saliva samples from CDV 
staff) in February 2008. The main survey was started in March 2008 and finished in June 2009. We 
gained the saliva samples from drivers in the cooperation with the traffic police patrols. The research 
(the personal data) was anonymous, driver´s participation was voluntary and practically the whole 
territory of Czech Republic was more or less represented.  
Besides saliva samples the researchers also collected drivers’ statistical data (type of driving license, 
mileage in the last year, car type and make, collection time, weather condition etc.). 
 
3.1.2 Research area and selection of research sites – geographic 
distribution 
Data on control drivers and saliva sampling were taken randomly at six regions of the Czech Republic. 
The Czech Republic is nowadays divided into 14 regions (13 regions and Prague). In order to simplify 
the division of the territory we used the former division of regions – two Moravian and four Bohemian 
regions. The saliva collection carried out in the fifth - Central Bohemia region – was allocated to the 
other Bohemia regions according to their geographical location. The saliva collection was carried out 
practically in the whole of the Czech Republic –  in 26 Bohemian and Moravian districts.  The 
collection in Moravia lasted usually one day, in Bohemia usually two days. According to the control 
plan of traffic police patrols we collected the saliva often in more places during one day. Some traffic 
police controls took place on the urban, other on rural traffic roads. During each session the traffic 
police patrols usually checked drivers successively at various checkpoints.  
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 Region Number of samples 
1. South Moravia 367 
2. North Moravia 326 
3. North Bohemia 326 
4. East Bohemia 346 
5. South Bohemia 367 
6. West Bohemia 307 
Figure 3.1. Regional distribution of samples 
 
In each sample collection session, a team consisting of two DRUID employees cooperated with the 
traffic police patrol. 
 
Table 3.1. Geographic distribution of drivers over the country 
DRUID regions Roadside sample fraction Fraction of traffic volume 
South Moravia  0.18 0.21 
North Moravia  0.16 0.18 
North Bohemia  0.16 0.15 
East Bohemia  0.17 0.14 
South Bohemia  0.18 0.11 
West  Bohemia  0.15 0.21 
In total 1 1 
 
3.1.3 Distribution of drivers by road type 
The saliva sampling was collected at random in all regions of the Czech Republic. We were dependent 
on diurnal or nocturnal control schedule of traffic police patrols. Number of samples from urban and 
rural roads were almost equal. 
 
Table 3.2. Distribution of drivers by road type 
Road type Roadside sample fraction Fraction of traffic volume 
Urban (type 1) 0.56  0.25  
Rural (type 2) 0.44  0.75  
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3.1.4 Distribution of drivers by season 
Within each region the samples were distributed into seasons (Spring: March – May; Summer: June – 
August; Autumn: September – November; Winter: December – February). We tried to get saliva 
samples throughout the whole year and irrespectively of weather conditions. The lower level of saliva 
samples acquired in winter months was caused by increased sick leave of researchers and adverse 
weather conditions in 2008-2009  winter (Month 01 – 03). 
 
Table 3.3. Distribution of drivers by seasons 
Season of the year / Months Roadside sample fraction Fraction of traffic volume 
Winter (Month 01 – 03) 0.13 0.248 
Spring (Month 04 – 06) 0.45 0.261 
Summer (Month 07 - 09 0.19 0.239 
Autumn (Month 10 – 12) 0.23 0.252 
 
3.1.5 Distribution of drivers by day of the week and time of the day 
We tried to collect saliva samples at any hour of the day and any day of the week. During March 2008 
– June 2009 we participated in 39 roadside sessions and obtained 2039 saliva samples. The most 
saliva samples (675) were taken during time period 2 (10 – 16 h on working days), when traffic is the 
heaviest. The least samples (82 saliva samples) were taken in time periods 4 and 8 (22 – 04 h on 
working days and weekend); in these time periods the traffic density is the lowest. The samples 
collection in the other six time periods was roughly divided according to traffic density in this time 
periods. Various time periods have been fully covered and there were not any systematically time 
period with no samples. 
 
Table 3.4. Distribution of drivers by DRUID time periods  
DRUID Time period 
Roadside sample 
fraction 
Fraction of traffic 
volume 
1 Weekday 04:00-09:59 0.18 0.2 
2 Weekday 10:00-15:59 0.34 0.29 
3 Weekday 16:00-21:59 0.17 0.16 
4 Weekday 22:00-03:39 0.06 0.02 
5 Weekendday 04:00-09:59 0.06 0.08 
6 Weekendday 10:00-15:59 0.07 0.11 
7 Weekendday 16:00-21:59 0.05 0.13 
8 Weekendday 22:00-03:39 0.07 0.01 
  
3.1.6  Distribution of drivers by gender and age 
On roads in the Czech Republic the total of 2039 saliva samples from drivers were acquired. 1593 
(78%) of drivers were men and 446 (22%) women. That is the result of random sampling of drivers 
who were stopped and controlled by traffic police patrols and who gave us their saliva. This result 
supports the claim that more males than females are driving cars. 
The number of drivers divided in four age categories is indicated in the table below.  
 
Table 3.5. Distribution of drivers by age 
Age group Fraction of males Fraction of females Fraction together 
18 - 24 0,12    0,20 0,16 
25 - 34 0,27    0,33 0,30 
35 - 49 0,34    0,34 0,34 
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50+ 0,27    0,13 0,20 
 
 
Comparatively, the most drivers in our sample belong to age group 25-34 (on average 57.3 drivers in 
this category every year), then to age group 35-49 (on average 46,5 drivers in this category every 
year) and to age group 18-24 (on average 38,6 drivers in this category every year). The age group 
50+ covers the widest age range – from 50 to 80 years. Here the average representation of drivers in 
one year is the lowest. 
 
3.2 Roadside data collection and analysis 
3.2.1 Ethical approval 
Before saliva sampling started we got in touch with the Ethical committee of teaching hospital in Brno. 
We informed the committee in detail about the methodology of saliva sampling and statistical data 
acquisition. The commission dealt with our request for approval of saliva sampling and sent us the 
following opinion: For saliva sampling we don't need approval. It is also not necessary to demand the 
informed approval from volunteers – their consent is sufficiently expressed by their agreement to the 
collection of the sample and to the publication of the statistical information.  
 
3.2.2 Body fluid collection and results, traffic police controls and 
suggestion 
CDV executed within the WP2 oral fluid - saliva sampling. Oral fluid was collected by the Saliva-
Sampler (Statsure Diagnostic Systems, Inc. Medford, New York, USA) device (Annex 2, Part 1). The 
device is intended for collection and transport of saliva Samples and consist of a Saliva collector with 
volume adequacy indicator and a Transport tube with a snap cap. In this device a variable amount of 
absorbed oral fluid (300 – 1500 mg) is diluted with a fixed buffer volume (1 mL). The buffer contains 
0,2% sodium azide as a preservative substance. Saliva collection proceeded in all regions of the 
Czech Republic in all seasons, in all days of the week and all hours of the day.  
In the course of saliva sampling the tubes were deposited in the frost-resistant box with the 
dimensions 13.5 x 13.5 x 10 centimeters and with the capacity of 25 tubes. In this box the samples 
were stored in deep freeze under the temperature of 22 degrees below zero. The same boxes were 
used for the transport of saliva samples – in the car freezer (by the temperature of 18 degrees below 
zero) – to the toxicological laboratory in Gent (Belgium).  
 
3.2.3 Driver selection and data collection procedures  
Drivers were stopped randomly by police and their identification and car documents were checked. 
The police occasionally checked the car technical condition as well. The police conducted the breath 
test for checking alcohol presence in accordance with the patrol day´s plan. Sometimes breath test 
was performed on all drivers, sometimes only on a few randomly chosen drivers, sometimes on none.  
After the  police control ended the police officer introduced CDV researchers to the driver and we 
asked him (her) to give us their saliva sample. In the course of the saliva collection we gave the driver 
more information about DRUID project and the influence of psychotropic substances (medicinal drugs 
and illegal drugs) on driving.  
 
3.2.4 Safe keeping of saliva samples and their transportation to the 
toxicological laboratory 
After the slice was saturated with saliva (the control spot changed colour) the driver removed the slice 
and the researcher gave it in the tube marked with the day order number. All tubes were placed in the 
small box which has the capacity of 25 tubes. The box was deposited in the car fridge. The fridge was 
necessary particularly in hot days when the inside car temperature was often more than fifty degrees.  
The researchers took collected saliva samples to CDV working place. Here the researcher indicated 
necessary data on the tube (date of saliva sample collection, sex of the driver and order number of the 
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sample). The small boxes with saliva samples in the tubes were then deposited into a deep freezer 
with the inside temperature of 22 degree centigrade below zero.  
For carrying out the toxicological analysis we transported the saliva samples to the toxicological 
laboratory of Ghent University in Belgium. When it comes to transport we made the resolution not to 
rely on the postal services (no matter whether samples would be sent by car or plane) because we 
could not guarantee the stable temperature below zero that has to be guaranteed throughout the 
course of transport. Finally we decided to deliver the saliva samples ourselves by a car where they 
were deposited in the car freezer. The purchased car freezer guaranteed the inside temperature of 18 
degree centigrade below zero. The business trip with our company car took two nights. During the 
night the freezer was transferred into a hotel room and plugged into the electric network and powered 
by 220V. 
Since the car freezer’s capacity was restricted (about 700 tubes with saliva samples in the small 
boxes) we had to make the journey Brno – Gent – Brno three times. The date of saliva samples 
delivery was always agreed in advance with the staff of toxicological laboratory in Ghent. After the 
CDV car arrived in front of university hospital of Ghent the researcher informed the toxicological 
laboratory staff over the phone and after the car was parked in the hospital parking house two 
employees of laboratory came and helped with the transport into the laboratory rooms. The laboratory 
staff took the tubes out of the car freezer and took small boxes out of the laboratory containers and 
stored them in the deep freezer. At this point the car freezer and CDV employee were ready for the 
way back. 
 
3.2.5 Description of method for toxicological analyses 
The toxicological analysis of 2039 saliva samples acquired from drivers on the roads of the Czech 
Republic were performed by DRUID partner University of Ghent (Belgium). The samples were carried 
out in the toxicological laboratory UNI Gent. The relevant staff of toxicological laboratory is the 
competent person to describe the method used for toxicological analysis. The toxicological analysis 
contained information about the number of positive samples, type of detected illegal drugs or medicine 
drugs in the sample. The laboratory also informed us about the number of samples that were not 
possible to analyze at all or only partially. 
In the first delivery of saliva sample the laboratory could not analyze four samples. In twenty other 
samples the content of saliva was low but the laboratory managed to accomplish the analysis. 
In the second delivery of saliva samples the laboratory could not to analyze one sample number due 
to an insufficient amount of saliva 
In the third delivery all samples were analyzed, no samples were not fit for analysis. 
 
3.2.6 Interviews 
After completion of saliva sampling the CDV researchers asked the drivers some statistical questions. 
Their answers we entered into the statistical questionnaire. We entered the date and time we obtained 
the saliva sample, day order number, type of road, density of traffic and weather conditions (daylight or 
night, cloudless sky/sunny weather or overcast, rain, snowfall, fog, frost, hot weather.  
We further collected information like car category (passenger car or van), car make, driver´s gender 
and age, their license type, year of license issue, if the driver is professional driver or not, current 
driving practice (how many kilometers he/she did in the past twelve months), number of motoring 
offences and traffic accidents in the past twelve months (offender or only traffic accident participation), 
place of residence (city or village), experience with drug use, medical drug usage and alcohol test 
result (in case of alcohol breath test performance).  
In the course of saliva sampling and interview we didn´t note the signs of impairment, because no one 
of CDV researcher was professionally trained for this competent appraisal.  
 
2.7 Analysis 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
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3.3 Non-response 
3.3.1 Size and nature of non response 
During the saliva sampling the CDV researchers asked 2 648 drivers for saliva samples. Only 2039 
drivers gave us the saliva, which means that 609 (22.9%) drivers refused to give their saliva.  
Table 3.6. Distribution of respondents and non-respondents by gender 
 Male Female Total 
Respondents 1593 (76%) 446 (83%) 2039 (77%) 
Non respondents 513 (24%) 96 (17%) 609 (23%) 
Total  2106 (100 %) 542 (100 %) 2648 (100%) 
 
In total 84%of the drivers who refused to give a saliva sample was men, whereas in the response 
group the share of men was 78%. Men are a bit overrepresented in the non response group. This 
reason for this was that men were more often „in rush“ than women. 
 
3.3.2 Possible confounding effect of non - response 
There were two types of answers, by which respondents explain why they don’t want to give saliva. 
Firstly, they were “in rush” and didn’t want to devote ten minutes. Secondly, drivers ask if it is 
necessary to give saliva and when they ascertained voluntary participation, they left. In the latter group 
we expect large shares of “potentially positive” samples. 
Many drivers who refused to give saliva argued: “We do not want to give our genetic code (DNA)”. Our 
commercial television NOVA (independently of our saliva sampling within the DRUID project) was 
telling in that time people that the DNA sample could be misused in different ways.  
We think the real reason for refusal was the alcohol or drug presence in the driver´s bloodstream at 
the time we asked for saliva samples. These drivers were most likely afraid that we would give police 
the information about the alcohol or drug presence in their tests plus their identification because they 
knew they breached the law. 
 
3.4 Results 
The toxicological laboratory found, that among 2039 saliva samples 108 were positive for one or more 
drugs. In total these positive samples contained 138 legal or illegal drugs. 
 
Illegal drugs: THC – in 33 samples, Alcohol - in 23 samples, Amphetamine – in 12 samples, 
Methamphetamine – in 12 samples, Cocaine - in 1 sample and Benzoylecgonine – in 2 samples. 
Legal drugs: Citalopram – in 18 samples, Nordiazepam – in 9 samples, Bromazepam – in 8 samples, 
Alprazolam – in 7 samples, Tramadol – in 6 samples, Trazodone – in 3 samples, Mitrazepin – in 3 
samples, Flunitrazepam – in 1 sample. 
 
In total, the toxicological laboratory detected 83 illegal drugs and 55 drugs, that have a negative 
impact on the ability to drive, in the saliva samples acquired from drivers on Czech roads. 
76 illegal drugs and 36 drugs were detected in saliva samples of 55 men. The most frequent illegal 
drug combination was Amphetamine with Methamphetamine which was detected in 11 saliva samples.  
Drugs were detected in saliva samples of 17 women, 4 female drivers were under influence of illegal 
drugs, one woman drove the car under influence of 4 illegal drugs (THC, Methamphetamine, Cocaine 
and Benzoylecgonine). 
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Table 3.7. Adjusted general distribution of core substance categories (N=2039) 
Substance category Prevalence (%) Confidence interval (%) 
Negative 97.20 96.39 - 97.83 
Alcohol 0.99 0.65 - 1.53 
Amphetamines 0.36 0.17 - 0.72 
Cocaine - - 
THC 0.46 0.25 - 0.86 
Illicit opiates - - 
Benzodiazepines 0.62 0.36 - 1.07 
Z-drugs - - 
Medicinal opioids 0.21 0.08 - 0.52 
Alcohol – drugs 0.05 0.01 - 0.28 
Multiple drugs 0.11 0.03 - 0.38 
 
 Table 3.8A. Adjusted distribution of core substance categories by gender and age (N=1593)  
Male 18-24 25-34 35-49 50+ All ages 
Substance 
 
Prevalence (%) 
C.I. (%) 
 
Prevalence (%) 
C.I. (%) 
 
Prevalence (%) 
C.I. (%) 
 
Prevalence (%) 
C.I. (%) 
 
Prevalence (%) 
C.I. (%) 
negative 94.48 89.73 - 97.10 
96.93 
94.81 - 98.21 
97.57 
95.94 - 98.56 
97.74 
95.92 - 98.76 
97.15 
96.21 - 97.86 
amphetamines 0.64 0.11 - 3.52 
1.50 
0.70 - 3.18 
0.00 
0.00 - 0.68 
0.00 
0.00 - 0.84 
0.46 
0.22 - 0.93 
cocaine - - - - - 
THC 2.84 1.16 - 6.78 
0.94 
0.37 - 2.42 
0.18 
0.03 - 1.00 
0.00 
0.00 - 0.84 
0.59 
0.32 - 1.10 
illicit opiates - - - - - 
benzodiazepines 0.00 0.00 - 2.39 
0.00 
0.00 - 0.91 
0.55 
0.19 - 1.58 
0.65 
0.22 - 1.91 
0.38 
0.17 - 0.82 
Z-drugs - - - - - 
medicinal opiates 0.00 0.00 - 2.39 
0.00 
0.00 - 0.91 
0.00 
0.00 - 0.68 
0.47 
0.13 - 1.63 
0.13 
0.04 - 0.47 
alcohol 1.33 0.38 - 4.62 
0.36 
0.08 - 1.54 
1.70 
0.91 - 3.15 
1.14 
0.50 
2.61 
1.15 
0.73 - 1.81 
alcohol+drugs 0.63 0.11 - 3.51 
0.00 
0.00 - 0.91 
0.00 
0.00 - 0.68 
0.00 
0.00 - 0.84 
0.06 
0.01 - 0.35 
drugs-drugs combi 0.08 0.00 - 2.55 
0.27 
0.05 - 1.39 
0.00 
0.00 - 0.68 
0.00 
0.00 - 0.84 
0.08 
0.02 - 0.38 
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Table3. 8B Adjusted distribution of core substance categories by gender and age (N=446) 
Female 18-24 25-34 35-49 50+ All ages   
Substance Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
negative 98.83 93.64 - 99.79 
96.95 
92.55 - 98.79 
97.19 
93.36 - 98.84 
96.92 
89.35 - 99.16 
97.39 
95.46 - 98.51 
amphetamines 0.00 0.00 - 4.32 
0.00 
0.00 - 2.73 
0.00 
0.00 - 2.31 
0.00 
0.00 - 5.68 
0.00 
0.00 - 0.85 
cocaine - - - - - 
THC 0.00 0.00 - 4.32 
0.00 
0.00 - 2.73 
0.00 
0.00 - 2.31 
0.00 
0.00 - 5.68 
0.00 
0.00 - 0.85 
illicit opiates - - - - - 
benzodiazepines 1.17 0.21 - 6.36 
0.80 
0.15 - 4.14 
1.60 
0.51 - 4.93 
3.08 
0.84 - 10.65 
1.49 
0.71 - 3.09 
Z-drugs - - - - - 
medicinal opiates 0.00 0.00 - 4.32 
1.53 
0.43 - 5.27 
0.00 
0.00 - 2.31 
0.00 
0.00 - 5.68 
0.47 
0.13 - 1.64 
alcohol 0.00 0.00 - 4.32 
0.00 
0.00 - 2.73 
1.21 
0.33 - 4.34 
0.00 
0.00 - 5.68 
0.44 
0.12 - 1.60 
alcohol+drugs 0.00 0.00 - 4.32 
0.00 
0.00 - 2.73 
0.00 
0.00 - 2.31 
0.00 
0.00 - 5.68 
0.00 
0.00 - 0.85 
drugs-drugs combi 0.00 0.00 - 4.32 
0.72 
0.13 - 4.01 
0.00 
0.00 - 2.31 
0.00 
0.00 - 5.68 
0.22 
0.04 - 1.25 
 
Table 3.8C. Adjusted distribution of core substance categories by gender and age (N=2039) 
Total 18-24 25-34 35-49 50+ All ages 
Substance Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
negative 96.01 92.74 - 97.84 
96.94 
95.15 - 98.08 
97.49 
96.07 - 98.40 
97.64 
95.94 - 98.64 
97.20 
96.39 - 97.83 
amphetamines 0.41 0.07 - 2.30 
1.13 
0.53 - 2.40 
0.00 
0.00 - 0.53 
0.00 
0.00 - 0.74 
0.36 
0.17 - 0.72 
cocaine - - - - - 
THC 1.84 0.75 - 4.44 
0.71 
0.28 - 1.83 
0.14 
0.02 - 0.78 
0.00 
0.00 - 0.74 
0.46 
0.25 - 0.86 
illicit opiates - - - - - 
benzodiazepines 0.41 0.07 - 2.30 
0.20 
0.04 - 1.04 
0.79 
0.35 - 1.74 
0.95 
0.40 - 2.22 
0.62 
0.36 - 1.07 
Z-drugs - - - - - 
medicinal opiates 0.00 0.00 - 1.56 
0.38 
0.11 - 1.33 
0.00 
0.00 - 0.53 
0.41 
0.12 - 1.43 
0.21 
0.08 - 0.52 
alcohol 0.86 0.24 - 3.02 
0.27 
0.06 - 1.16 
1.59 
0.90 - 2.79 
1.00 
0.44 - 2.29 
0.99 
0.65 - 1.53 
alcohol+drugs 0.41 0.07 - 2.30 
0.00 
0.00 - 0.69 
0.00 
0.00 - 0.53 
0.00 
0.00 - 0.74 
0.05 
0.01 - 0.28 
drugs-drugs combi 0.05 0.00 - 1.66 
0.38 
0.11 - 1.34 
0.00 
0.00 - 0.53 
0.00 
0.00 - 0.74 
0.11 
0.03 - 0.38 
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Table 3.9. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=2039) 
Period 
of the week 
weekday  
04:00-21:59 
weekday  
22:00-03:59 
weekend  
04:00-21:59 
weekend  
22:00-03:59 All periods 
Substance Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
negative 97.45 96.45 - 98.17 
98.77 
89.25 - 99.87 
96.76 
95.10 - 97.87 
91.98 
72.61 - 98.02 
97.20 
96.39 - 97.83 
amphetamines 0.22 0.08 - 0.66 
0.00 
0.00 - 8.62 
0.64 
0.25 - 1.60 
0.62 
0.02 - 16.88 
0.36 
0.17 - 0.72 
cocaine - - - - - 
THC 0.43 0.19 - 0.95 
0.00 
0.00 - 8.62 
0.51 
0.18 - 1.42 
1.85 
0.15 - 18.82 
0.46 
0.25 - 0.86 
illicit opiates - - - - - 
benzodiazepines 0.79 0.44 - 1.43 
0.00 
0.00 - 8.62 
0.32 
0.09 - 1.13 
0.62 
0.02 - 16.88 
0.62 
0.36 - 1.07 
Z-drugs - - - - - 
medicinal opiates 0.07 0.01 - 0.41 
0.00 
0.00 - 8.62 
0.51 
0.18 - 1.42 
0.00 
0.00 - 15.86 
0.21 
0.08 - 0.52 
alcohol 0.83 0.46 - 1.47 
1.23 
0.13 - 10.75 
1.26 
0.64 - 2.44 
3.09 
0.39 - 20.67 
0.99 
0.65 - 1.53 
alcohol+drugs 0.07 0.01 - 0.42 
0.00 
0.00 - 8.62 
0.00 
0.00 - 0.59 
0.00 
0.00 - 15.86 
0.05 
0.01 - 0.28 
drugs-drugs combi 0.14 0.04 - 0.53 
0.00 
0.00 - 8.62 
0.00 
0.00 - 0.59 
1.85 
0.15 - 18.82 
0.11 
0.03 - 0.38 
 
 
Table 3.10. Adjusted general distribution of alcohol by concentration class (N=2039)  
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 0.54 0.30  -  0.97 
Alcohol 0.5 – 0.79 g/L 0.24 0.10  - 0.57 
Alcohol 0.8 – 1.19 g/L 0.15 0.05  -  0.44 
Alcohol 1.2+ 0.06 0.01 - 0.30 
In total 0.99 0.65  - 1.53 
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Table 3.11. Adjusted distribution of alcohol alone by gender and age (N=2039)  
Male 18-24 25-34 35-49 50+ All ages 
BAC Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.08 0.00 - 2.55 - 
0.87 
0.37 - 2.04 
1.14 
0.50 - 2.61 
0.64 
0.35 - 1.17 
0.5 – 0.79 g/L 1.25 0.34 - 4.50 
0.33 
0.07 - 1.49 
0.29 
0.07 - 1.18 - 
0.31 
0.13 - 0.73 
0.8 – 1.19 g/L - - 0.55 0.19 - 1.58 - 
0.19 
0.07 - 0.56 
alcohol 1.2+ - 0.03 0.00 - 0.97 - - 
0.01 
0.00 - 0.26 
In total 1.33 0.38 - 4.62 
0.36 
0.08 - 1.54 
1.70 
0.91 - 3.15 
1.14 
0.50 - 2.61 
1.15 
0.73 - 1.81 
 1.33   0.36   1.70     
Female 18-24 25-34 35-49 50+ All ages 
BAC Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L - - 0.53 0.09 - 3.27 - 
0.19 
0.03 - 1.20 
0.5 – 0.79 g/L - - - - 0.00 0.00 - 0.85 
0.8 – 1.19 g/L - - - - 0.00 0.00 - 0.85 
alcohol 1.2+ - - 0.67 0.13 - 3.49 - 
0.24 
0.05 - 1.29 
In total 0.00 0.00 - 4.32 
0.00 
0.00 - 2.73 
1.21 
0.33 - 4.34 
0.00 
0.00 - 5.68 
0.44 
0.12 - 1.60 
 0.00   0.00   1.21     
Total 18-24 25-34 35-49 50+ All ages 
BAC Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.05 0.00 - 1.66 - 
0.79 
0.36 - 1.75 
1.00 
0.44 - 2.29 
0.54 
0.30 - 0.97 
0.5 – 0.79 g/L 0.81 0.22 - 2.94 
0.25 
0.05 - 1.12 
0.22 
0.05 - 0.92 - 
0.24 
0.10 - 0.57 
0.8 – 1.19 g/L - - 0.43 0.15 - 1.23 - 
0.15 
0.05 - 0.44 
alcohol 1.2+ - 0.02 0.00 - 0.73 
0.15 
0.03 - 0.80 - 
0.06 
0.01 - 0.30 
In total 0.86 0.24 - 3.02 
0.27 
0.06 - 1.16 
1.59 
0.90 - 2.79 
1.00 
0.44 - 2.29 
0.99 
0.65 - 1.53 
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Table 3.12. Adjusted distribution of alcohol alone by day of the week and time of the day (N=2039) 
Period 
of the week 
weekday 
04:00-21:59 
weekday 
22:00-03:59 
weekend 
04:00-21:59 
weekend 
22:00-03:59 All periods 
Alcohol alone Prevalence (%) C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.44 0.20 - 0.96 - 
0.75 
0.32 - 1.75 
1.85 
0.15 - 18.82 
0.54 
0.30 - 0.97 
0.5 – 0.79 g/L 0.23 0.08 - 0.67 
1.23 
0.13 - 10.75 
0.19 
0.04 - 0.93 
0.62 
0.02 - 16.88 
0.24 
0.10 - 0.57 
0.8 – 1.19 g/L 0.07 0.01 - 0.42 - 
0.32 
0.09 - 1.13 - 
0.15 
0.05 - 0.44 
alcohol 1.2+ 0.08 0.02 - 0.44 - - 
0.62 
0.02 - 16.88 
0.06 
0.01 - 0.30 
In total 0.83 0.46 - 1.47 
1.23 
0.13 - 10.75 
1.26 
0.64 - 2.44 
3.09 
0.39 - 20.67 
0.99 
0.65 - 1.53 
 
 
Alcohol was detected in 0.99% of the samples. The prevalence was higher among men (1.15%) than 
women (0.44), and higher at weekend nights than during the weekdays. Combinations of alcohol and 
drugs were found in only 0.05% and multiple drugs were found in 0.11% of the samples. 
 
The prevalence of benzodiazepines was 0.62%. The prevalence was higher among women (1.49%) 
than among men (0.38%), but the difference is not statistically significant. Z-drugs, cocaine and illicit 
opiates were not found.  
 
The most commonly found illegal drugs were THC and amphetamines. The total prevalence of THC 
was 0.46% and it was found only among male drivers. The prevalence was highest among drivers 
below 24 years (2.84%). The prevalence was higher during weekend nights and lower during 
weekdays.  
 
Amphetamines were detected in 0.36% of the samples and it were found only among men. The 
prevalence was highest among age group 25 – 34 years (1.50%). The prevalence were higher during 
weekend nights and lower during weekdays. 
3.5 Discussion 
The research was really useful because it provided important information about prevalence of drugs 
and alcohol among drivers. In Czech Republic there are no previous studies that provide an overview 
of the situation among drivers in general traffic. For that reason, it is not possible to make any 
comparative analysis; moreover, we have to deal with a significant amount of respondents who 
refused to cooperate at the research (23%). This problem has probably several potential reasons and 
some of them were mentioned in paragraph 3. As we cooperated with police we cannot forget that the 
reputation and status of Czech police is very weak. Furthermore, Czech police has serious problems 
to conduct the breath test for checking alcohol presence among drivers as they refuse to cooperate. 
 
If we focus on the results, the presence of at least one psychoactive substance was found in 2.8% of 
the drivers. Alcohol, benzodiazepines, amphetamines and THC, were the substances more often 
detected among participants, whereas cocaine, illicit opiates and Z-drugs were not found at all. The 
results illustrate generally easy access to amphetamines and drugs based on THC in Czech society 
and on the other hand the low popularity of cocaine. All mentioned substances had the highest 
prevalence among young males (age: 18-34), where the presence of at least one substance was 
found among 5.5% of the participants.  
 
The results imply that drivers' drugs abuse is becoming more serious problem than alcohol abuse. 
One of the reasons of drug abuse in general traffic could be the limited ability of traffic police to control 
illegal drugs. The main reason is the price of carrying out controls. The price of alcohol check is max. 7 
CZK whereas the price of saliva test DRUGWIPE5 is about 700 CZK. For that reason the probability of 
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drug control is very low. The police alcohol controls on the roads are carried out frequently, since 2010 
the alcohol test has been regularly performed on all drivers controlled by traffic police.  
 
The drivers in Czech Republic are fully aware of this fact and they therefore drive under the influence 
of drugs much more often than under the influence of alcohol. From the financial point of view the 
saliva drug tests for detection of only one drug (the price 70 CZK) would be preferential, but the Czech 
traffic police is not equipped with this screening device. Urine sample controls would be completely 
different – they would be less costly and the tests on urine are repeated several times – are retake 
capable.  However, the implementation of such controls would require the law to be amended. 
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4 Country report Denmark 
 
Authors: Tove Hels and Inger Marie Bernhoft, Technical University of Denmark, Department of 
Transport.  
Toxicological analyses: Kirsten Wiese Simonsen and Anni Steentoft, University of Copenhagen.   
 
4.1 Description of the roadside driver sample 
 
4.1.1 Introduction  
The roadside survey in Denmark fully complies with the general guidelines mentioned in Annex 1 of 
the Summary Report. A pilot data collection was carried out in August 2007, whereas the main survey 
was carried out in the period 1 March 2008 – 31 May 2009. Police officers were in charge of stopping 
passenger cars and vans where after personnel employed by DTU were in charge of filling in the 
driver information and of taking the samples. Driver participation in the road side survey was voluntary. 
 
In each sample collection session, a team consisting of two DRUID employees cooperated with the 
police team. The police stopped a driver and breath tested him/her for alcohol. 
 
If the driver showed a BAC reading that indicate an illegal alcohol concentration, he was charged with 
drink driving and taken in custody of the police to a medical doctor for a blood sample. The driver was 
asked by the police to volunteer by giving a saliva sample to the DRUID personnel before being taken 
to the medical doctor. If he accepted, the DRUID personnel approached the police car, took a saliva 
sample, informed about the DRUID project, offered the driver a flyer with information on the project 
and filled in the driver information. The breath test reading was delivered by the police to the DRUID 
personnel and recorded in the interview. 
  
If the driver was not illegally affected by alcohol, he was asked by the police to volunteer by giving a 
saliva sample to the DRUID-personnel. If he accepted, he drove on to the DRUID personnel. They 
then took a saliva sample, informed about the DRUID project, offered the driver an information flyer 
and carried out the interview. Sample and interview were provided with the same unique label. The 
breath test reading was delivered by the police and recorded on the interview. 
 
In both situations the DRUID personnel filled out the refuser’s interview if the driver rejected 
participation, including the result of the breath test reading from the police.  
 
All saliva samples were stored in a cool box and after the session they were brought to the nearest of 
the cooperating hospitals where they were stored in a deep freezer in the laboratory. At regular 
intervals (app. each three months), samples from all laboratories were picked op by a courier and 
transported on ice to the DRUID partner University of Copenhagen for toxicological analysis. All 
interviews from participants and those who refused to participate were mailed to DTU immediately 
after the session. 
 
The DRUID personnel were carefully informed of the importance of random sampling. The head of the 
police departments were then informed by the DRUID personnel to sample drivers randomly. 
Moreover, they instructed the police officers at the beginning of each session separately. The police 
officers were asked to stop each driver – or in case of resource problems – to stop every 5th or 10th 
driver. 
 
 
4.1.2 Geographic distribution of drivers over the country  
The intended number of samples from drivers was to be 3000, but in total, 3030 samples were 
collected. Drivers were stopped in three regions of the country, as shown in Figure 4.1. The regions 
were chosen according to the catchment areas of the hospitals that would be willing to take part in the 
DRUID hospital case study (Isalberti et al, 2011) and thus enabling a collection of the ideal control 
population for the DRUID case-control study, see Annex 1.   
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Figure 4.1 Map of Denmark showing the three regions for the road side survey 
 
Samples were taken proportionately to population size in the three regions by September 2007, as 
reported by Statistics Denmark. The distribution of controls by region compared to the fraction of 
population is shown in table 4.1. 
 
Table 4.1. Distribution of drivers by region, N=3030 
DRUID 
regions 
Road side sample fraction Population size Fraction of population  
1 0.4899 516,135 0.495 
2 0.4062 422,923 0.405 
3 0.1039 106,645 0.10 
 
 
4.1.3 Distribution of drivers by road type  
Samples from drivers were taken on rural and urban roads. As a main rule, the definition of rural and 
urban areas was used as the criterion for the road type being a rural road or an urban road. But if the 
traffic clearly differed from the classification of the road, e.g. rural traffic on a highway within an urban 
area, then the type of traffic (rural vs. urban traffic) decided the road type. 
 
The number of collected samples was distributed evenly on urban and rural roads (i.e. 50% of the 
samples at each road type), although, as shown in table 4.2, this differs to a high degree from the 
distribution of traffic by road type. 
 
Table 4.2.  Distribution of drivers by road type, N=3030 
Road type Road side sample fraction Fraction of traffic volume 
Urban (type 1) 0.503 0.20 
Rural (type 2) 0.497 0.80 
 
2 3 
1 
 38 
 
4.1.4 Distribution of drivers by season  
Within each region, the samples were distributed into seasons (spring: March-May – summer: June-
August – autumn: September-November – winter: December -February), according to the number of 
seriously injured drivers in the given season during the period 2004-2006 (slightly more in winter). This 
was decided in order to meet the assumptions of an ideal control sample for a population based case-
control study. However, due to comparison with the other countries in the DRUID road side surveys, 
table 4.3 shows the distribution within the quarters of the year.  
 
Table 4.3. Distribution of drivers by quarter of the year, N=3030 
Quarter of the year Road side sample fraction Fraction of traffic volume 
January-March 0.351 0.237 
April-June 0.238 0.269 
July-September 0.228 0.254 
October-December 0.183 0.241 
 
4.1.5 Distribution of drivers by day of the week and time of the day  
Within each region, the samples were distributed into type of day (weekdays – weekend) and time of 
day (4-10, 10-16, 16-22, 22-04), following the 8 DRUID time periods, according to the number of 
seriously injured drivers in the given type of day/time of day during the period 2004-2006. This was 
decided in order to meet the assumptions of an ideal control sample for a case-control study.  
 
The distribution of the drivers in the survey in the eight DRUID time periods is shown in table 4.4. 
  
Table 4.4. Distribution of drivers by DRUID time period, N=3030 
DRUID time period Road side sample fraction Fraction of traffic volume 
1. Mon – Fri, 04:00 - 09:59 0.165 0.22 
2. Mon – Fri, 10:00 - 15:59 0.227 0.31 
3. Mon – Fri, 16:00 - 21:59 0.169 0.17 
4. Mon – Fri, 22:00 - 03:59 0.067 0.02 
5. Sat & Sun, 04:00 - 09:59 0.062 0.03 
6. Sat & Sun, 10:00 - 15:59 0.082 0.11 
7. Fri – Sun,  16:00 - 21:59 0.144 0.11 
8. Fri – Mon, 22:00 - 03:59 0.082 0.02 
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The differences between the distribution of the road side sample and the traffic volume by time period 
reflects the fact that there is an overrepresentation of seriously injured drivers during evenings and 
nights (DRUID time periods 3,4,7 and 8) compared to the traffic in these time periods. 
 
4.1.6 Distribution of drivers by gender and age  
Following the random way the cars were stopped in the survey, the distribution of drivers by gender 
and age was at random. However, one of the drivers in the sample was below the age of 18. Age was 
unknown for seven drivers and gender was unknown for four of the drivers aged 18 and above. 
 
Table 4.5. Distribution of drivers by age (18-24; 25-34; 35-49 and 50+), N=3022  
Age group Road side sample fraction Fraction of traffic volume 
18-24 0.086 0.057 
25-34 0.166 0.167 
35-49 0.353 0.396 
50+ 0.394 0.380 
 
Table 4.6. Distribution of drivers by gender, N=3026 
Gender Road side sample fraction Fraction of traffic volume 
Men 0.66 0.64 
Women 0.34 0.36 
 
The distribution by age is shown in table 4.5 and by gender in table 4.6 for the drivers in the sample for 
whom this information was known. Table 4.5 shows that young drivers are overrepresented in the road 
side survey sample compared to their share of the traffic, whereas the age group 35-49 is slightly 
underrepresented. The distribution by gender in the road side survey sample (table 4.6) is very similar 
to that of the traffic. 
 
Table 4.7. Distribution of drivers by age and gender in the road side sample (18-24; 25-34; 35-49 and 50+) 
Age group Fraction of men, N=1993 Fraction of women, N=1025 
18-24 0.089 0.081 
25-34 0.166 0.165 
35-49 0.333 0.394 
50+ 0.412 0.360 
 
The percentages of men and women differ slightly for drivers aged 35 and above (table 4.7), with a 
lower fraction of men aged 35-49 than of women and a higher fraction of men aged 50 and above than 
of women. 
 
 
4.2 Roadside data collection and analysis 
4.2.1 Ethical approval  
No ethical approval was needed in Denmark. After having been informed about the project, the Ethical 
Committee answered that “the project is not encompassed by the law on Ethical Committees and 
consideration regarding bio-medical research projects. Therefore, the project should not be 
announced to the ethical Committee”. Hence, no informed consent was requested. 
 
 
4.2.2 Body fluid collection  
Oral fluid was collected by the Saliva-Sampler (Statsure Diagnostic Systems, Framingham, MA, USA) 
device (Annex 2, Part 1).  
 
In this device, a variable amount of absorbed oral fluid (300 – 1500 mg) was diluted with a fixed buffer 
volume (1 mL). On the basis of measurements of 10 devices, we found that the average buffer content 
amounted to 1080 mg (SD = 22 mg). By weighing the device with absorbed oral fluid, the amount of 
oral fluid was determined in the individual case (xor) by subtracting the average device weight.  By 
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using the formula zor = ((xor + 1080 mg)/xor) x 200 mg an amount (zor) of oral fluid-buffer mixture was 
weighed for extraction corresponding to 200 mg of pure oral fluid. Correction was made for the exact 
weighed amount of OF + buffer. Thus, a quantitative determination of compound found in 200 mg oral 
fluid was achieved in each case. The minimum accepted xor amount was 600 mg, so that a duplicate 
determination could be carried out. 
 
 
4.2.3 Toxicological analysis  
To analyze the oral fluid samples for the European DRUID project an ultra performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for 
detection of 29 medicinal and illicit drugs. The drugs detected were: morphine, 6-acetylmorphine, 
codeine, amphetamine, methamphetamine, MDA, MDMA, MDEA, methadone, cocaine, 
benzoylecgonine, zolpidem, tramadol, buprenorphine, diazepam, nordiazepam, nitrazepam, 7-
aminonitrazepam, clonazepam, 7-aminoclonazepam, flunitrazepam, 7-aminoflunitrazepam, 
bromazepam, oxazepam, chlordiazepoxide, alprazolam, lorazepam, zopiclone, and ∆-9-
tetrahydrocannabinol. 
 
Solid phase extraction was performed with a Gilson ASPEC XL4 system equipped with Bond Elut 
Certify SPE sample cartridges. OF samples (200 mg) diluted with 5 ml of ammonium acetate/methanol 
(v/v, 90:10) buffer were applied to the columns and eluted with 3 ml of acetonitrile containing 0.5% 
(v/v) aqueous ammonia. Target drugs were quantified using a Waters ACQUITY UPLC system 
coupled to a Waters Quattro Premier XE triple quadrupole (ESI+, MRM mode). The column used for 
the chromatography was a 100 mm × 2.1 mm, 1.8 µm Acquity UPLC HSS T3 C18, which was 
maintained at a column temperature of 35°C and a constant flow rate of 0.4 mL/min. The mobile 
phase was composed of solvents A (2 mmol/L ammonium acetate, pH 6.2) and B (100% methanol). A 
chromatographic gradient program was run for 15 min. The injection volume was 10 µL. 
 
Extraction recoveries were 36%–114% for all analytes. Lower limits of quantification (LloQ) was 0.5 
µg/kg for all analytes; measuring range: 0.5-100 µg/kg. Total imprecision (CV) of the method was 5.9-
19.4%. 
 
4.2.4 Method of BAC quantification  
BAC was measured in breath by means of hand hold alcolmeters of the police teams. The following 
four types from Lion Laboratories were used: SM-3, S-D2, S-300 and S-500. All alcolmetres of the 
police are calibrated to show a reading of 0.6 g/L ethanol when calibrated by means of breath 
containing 0.35 mg/L.  
 
The calculated blood ethanol (g/L) is thus equal to the reading of the alcolmeter (mg/L) * 2.1 / 
(0.6/0.35) = the reading of the alcolmeter (mg/L) * 1.225.  
  
However, due to missing information of the police, no breath test was carried out in 16 sessions 
comprising 194 samples. An Agilent GC-FID 6890 equipped with a headspacesampler G1888 was 
used for determination of ethanol in these 194 oral fluid samples.   
 
100 µl sample volume (oral fluid + buffer) was sampled 2 times and analyzed on 2 different Restek 
columns, length: 30 m and I.D. 0.25 mm. 2-butanol was used as internal standard for the analysis on 
Restek column-1 and 2-methyl-2-propanol used as internal standard for Restek column-2. The 
chromatographic was done isotermic at 30 0C. Carrier gas was nitrogen 5.0. LoQ was 0.05 mg/g. The 
concentration in saliva was multiplied by 1.22 (Annex 2 of Part 1). 
 
4.2.5 Interviews  
Same information was collected for participants and for non-respondents (refusers): 
Session number, control site, DRUID time period, road type, month, date and time of sampling, age 
and gender of driver, domestic/foreign vehicle, passenger car or van (up to 3.500 kg), result of alcohol 
breath test, saliva sample taken (yes/no).For refusers also the reason for refusal was recorded. 
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4.2.6 Statistical analysis 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS version 9.2. Tables have been created by using the "proc freq statement", including a 
statement on the weight factors to be used. The weighted prevalence of the substance under scrutiny 
was calculated by dividing the weighted number of positives for this substance by the weighted total of 
samples. Because lower and upper confidence limits calculated using traditional approximations may 
result in limits outside the (0.1) interval, a more elaborate approximation was used. To that end, the 
Wilson confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
 
4.3 Non-response 
In total, 3176 drivers were asked to take part in the road side survey in Denmark. Of these, 3030 gave 
saliva samples and 146 persons (4.6%) did not want to take part in the survey. The distribution by 
gender and age for the participants (respondents) and those who refused to take part (non-
respondents) is shown in table 4.8 below. 
 
Table 4.8. Distribution of respondents and non-respondents by gender and age (18-24; 25-34; 35-49 and 
50+) 
Age group Respondents, 
male 
Non-
respondents 
male 
Respondents 
female 
Non-
respondents 
female 
18-24 177 (0.089%) 14 (0.152%) 83 (0.081%) 4 (0.075%) 
25-34 331 (0.166%) 15 (0.163%) 169 (0.165%) 9 (0.170%) 
35-49 663 (0.333%) 32 (0.348%) 404 (0.394%) 27 (0.509%) 
50+ 822 (0.412%) 31 (0.337%) 369 (0.360%) 13 (0.245%) 
 
Men aged 18-24 years and women aged 35-49 were slightly overrepresented among non-respondents 
whereas both men and women aged 50 and above were slightly underrepresented among non-
respondents. However, χ2 - tests showed that the differences are not statistically significant (p=0.16 for 
men and p=0.31 for female). Therefore, the non-respondents are considered not to influence the 
results. 
  
 
4.3.1 Possible confounding effect of non-response 
The size of the non response is so small that even if there is a selective sample of non- respondents, 
the effect would be very small. 
 
 
4.4 Results  
The road sample consisted of 3030 drivers. One driver below the age of 18 was excluded of the 
database. In addition to this, for 27 of the samples there was not enough saliva to carry out the 
toxicological analyses. The following results are therefore based on a study sample of 3002 drivers. 
Table 4.9 shows the number of positive samples by core substance group. The core substance groups 
are shown in Annex 2, and the cut-offs, above which the samples have been included in the 
calculations as positive, are also shown in Annex 2. 
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Table 4.9.  Number of positive drivers by core substance categories, N=3002 
Substance category Number of samples 
Negative 2858 
Alcohol 81 
Amphetamine 1 
Cocaine (incl. BZE) 0 
THC 7 
Illicit opiates 0 
Benzodiazepines 14 
Z-drugs 8 
Medicinal opioids 26 
Alcohol – drugs 5 
Multiple drugs 2 
 
As described in chapter 3 of Part 1, method, the samples in each DRUID time period have been 
adjusted by the traffic in the time period in question (see table 4.4). Table 4.10 and 4.11 show the 
adjusted general prevalence of driving under the influence of the core substance groups, calculated by 
the method described in chapter 3. 
 
Table 4.10. Adjusted general distribution of core substance categories, N=3002 
Substance category Prevalence (%) Confidence interval (%) 
Negative 95.52  94.72 – 96.20 
Alcohol 2.53 2.02 – 3.15 
Amphetamine 0.02 0.00 – 0.16 
Cocaine (incl. BZE) - - 
THC 0.20 0.09 – 0.43 
Illicit opiates - - 
Benzodiazepines 0.47 0.28 – 0.79 
Z-drugs 0.32 0.17 – 0.59 
Medicinal opioids 0.79 0.53 – 1.18 
Alcohol – drugs 0.10 0.03 – 0.30 
Multiple drugs 0.06 0.02 – 0.24 
 
Table 4.11. Adjusted general distribution of alcohol by concentration class, N=3002 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 2.05 1.60 – 2.62 
Alcohol 0.5 – 0.79 g/L 0.28 0.14 – 0.54 
Alcohol 0.8 – 1.19 g/L 0.18 0.08 – 0.41 
Alcohol 1.2+ 0.02 0.00 – 0.16 
 
The overall prevalence of alcohol is 2.53% (CI 2.02 – 3.15). But most of the driving with alcohol takes 
place with a concentration below the legal limit in Denmark of 0.5 g/L. Only a very small share of the 
alcohol impaired driving is with concentrations above 1.2 g/L 0.02% (CI 0 – 0.16). 
 
The prevalence of driving with an alcohol concentration over the limit amounts to 0.48%. Driving with 
illicit drugs is 0.02% (CI 0.00 – 0.16) for amphetamines and 0.20% (CI 0.09 – 0.43) for THC. No 
samples were found over the cut-off for cocaine and illicit opiates alone. However, it seems that driving 
with medicinal drugs is more common, that is 0.47% (CI 0.28 – 0.79) with benzodiazepines, 0.32% (CI 
0.17 – 0.59) with z-drugs and 0.79% (CI 0.53 – 1.18) with medicinal opioids, in total 1.49%.  
 
Combinations of alcohol and/or drugs are rare in this study. The prevalence of 0.10% for combined 
alcohol and drugs comprise five samples, one positive for cocaine, one for THC, two for 
benzodiazepines and one for medicinal opioids in combination with alcohol.  
 
The multiple drug combinations were one sample positive for amphetamines and THC, and one 
positive for cocaine and THC.  
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It should be mentioned, however, that the decision on the cut-offs do not indicate that a positive 
concentration of illicit or medicinal drugs does impair driving, it merely reflects driving with a substance 
concentration at or above the analytical cut-off as decided by the toxicological partners of DRUID.  
 
Table 4.12 and 4.13 show the prevalence of driving under the influence of the core substance groups 
by age. The total number (N) includes drivers for whom age was known (N=2993).  
 
Table 4.12. Adjusted distribution of core substance categories by age, N=2993 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 96.69 
93.41 – 98.36 
96.59 
94.57 – 97.87 
96.05 
94.71 – 97.06 
94.37 
92.93 – 95.53 
95.52 
94.72 – 96.20 
Alcohol 1.48 
0.53 – 4.10 
1.40 
0.67 – 2.89 
2.34 
1.59 – 3.43 
3.35 
2.47 – 4.52 
2.53 
2.02 – 3.15 
Amphetamine 0.00 
0.00 – 1.71 
0.10 
0.01 – 0.98 
0.00 
0.00 – 0.36 
0.00 
0.00 – 0.32 
0.02 
0.00 – 0.16 
Cocaine – – – – – 
THC 0.75 
0.18 – 3.00 
0.61 
0.21 – 1.79 
0.13 
0.03 – 0.58 
0.00 
0.00 – 0.32 
0.20 
0.09 – 0.43 
Illicit opiates – – – – – 
Benzodiazepines 0.46 
0.08 – 2.53 
0.06 
0.00 – 0.91 
0.53 
0.24 – 1.17 
0.59 
0.29 – 1.20 
0.47 
0.28 – 0.79 
Z-drugs 0.00 
0.00 – 1.71 
0.00 
0.00 – 0.78 
0.22 
0.07 – 0.73 
0.59 
0.29 – 1.21 
0.32 
0.17 – 0.59 
Medicinal 
opioids 
0.00 
0.00 – 1.71 
0.90 
0.36 – 2.20 
0.56 
0.26 – 1.21 
1.10 
0.65 – 1.86 
0.79 
0.53 – 1.18 
Alcohol – drugs 0.00 
0.00 – 1.71 
0.34 
0.08 – 1.37 
0.13 
0.03 – 0.59 
0.00 
0.00 – 0.32 
0.10 
0.03 – 0.30 
Multiple drugs 0.62 
0.14 – 2.80 
0.00 
0.00 – 0.78 
0.05 
0.00 – 0.44 
0.00 
0.00 – 0.32 
0.06 
0.02 – 0.24 
  
Table 4.13. Adjusted distribution of alcohol alone by age (N=2993)  
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.26 
0.41 – 3.77 
1.19 
0.54 – 2.61 
1.84 
1.19 – 2.83 
2.74 
1.96 – 3.82 
2.05 
1.60 – 2.62 
 0.5 – 0.79 g/L – – 0.21 0.06 – 0.71 
0.50 
0.23 – 1.08 
0.28 
0.14 – 0.54 
 0.8 – 1.19 g/L – 0.21 0.04 – 1.16 
0.29 
0.10 – 0.84 
0.11 
0.02 – 0.51 
0.18 
0.08 – 0.41 
1.2+ 0.23 
0.02 – 2.13 – – – 
0.02 
0.00 – 0.16 
  
Alcohol is most prevalent among the age groups 34-50 and above 50 years. However, the highest 
concentrations at and above 1.2 g/L are only found for the young drivers aged 18-24, and for this age 
group, the prevalence is 0 for the concentrations between the legal limit (0.5 g/L) and 1.2 g/L.  
 
For medicinal drugs, generally the prevalence is higher for drivers above 34 years, except for 
benzodiazepines that has got a high prevalence for the age group 18-24.  
 
For THC, the prevalence increases by decreasing age. The same picture is found for multiple drug 
use.  
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Table 4.14 and 4.15 show the prevalence of driving under the influence of the core substance groups 
by age and gender. The total number of men for whom the age is known is 1975, and for women 
1014.  
  
Table 4.14. Adjusted distribution of core substance categories by gender and age  
Men (N=1975) 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 95.92 
91.37 – 98.12 
96.06 
93.27 – 97.72 
95.55 
93.71 – 96.87 
93.15 
91.25 – 94.66 
94.63 
93.55 – 95.54 
Alcohol 1.31 
0.35 – 4.76 
2.19 
1.06 – 4.50 
3.25 
2.15 – 4.89 
4.50 
3.30 – 6.11 
3.47 
2.75 – 4.37 
Amphetamine 0.00 
0.00 – 2.56 
0.16 
0.02 – 1.52 
0.00 
0.00 – 0.57 
0.00 
0.00 – 0.45 
0.03 
0.00 – 0.24 
Cocaine – – – – – 
THC 1.13 
0.28 – 4.50 
0.96 
0.32 – 2.79 
0.20 
0.04 – 0.93 
0.00 
0.00 – 0.45 
0.30 
0.14 – 0.66 
Illicit opiates – – – – – 
Benzodiazepines 0.69 
0.12 – 3.79 
0.10 
0.01 – 1.41 
0.62 
0.25 – 1.57 
0.75 
0.35 – 1.59 
0.60 
0.34 – 1.05 
Z-drugs 0.00 
0.00 – 2.56 
0.00 
0.00 – 1.22 
0.15 
0.03 – 0.85 
0.60 
0.26 – 1.38 
0.31 
0.14 – 0.67 
Medicinal 
opioids 
0.00 
0.00 – 2.56 
0.00 
0.00 – 1.22 
0.05 
0.00 – 0.66 
1.00 
0.52 – 1.93 
0.45 
0.23 – 0.85 
Alcohol – drugs 0.00 
0.00 – 2.56 
0.53 
0.13 – 2.14 
0.10 
0.01 – 0.76 
0.00 
0.00 – 0.45 
0.12 
0.03 – 0.39 
Multiple drugs 0.94 
0.21 – 4.19 
0.00 
0.00 – 1.22 
0.07 
0.01 – 0.71 
0.00 
0.00 – 0.45 
0.09 
0.02 – 0.36 
Women (N=1014) 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 98.14 
91.90 – 99.59 
97.50 
93.98 – 98.99 
96.87 
94.68 – 98.17 
97.22 
94.98 – 98.48 
97.21 
96.01 – 98.06 
Alcohol 1.86 
0.41 – 8.10 
0.00 
0.00 – 2.15 
0.84 
0.30 – 2.30 
0.66 
0.20 – 2.15 
0.70 
0.34 – 1.43 
Amphetamine 0.00 
0.00 – 4.97 
0.00 
0.00 – 2.15 
0.00 
0.00 – 0.94 
0.00 
0.00 – 1.05 
0.00 
0.00 – 0.38 
Cocaine – – – – – 
THC 0.00 
0.00 – 4.97 
0.00 
0.00 – 2.15 
0.00 
0.00 – 0.94 
0.00 
0.00 – 1.05 
0.00 
0.00 – 0.38 
Illicit opiates – – – – – 
Benzodiazepines 0.00 
0.00 – 4.97 
0.00 
0.00 – 2.15 
0.37 
0.09 – 1.59 
0.21 
0.03 – 1.43 
0.22 
0.06 – 0.75 
Z-drugs 0.00 
0.00 – 4.97 
0.00 
0.00 – 2.15 
0.33 
0.07 – 1.53 
0.58 
0.16 – 2.03 
0.34 
0.12 – 0.92 
Medicinal 
opioids 
0.00 
0.00 – 4.97 
2.50 
1.01 – 6.02 
1.41 
0.63 – 3.10 
1.34 
0.56 – 3.13 
1.46 
0.89 – 2.40 
Alcohol – drugs 0.00 
0.00 – 4.97 
0.00 
0.00 – 2.15 
0.19 
0.03 – 1.28 
0.00 
0.00 – 1.05 
0.07 
0.01 – 0.51 
Multiple drugs 0.00 
0.00 – 4.97 
0.00 
0.00 – 2.15 
0.00 
0.00 – 0.94 
0.00 
0.00 – 1.05 
0.00 
0.00 – 0.38 
 
Generally, the prevalence is higher for men that for women, except for medicinal opioids, where 
women aged 25-34 show the highest prevalence of 2.50% (CI 1.01 – 6.02). 
 
The prevalence of alcohol shows the same picture for men as for the total population, whereas for 
women, only drivers in the age group of 35-49 drive with alcohol over the legal limit, see table 4.15. 
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Table 4.15. Adjusted distribution of alcohol alone by gender and age  
Men (N=1975) 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.96 
0.21 – 4.23 
1.87 
0.85 – 4.06 
2.60 
1.64 – 4.10 
3.63 
2.56 – 5.11 
2.80 
2.16 – 3.62 
 0.5 – 0.79 g/L – – 0.34 0.10 – 1.14 
0.71 
0.33 – 1.54 
0.42 
0.22 – 0.82 
 0.8 – 1.19 g/L – 0.33 0.06 – 1.81 
0.32 
0.09 – 1.11 
0.16 
0.03 – 0.73 
0.23 
0.09 – 0.55 
1.2+ 0.34 
0.04 – 3.19 – – – 
0.03 
0.00 – 0.24 
Women (N=1014) 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.86 
0.41 – 8.10 – 
0.58 
0.18 – 1.92 
0.66 
0.20 – 2.15 
0.60 
0.28 – 1.29 
 0.5 – 0.79 g/L – – – – 0.00 0.00 –0.38 
 0.8 – 1.19 g/L – – 0.25 0.04 – 1.40 – 
0.10 
0.02 – 0.56 
1.2+ – – – – 0.00 0.00 – 0.38 
 
Table 4.16 and 4.17 show the prevalence of driving under the influence of the core substance groups 
by time of the day and week.  
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Table 4.16. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=3002) 
4 categories: weekdays, weekday nights, week-end days, week-end nights 
Period 
of the week 
Weekdays 
04:00 – 
21:59 
Weekday 
nights 
22:00 – 
03:59 
Weekend 
days 
04:00 – 
21:59 
Weekend 
nights 
22:00 – 
03:59 
In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 95.96 
95.03 – 96.72 
96.55 
89.46 – 98.93 
94.51 
92.65 – 95.92 
92.24 
83.94 – 96.44 
95.52 
94.72 – 96.20 
Alcohol 2.25 
1.69 – 2.97 
2.46 
0.63 – 9.10 
3.31 
2.25 – 4.84 
2.45 
0.64 – 8.89 
2.53 
2.02 – 3.15 
Amphetamine 0.00 
0.00 – 0.18 
0.00 
0.00 – 5.06 
0.07 
0.01 – 0.63 
0.00 
0.00 – 4.87 
0.02 
0.00 – 0.16 
Cocaine – – – – – 
THC 0.24 
0.10 – 0.56 
0.00 
0.00 – 5.06 
0.00 
0.00 – 0.51 
1.22 
0.20 – 6.99 
0.20 
0.09 – 0.43 
Illicit opiates – – – – – 
Benzodiazepin
es 
0.48 
0.26 – 0.88 
0.00 
0.00 – 5.06 
0.49 
0.19 – 1.30 
0.41 
0.03 – 5.62 
0.47 
0.28 – 0.79 
Z-drugs 0.29 
0.13 – 0.63 
0.00 
0.0 – 5.06 
0.46 
0.17 – 1.26 
0.00 
0.00 – 4.87 
0.32 
0.17 – 0.59 
Medicinal 
opioids 
0.72 
0.44 – 1.18 
0.49 
00.4 – 5.96 
0.18 
0.37 – 1.74 
2.86 
0.82 – 9.49 
0.79 
0.53 – 1.18 
Alcohol – drugs 0.06 
0.01 – 0.30 
0.49 
0.04 – 5.96 
0.10 
0.01 – 0.69 
0.82 
0.10 – 6.32 
0.10 
0.03 – 0.30 
Multiple drugs 0.00 
0.00 – 0.18 
0.00 
0.00 – 5.06 
0.25 
0.07 – 0.93 
0.00 
0.00 – 4.87 
0.06 
0.02 – 0.24 
 
 
Table 4.17. Adjusted distribution of alcohol alone by day of the week and time of the day (N=3002) 
4 categories: weekdays, weekday nights, week-end days, week-end nights 
Period 
of the week 
Weekdays 
04:00 – 
21:59 
Weekday 
nights 
22:00 – 
03:59 
Weekend 
days 
04:00 – 
21:59 
Weekend 
nights 
22:00 – 
03:59 
In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.94 
1.43 – 2.63 
1.97 
0.44 – 8.36 
2.36 
1.49 – 3.70 
2.04 
0.48 – 8.27 
2.05 
1.60 – 2.62 
 0.5 – 0.79 g/L 0.14 
0.05 – 0.42 
0.49 
0.04 – 5.96 
0.61 
0.25 – 1.47 
0.41 
0.03 – 5.62 
0.28 
0.14 – 0.54 
 0.8 – 1.19 g/L 0.16 
0.06 – 0.45 – 
0.28 
0.08 – 0.98 – 
0.18 
0.08 – 0.41 
1.2+ – – 0.07 0.01 – 0.63 – 
0.02 
0.00 – 0.16 
 
The highest prevalence of alcohol is found on weekend days. This part of the week is the only period 
where alcohol concentrations at and above 1.2 g/L are found.  
 
It is interesting that neither in weekday nights or weekend nights, alcohol concentrations above 0.79 
g/L were found. 
 
Overall, the period weekend nights is the most prevalent period of the week, especially the prevalence 
of THC, medicinal opioids and alcohol combined with drugs are high in this time of the day and week. 
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4.5 Discussion 
 
4.5.1 Representativeness 
The road side samples have been collected in three regions of Denmark in numbers according to the 
population in the various regions and evenly distributed on urban and rural roads. But as only 20% of 
the traffic volume in Denmark is driven on urban roads, this means that drivers in urban traffic are 
overrepresented in the survey.  
 
The samples were collected by season of the year and time of the day and week according to the 
distribution of seriously injured drivers. This means that there are deviations from the distribution of the 
traffic volume both for season and time period. However, the deviations in the time periods have been 
adjusted for by weighting the samples by the traffic fraction in the eight time periods in the calculation 
of prevalence. 
 
In each planned session, the drivers in the survey were included randomly. The age distribution turned 
out to match the distribution of the traffic volume, whereas drivers aged 18-24 were underrepresented 
and drivers aged 35-49 slightly overrepresented. This is not adjusted for in the prevalence 
calculations. 
4.5.2 Effects of non-response 
The non-response rate in the survey was 4.6%, with an overrepresentation of men aged 18-24 and 
women aged 35-49 and an underrepresentation of both men and women aged 50 and above.  
 
However, the size of the non-response is considered not to have any effect on the result.  
 
4.5.3 Highlights 
Alcohol is still the main problematic substance in drivers in the traffic in Denmark. Overall, the 
prevalence of alcohol is 2.53%, the prevalence of illicit drugs is 0.22%, the prevalence of medicinal 
drugs is 1.58% and the prevalence of combined use is 0.16%.  
 
However, if only alcohol concentrations at and above the limit are considered, then the prevalence of 
illegal alcohol is 0.48%, with 0.68% for men and 0.10% for women. The nationwide road side survey 
that was carried out in Denmark 1985-1987 and comprised about 60.000 drivers from traffic outside 
urban areas, showed an overall prevalence of  alcohol concentrations at and above 0.5 g/L of 1.45% 
for men and 0.24% for women. This indicates that the prevalence has decreased to less than half the 
prevalence in the mid-eighties (Behrensdorff et al. 1989). 
 
Regarding the prevalence of illicit and medicinal drugs, a road side survey that was carried out in one 
police district in Denmark in year 2000 and comprised about 1000 drivers showed that about 1.3% of 
the drivers were positive for one of the following illicit drugs: Amphetamines, THC, cocaine or illicit 
opiates, whereas about 0.7% were positive for benzodiazepines (Behrensdorff, 2002). The former 
road side survey was also based on saliva samples, but the substances analysed for and cut-offs 
differed from the present study, especially for the illicit drugs where they were substantially lower in the 
former study whereas the cut-offs of benzodiazepines are comparable. Compared to the results of the 
present road side survey of DRUID in Denmark, it seems that the problem of medicinal drugs has 
increased. Due to the low cut-offs of the illicit drugs analysed for in the former study, it is not possible 
to compare the prevalence of illicit drugs. 
 
Nevertheless, the information on drug use in the general population (Ravera and de Gier, 2008) 
indicates that cocaine use is increasing in Denmark and the use of sedatives and hypnotics has been 
fairly stable over the years in Denmark.    
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4.5.4 Conclusion 
Highlights of the results for alcohol are: 
 Only one fifth of the alcohol positive driving population had alcohol concentrations at or above the 
legal limit of 0.5 g/L in Denmark, that is about 0.5% of the driving population 
 For women, only the age group 35-49 drove with alcohol over the limit. As for men, only the young 
drivers aged 18-24 drove with an alcohol concentration at 1.2 g/l and above.  
 The most prevalent time of the day and week for drink driving was weekend-days between 04:00 
and 21:59. 
 
Highlights of the results for illicit drugs are: 
 Illicit drugs alone were only found in male drivers. 
 Of the illicit drugs analysed for in this study, only amphetamines and THC were found alone 
among the driving population. No cocaine or illicit opiates were found alone.  
 However, cocaine was found in combination with THC and with alcohol. 
 Amphetamines alone were only found in the age group 25-34, whereas THC was found among 
drivers aged 18-24 and 25-34 with a similar prevalence in the two age groups (app 1%) whereas 
the prevalence in the age group 35-49 was much lower. 
 Amphetamines were only found on weekend-days between 04:00 and 21:59 whereas THC was 
found on week-days between 04:00 and 21:59 and weekend-nights between 22:00 and 03:59.  
 
Highlights of the results for medicinal drugs are: 
 Benzodiazepines were more prevalent among men, whereas medicinal opioids were more 
prevalent among women.  
 Benzodiazepines and z-drugs were only found in drivers aged 35 and above 
 Whereas medicinal opioids were only prevalent in male drivers aged 50 and above, this drug was 
found in all female age groups at 25 and above, with the highest prevalence among the age group 
25-34. 
 All three types of medicinal drugs were found in all days of the week. Benzodiazepines were also 
found in weekend-nights and medicinal opioids in all nights of the week, with the highest 
prevalence in weekend-nights.  
 
 
4.6 Acknowledgements 
DTU is very thankful for the cooperation of the traffic police in the three police districts Nordjylland, 
Sydøstjylland and Midt- and Vestsjælland, who contributed in all 192 sessions with stopping the 
drivers.  
 
The personnel that were employed by DTU to carry out the saliva tests and interviews cooperated in a 
splendid way with on the one  hand the demands of DTU for being out in all types of weather and 
during day and night and on the other hand with the police in ensuring the anonymity of the 
participating drivers. 
 
Furthermore, the correct storing of the samples was very much facilitated, thanks to the participating 
hospital laboratories, where the saliva samples could be delivered at any time of the day and night. 
    
Finally, we are grateful that Foreningen Østifterne co-funded the study with regard to the expenses for 
saliva samplers, travel to the control sites and courier service.  
 
 
4.7 References 
Badawi N, Simonsen KW, Steentoft A, Bernhoft IM, Linnet K (2009): Simultaneous Screening and 
Quantification of 29 Drugs of Abuse in Oral Fluid by Solid-Phase Extraction and Ultraperformance LC-
MS/MS. Clin. Chem., 2009; 55: 2004 - 2018. 
 
Behrensdorff I (2001): Medicin og narkotika blandt bilister (with a summary in English). Rapport 
3/2001, Danmarks TransportForskning, Kgs. Lyngby, 67p. 
 
 49 
Behrensdorff I, Bernhoft IM, Christensen J: (1989). Spritkørsel i Danmark. Hvem, hvor meget og 
hvornår (with a summary in English). Rapport 28, Rådet for Trafiksikkerhedsforskning, København, 
111p.   
 
Isalberti et al. (2011). Prevalence of alcohol and other psychoactive substances in injured and killed 
drivers. DRUID Deliverable 2.2.5, 349 p, www.druid-project.eu. 
 
Ravera S, de Gier JJ (2008): Prevalence of psychoactive substances in the general population. 
DRUID deliverable 2.1.1, 67p, www.druid-project.eu.  
 50 
Annex 4.1  Description of method for toxicological analyses of illicit 
compounds in oral fluid 
 
Toxicological analyses of body fluids were performed by the DRUID partner UKHB: Section of 
Forensic Chemistry, Department of Forensic Medicine, Faculty of Health Sciences, University of 
Copenhagen. 
 
Introduction 
An ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for 
detection of 29 drugs and illicit compounds in oral fluid (OF) was developed and validated. The drugs 
detected were the 21 core DRUID substances (see Annex 2 of part 1) and eight extra substances 
chosen for Denmark: tramadol, buprenorphine, nitrazepam, 7-aminonitrazepam, 7-aminoclonazepam, 
7-aminoflunitrazepam, bromazepam and chlordiazepoxide. 
 
Extraction procedure 
A Gilson SPE robot (ASPEC XL4) (Gilson Inc., Columbus, Ohio, USA) equipped with Bond Elut Certify 
SPE (130 mg, 3 mL; Varian, Inc., Palo Alto, Ca, USA) columns was used for SPE. The columns were 
conditioned with 2 mL of methanol and 2 mL of purified water. OF samples (200 mg) spiked with 20 µL 
of internal standard solution were diluted with 5 mL of ammonium acetate (0.1 mol/L, pH 4.1)/methanol 
(v/v, 90:10) buffer and introduced into the SPE columns at a constant flow rate of 1 mL/min. The 
columns were washed with 2 mL of purified water followed by 2 mL of purified water/methanol (v/v, 
95:5). The analytes were eluted with 3 mL of freshly prepared acetonitrile with 0.5% aqueous 
ammonium. The elution was carried out in two steps by eluting twice with 1.5 ml into one collection 
tube without intermediate drying of the columns. Eluates were evaporated at room temperature under 
a stream of nitrogen and redissolved in 200 µL of mobile phase (2 mmol/L ammonium acetate buffer, 
pH 6.2/methanol [v/v, 20:80]). 
 
Internal standards 
Deuterated internal standards were used for most of the compounds. Two major internal standard (IS) 
stock solutions (A and B) 1 mg/L were prepared monthly in methanol. A contained the following 
deuterated internal standards: OXZ, AMF, COD, COC, BZL, 6-AM, MDN, MAMF, DZM, MDA, ZOL, 
MDMA, TRM, MDEA and B: 7-AMF, 7-AMN, APZ,  CLZ, 7-AMC, FLZ, BUP, NDZM, NTZ. For practical 
reasons, the deuterated internal standards of MOF (1 mg/mL), THC (10 mg/L) and ZOP (1 mg/L) were 
stored separately. Dilutions were freshly made in methanol to yield final concentrations of either 10 
µg/L or 2.0 µg/L when spiked (20 µL) to 200 mg of OF, except ZOP, which was diluted with 
acetonitrile. 
 
Chromatographic conditions 
The chromatography was performed using an ACQUITY UPLC system (Waters Corporation, Milford, 
MA, USA). The column used was a 100 mm × 2.1 mm, 1.8 µm Acquity UPLC HSS T3 C18, which was 
maintained at a column temperature of 35°C and a constant flow rate of 0.4 mL/min. The mobile 
phase was composed of solvents A (2 mmol/L ammonium acetate, pH 6.2) and B (100% methanol). 
The gradient program is shown in Table A4.1. The injection volume was 10 µL. 
Table A4.1. UPLC gradient program (20 min total run time). 
 
Time (min) %A %B 
0.0 98 2 
4.0 75 25 
5.8 62 38 
7.3 55 45 
8.6 45 55 
9.6 35 65 
11.0 32 68 
11.1 15 85 
16.1 15 85 
16.2 98 2 
 
MS Spec conditions 
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Mass spectrometry was performed using a Quattro Premier XE triple quadrupole (Waters). Positive 
electrospray ionization mode (ESI+) was used for all mass spectrometric analyses. The ionization 
parameters were: a capillary voltage of 1 kV and source and desolvation temperatures of 120 and 
400°C, respectively. Cone and desolvation gas (N2) flows were set at 1,100 and 100 L/h, respectively. 
Argon was used as the collision gas at a pressure of 4.21 × 10−3 mBar, corresponding to a flow of 0.18 
mL/min. Retentiontime, collision energy etc. is shown in Table A4.2. 
 
Table A4.2. Abbreviations, retention time, MRM transitions, and operating parameters for the analyzed 
drugs (MRM transitions are listed for each analyte with quantifier transition on top and qualifier transition 
below)  
Compound Abbreviation 
Retention 
time 
(min) 
MRM transitions 
(m/z) 
Con
e 
volt
age 
(V) 
Collision 
energy 
(eV) 
IS 
Det. window 1       
Morphine MOF 4.63 286.16>201.09 286.16>165 43 
24 
38 morphine-d6 
Amphetamine AMF 5.92 135.9>118.81 135.9>90.70 16 
9 
16 Amphetamine-d5 
MDA MDA 5.95 180.2>104.8 180.2>162.93 15 
21 
11 MDA-d5 
Benzoylecgonine BZL 5.92 290.1>167.95 290.1>104.75 30 
20 
29 benzoylecgonine-d8 
 Det. window 2       
MDMA MDMA 6.65 194.07>162.91 194.07>104.76 22 
13 
23 MDMA-d5 
Methamphetamine MAMF 6.74 149.97>90.74 149.97>118.84 20 
18 
10 methamphetamine-d5 
MDEA MDEA 6.88 208.11>162.93 208.11>104.78 22 
13 
24 MDEA-d5 
6-Acetylmorphine 6-AM 6.53 328.09>164.93 328.09>211.03 43 
38 
25 6-Acetylmorphine-d6 
Codeine COD 6.50 300.13>164.95 300.13>215.1 46 
40 
25 codeine-d6 
7-amino-
nitrazepam 7-AMN 6.59 
252.11>120.85 
252.11>93.74 40 
26 
40 7-aminonitrazepam-d5 
7-amino-
clonazepam 7-AMC 6.66 
286.04>120.8 
286.04>222.04 40 
30 
25 7-aminoclonazepam-d4 
Det. window 3       
7-amino-
flunitrazepam 7-AMF 7.36 
284.08>134.92 
284.08>227.11 45 
27 
22 
7-aminoflunitrazepam-
d3 
Tramadol TRM 7.66 264.19>57.78 264.19>246.15 20 
16 
11 tramadol-d3 
Det. window 4       
Cocaine COC 8.51 304.11>182 304.11>81.75 32 
20 
34 cocaine-d3 
Bromazepam BRZ 9.44 315.90>181.94 315.90>209 37 
32 
26 diazepam-d5 
Zopiclone ZOP 9.38 388.90>244.96 388.90>216.96 18 
18 
36 zopiclone-d8 
Det. window 5       
Clonazepam CLZ 9.78 316.04>270.02 316.04>214 45 
24 
35 clonazepam-d4 
Flunitrazepam FLZ 9.89 314.06>268.13 314.06>239.15 40 
25 
32 Flunitrazepam-d3 
Nitrazepam NTZ 9.75 282.12>236.1 282.12>180.02 45 
25 
35 nitrazepam-d5 
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Det. window 6       
Alprazolam APZ 10.33 309.06>205.02 309.06>281.03 47 
41 
25 alprazolam-d5 
Oxazepam OXZ 10.28 286.99>240.98 286.99>268.98 32 
22 
15 oxazepam-d5 
Chlordiazepoxide CLDZ 10.79 300.03>227.03 300.03>283.06 25 
25 
13 diazepam-d5 
Lorazepam LRZ 10.28 321>275.03 321>303 30 
20 
15 diazepam-d5 
Zolpidem ZOL 10.45 308.13>235.12 308.13>91.74 45 
35 
49 zolpidem-d6 
Det. window 7       
Nordiazepam NDZM 10.95 271.05>139.87 271.05>164.89 45 
30 
29 nordiazepam-d5 
Diazepam DZM 11.27 285.1>153.9 285.1>193.05 43 
26 
31 diazepam-d5 
Methadone MDN 11.39 310.21>265.15 310.21>104.81 25 
15 
27 methadone-d3 
Det. window 8       
THC THC 14.44 315.12>193.05 315.12>259.15 35 
20 
23 THC-d3 
Buprenorphine BUP 14.54 468.1>54.85 468.1>100.8 55 
50 
48 buprenorphine-d4 
 
Calibrators 
Calibrators were made by spiking 200 mg of OF mixed with 200 µL Statsure buffer solution with 
standard solutions containing all 29 compounds, yielding a final calibration range of: 0.5, 1.0, 10.0, 
and 100 µg/kg. (Badawi et al. 2009). 
 
Quality control samples 
Quality control samples (QCs) containing all compounds were prepared in pooled OF and stored at 
−80°C. The pooled OF was spiked with methanol or acetonitrile stock solutions of the compounds 
independently of the preparation of calibrator solutions. 
 
Procedure for dilution of samples with high concentration 
The highest standard (100 µg/kg) defined the upper limit of quantification for all of the analytes (UloQ). 
All of the samples with concentrations higher than the UloQ were diluted with purified water (1+9). 
 
Validation parameters 
Results of the validation parameters is shown in table 3. A weighted (1/x) linear regression fit was 
achieved for all compounds in the range 0.5 to 100 µg/kg (Table A4.3). The highest standard (100 
µg/kg) defined the upper limit of quantification for all of the analytes (UloQ). 
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Table A4.3. Validation results for oral fluid mixed with Statsure buffer  
 
 
Analyte 
Correlati
on 
Coefficie
nt 
R2 
LloQ 
(µg /kg) 
Theoretical 
concentrati
on 
(µg/kg) 
Measured 
concentrati
on 
(n = 8) 
(µg /kg) 
Truene
ss 
Bias 
(%) 
 
Preci
sion 
CV 
(%) 
Extraction 
Recovery 
(%) 
(SD) (n=6) 
ME 
(%) 
THC 0.9960 0.5 
0.5 
1 
10 
100 
0.6 
1.0 
9.5 
95.0 
11.7 
-1.8 
-5.0 
-5.3 
12.2 
4.5 
6.2 
4.5 
33 
(19) 2.1 
Buprenorphine 0.9940 0.5 
0.5 
1 
10 
100 
0.5 
0.9 
9.7 
104.8 
-7.7 
-8.3 
-3.3 
4.8 
7.2 
2.5 
3.7 
3.7 
91 
(13) -9.2 
7-AMN 0.9953 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.3 
100 
-3.5 
0.1 
2.8 
0.6 
6.8 
5.2 
5.9 
3.0 
84 
(7.1) 19 
7-AMC 0.9944 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
9.1 
103 
4.5 
-5 
-8.9 
2.8 
10.9 
11.9 
5.9 
2.4 
88 
(10) 36 
7-AMF 
 0.9916 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
9.6 
99 
4.5 
-4.9 
-4.1 
-0.7 
5.0 
8.9 
6.7 
4.1 
87 
(13) 
36.
1 
 
Bromazepam 
 
0.9920 0.5 
0.5 
1 
10 
100 
0.5 
0.9 
9.3 
96 
3.0 
-5.1 
-6.8 
-3.9 
10.5 
3.4 
2.7 
6.6 
92 
(23) 6.1 
Zopiclone 0.9985 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
10.1 
107 
-7.2 
10.3 
1.3 
7.3 
15.0 
7.2 
7.0 
2.3 
106 
(7.5) 8.0 
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Analyte 
Correlati
on 
Coefficie
nt 
R2 
LloQ 
(µg /kg) 
Theoretical 
concentrati
on 
(µg/kg) 
Measured 
concentrati
on 
(n = 8) 
(µg /kg) 
Truene
ss 
Bias 
(%) 
 
Preci
sion 
CV 
(%) 
Extraction 
Recovery 
(%) 
(SD) (n=6) 
ME 
(%) 
Nitrazepam 0.9986 0.5 
0.5 
1 
10 
100 
0.5 
0.9 
98 
103 
6.5 
-6.0 
-2.4 
2.5 
5.4 
12.5 
6.5 
6.1 
88 
(21) -0.3 
Oxazepam 0.9912 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.6 
102 
-5.2 
0.6 
5.6 
1.5 
9.9 
3.1 
1.8 
2.7 
87 
(29) -3.5 
Clonazepam 0.9894 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
11.0 
102 
-1.5 
6.1 
7.1 
2.4 
9.5 
8.7 
6.0 
3.4 
99 
(25) 
16.
8 
Lorazepam  0.9874 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
11.2 
91.4 
-2.3 
2.5 
12.2 
-8.6 
10.4 
5.8 
5.1 
1.4 
85 
(20) -2.1 
Chlordiazepoxid
e  0.9953 0.5 
0.5 
1 
10 
100 
0.5 
0.9 
8.8 
102 
-0.2 
-6.2 
-12.3 
2.3 
8.1 
6.8 
7.7 
3.1 
91 
(4.5) 
-
22.
7 
Alprazolam 0.9991 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.0 
98 
-1.0 
-0.7 
0.3 
-1.9 
8.5 
3.4 
3.9 
3.9 
91 
(9.7) 9.5 
Flunitrazepam 0.9947 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
11.8 
96 
-9.5 
7.6 
17.5 
-2.4 
11.7 
6.4 
6.1 
5.4 
100 
(26) 
19.
6 
Nordiazepam 0.9969 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
11.0 
108 
2.5 
6.9 
7.6 
7.6 
5.8 
4.0 
4.1 
5.5 
96 
(22) 
15.
3 
Diazepam 0.9963 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.0 
103 
2.0 
-1,1 
3.0 
3.0 
5.6 
4.1 
4.1 
2.0 
95 
(9.8) 
13.
2 
Zolpidem 0.9936 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
9.8 
109 
3.8 
-1.5 
-1.6 
9.3 
4.4 
5.9 
3.2 
1.5 
91 
(4.6) 5.4 
Methadone 0.9983 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.1 
99.7 
-8.7 
-4.1 
1.0 
-0.3 
6.0 
1.5 
3.9 
1.3 
88 
(11) 
-
24.
6 
Tramadol 0.9981 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
10.2 
108 
5.2 
4.7 
1.7 
8.0 
8.2 
3.4 
3.4 
4.1 
93 
(6.5) -3.4 
6-
Acetylmorphine 0.9956 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
10.5 
101 
7.8 
8.3 
5.0 
0.7 
11.1 
7.0 
4.5 
3.6 
87 
(16) -1.7 
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Ion suppression from OF was also tested by infusion experiments for all analytes using OF from five 
different drug-free volunteers. The experiments showed that there were no major ion suppression or 
enhancement in OF from any of the five volunteers. Ion suppression in synthetic OF and the buffer 
solution of the Saliva-Sampler was also tested (Badawi et al. 2009). No critical ion suppression was 
observed in the buffer solution, but the synthetic OF caused ion suppression of up to almost 100% for 
nine of the analytes (CLDZ, DZM, NDZM, FLZ, OXZ, APZ, ZOL, and MDON).   
 
 
 
 
 
 
 
Analyte 
Correlati
on 
Coefficie
nt 
R2 
LloQ 
(µg /kg) 
Theoretical 
concentrati
on 
(µg/kg) 
Measured 
concentrati
on 
(n = 8) 
(µg /kg) 
Truene
ss 
Bias 
(%) 
 
Preci
sion 
CV 
(%) 
Extraction 
Recovery 
(%) 
(SD) (n=6) 
ME 
(%) 
Benzoylecgonin
e 0.9939 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
9.6 
97 
1.0 
2.6 
-3.7 
-3.0 
11.9 
5.1 
5.4 
2.2 
47 
(9.1) 
12.
6 
Codeine 0.9958 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.0 
100 
2.0 
-4.2 
2.1 
0.4 
10.3 
6.4 
5.9 
6.4 
113 
(13) 4.6 
Cocaine 0.9917 0.5 
0.5 
1 
10 
100 
0.5 
1.1 
9.8 
104 
1.8 
5.5 
-1.9 
3.5 
8.0 
6.6 
2.9 
1.6 
103 
(20) 
14.
9 
Morphine 0.9886 0.5 
0.5 
1 
10 
100 
0.6 
1.0 
10.5 
104 
18.8 
3.4 
4.8 
4.4 
16.7 
10.6 
4.0 
3.8 
48 
(21) 
19.
8 
Amphetamine 0.9921 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.0 
103 
0 
-1.2 
2.8 
2.7 
16.4 
5.1 
3.4 
2.6 
69 
(10) -39 
Methamphetami
ne 0.9992 0.5 
0.5 
1 
10 
100 
0.5 
0.9 
10.1 
98 
7.5 
-6.0 
0.5 
-2.2 
13.2 
4.5 
5.8 
4.1 
76 
(18) 8.7 
MDA 0.9984 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.2 
105 
-0.7 
1.0 
1.8 
4.9 
7.1 
4.2 
3.6 
2.9 
78 
(12) 
-
14.
7 
MDMA 0.9944 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.4 
104 
-3.2 
0.4 
3.6 
4.2 
9.6 
5.1 
4.1 
3.1 
72 
(9.5) -9.8 
MDEA 0.9960 0.5 
0.5 
1 
10 
100 
0.5 
1.0 
10.0 
101 
-0.7 
-1.7 
-0.3 
1.3 
6.0 
3.1 
1.7 
4.5 
92 
(9.9) -1.5 
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5.1 Description of the roadside driver sample 
5.1.1 Aims of the study 
The main aim is to asses the prevalence of driving after psychoactive substance use (alcohol, illegal 
drug and medicines) in vehicle drivers on Spanish roads. Established secondary aims are as follows: 
to characterize the socio-demographic profile of drivers who consume substances and to explore the 
associations between alcohol consumption and that of other illicit drugs. 
 
5.1.2 Study design 
The study that was conducted was a descriptive cross-sectional study in which each subject gave 
samples on only one occasion. The target population were motor vehicle drivers, except bikes and 
vehicles of over 3,500 Kg, users of Spain’s public roads, both rural and urban. The sample population 
was made up of recruited drivers from 4 regions and 32 different areas in the 128 control points used 
in the study, in accordance with the criteria set out below. Two biological saliva samples and one of 
breath were obtained from the participating drivers. The sample unit is the driver. 
For each driver the following information was gathered: 
a. Questionnaire with information on the place and time of the session control and on the 
selected drivers (see the questionnaire section below).  
b. Information on risk exposure: Information was gathered concerning traffic volume per hour 
at each of the 128 points selected for the study by means of automatic traffic counters for 
along a week every two months during twelve month period, according to the habitual 
methodology [1]. 
In total 3,407 cases were recruited by using stratified sampling of municipalities based on population 
size. This number of cases, supposes aggregate results for the population as a whole, with a 
confidence level of 95% and an accuracy of within 1%. Of these cases, the database sent to the 
DRUID database comprised 3,226 cases, after excluding heavy goods vehicle drivers and 
motorcyclists, as well as rejected cases, according DRUID WP2 agreements. 
The police controls were mandatory, while the study controls were voluntary subject to informed 
consent; however, the participation of drivers was requested while the same drivers were waiting for 
the results of the mandatory police tests, so refusals were much reduced. Two associated-researchers 
collaborated in the field with the police officers who were carrying out the mandatory controls in each 
of the 731 sessions of the study. When the first sample (screening test) was positive, a second one 
was mandatory, taken using the StatSure device (see below) in order to confirm the results. In this 
case, drivers’ signatures for informed consent were not necessary as the information would belong to 
the police; the Ethics Committee only had to approve data anonymity control. When the screening test 
was negative, a second sample was requested on a voluntary basis and carried out after obtaining the 
corresponding informed consent (see Ethical issues). 
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Case (driver) selection in each session was done at random in accordance with the inclusion and 
exclusion criteria established in the study. Although participation was obligatory, the police officers 
stopped drivers on a random basis, depending on the saturation of the control point: when finishing 
with a selected case, the officers stopped the next vehicle that reached the control point. The field 
researchers ensured the random nature of recruitment. 
 
 
5.1.3 Geographical distribution of sessions and cases  
The country was divided into four big geographical regions (see Figure 5.1). Eight municipalities were 
chosen at random from each region using a systematic random sampling in each size-population 
strata of municipalities: <20,000; 20,000-100,000; 100,001-500,000 and >500,000 inhabitants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Geographical distribution of sessions and cases 
 
From each of above strata, one municipality was assigned randomly to urban areas and the other to 
rural roads. Then, four control points were selected for each municipality in order to improve the 
study’s representativeness and to reduce the controls predictability. Each of the four points 
represented a different level of volume of traffic. In total, therefore, 128 control points were set up for 
the study on a national level. A certain number of sessions were assigned for each control point to be 
carried out during the period of the study. This assignation was done in accordance with the 
population size of each municipality, following the four divisions defined: populations of <20,000 
inhabitants: 8 sessions; from 20,000 to 100,000, 12 sessions; from 100,001 to 500,000, 32 sessions; 
and >500,000, 40 sessions. Finally, 731 control sessions were carried out over the 11 month field 
study period, with an average of 4.5 samples obtained per session (Standard Deviation ±1.2). 
 
The distribution of cases according to geographic location is shown in the Table 5.1 
 58 
 
Table 5.1. Cases distribution according regions 
Region Type Road #Sessions #Cases DRUID 
data 
Cantabrice (3401) Rural 91 379 
Urban 93 433 
Total  183 812 
Mediterranean (3402) Rural 91 419 
Urban 91 465 
Total  182 884 
North (3403) Rural 88 356 
Urban 92 348 
Total  180 704 
South (3404) Rural 93 417 
Urban 92 409 
Total  185 826 
Road Type Total Rural 363 1571 
 Urban 368 1655 
TOTAL 731 3226 
(Chi-square between groups: 3.9687; p>0.05) 
 
5.1.4 Distribution over day and time  
 
Four different time periods were established for the control sessions in order to take samples: 
Period a (weekday: Monday through Friday): 7am to 23:59pm. 
Period b (weekday: Tuesday through Friday): 24:00 to 6:59am. 
Period c (weekend: Saturday/Sunday/Bank Holiday): 7am to 23:59pm. 
Period d (weekend: Saturday/Sunday/Monday/Bank Holiday): 24:00 to 6:59am. 
 
Additionally, the year was divided into two periods: 
a. “Holiday” or “Bank Holiday” periods: when a large part of the population enjoys prolonged 
holiday periods, of either a national, regional or local nature, as this affects drivers’ 
behaviour. 
b. “Working” periods: the rest of the year. 
 
In order to compare these data with those of other countries participating in WP2, these periods have 
been further broken down into the 8 periods set out in the Summary Report (Table 5.2). The total 
sample was distributed over the 4 periods used initially in the Spanish study, each one corresponding 
to an average of 851 cases (SD 30), in order to guarantee sufficient accuracy in all 4 periods. The 
differences in the sample distribution of the 8 periods initially designed for DRUID are because of a 
later categorization carried out to adapt to the DRUID periods. 
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Table 5.2. Distribution of cases according to time period 
Periods according to Spanish study Periods according to DRUID 
Time Period Cases % Time Period Cases % 
A 884 25.95 % 1 189 5.9% 
B 831 24.39 % 2 339 10.5% 
C 821 24.10 % 3 311 9.6% 
D 871 25.55 % 4 615 19.1% 
   5 299 9.3% 
   6 251 7.8% 
   7 362 11.2% 
   8 860 26.7% 
Totals 3407 100%  3226 100% 
 
5.1.5 Distribution by sex and age 
Distribution by sex and age is shown in Table 5.3. The differences observed, in the distribution by 
gender and age of the sample, are due to the real gender and age differences in exposition, according 
to the estimated information available in our country. This is why the sample was not standardized 
according to the census of drivers, as this would not fit the reality of the situation in Spain. 
 
Table 5.3. Distribution of cases by sex and age 
Age Male Female TOTAL 
18 to 24 
Row % 
Col % 
600 
81.5 
22.9 
136 
18.5 
22.4 
736 
100.0 
22.8 
25 to 34 
Row % 
Col % 
883 
78.8 
33.7 
237 
21.2 
39.0 
1120 
100.0 
34.7 
35 to 49 
Row % 
Col % 
778 
82.2 
29.7 
169 
17.8 
27.8 
947 
100.0 
29.4 
50+ 
Row % 
Col % 
324 
85.9 
12.4 
53 
14.1 
8.7 
377 
100.0 
11.7 
NA 
Row % 
Col % 
33 
71.7 
1.3 
13 
28.3 
2.1 
46 
100.0 
1.4 
TOTAL 
Row % 
Col % 
2618 
81.2 
100.0 
608 
18.8 
100.0 
3226 
100.0 
100.0 
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5.2 Roadside data collection and analysis 
 
5.2.1 Ethical approval 
The study was approved by the Research Ethics Committee of the University of Valladolid on January 
31st 2007. The said Committee approved the design and aims of the study, as well as the documents 
comprising “Information for participants” and “Informed Consent” (see models below, figure 5.2), to be 
filled out by the drivers who volunteered to give a second biological oral fluid sample exclusively for 
research purposes (cases of negative screening test). In the case of those drivers whose first saliva 
test was positive, the Committee only had to approve the data anonymity control as the information 
belonged to the police. These documents guaranteed the sole research nature of the analysed 
samples, their confidential use and the prohibition of their use for sanctioning purposes. 
 
 
Figure 5.2. Models of “Information for participants” and “Informed Consent” used. 
 
5.2.2 Body fluid collection  
Oral fluid was used as a biological sample to determine substances. The procedure used was that 
described in the Summary Report, Annex 2, for obtaining oral fluid by means of the StatSure© Saliva 
SamplerTM from StatSure Diagnostic Systems, Inc. (Medford, NY, USA). The test tubes were sent to 
the participating laboratory refrigerated at all times (between 2 and 8 degrees centigrade, or frozen if 
transport was to take over 24 hours), using devices with frozen gel (thermovials Kern©) and 
isothermal boxes. Transport to the laboratory was by urgent courier from the municipality where the 
session was carried out. 
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5.2.3 Toxicological analysis of body fluids 
Toxicological Laboratory of Santiago de Compostela University, Medicine Department, was in charge 
of sample analysis. 
Saliva collection devices  
The saliva collection devices consisted of a collector and a transport tube. The pad was able to collect 
approximately 1mL of oral fluid (blue indicator), and the transport tube contained 1mL of a buffer, so 
the sample was diluted 1:2. 
Extraction  
The calibrating standards were prepared by spiking blank oral fluid samples with the appropriate 
working solution volumes. After conditioning, the previously prepared samples were applied onto the 
SPE cartridges. Clean-up was accomplished and the cartridges were dried before elution. The elution 
solution was evaporated and the dry extract was re-dissolved. The sample was transferred into auto-
sampler vials, and 20nL were injected into the LC-MS/MS.  
Chromatography  
Chromatographic separation was performed with an Atlantis dC18, reversed-phase column at 35ºC. 
The mobile phase, delivered at a flow rate of 0.3mL/min, was a gradient mode. 
MS-MS  
Best results were obtained with a capillary voltage of 3kV, source block temperature of 125ºC, 
desolvation gas (nitrogen) heated to 400ºC and delivered at 800L/h, and cone gas at 50L/h. Collision 
cell pressure was 3x10-6 Bar of argon. Data were recorded in the multiple reaction monitoring (MRM) 
mode. The MS method was divided into four MRM functions to obtain at least 15 acquisition points per 
peak.  
Validation 
The analytical validation was performed according to the recommendations of international 
organizations, FDA [2] and ICH [3], and of Shah et al. [4] and Peters and Maurer [5]. 
Calibration  
The calibration range, with at least 7 levels, was 1-200ng/L for 6-AM, alprazolam, oxazepam, 
flunitrazepam, diazepam and THC, 5-200ng/L for morphine, codeine, amphetamine, 
methamphetamine, MDA, MDMA, MDEA, Benzoylecgonine, cocaine, zolpidem, difenhidramine and 
amitryptiline, and 1-100ng/L for zopiclone, clonazepam, nordiazepam and lorazepam. The within-day 
precision and accuracy, as well as the between-day precision and accuracy were satisfactory for all 
tested samples. But since required DRUID limits were satisfied, no further experiments were 
performed to determine the exact LOD and LOQ for each compound. 
Confirmation  
An LC-MS/MS method [9] was developed and fully validated for the simultaneous determination of 23 
compounds (illegal drugs, medicines and their metabolites) taking into account the criteria for 
confirmation of compound identity. The calibration range (1-200ng/L) made it a useful confirmation 
method of DRUID cases. 
 
5.2.4 Method of BAC quantification 
After obtaining the oral fluid samples, the drivers were subjected to an alcohol breath test using the 
device Dräger© Alcotest 6810. When a positive result was obtained, in accordance with the national 
legal requirements, a second breath test was performed using the Dräger© Alcotest 7110 MKIII, for 
the purpose of evidence. In this case, the results of the first samples obtained were collected for 
research. Even though Spanish law envisages the possibility of contrasting blood sample results upon 
request by the person concerned or by criminal authorities, in this study there were no cases where 
this happened. The ethyl meters used measure the ethanol in milligrams per litre of air in breath. 
Result has been transformed into grams of ethanol per litre of blood following criteria of the WP2, by 
means of blood ethanol (gm/L) = ethanol in breath (mg/L) x 2.10. 
 62 
 
5.2.5 Statistical Analysis 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
5.2.6 Interviews (types of collected data: sex, age, self-reported drug use, 
signs of impairment, etc.). 
During each session, and for each one of the cases selected or rejected for the study, the following 
information was obtained, recorded in a questionnaire filled in by the researchers participating in the 
fieldwork: 
- Socio-demographic data of the driver (sex, age, etc.). 
- Day, hour and place where the control was carried out. 
- Vehicle type. 
- Number of vehicles occupants. 
- Driving pattern. 
- Signs of apparent intoxication in the driver. 
- Recent history (the previous 2 weeks) of illicit drug or medicines consumption, 
- Results of the alcohol breath test, in situ drugs in saliva test and drugs in saliva laboratory 
test. 
 
5.3 Non-response 
As already mentioned, drivers were obliged to submit to both the alcohol breath test and the drugs 
test, in accordance with the current penal and administrative laws. In compliance with the study’s 
inclusion and exclusion criteria, rejection was considered as the following: 
• Refusing to consent to the giving of the second oral fluid sample for research purposes, 
when the screening test was negative. 
• When a sample could not be obtained due to an evident lack of saliva. 
• Refusing to take the mandatory control tests. 
 
Out of a total of 3,407 drivers in the total sample, 63 (1.8%) were rejection cases. The causes were as 
follows: 
• Refusal to give a sample: 59 cases (93.7% of the rejections). 
• Insufficient saliva: 3 cases (4.8% of the rejections). 
• Refusal to submit to the legally established tests: 1 case (1.6% of the rejections). 
 
The reasons for not giving a sample were as follows: 57.6% did not wish to participate, 27.1% gave no 
reason, 5.1% declared they did not have time and 10.2% gave other reasons (did not believe in such 
studies, did not trust the results, etc.). The distribution of case rejection was 53 men and 10 women; 
the average age was 38 (Standard Deviation: 14).  
Due to the characteristics of the design and of the sampling, it is not reasonable to suppose that the 
cases of rejection should be related to any of the factors connected with the frequency of drug 
consumption. In fact, the socio-demographic and geographic characteristics of the rejection cases are 
quite in line with those of the sample population. No significant differences in sex and just ones in age 
appeared among rejected and recruited cases (Table 5.4). 
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Table 5.4. Age and Gender differences between rejected and not rejected cases (total sample population). 
 Rejected  No rejected 
Age* 
Obs 62 3299 
Unknown age 1 45 
Mean (years) 38.1935   34.3074  
Std Dev  13.9011  11.6858  
Gender** 
Male 53 (85.5%) 2723 (81.4%) 
Female 10 (14.5%) 621 (18.6%) 
*  P value =  0,0428 between rejected and not rejected cases 
** No statistically significant differences between rejected and not rejected cases 
 
 
 
5.4 Results  
 
Table 5.5. Adjusted general distribution of core substance categories (N=3174) 
Substance category Prevalence (%) Confidence interval (%) 
 
Negative 85.15 83.87 - 86.34 
Amphetamines 0.11 0.04 - 0.30 
Cocaine 1.49 1.12 - 1.97 
THC 5.99 5.22 - 6.87 
Illicit opiates 0.05 0.01 - 0.20 
Benzodiazepines 1.40 1.05 - 1.87 
Z-drugs - - 
Medicinal opiates and opioids 0.19 0.09 - 0.41 
Alcohol 3.92 3.30 - 4.66 
Alcohol+drugs 1.14 0.83 - 1.58 
Drugs-drugs combi 0.57 0.36 - 0.89 
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Table 5.6. Adjusted distribution of core substance categories by gender and age (N=3174) 
 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 78.25 
74.28 - 81.75 
78.64 
75.68 - 81.33 
87.30 
84.85 - 89.41 
89.90 
86.67 - 92.42 
83.30 
81.81 - 84.70 
Alcohol 2.41 
1.36 - 4.24 
3.55 
2.48 - 5.06 
4.31 
3.12 - 5.92 
6.81 
4.78 - 9.62 
4.14 
3.43 - 4.98 
Amphetamine 0.29 
0.06 - 1.33 
0.02 
0.00 - 0.52 
0.00 
0.00 - 0.46 
0.00 
0.00 - 0.90 
0.06 
0.01 - 0.26 
Cocaine 1.49 
0.72 - 3.05 
2.58 
1.69 - 3.92 
1.84 
1.12 - 3.01 
0.05 
0.00 - 0.99 
1.69 
1.26 - 2.27 
THC 14.93 
11.99 - 18.45 
11.27 
9.27 - 13.64 
2.39 
1.54 - 3.67 
0.05 
0.00 - 0.99 
7.22 
6.28 - 8.29 
Illicit opiates 0.00 
0.00 - 0.82 
0.00 
0.00 - 0.47 
0.15 
0.03 - 0.74 
0.00 
0.00 - 0.90 
0.05 
0.01 - 0.24 
Benzodiazepines 0.04 
0.00 - 0.90 
1.08 
0.56 - 2.06 
1.46 
0.83 - 2.53 
2.97 
1.73 - 5.05 
1.31 
0.94 - 1.83 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 - 0.82 
0.20 
0.05 - 0.83 
0.52 
0.21 - 1.29 
0.00 
0.00 - 0.90 
0.23 
0.11 - 0.51 
Alcohol – drugs 2.22 
1.22 - 3.99 
1.86 
1.13 - 3.04 
1.03 
0.53 - 1.99 
0.18 
0.03 - 1.22 
1.35 
0.97 - 1.88 
Multiple drugs 0.37 
0.09 - 1.46 
0.79 
0.37 - 1.67 
1.00 
0.51 - 1.94 
0.04 
0.00 - 0.98 
0.65 
0.40 - 1.04 
 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 93.34 
87.34 - 96.61 
92.80 
88.65 - 95.51 
93.06 
88.63 - 95.85 
88.30 
78.30 - 94.04 
92.71 
90.39 - 94.50 
Alcohol 1.39 
0.34 - 5.50 
3.82 
1.99 - 7.20 
3.71 
1.84 - 7.36 
2.19 
0.49 - 9.21 
3.05 
1.96 - 4.72 
Amphetamine 0.86 
0.15 - 4.67 
0.29 
0.04 - 2.22 
0.09 
0.00 - 2.09 
0.00 
0.00 - 5.56 
0.30 
0.08 - 1.13 
Cocaine 0.16 
0.01 - 3.45 
0.23 
0.02 - 2.11 
1.70 
0.61 - 4.63 
0.00 
0.00 - 5.56 
0.65 
0.26 - 1.65 
THC 2.58 
0.89 - 7.27 
1.31 
0.44 - 3.81 
0.00 
0.00 - 1.91 
0.00 
0.00 - 5.56 
0.96 
0.44 - 2.08 
Illicit opiates 0.16 
0.01 - 3.45 
0.00 
0.00 - 1.68 
0.00 
0.00 - 1.91 
0.00 
0.00 - 5.56 
0.03 
0.00 - 0.67 
Benzodiazepines 0.00 
0.00 - 3.16 
1.24 
0.41 - 3.71 
1.06 
0.30 - 3.70 
9.51 
4.49 - 19.03 
1.78 
1.00 - 3.16 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 - 3.16 
0.00 
0.00 - 1.68 
0.00 
0.00 - 1.91 
0.00 
0.00 - 5.56 
0.00 
0.00 - 0.61 
Alcohol – drugs 0.28 
0.02 - 3.68 
0.31 
0.04 - 2.25 
0.37 
0.05 - 2.58 
0.00 
0.00 - 5.56 
0.28 
0.07 - 1.10 
Multiple drugs 1.24 
0.28 - 5.27 
0.00 
0.00 - 1.68 
0.00 
0.00 - 1.91 
0.00 
0.00 - 5.56 
0.23 
0.05 - 1.03 
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In total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 81.29 
77.93 - 84.25 
81.72 
79.25 - 83.96 
88.42 
86.31 - 90.24 
89.69 
86.68 - 92.08 
85.15 
83.87 - 86.34 
Alcohol 2.20 
1.29 - 3.74 
3.61 
2.63 - 4.93 
4.19 
3.12 - 5.60 
6.19 
4.38 - 8.69 
3.92 
3.30 - 4.66 
Amphetamine 0.40 
0.12 - 1.33 
0.08 
0.01 - 0.52 
0.02 
0.00 - 0.41 
0.00 
0.00 - 0.78 
0.11 
0.04 - 0.30 
Cocaine 1.22 
0.60 - 2.48 
2.07 
1.36 - 3.13 
1.81 
1.16 - 2.83 
0.04 
0.00 - 0.86 
1.49 
1.12 - 1.97 
THC 12.44 
10.01 - 15.37 
9.10 
7.50 - 11.01 
1.93 
1.25 - 2.97 
0.04 
0.00 - 0.86 
5.99 
5.22 - 6.87 
Illicit opiates 0.03 
0.00 - 0.71 
0.00 
0.00 - 0.37 
0.12 
0.03 - 0.59 
0.00 
0.00 - 0.78 
0.05 
0.01 - 0.20 
Benzodiazepines 0.04 
0.00 - 0.72 
1.11 
0.63 - 1.96 
1.38 
0.82 - 2.30 
3.84 
2.47 - 5.94 
1.40 
1.05 - 1.87 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 - 0.65 
0.16 
0.04 - 0.65 
0.42 
0.17 - 1.05 
0.00 
0.00 - 0.78 
0.19 
0.09 - 0.41 
Alcohol – drugs 1.82 
1.01 - 3.27 
1.52 
0.93 - 2.47 
0.90 
0.48 - 1.70 
0.15 
0.02 - 1.06 
1.14 
0.83 - 1.58 
Multiple drugs 0.54 
0.19 - 1.54 
0.62 
0.29 - 1.31 
0.80 
0.41 - 1.57 
0.04 
0.00 - 0.85 
0.57 
0.36 - 0.89 
 
 
Table 5.7.  Adjusted distribution of core substance categories by day of the week and time of the day 
(N=3174) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 87.83 
86.36 - 89.16 
76.15 
68.04 - 82.73 
81.51 
78.66 - 84.06 
75.06 
67.79 - 81.14 
85.15 
83.87 - 86.34 
Alcohol 2.40 
1.83 - 3.15 
8.22 
4.59 - 14.32 
5.78 
4.36 - 7.63 
11.24 
7.22 - 17.10 
3.92 
3.30 - 4.66 
Amphetamine 0.00 
0.00 - 0.18 
0.00 
0.00 - 2.94 
0.38 
0.13 - 1.11 
0.23 
0.02 - 2.80 
0.11 
0.04 - 0.30 
Cocaine 1.25 
0.86 - 1.82 
1.97 
0.61 - 6.15 
1.91 
1.16 - 3.12 
2.11 
0.76 - 5.72 
1.49 
1.12 - 1.97 
THC 5.97 
5.04 - 7.07 
7.24 
3.88 - 13.11 
5.96 
4.52 - 7.83 
5.39 
2.81 - 10.07 
5.99 
5.22 - 6.87 
Illicit opiates 0.00 
0.00 - 0.18 
0.00 
0.00 - 2.94 
0.16 
0.03 - 0.76 
0.12 
0.01 - 2.59 
0.05 
0.01 - 0.20 
Benzodiazepines 1.36 
0.95 - 1.96 
0.49 
0.06 - 3.83 
1.77 
1.06 - 2.95 
0.82 
0.17 - 3.79 
1.40 
1.05 - 1.87 
Z-drugs - - - - - 
Medicinal opioids 0.14 
0.05 - 0.41 
0.16 
0.01 - 3.25 
0.32 
0.10 - 1.01 
0.23 
0.02 - 2.80 
0.19 
0.09 - 0.41 
Alcohol – drugs 0.66 
0.39 - 1.10 
4.11 
1.80 - 9.12 
1.37 
0.76 - 2.44 
4.10 
1.95 - 8.42 
1.14 
0.83 - 1.58 
Multiple drugs 0.38 
0.20 - 0.75 
1.64 
0.46 - 5.67 
0.84 
0.40 - 1.76 
0.70 
0.13 - 3.60 
0.57 
0.36 - 0.89 
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Table 5.8. Adjusted general distribution of alcohol by concentration class (N=125) 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 2.31 1.84 - 2.89 
Alcohol 0.5 – 0.79 g/L 0.90 0.62 - 1.29 
Alcohol 0.8 – 1.19 g/L 0.23 0.11 - 0.47 
Alcohol 1.2+ 0.49 0.30 - 0.80 
In total 3.92 3.30 - 4.66 
 
 
Table 5.9.  Adjusted distribution of alcohol alone by gender and age (N= 125) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.25 
0.57 - 2.72 
2.37 
1.53 - 3.67 
2.15 
1.36 - 3.38 
3.87 
2.41 - 6.17 
2.31 
1.80 - 2.97 
 0.5 – 0.79 g/L 0.30 
0.07 - 1.35 
0.72 
0.33 - 1.58 
0.89 
0.44 - 1.80 
2.01 
1.04 - 3.84 
0.96 
0.65 - 1.41 
 0.8 – 1.19 g/L 0.18 
0.03 - 1.15 
0.27 
0.08 - 0.93 
0.09 
0.01 - 0.63 
0.84 
0.31 - 2.25 
0.29 
0.14 - 0.58 
1.2+ 0.68 
0.24 - 1.93 
0.19 
0.05 - 0.81 
1.18 
0.63 - 2.17 
0.09 
0.01 - 1.07 
0.58 
0.35 - 0.96 
In total 2.41 
1.36 - 4.24 
3.55 
2.48 - 5.06 
4.31 
3.12 - 5.92 
6.81 
4.78 - 9.62 
4.14 
3.43 - 4.98 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.95 
0.18 - 4.81 
2.25 
0.97 - 5.13 
3.45 
1.67 - 7.02 
1.87 
0.38 - 8.72 
2.28 
1.37 - 3.78 
 0.5 – 0.79 g/L 0.16 
0.01 - 3.45 
1.40 
0.49 - 3.95 
0.26 
0.03 - 2.39 
0.32 
0.02 - 6.15 
0.65 
0.26 - 1.66 
 0.8 – 1.19 g/L - - - - 0.00 
0.00 - 0.61 
1.2+ 0.28 
0.02 - 3.68 
0.18 
0.02 - 2.01 
- - 0.12 
0.02 - 0.83 
In total 1.39 
0.34 - 5.50 
3.82 
1.99 - 7.20 
3.71 
1.84 - 7.36 
2.19 
0.49 - 9.21 
3.05 
1.96 - 4.72 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.19 
0.57 - 2.44 
2.34 
1.58 - 3.46 
2.40 
1.62 - 3.53 
3.61 
2.28 - 5.66 
2.31 
1.84 - 2.89 
 0.5 – 0.79 g/L 0.27 
0.06 - 1.13 
0.87 
0.46 - 1.64 
0.77 
0.39 - 1.52 
1.79 
0.93 - 3.39 
0.90 
0.62 - 1.29 
 0.8 – 1.19 g/L 0.14 
0.02 - 0.92 
0.21 
0.06 - 0.73 
0.07 
0.01 - 0.51 
0.72 
0.27 - 1.95 
0.23 
0.11 - 0.47 
1.2+ 0.60 
0.22 - 1.63 
0.19 
0.05 - 0.70 
0.95 
0.51 - 1.76 
0.08 
0.01 - 0.92 
0.49 
0.30 - 0.80 
In total 2.20 
1.29 - 3.74 
3.61 
2.63 - 4.93 
4.19 
3.12 - 5.60 
6.19 
4.38 - 8.69 
3.92 
3.30 - 4.66 
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Table 5.10.  Adjusted distribution of alcohol alone by day of the week and time of the day (N=125) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.03 
0.68 - 1.56 
5.76 
2.86 - 11.25 
4.19 
3.00 - 5.81 
7.03 
3.98 - 12.10 
2.31 
1.84 - 2.89 
 0.5 – 0.79 g/L 0.86 
0.54 - 1.35 
1.64 
0.46 - 5.67 
0.58 
0.24 - 1.39 
2.46 
0.95 - 6.22 
0.90 
0.62 - 1.29 
 0.8 – 1.19 g/L 0.11 
0.03 - 0.37 
0.33 
0.03 - 3.55 
0.41 
0.15 - 1.15 
0.82 
0.17 - 3.79 
0.23 
0.11 - 0.47 
1.2+ 0.41 
0.21 - 0.79 
0.49 
0.06 - 3.83 
0.61 
0.26 - 1.44 
0.94 
0.22 - 3.98 
0.49 
0.30 - 0.80 
In total 2.40 
1.83 - 3.15 
8.22 
4.59 - 14.32 
5.78 
4.36 - 7.63 
11.24 
7.22 - 17.10 
3.92 
3.30 - 4.66 
 
In Spain, 14.85% of drivers who participated in the present study showed concentrations in saliva 
equal to or over the specified DRUID cut off in at least one of the substances analyzed. The larger part 
of positive cases were due to cannabis, alcohol or cocaine, either alone or combined with other 
substances (Table 5). 
 
The frequency of positive cases for some substance was greater among male drivers than among 
female drivers (6.70% and 7.29% respectively; Χ2=35.401, p<0.0001). Differences in rates of positive 
cases according to the age range for some substance were observed among the males but not among 
the females (Χ23=44.001; p<0.0001 and Χ23=2.195; p>0.05 respectively). Worthy of note is the high 
frequency of positive cases found among male drivers aged fewer than 35 (over 20%). 
 
There were significant differences for the sample as a whole (Table 5.6) with respect to age in positive 
cases for alcohol (Χ23=11.403; p<0.05), cocaine (Χ23=10.670; p<0.05), THC (Χ23=122.176; 
p<0.0001), benzodiazepines (Χ23=30.841; p<0.0001) and the combination alcohol-drugs (Χ23=8.409; 
p<0.05). These age differences in males were not observed for cocaine.  
 
The percentage of males who were positive for alcohol (Table 5.6) increased with age (taken with age 
ranges). The highest percentage was for males aged over 50 (6.8%). The opposite occurred for THC, 
with the highest percentage of positive cases among males aged 18-24 (14.9%). Among females, 
differences were only observed with respect to age in positive cases for benzodiazepines 
(Χ23=23.200; p<0.0001). 9.5% of female drivers aged over 50 were positive for benzodiazepines.  
 
As for the positive cases for the various substances grouped by hours on workdays or weekends 
(Table 5.7), differences were observed for alcohol (Χ23=49.155; p<0.0001), amphetamines 
(Χ23=9.001; p<0.05) and the combination of alcohol + drugs (Χ23=27.765; p<0.0001). The percentage 
of positive cases for alcohol and alcohol + drugs combined is greater during the night than during the 
day, and is even larger at the weekends for both night and day. Positive cases for amphetamines were 
only found at weekends, during both night and day. 
 
3.92% of drivers (table 5.8) showed positive levels of alcohol (BAC≥0.1 g/L) and were negative for the 
rest of the substances analyzed. 1.61% of drivers showed levels of alcohol equal to or over 0.5 g/L, 
the maximum BAC allowed in Spain for non-professionals drivers. There were no significant 
differences between males and females with regard to the levels of alcohol found (Χ23=3.670; 
p>0.05). There were differences among males for levels of alcohol found according to age 
(Χ29=19.387; p<0.05). 
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The positive cases in the different alcohol levels were distributed fairly homogeneously among the four 
time periods established (Χ29=10.788; p>0.05; Table 5.10). 
 
5.5 Discussion 
The study was designed so as to make it representative at a national level, but not separately to each 
of the 17 regions that make up Spain. The sample used in the study, the number and random nature 
of the tested drivers, the distribution of the tests according to time and days, which was done to 
determine which substances as well as the number of substances analyzed, all make this study the 
most ambitious study ever carried out so far in Spain concerning drugs and driving.  
 
The characteristics of the sample, the low frequency of refusals (63 drivers), as well as the 
homogeneous nature of the socio-demographic and geographic characteristics of the drivers who 
participated in the study and those who refused to take part, indicate that there was no selection bias 
in the study. 
 
The study shows that the consumption of psychoactive substances while driving is a frequent fact in 
Spain, affecting at least 15% of Spanish drivers. Apart from ethanol, 11% of drivers do so after having 
consumed substances that can affect their fitness to drive. Cannabis (THC) and cocaine were the two 
substances most frequently found. These data are consistent with those published by the Spanish 
Observatory on Drugs for the Spanish population as a whole, based on self-referred information, 
where the prevalence of consumption for cannabis and cocaine in the “previous month” was 7.2% and 
1.9%, respectively [6]. In the general population of Castile and Leon (Spain), 9.7% of those who 
consumed cannabis during the “previous year” referred to driving under the effects of cannabis in the 
year prior to carrying out the survey [7].  Of the drivers who died due to a traffic accident in Spain in 
2009, 30% showed levels of alcohol equal to or over 0.3 g/L. Of these, 22.4% were positive as well for 
illegal and/or medicinal drugs [8]. 12.35% of fatally injured drivers were positive for illegal drugs. The 
most frequent illegal drug found was cocaine, in 8.5% of fatally drivers, followed by THC (3.9%) and 
opiates and derivatives (3.5%). 
 
Unlike for alcohol, in Spain there has up to now been no preventive policy for illegal drugs and driving. 
The tests carried out for this study were the first of a compulsory nature at state level. Thus, the 
disassociation between the use of drugs and driving in Spain will be predictably scarce.  
As happens with consumption in the general population, the distribution by age shows differences 
between cannabis and cocaine, the latter being the most widely distributed substance with respect to 
both age and socio-cultural origin.  
In addition, the experience of the prevalence study developed within the DRUID project has served to 
lay the foundations of the development of regulations and the real application of roadside drug 
controls, to raise awareness levels of the public to the problem and to support preventive interventions 
developed in this matter in Spain.  
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6.1 Description of the roadside driver sample 
6.1.1 Introduction 
The aim of the survey was to form an estimate of alcohol and drug use among drivers in the Finnish 
general traffic flow. The material was collected in the counties of Uusimaa and Itä-Uusimaa, in 
southern Finland, and Pohjois-Savo in central Finland. 
The survey was conducted in accordance with the guidelines for the roadside survey, as set out by the 
task leader for this survey. 
The samples were collected in co-operation between the police and researchers. The police could not 
stop the traffic flow solely for the purposes of the research, so they stopped the drivers in the traffic 
flow and performed a breath test for the use of alcohol. During any given session the police stopped 
either all cars passing through the checkpoint, or if the volume of traffic was too great, only a 
manageable portion of traffic. For the DRUID survey the police picked vehicles from the traffic flow at 
random, without any presupposition about the drivers. They stopped mainly cars and vans but, in 
addition, some buses, trucks, motorcycles, mopeds and bicycles were also included to the survey. The 
demographics presented in the report are based on the whole survey population but only cars and 
vans are included in the international database. It was mandatory for the drivers to obey the directions 
of the police and to participate in the alcohol breath testing, whereas taking part in the survey was 
voluntary. The volume of passing traffic was recorded by video camera and the police counted all the 
breath alcohol tested drivers whether or not they participated in the survey, during each collection 
session. 
The inclusion criteria for the respondents were that they should be driver of a motor vehicle passing 
through any of the collection sessions, or bicyclist in the proximity. As written consent was required for 
participation in the survey the drivers had to be over 18 years old. During a session, whenever a 
researcher was free, the police officers performing the alcohol screening would ask the driver if they 
had about 10 minutes to take part in a survey conducted by THL. The police officers were instructed 
not to mention drugs or drug testing when asking the drivers to participate. If the driver declined and 
was not suspected for any offence they were then free to leave. If the driver initially consented, they 
were directed to a researcher at the roadside. The researcher informed the driver about the survey 
and asked them to give a written informed consent to participate. The voluntary participation to the 
survey and written informed consent were compulsory requirements of the ethical advisory board. If 
the driver consented, an oral fluid sample was taken and a short interview was conducted. If the driver 
was suspected of DUI, they were taken into police custody. Depending on the location or type of DUI, 
the driver was taken as soon as possible to an evidential breath analyser or for blood sampling. If 
police procedure allowed for it, the suspected driver was asked to participate in the survey. Therefore 
not all alcohol positive cases were given the opportunity to participate. 
6.1.2 Geographic distribution of drivers over the country 
About 28% of the Finnish population lives in the research region of Uusimaa (the counties of Uusimaa 
and Itä-Uusimaa) in southern Finland, which includes the Helsinki area. In addition to the Uusimaa 
region a second research area, Pohjois-Savo in central Finland, was chosen. The geographical 
locations of the two research regions are shown in figure 6.1. Pohjois-Savo was chosen based on an 
earlier survey (1) of the distribution of DUI cases in Finland. The comparative distributions of survey 
samples and national traffic volumes are shown in table 6.1. 
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Table 6.1. Distribution of survey samples and traffic over regions 
Regions Survey sample fraction Fraction of total traffic*  
Uusimaa 0.684  0.856 
Pohjois-Savo 0.316  0.144 
* Based on population, data is weighted according to national traffic data for these regions 
 
 
Figure 6.1. Finnish sample collection regions (highlighted red) 
6.1.3 Distribution of drivers by road type 
Initially five areas were targeted in both of the research areas (Uusimaa and Pohjois-Savo) and within 
each area six research sites were selected: two each on main roads, regional/connecting roads and 
municipal roads. There were two main requirements each site needed to fulfil. Assignment of research 
sites was restricted by the availability of a suitable roadside area to safely carry out the sampling and 
interviews. It was also necessary to establish a minimum expected volume of traffic to allow efficient 
sampling, this was set as 18 vehicles per session. Altogether there were 90 research sites. For the 
survey design the aforementioned three road categories was used. All the research sites were later 
reclassified as rural or urban roads. The road type distribution is shown in table 6.2. 
 
Table 6.2. Road type distribution 
Road type Survey sample fraction Fraction of total traffic* 
Urban (type 1) 0.519 0.620 
Rural (type 2) 0.481 0.380 
* Traffic performance (vehicle-km) 
6.1.4 Distribution of drivers by season 
The collection sessions were held between 29th September 2007 and 7th June 2009. For the 
research area Uusimaa, a sample collection week was assigned for each season of the year, and for 
Pohjois-Savo, two sample collection weeks were assigned, one for autumn and one for summer. 
Additional collection days were also held throughout the year. The final distribution of the total sample 
collection was calculated for the quarters of the year (table 6.3). 
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Table 6.3. Quarterly distribution 
Quarter of the year Survey sample fraction Fraction of total traffic* 
Jan, Feb, Mar 0.121 0.223 
Apr, May, Jun 0.460 0.261 
Jul, Aug, Sep 0.170 0.275 
Oct, Nov, Dec 0.249 0.241 
* Traffic performance (vehicle-km) 
6.1.5 Distribution of drivers by day of the week and time of the day 
Based on the division of the week into time codes as proposed in the Deliverable 2.1.2 guidelines for 
roadside surveys, each research day was divided in three working periods, from 07:00 to 10:00, from 
12:00 to 16:00 and from 20:00 to 01:00. The sessions were scheduled to last between 45-60 min. at 
each research site. The timing of the sessions was such that data were collected for all periods of the 
day for each road type. The exact time of the session was recorded. Small deviations from the timing 
plan, for practical reasons, resulted in samples also being collected outside the three aforementioned 
periods. The distribution of drivers, according to DRUID time codes, is shown in table 6.4. 
 
Table 6.4. Distribution of drivers over DRUID road survey time periods 
DRUID time period Survey sample fraction Fraction of total traffic* 
Weekday 04:00-10:00 0.152 0.186 
Weekday 10:00-16:00 0.316 0.289 
Weekday 16:00-22:00 0.166 0.197 
Weekday 22:00-04:00 0.079 0.033 
Weekend 04:00-10:00 0.064 0.057 
Weekend 10:00-16:00 0.130 0.088 
Weekend 16:00-22:00 0.058 0.131 
Weekend 22:00-04:00 0.036 0.021 
* Traffic performance (vehicle-km) 
 
Cooperation with the police necessitated certain limitations as to times of the day when sampling was 
possible, for this reason no roadside sampling was undertaken between 01:00-07:00. However, as 
can be seen from Table 6.4, the fraction of total traffic in Finland during three of the periods covering 
the night time (Weekday 22:00-04.00, Weekend 04:00-10:00 and Weekend 22:00-04:00) is very low 
and in the period Weekday 04:00-10.00 it is reasonable to assume that a considerable part of this 
traffic is constituted of drivers going to work (i.e. after 07:00). Analysis by a traffic statistician also 
suggested that sampling in the time period 01:00-07:00 would anyway be inefficient, yielding only a 
very small number of survey samples, so in effect the fact that there were no roadside sessions in this 
time period would not affect representativeness of the survey. Nonetheless, the prevalence studies for 
neighbouring countries, i.e. Sweden or Norway, which might reasonably be expected to show strong 
similarities to the Finnish DUI situation, could be used to estimate prevalences in the night time 
periods – provided there are sufficiently strong similarities in the compared countries for other time 
periods of the DRUID survey.  
6.1.6 Distribution of drivers by gender and age 
The total number of cases was 4192. The age was recorded for 4185 drivers and the gender was 
recorded for 4174 drivers. The youngest man in the survey was 18 and oldest 85. The youngest 
woman was 18 and the oldest was 79. The age distribution by gender is shown in graph 6.1. 
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Graph 6.1. Age distribution over gender 
 
The distribution when categorising the drivers’ ages into four groups is shown in table 6.5. The number 
of cases where gender and/or age data is missing is 25.  
 
Table 6.5. Number of respondents per age group over gender 
Age (yrs) 18-24 25-34 35-49 50+ Total 
No. of males 318 (8%) 531 (13%) 782 (19%) 1179 (28%) 2810 (67%) 
No. of females 152 (4%) 282 (7%) 519 (13%) 404 (10%) 1357 (33%) 
Total 470 (11%) 813 (20%) 1301 (31%) 1583 (38%) 4167 (100%) 
 
6.2 Roadside data collection and analysis 
6.2.1 Ethical approval 
The research survey plan was submitted to the coordinating ethical advisory board of the Hospital 
District of Helsinki and Uusimaa and approved. Signed informed consent was necessary for all 
respondents.  The identity of the driver was not recorded. 
6.2.2 Body fluid collection 
Oral fluid was collected using the StatSure Saliva·SamplerTM device (Annex 2). Any deviation from the 
normal collection procedure was recorded and entered to the database. Upon arrival to the laboratory, 
and within 6 hours of collection, the samples were frozen and stored at -18°C until analysis. 
6.2.3 Toxicological analysis of body fluids 
All samples were analysed at THL. Frozen OF samples were thawed and the weight was recorded for 
each sample. Any deviations noticed at this stage, e.g. part of collector missing, led to exclusion of the 
sample. The sample preparation procedure for OF samples is presented in Annex 6.I. 1 ml of sample 
was pipetted to test tubes. In some cases very little OF was collected and hence it was not possible to 
obtain 1 ml of sample for analysis. In these cases the volume of pipetted OF was noted and taken into 
account when calculating the results. LLE and/or SPE (MCX 3cc/60mg mixed-mode polymeric sorbent 
cartridges, Waters Oasis) were used for analyte extraction. The samples were silylized and analysed 
with GC–EI/MS or GC–NCI/MS. Further information on toxicological analysis is presented in Annex 
6.I. 
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6.2,4 Method of BAC quantification  
Oral fluid analyses for alcohol were not performed for the survey samples, because breath alcohol 
screening was performed at the roadside. The police routinely breath tested 99.9% of the drivers 
passing through the survey checkpoint during the survey sessions. The device used by the police for 
breath alcohol screening was the Alco-Sensor IIIR (Intoximeters Inc., Saint Loius, Missouri, U.S.). All 
ethanol results above zero were recorded for the drivers participating in the roadside survey. All 
results at, or above, the legal limit (0.5‰) were further confirmed using an evidential breath test or 
alcohol analysis of a blood sample, as per normal police procedure. The police also recorded the 
number of all drivers who gave a positive ethanol screening result below the legal limit during the 
roadside sessions, but these results were recorded as “below legal limit”.  
6.2.5 Interviews  
The interview form collected the following data: 
 Gender 
 Year of birth 
 Year that first motor vehicle licence was achieved 
 Whether or not the driver is currently in possession of a valid licence 
 Whether or not the driver is a professional driver 
 Type of vehicle 
 Annual mileage (professionally and privately) 
 Breath alcohol screening result (as measured and confirmed by the police officer) 
 Time of oral fluid sample 
 Ordinary collection (5 min limit) of oral fluid or other, any deviation recorded 
 Time of possible blood sample in case of DUI 
 Time and result of possible evidential breath analysis in case of DUI 
 Self-reported use of alcohol, drugs or traffic hazardous medicinal drugs during the past 24 h 
6.2.6 Statistical analysis  
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
6.3 Non-response 
6.3.1 Size and nature of non-response 
 
In all there were 225 roadside survey sessions. The total number of non-consenting drivers was 5381, 
of which 5125 refused at the initial request to participate in the survey by the police and 256 refused 
after learning of the nature of the survey. The overall inclusion rate from the traffic flow was 39.6%. 
Data concerning non-consent rates are shown in table 6.6. 
 
Table 6.6. Descriptive data of the roadside sessions 
Type of information Min. Max. Mean No. of sessions 
data missing 
Non-consent rate researcher 0% 33.4% 3.5% 1 
Non-consent rate police 0% 84.6% 44.4% 2 
Non-consent rate total 0% 84.6% 47.9% 2 
 
The mean non-consent rate to the researchers was low at only 3.5%.  
The respective refusal rates to police and researchers for sessions within each DRUID time code were 
determined (table 6.7). As can be seen the only periods where the refusal rate to the researchers was 
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above 4% were Weekday 04:00-10:00 and Weekday 10:00-16:00. These are both periods where the 
flow of traffic can be expected to include a large number of drivers travelling to and from work. The 
refusal rate to police, at the initial request to participate, was substantially higher in each time period. 
 
Table 6.7. Comparison of DRUID refusal rate by time code 
    Refusal rate   
Time period Police Researcher* Overall 
Weekday 04.00-10.00 44% 10% 49% 
Weekday 10.00-16.00 43% 7% 47% 
Weekday 16.00-22.00 66% 4% 68% 
Weekday 22.00-04.00 65% 4% 66% 
Weekend 04.00-10.00 45% 4% 47% 
Weekend 10.00-16.00 45% 4% 47% 
Weekend16.00-22.00 65% 2% 66% 
Weekend 22.00-04.00 54% 4% 56% 
*Refusal rates are shown as percentage of all drivers who proceeded to a researcher    
 
The police, who initially asked the drivers to participate in the survey, did not record any information on 
the drivers at that stage, regardless of participation. Once the drivers had proceeded to a researcher, 
information, e.g. gender and age, for those who declined to participate at that stage was possible to 
record only if the non-respondent gave verbal consent. Hence, a direct comparison between the 
respondents and non-respondents in the survey cannot be made. 
However, the demographics of the survey respondents can be compared to those from previous 
national research, ‘henkilöliikennetutkimus’ (HLT), in Finland (table 6.8). The Finnish Road 
Administration conducted research in 2004 – 2005, estimating the age and gender of road users 
based on trip mileage reported by a large number of respondents (www.hlt.fi).  Data from this research 
was weighted to correspond to the DRUID regional distribution (Uusimaa 68.4% and Pohjois-Savo 
31.6%).  
 
Table 6.8. Comparison of DRUID respondent age group and gender to weighted HLT distribution 
 HLT DRUID 
Age (yrs) 18-24 25-34 35-49 50+ Total 18-24  25-34 35-49 50+ Total 
Males 4% 12% 
%%% 
27% 28% 70% 8% 13% 19% 28% 67% 
Females 3% 7% 11% 10% 30% 4% 7% 13% 10% 33% 
Total 6% 18% 38% 37% 100% 11% 20% 31% 38% 100% 
 
A further comparison of the demographics of drivers sampled when the survey refusal rates were high 
and low was made (Annex 6.2). The two response groups showed strong similarities in their 
demographic make-ups. Statistically significant difference was seen for gender in the time period 
Weekday 04:00-10:00 only and for age groups in the time period Weekend 10:00-16:00 only. 
6.3.2 Possible confounding effect of non-response 
Although the overall refusal rate to participate was high, the majority of the refusals were received at 
the initial request to participate by the police, before the drivers learnt about the nature of the survey. 
At this point drivers were only asked by the police if they would spare 10 minutes of their time for the 
survey. Drivers were informed about the survey only when they had proceeded to a researcher. Hence 
it is reasonable to assume that those who refused at this stage did so because of lack of time. The 
refusal rate once the drivers had proceeded to a researcher was 2-10% for individual DRUID time 
codes, and only above 4% in periods when a large number of drivers were travelling to or from work. It 
therefore seems unlikely that there is any significant confounding effect of non-response due to 
drivers’ reluctance to participate in an epidemiological survey of DUI.  
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The comparison of demographics of survey respondents to previous national data, table 6.8, shows 
that the distributions of age and gender, expressed as percentages of the total, for the two studies 
bear strong similarities. The sample of respondents in the DRUID survey can therefore be assumed to 
correspond well to the demographics of the road users in Finland, suggesting that no individual 
demographic group was more inclined to refuse to participate. 
Furthermore, comparison of demographics for sessions with high and low participation levels in the 
survey (Annex 6.2) show that there is little difference in these two groups for the separate time codes 
as well. 
Overall, it is probable there is little confounding effect, if any, to be expected due to the nature of the 
vast majority of the non-response group (i.e. ignorance of the purpose of the survey).  
 
6.4 Results 
Only drivers of cars and vans were included for the results, therefore 101 drivers of other vehicles 
were excluded. In addition 250 cases with incomplete results for the toxicological analyses were 
removed from the database. The total number of cases included was 3841. Prevalences presented 
are adjusted by weighting the results according to traffic flow. This adjustment was performed by 
SWOV Institute for Road Safety Research, the Netherlands. Results are presented according to 
substance categories and are shown as prevalence for the relevant drug category alone, i.e. not in the 
presence of other core substance categories. Prevalence of cases with alcohol-drugs and multiple 
drugs categories are also presented. No cases with illicit opioids were determined therefore 
prevalence for this substance category is not presented. Results for alcohol findings should be 
interpreted with some caution (see Section 6.5.1 Representativeness). 
6.4.1 Adjusted general distribution of core substance categories 
Table 6.9 shows the adjusted prevalences of core substance categories. As might be expected, after 
adjustment the vast majority of the cases (more than 97%) sampled from the general driving 
population were negative for all substances. The substances which were most prevalent were, in 
descending order, benzodiazepines, alcohol, opioids and Z-drugs. Cases with multiple drugs were 
also relatively prevalent, but this was not so much the case for the combination of alcohol and drugs. 
 
Table 6.9. Adjusted general distribution of core substance categories (N=3841) 
Substance category Prevalence (%) Confidence interval (%) 
Negative 97.15 96.58 – 97.63 
Alcohol 0.64 0.43 – 0.94 
Amphetamines 0.05 0.02 – 0.19 
Cocaine 0.03 0.01 – 0.16 
THC 0.04 0.01 – 0.17 
Benzodiazepines 0.79 0.56 – 1.13 
Z-drugs 0.36 0.21 – 0.60 
Medicinal opioids 0.56 0.37 – 0.85 
Alcohol – drugs 0.08 0.03 – 0.23 
Multiple drugs 0.29 0.16 – 0.52 
6.4.2 Adjusted distribution of core substance categories according to 
gender and age 
Table 6.10 shows the adjusted prevalence of substance categories according to age group for male 
and female drivers separately and both genders taken together. For male drivers only alcohol and 
benzodiazepines were prevalent across all age groups. Prevalence of benzodiazepines was also 
roughly equivalent to that of alcohol in each group except for the youngest drivers (18-24), where the 
prevalence of alcohol was significantly higher. The prevalence of alcohol in the age groups 18-24 and 
25-34 also appears to be somewhat higher than for older male drivers. Contrastingly, alcohol was not 
prevalent at all for younger female drivers, but then appears to increase in prevalence in the older age 
groups 35-49 to 50+ (as is also seen in the male age groups, from 0.44% to 0.85%). Prevalences in 
these two female age groups were still lower than the respective male counterpart age groups. The 
next drug category most widely prevalent across female age groups was benzodiazepines, although 
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these were not seen in the age group 25-34. For Z-drugs, opioids and multiple drugs the pattern of 
distribution in age groups were broadly similar for both males and females; they tended to be prevalent 
in the age groups from 25 years up for the male drivers (except for Z drugs in the 35-49 group) and 35 
years upwards for female drivers. Where Z-drugs and opioids were found in female age groups they 
were more prevalent than for the corresponding male groups, whilst multiple drug findings were more 
prevalent in the male age groups. Similarly, alcohol-drug prevalences were seen only in the male 35-
49 and 50+ age groups and not at all in the female age groups. In the age groups 18-24 and 50+ 
some prevalence of THC was seen in male drivers and for female drivers amphetamines were 
observed in the 25-34 age group and cocaine in the 35-49 age group. These individual prevalence 
values were generally very low (below 0.5%), except for the amphetamines prevalence in the female 
25-34 group (0.79%). The overall results suggest that drugs and alcohol are more prevalent in older 
female drivers (35 and over) and this is also generally true for male drivers, except for the 
aforementioned prevalence of alcohol and benzodiazepines. The prevalence of drugs and alcohol for 
both genders largely reflects that of the male drivers age groups, which is because of the dominance 
of male drivers in the study sample. Prevalence values were generally very low: only above 1% for 9 
values - men with alcohol (18-24 & 25-34), benzodiazepines (25-34 & 50+) and opioids (25-34); 
women with Z-drugs (50+) and opioids (50+); both genders with benzodiazepines (50+) and opioids 
(50+). The highest individual prevalence value (1.46%) was seen for women with opioids (50+). 
 
Table 6.10. Adjusted distribution of core substance categories by gender and age (N=3841) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 98.43 
96.20 – 99.36 
95.88 
93.69 – 97.33 
98.63 
97.46 – 99.26 
95.73 
94.35 – 96.78 
96.86 
96.11 – 97.47 
Alcohol 1.08 
0.37 – 3.11 
1.19 
0.53 – 2.62 
0.44 
0.15 – 1.27 
0.85 
0.45 – 1.60 
0.82 
0.54 – 1.26 
Amphetamines 0.00 
0.00 – 1.35 
0.00 
0.00 – 0.80 
0.00 
0.00 – 0.55 
0.00 
0.00 – 0.35 
0.00 
0.00 – 0.15 
Cocaine 0.00 
0.00 – 1.35 
0.00 
0.00 – 0.80 
0.00 
0.00 – 0.55 
0.00 
0.00 – 0.35 
0.00 
0.00 – 0.15 
THC 0.16 
0.02 – 1.65 
0.00 
0.00 – 0.80 
0.00 
0.00 – 0.55 
0.11 
0.02 – 0.55 
0.06 
0.02 – 0.26 
Benzodiazepines 0.33 
0.05 – 1.93 
1.24 
0.57 – 2.70 
0.39 
0.12 – 1.19 
1.27 
0.76 – 2.13 
0.92 
0.61 – 1.37 
Z-drugs 0.00 
0.00 – 1.35 
0.19 
0.03 – 1.15 
0.00 
0.00 – 0.55 
0.56 
0.26 – 1.21 
0.27 
0.13 – 0.56 
Medicinal opioids 0.00 
0.00 – 1.35 
1.06 
0.46 – 2.46 
0.07 
0.01 – 0.67 
0.88 
0.47 – 1.64 
0.59 
0.36 – 0.97 
Alcohol – drugs 0.00 
0.00 – 1.35 
0.00 
0.00 – 0.80 
0.18 
0.04 – 0.87 
0.17 
0.04 – 0.65 
0.12 
0.04 – 0.35 
Multiple drugs 0.00 
0.00 – 1.35 
0.44 
0.12 – 1.55 
0.30 
0.08 – 1.05 
0.44 
0.18 – 1.04 
0.35 
0.18 – 0.66 
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Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 99.60 
96.57 – 99.96 
99.21 
97.23 – 99.78 
97.94 
96.25 – 98.87 
95.72 
93.25 – 97.32 
97.70 
96.72 – 98.39 
Alcohol 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.35 
0.09 – 1.38 
0.45 
0.12 – 1.74 
0.27 
0.10 – 0.74 
Amphetamines 0.00 
0.00 – 2.71 
0.79 
0.22 – 2.77 
0.00 
0.00 – 0.78 
0.00 
0.00 – 0.96 
0.16 
0.05 – 0.57 
Cocaine 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.26 
0.05 – 1.24 
0.00 
0.00 – 0.96 
0.10 
0.02 – 0.47 
THC 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.00 
0.00 – 0.78 
0.00 
0.00 – 0.96 
0.00 
0.00 – 0.30 
Benzodiazepines 0.40 
0.04 – 3.43 
0.00 
0.00 – 1.44 
0.61 
0.21 – 1.78 
0.92 
0.34 – 2.44 
0.56 
0.27 – 1.14 
Z-drugs 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.42 
0.12 – 1.49 
1.21 
0.51 – 2.85 
0.53 
0.26 – 1.10 
Medicinal opioids 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.14 
0.02 – 1.03 
1.46 
0.66 – 3.20 
0.50 
0.24 – 1.06 
Alcohol – drugs 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.00 
0.00 – 0.78 
0.00 
0.00 – 0.96 
0.00 
0.00 – 0.30 
Multiple drugs 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.29 
0.07 – 1.29 
0.23 
0.04 – 1.38 
0.18 
0.05 – 0.61 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 98.82 
97.27 – 99.50 
97.07 
95.60 – 98.07 
98.35 
97.45 – 98.93 
95.75 
94.60 – 96.66 
97.15 
96.58 – 97.63 
Alcohol 0.72 
0.25 – 2.09 
0.76 
0.34 – 1.69 
0.40 
0.17 – 0.96 
0.74 
0.41 – 1.32 
0.64 
0.43 – 0.94 
Amphetamines 0.00 
0.00 – 0.90 
0.28 
0.08 – 1.00 
0.00 
0.00 – 0.32 
0.00 
0.00 – 0.26 
0.05 
0.02 – 0.19 
Cocaine 0.00 
0.00 – 0.90 
0.00 
0.00 – 0.52 
0.11 
0.02 – 0.51 
0.00 
0.00 – 0.26 
0.03 
0.01 – 0.16 
THC 0.11 
0.01 – 1.11 
0.00 
0.00 – 0.52 
0.00 
0.00 – 0.32 
0.08 
0.02 – 0.40 
0.04 
0.01 – 0.17 
Benzodiazepines 0.35 
0.08 – 1.51 
0.80 
0.36 – 1.74 
0.48 
0.21 – 1.06 
1.17 
0.74 – 1.86 
0.79 
0.56 – 1.13 
Z-drugs 0.00 
0.00 – 0.90 
0.12 
0.02 – 0.74 
0.17 
0.05 – 0.62 
0.73 
0.41 – 1.31 
0.36 
0.21 – 0.60 
Medicinal opioids 0.00 
0.00 – 0.90 
0.68 
0.29 – 1.58 
0.09 
0.02 – 0.49 
1.03 
0.63 – 1.69 
0.56 
0.37 – 0.85 
Alcohol – drugs 0.00 
0.00 – 0.90 
0.00 
0.00 – 0.52 
0.11 
0.02 – 0.51 
0.12 
0.03 – 0.47 
0.08 
0.03 – 0.23 
Multiple drugs 0.00 
0.00 – 0.90 
0.28 
0.08 – 1.00 
0.29 
0.11 – 0.80 
0.38 
0.17 – 0.84 
0.29 
0.16 – 0.52 
6.4.3 Adjusted distribution of core substance categories by day of the 
week and time of the day 
Table 6.11 shows the adjusted distribution of core substance categories by day of the week and time 
of the day. Only two substance categories, alcohol and benzodiazepines, appear to be prevalent in all 
four time periods. Notably, during weekend-days and, particularly, at night time (week or weekend, 
22:00-03:59), the prevalence of alcohol is higher than that of benzodiazepines. However, during 
weekdays the prevalence of benzodiazepines is almost double that of alcohol. No other single drug 
categories were prevalent on weekend nights, although multiple drugs were observed. Z-drugs and 
opioids were prevalent in each of the other time periods. Amphetamines were prevalent only on 
weekend days (0.20%), cocaine on weekdays (0.05%) and THC on weekdays (0.05%) and 
weeknights (0.36%). The combination of alcohol-drugs was only seen for weekdays (0.12%), however 
drug-drug combinations were prevalent in all periods except weeknights; the prevalence on weekend 
periods was somewhat higher. Prevalence values were again low: generally below 0.5% except for 10 
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values – alcohol all periods except weekdays; benzodiazepines all periods except weeknights; opioids 
weekdays and weeknights; multiple drugs weekend days and weekend nights. The highest individual 
prevalences, and the only values over 1%, were for alcohol on weeknights (1.08%) and on weekend 
nights (2.03%). The combination of alcohol-drugs was rarely seen (weekdays: 0.12%). The relatively 
large confidence intervals seen for all substance categories on weekday nights and weekend nights 
seem to reflect the relatively low number of cases that were sampled in the time period 22:00 – 03.59.  
 
Table 6.11. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=3841) 
4 categories: weekdays, weekday nights, week-end days, week-end nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 97.04 
96.31 – 97.63 
97.13 
92.57 – 98.93 
97.47 
96.33 – 98.26 
96.59 
89.84 – 98.91 
97.15 
96.58 – 97.63 
Alcohol 0.49 
0.29 – 0.85 
1.08 
0.23 – 4.79 
0.83 
0.43 – 1.58 
2.03 
0.48 – 8.14 
0.64 
0.43 – 0.94 
Amphetamines 0.00 
0.00 – 0.15 
0.00 
0.00 – 2.94 
0.20 
0.05 – 0.70 
0.00 
0.00 – 4.76 
0.05 
0.02 – 0.19 
Cocaine 0.05 
0.01 – 0.24 
0.00 
0.00 – 2.94 
0.00 
0.0 – 0.36 
0.00 
0.00 – 4.76 
0.03 
0.01 – 0.16 
THC 0.05 
0.01 – 0.23 
0.36 
0.03 – 3.60 
0.00 
0.00 – 0.36 
0.00 
0.00 – 4.76 
0.04 
0.01 – 0.17 
Benzodiazepines 0.91 
0.61 – 1.35 
0.36 
0.03 – 3.60 
0.57 
0.26 – 1.23 
0.71 
0.08 – 6.03 
0.79 
0.56 – 1.13 
Z-drugs 0.46 
0.26 – 0.80 
0.36 
0.03 – 3.60 
0.15 
0.03 – 0.62 
0.00 
0.00 – 4.76 
0.36 
0.21 – 0.60 
Medicinal opioids 0.69 
0.43 – 1.09 
0.72 
0.12 – 4.21 
0.27 
0.09 – 0.82 
0.00 
0.00 – 4.76 
0.56 
0.37 – 0.85 
Alcohol – drugs 0.12 
0.04 – 0.35 
0.00 
0.00 – 2.94 
0.00 
0.00 – 0.36 
0.00 
0.00 – 4.76 
0.08 
0.03 – 0.23 
Multiple drugs 0.20 
0.09 – 0.46 
0.00 
0.00 – 2.94 
0.52 
0.23 – 1.17 
0.68 
0.07 – 5.97 
0.29 
0.16 – 0.52 
6.4.4 Adjusted general distribution of alcohol alone by concentration 
Table 6.12 shows the adjusted general distribution of alcohol by concentration level. As previously 
mentioned these results should be interpreted with some caution (see Section 5.1 
Representativeness). As can be seen blood alcohol levels of between 0.1 and 0.49 g/L are most 
prevalent, accounting for almost 60% of all alcohol positive cases (adjusted). The prevalence of the 
other three blood alcohol concentration levels studied was much lower (e.g. 0.13% for 1.2 g/L and 
higher) and in fact almost zero for cases in the range 0.8-1.19 g/L. 
 
Table 6.12. Adjusted general distribution of alcohol alone by concentration (N=3841) 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 0.38 0.23 – 0.63 
Alcohol 0.5 – 0.79 g/L 0.10 0.04 – 0.27 
Alcohol 0.8 – 1.19 g/L 0.02 0.00 – 0.14 
Alcohol 1.2+ g/L 0.13 0.05 – 0.30 
In total 0.64 0.43 – 0.94 
6.4.5 Adjusted distribution of alcohol alone by gender and age 
Table 13 shows the adjusted general distribution of cases with alcohol alone according to age and 
gender. Of the four concentration ranges studied prevalence of alcohol cases below the legal limit (i.e. 
0.1-0.49 g/L) is highest for both male and female drivers. For male drivers these concentrations are 
prevalent in all age groups, varying between 0.18% (35-49 age group) and 0.68% (25-34 age group). 
In female drivers they are observed only in the older drivers, i.e. 35-49 (0.35%) and 50+ (0.22%) age 
groups. The most notable other findings in male drivers were a prevalence of 0.74% for blood alcohol 
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at, or above, 1.2 g/L in drivers aged 18-24 and of 0.50% for concentrations in the range 0.5-0.79 g/L in 
the 25-34 age group. Other prevalence values ranged from 0.08% to 0.18%. For all age groups no 
prevalence was recorded in either one or two of the concentration levels studied. For female drivers 
the only prevalence recorded above the legal limit was for concentrations at, or above, 1.2 g/L in 
drivers aged 50+ (0.23%), which was equivalent to that for cases below the legal limit in the same age 
group. No prevalence was recorded in 13 of the 16 age – concentration level cells. The prevalence 
values for both genders were reflective of those for male drivers. 
 
Table 6.13. Adjusted distribution of alcohol alone by gender and age (N= 3841) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.35 
0.06 – 1.97 
0.68 
0.24 – 1.92 
0.18 
0.04 – 0.87 
0.62 
0.29 – 1.29 
0.48 
0.27 – 0.83 
 0.5 – 0.79 g/L - 0.50 
0.15 – 1.65 
- 0.15 
0.04 – 0.61 
0.16 
0.06 – 0.40 
 0.8 – 1.19 g/L - - 0.13 
0.02 – 0.79 
- 0.04 
0.01 – 0.22 
1.2+ g/L 0.74 
0.21 – 2.59 
- 0.13 
0.02 – 0.79 
0.08 
0.01 – 0.51 
0.15 
0.06 – 0.40 
In total 1.08 
0.37 – 3.11 
1.19 
0.53 – 2.62 
0.44 
0.15 – 1.27 
0.85 
0.45 – 1.60 
0.82 
0.54 – 1.26 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L - - 0.35 
0.09 – 1.38 
0.22 
0.03 – 1.36 
0.20 
0.06 – 0.63 
 0.5 – 0.79 g/L - - - - 0.00 
0.00 – 0.30 
 0.8 – 1.19 g/L - - - - 0.00 
0.00 – 0.30 
1.2+ g/L - - - 0.23 
0.04 – 1.38 
0.07 
0.01 – 0.43 
In total 0.00 
0.00 – 2.71 
0.00 
0.00 – 1.44 
0.35 
0.09 – 1.38 
0.45 
0.12 – 1.74 
0.27 
0.10 – 0.74 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.23 
0.04 – 1.32 
0.44 
0.15 – 1.23 
0.25 
0.08 – 0.73 
0.51 
0.25 – 1.02 
0.38 
0.23 – 0.63 
 0.5 – 0.79 g/L - 0.32 
0.10 – 1.06 
- 0.11 
0.03 – 0.45 
0.10 
0.04 – 0.27 
 0.8 – 1.19 g/L - - 0.08 
0.01 – 0.46 
- 0.02 
0.00 – 0.14 
1.2+ g/L 0.49 
0.14 – 1.74 
- 0.08 
0.01 – 0.46 
0.12 
0.03 – 0.47 
0.13 
0.05 – 0.30 
In total 0.72 
0.25 – 2.09 
0.76 
0.34 – 1.69 
0.40 
0.17 – 0.96 
0.74 
0.41 – 1.32 
0.64 
0.43 – 0.94 
 
6.4.6 Adjusted distribution of alcohol alone by day of the week and time 
of the day 
Table 6.14 shows the adjusted distribution of cases with alcohol alone according to the time that they 
were recorded. Cases in the range 0.1-0.49 g/L were most prevalent in any individual time period and 
these were also the only cases for which a prevalence value was recorded in each period. Prevalence 
was higher at night (22:00-03:59) than daytime (04:00-21:59) and the prevalence on weekend nights 
was especially high (2.03%). The lowest value was for weekdays (0.27%). Weekdays were also the 
only period in which a prevalence value was recorded for all alcohol concentration levels studied, 
which may reflect the fact that these were the periods when there was most traffic flow during the 
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survey sessions. Prevalence values recorded in this period were also lowest for each concentration 
level in comparison to other time periods, when a value was recorded. The prevalence values for 
cases above the legal limit were between 0.04% (0.8-1.19 g/L) and 0.11% (at, or above 1.2 g/L). 
Although no prevalence of alcohol cases was recorded above 0.79 g/L on weeknights or at, or above, 
the legal limit on weekend nights these were still the periods when the total prevalence of cases with 
alcohol alone were highest (1.08% and 2.03% respectively). Total prevalence on weekend days was 
also higher than for weekdays (0.83% vs. 0.49%), although no prevalence was recorded between 0.8-
1.19 g/L. The absence of prevalence values, particularly in the night time periods is attributable to the 
relatively low traffic flows in these periods. 
 
Table 6. 14 Adjusted distribution of alcohol alone by day of the week and time of the day (N=3841) 
4 categories: weekdays, weekday nights, week-end days, week-end nights 
Period 
of the week 
Weekdays 
04:00 – 
21:59 
Weeknights 
22:00 – 
03:59 
Weekendday
s 
04:00 – 
21:59 
Weekendnig
hts 
22:00 – 
03:59 
In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.27 
0.13 – 0.55 
0.72 
0.12 – 4.21 
0.50 
0.22 – 1.15 
2.03 
0.48 – 8.14 
0.38 
0.23 – 0.63 
 0.5 – 0.79 g/L 0.08 
0.02 – 0.29 
0.36 
0.03 – 3.60 
0.13 
0.03 – 0.59 
- 0.10 
0.04 – 0.27 
 0.8 – 1.19 g/L 0.04 
0.01 – 0.21 
- - - 0.02 
0.00 – 0.14 
1.2+ g/L 0.11 
0.03 – 0.33 
- 0.20 
0.05 – 0.70 
- 0.13 
0.05 – 0.30 
In total 0.49 
0.29 – 0.85 
1.08 
0.23 – 4.79 
0.83 
0.43 – 1.58 
2.03 
0.48 – 8.14 
0.64 
0.43 – 0.94 
 
6.5 Discussion of results 
6.5.1 Representativeness 
The collection sessions were planned by a statistician of the Finnish Road Administration to give a 
representative sample of the national Finnish traffic flow. The comparison of age and gender 
distribution of the survey population with previous national research (HLT) from 2004-2005, in Section 
6.3.1, shows that the demographics of the two studies show strong similarities. Therefore it is apparent 
that the demographics of the survey population are indeed largely representative of the national traffic 
flow. Similarly the evaluation of age and gender of respondents (Annex 6.2) suggests that the high 
rate of refusal to participate in the survey for some collection sessions did not significantly affect the 
demographics of respondents. Although there was no sample collection between the hours 01:00-
07:00 this was not deemed to affect the representativeness of the survey due to the low levels of traffic 
in this period. 
The issue of alcohol positive cases also deserves further attention. Drunk driving cases above the 
legal limit 0.5‰ were detained for further examination by the police. Not all these cases were asked by 
police if they wished to participate in the survey, and in some cases participation was not possible (see 
Section 6.1.1.). Nonetheless, the percentage of alcohol positive cases above the legal limit included in 
the survey results (0.31%) was higher than that recorded for all traffic during DRUID sessions (0.20%), 
since these drivers were actually enthusiastic to take part in the survey when police procedure allowed 
it. Contrastingly, the percentage of cases which were alcohol positive, but below the legal limit, in all 
traffic passing through the check point (0.76%) was higher than that of drivers included in the survey 
results (0.44%). The prevalence of all ethanol positive (i.e. above zero) screening results for all drivers 
passing through the checkpoint (all drivers prevalence, N=36109) and those included in the survey 
results (DRUID prevalence, N=3841) are shown in Figure 2. The most significant differences seen are 
for weekday 16:00-22:00, weekend 04:00-10:00 and weekend 10:00-16:00: for all these periods the 
prevalence in all drivers is noticeably higher than that for drivers included in the DRUID survey results. 
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Figure 6.5. Prevalence of ethanol positive screening results (unadjusted)  
 
In Finland, the prevalence of DUI cases in Uusimaa region has been systematically studied for several 
decades. A recent report on drunk driving cases in Finland (2), called “Profile of a drunk driver and 
recidivism risk factors. Findings on the prevalence and development of drunk driving in roadside 
testing in Uusimaa 1990–2008”, has been published online and it contains, among other things, 
comprehensive statistics on the prevalences of DUI cases over the aforementioned time period. 
6.5.2 Effects of non-response 
Due to the requirements of the ethical advisory board participation in the Finnish roadside survey was 
voluntary. The resulting high non-response rate raised concerns that drivers who had used drugs 
would not participate. However, for the reasons presented in section 6.3.2, it seems that this was not 
necessarily a valid concern; the participation rate of drivers after learning about the purpose of the 
survey was very high. Furthermore, as a part of the police roadside procedure, which was prior to 
participating in the survey, the drivers were observed for signs of possible DUI. During the survey 
there was in fact only one driver who the police suspected of drug driving, who actually participated in 
the survey. In addition, the analytical findings for all drivers who originally participated in the DRUID 
survey (N=4192) show that there was quite a high number of cases (7%), which were positive (above 
the analytical cut-off) for a substance other than alcohol (including those not recorded for the DRUID 
survey, full listing see Annex I). Of these, 9 cases (0.21%) showed some indication of illegal drug use. 
6.5.3 Most important results 
As shown in table 6.9, overall the prevalence values presented are quite low (more than 97% of cases 
were negative). The  predominant findings in the Finnish DRUID survey sample are for 
benzodiazepines, or the similar acting Z-drugs, and cases with alcohol alone or medicinal opioids. Use 
of alcohol together with another drug was comparatively uncommon. Prevalence of alcohol or 
benzodiazepines alone and alcohol–drug or multiple drug combinations were generally higher among 
the male drivers compared to female drivers, whilst the reverse was true for Z-drugs and medicinal 
opioids. Findings for the illicit drugs amphetamines, cocaine and THC were clearly more isolated: in 
total, five cases out of 3841 were positive for illegal drugs (0.13%, unadjusted). It is apparent that, 
aside from alcohol alone, when both genders are considered together the prevalence values for the 
substance categories/combinations studied are lowest, or even zero, for the youngest age group (18-
24 years). For female drivers prevalence values above zero are almost exclusively in the age groups 
35-49 and 50+ years for all categories or combinations studied. For male drivers there are no such 
clear trends: prevalence values for many of the categories (e.g. benzodiazepines and opioids) appear 
to fluctuate with age group – one notable exception is alcohol alone which is clearly more prevalent in 
male drivers below 35 years of age. Concerning individual prevalence values according to time period, 
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the key findings appear to be for benzodiazepines on weekdays and for alcohol alone on nights and 
weekend periods, particularly weekend nights. Other notable results were comparatively high 
prevalence values for medicinal drugs, e.g. opioids and Z-drugs, on weekdays and nights as opposed 
to weekend periods. Contrastingly, the reverse was true for multiple drug combinations. It is 
emphasised that confidence intervals for the night time periods (22:00-03:59) were significantly wider 
than the day time periods. 
Regarding the results for alcohol alone positive cases according to concentration, almost 60% of these 
cases were below the legal limit (0.5‰). Among male drivers alcohol concentrations below 0.5 g/L 
were prevalent in all age groups and there was a noticeably high prevalence of cases with a 
concentration of 1.2 g/L, or more, in those aged under 25 years. For female drivers total prevalence 
(for all age groups) of alcohol alone was lower at all concentration levels and prevalence values were 
only observed in drivers aged above 34 years. Cases with alcohol alone were most prevalent at night 
and particularly on weekend nights. The blood alcohol concentrations of cases in these periods were 
all in the lowest two BAC concentration groups studied (i.e. below 0.8 g/L).  
Alcohol results should be interpreted with some caution due to the fact that these cases were not 
always asked to participate in the study as randomly as the other drivers due to reasons mentioned in 
Section 6.1.1 (concerning the normal police procedure in DUI cases). In addition, a number of cases, 
which were excluded from the database due to incomplete results for the toxicological analyses, were 
also found to be positive for some substance(s). Principal findings in this group were six alcohol 
positive cases and one benzodiazepine and Z-drug positive case – the total number of drug (other 
than alcohol) positive cases, including additional substances (see Annex 6.1), was seven. 
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Annex 6.1  
 
Calibration standards for analysis were made by spiking 0.5 ml of blank OF with stock solution 
containing all analytes. A blank OF sample was included in every run. For the standard preparation, 
blank OF was collected from laboratory personnel, frozen and thawed. Deuterated analogues of the 
analytes were used as internal standards. A LLOQ sample was run in every analysis as a quality 
control sample. For samples with concentrations higher than the ULOQ, it was not possible to make a 
subsequent analysis with a dilution because of the low initial sample volume available for analysis. In 
these cases, the results were extrapolated from the calibration curve. 
 
The OF samples were analysed with Agilent Technologies GC–MS systems. The analysis on EI mode 
was carried out with two devices: 6890N Network GC System with 5975B Mass Selective Detector 
(Fraction 1, see Figure 1 and 6890 GC System with Dean’s Switch and 5973 MSD (Fraction 2). The 
analysis on NCI mode was carried out with a 6890N Network GC System with 5975B MSD (Fraction 
3). GC-MS parameters are presented in figure 2. Retention times and the ions monitored in all three 
methods are presented in table 1. Ethanol was analysed only from the external quality control samples 
with a headspace–GC method previously described by Langel et al. 2008 (1). 
 
The OF analysis method has been fully validated. Validation results for all analytes are listed in table 
2. For linearity experiments, six replicates at six concentration levels were analysed in order to obtain 
a linear calibration model. The inverse of the squared concentration was used as a weighting factor. 
For analysis of ethanol (for quality control samples), the linearity was tested at nine concentration 
levels and in seven replicates. For precision and accuracy calculations, three concentration levels 
were chosen (LLOQ, medium concentration, ULOQ; and for ethanol low, medium and high 
concentration) for testing. Three replicates were prepared and measured against a calibration curve 
on five different days. From these results, precision and accuracy were calculated. For selectivity 
experiments, 10 blank OF samples from different persons were analysed to see if there were any 
selectivity problems. The selectivity of the methods was found to be very good for all analytes. 
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Figure 1. Flow chart of the sample preparation and analysis method for OF samples. Fraction 1: 
illicit drugs and medicinal drugs other than benzodiazepines, Fraction 2: benzoylecgonine, 
Fraction 3: benzodiazepines. 
 
 
 
 
 
 
 
water phase 1.4 ml of solvent 1.4 ml of solvent 
Derivatization of Fraction 1 
- solvent evaporation (75 °C, N2)  
- derivatization with 40 μl of 
derivatization solution: 3 parts 
BuAc:ACN (1:1) + 1 part 
MSTFA 
- incubation 30 min, 80 °C 
SPE extraction of Fraction 3 
- equilibration of SPE columns 
- sample loading (1.4 ml) 
- wash with i-Pr:EtAc 1:4 
- drying (N2) 
- sample elution 3 ml ACN with 3% 
NH3  
LLE extraction of Fraction 
2 (the water phase) 
- extraction with 5 ml DCM 
(30 s) 
- centrifugation (5 min, 
2000g) 
Derivatization of Fraction 2 
- evaporation of solvent (60 
°C, N2) 
- derivatization with 40 μl of 
derivatization solution: 3 
parts BuAc:ACN (1:1) + 1 
part MSTFA 
- incubation 30 min, 80 °C 
 
GC/EI–MS analysis 
- Agilent DB-5MS UI capillary 
column (15 m x 0.25 mm I.D. x 
0.25 μm) 
- carrier gas helium 
- temperature gradient 120 °C 
(0.5 min) -> 50 ºC/min -> 330 °C 
(3.0 min) 
- run time 9.73 min 
 
GC/NCI–MS analysis 
- Agilent DB-5HT capillary column 
(30 m x 0.32 mm I.D. x 0.1 μm) 
- carrier gas hydrogen 
- temperature gradient 160 °C (0.7 
min) -> 50 ºC/min -> 330 °C (0.4 
min) 
- run time 4.50 min 
LLE extraction 
- pH adjustment of all samples and standards with borate buffer (pH 10) 
- extraction with 3 ml BuAc (45 s) 
- centrifugation (5 min, 2000 g) 
- separation of 2.8 ml of solvent to clean test tubes 
Sample and calibration standard preparation 
- 0.5 ml of Statsure buffer is added to 0.5 ml calibration standards in OF 
- 1 ml of (or all available) sample (OF + buffer) is taken for analysis 
 
Derivatization of Fraction 3 
- evaporation of solvent (75 °C, N2) 
- derivatization with 40 μl of 
derivatization solution: 3 parts 
BuAc:ACN (1:1) + 1 part 
MTBSTFA 
- incubation 30 min, 80 °C 
 
GC/EI–MS analysis 
- Agilent DB-5MS UI 
capillary column (15 m x 
0.25 mm I.D. x 0.25 μm) 
- carrier gas helium 
- temperature gradient 150 °C 
(1 min) -> 40 ºC/min -> 330 
°C (1.0 min) 
- run time 5.75 min 
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Table 1. Retention times (RT) of the analytes and the ions monitored (quantifier in bold) for all 
three methods. 
Analyte RT [min] SIM ions 
[m/z] 
 Analyte RT [min] SIM ions 
[m/z] 
Fraction 1, GC–EI/MS 
Amphetamine 1.401 116, 91, 192  Carbamazepine 4.893 193, 194, 195 
Methamphetamine 1.729 130, 91, 206  Mirtazapine 4.903 195, 194, 208 
Ecgonine methyl 
 
2.538 182, 271, 240  THC 5.062 371, 386, 387 
Carisoprodol 2.610 160, 176, 187  Promazine 5.105 58, 284, 238 
MDA 2.775 116, 100, 236  Citalopram 5.330 324, 238, 208 
MDMA 3.081 130, 131, 250  Clomipramine 5.309 269, 268, 270 
MBDB 3.379 144, 145, 250  Codeine 5.369 371, 343, 313 
MDEA 3.411 144, 145, 264  Ethylmorphine 5.449 357, 385, 384 
PCP 3.797 200, 242, 243  Morphine 5.466 429, 414, 287 
Orphenadrine 3.941 58, 165, 178  Chlorprothixene 5.569 58, 221, 222 
Tramadol 3.962 58, 245, 335  Chlorpromazine 5.573 318, 272, 320 
Fluoxetine 4.095 219, 262, 381  Levomepromazine 5.611 328, 228, 329 
Methadone 4.521 72, 165, 178  6-acetylmorphine 5.664 399, 287 
Dextropropoxyphene 4.634 58, 208, 193  Zolpidem 6.329 235, 236, 220 
Amitriptyline 4.712 58, 202, 203  Hydroxyzine 6.526 201, 203, 165 
Cocaine 4.757 182, 303, 198  Norbuprenorphine 6.894 468, 500, 524 
Mianserine 4.778 264, 193, 220  Thioridazine 6.920 98, 370, 258 
Doxepin 4.820 58, 178, 202  Buprenorphine 7.343 450, 482, 451 
Fraction 2, GC–EI/MS 
Benzoylecgonine 4.896 361, 82, 240     
Fraction 3, GC–NCI/MS 
Diazepam 2.835 284, 286  Nitrazepam 3.325 395, 396 
Nordiazepam 2.911 234, 384  Temazepam 3.396 414, 282 
Midazolam 3.089 325, 327  Lorazepam 3.506 302, 304 
Flunitrazepam 3.121 313, 314  Clonazepam 3.522 429, 431 
Bromazepam 3.183 79, 429  Alprazolam 3.626 308, 310 
Phenazepam 3.285 314, 312  Zopiclone 3.824 143, 246 
Oxazepam 3.302 268, 270     
 
Table 2. Validation data for DRUID core substances and for the extra substances analysed in 
Finland. 
Analyte Internal standard Linearity 
range* 
[ng/mL] 
R2 Tested 
concentrations 
[ng/mL] 
Precision  
[%] 
high/mid/low 
Accuracy 
(bias)  
[%]  
high/mid/low 
DRUID core substances 
6-acetylmorphine 6-acetylmorphine-
d6 
1-50 0.9989 50/5/1 8.6/5.5/16.8 12.8/4.9/14.8 
Alprazolam Alprazolam-d5 0.5-25 0.9904 25/5/0.5 11.8/6.0/10.3 -9.2/8.4/0.9 
Amphetamine Amphetamine-d11 25-1250 0.9999 1250/125/25 7.2/6.2/5.2 7.4/7.2/5.8 
Benzoylecgonine Benzoylecgonine-
d3 
10-500 0.9927 500/100/10 12.0/8.8/18.8 -0.8/-2.1/-9.4 
Clonazepam Clonazepam
-d4 
0.5-25 0.9993 25/5/0.5 6.5/5.5/15.0 3.1/4.1/-3.7 
Cocaine Cocaine-d3 10-500 0.9999 500/50/10 6.0/5.0/8.5 7.9/4.7/4.6 
Codeine Codeine-d6 5-250 0.9998 250/25/5 8.6/7.0/6.0 9.7/4.1/5.9 
Diazepam Diazepam-d5 0.5-25 0.9974 25/5/0.5 6.5/6.9/13.0 9.3/4.2/0.2 
Flunitrazepam Clonazepam
-d4 
0.2-10 0.9980 10/2/0.2 9.3/7.2/17.4 4.4/-2.6/-10.4 
Lorazepam Oxazepam-d5 0.2-10 0.9930 10/2/0.2 9.6/9.1/13.7 -8.0/-3.2/2.7 
MDA MDMA-d5 25-1250 0.9995 1250/125/25 9.5/9.8/9.5 4.1/3.1/9.2 
MDEA MDMA-d5 25-1250 0.9933 1250/125/25 9.3/11.4/10.6 -0.2/7.4/-1.3 
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MDMA MDMA-d5 25-1250 0.9990 1250/125/25 8.5/7.2/7.2 6.1/8.9/4.5 
Methadone Methadone-d9 20-1000 0.9996 1000/100/20 11.6/9.7/11.3 13.9/7.8/13.1 
Methamphetamine Methamphetamine-
d14 
25-1250 0.9990 1250/125/25 7.6/8.5/9.3 4.5/10.8/5.7 
Morphine Morphine-d6 5-250 0.9970 250/25/5 7.2/13.8/13.9 3.8/5.6/-2.4 
Nordiazepam Nordiazepam-d5 0.5-25 0.9988 25/5/0.5 4.0/7.5/11.3 1.0/-3.8/-3.1 
Oxazepam Oxazepam-d5 0.5-25 0.9995 25/5/0.5 6.1/2.0/2.2 5.8/1.2/0.6 
THC THC-d3 1-50 0.9996 50/5/1 7.9/7.0/13.2 8.9/5.8/-0.0 
Zolpidem Cocaine-d3 10-500 0.9940 500/50/10 8.6/13.9/10.1 12.6/-9.2/1.1 
Zopiclone Alprazolam-d5 10-500 0.9900 500/100/10 15.8/17.5/11.5 0.1/-0.3/0.0 
Ethanol t-ButOH 0.1-6.0** 0.9999 3.0/1.5/0.5 3.0/1.9/2.9 -1.6/-2.8/1.0 
Extra substances 
Amitriptyline Cocaine-d3 20-1000 0.9993 1000/100/20 7.0/5.6/9.5 9.9/2.5/4.8 
Bromazepam Nordiazepam-d5 1-50 0.9925 50/10/1 12.1/11.5/13.1 16.5/-6.5/6.7 
Buprenorphine Buprenorphine-d4 0.5-25 0.9992 25/2.5/0.5 
6.9/7.4/
8.8 
12.3/6.
6/5.5 
Carbamazepine Cocaine-d3 20-1000 0.9962 1000/100/20 10.7/12.6/15.1 6.3/-1.6/1.9 
Carisoprodol MDMA-d5 50-2500 0.9999 2500/250/50 9.7/12.2/13.1 -1.6/-4.4/1.3 
Chlorpromazine Cocaine-d3 20-1000 0.9987 1000/100/20 
8.8/8.8/
12.5 
11.7/5.
9/8.4 
Chlorprothixene Cocaine-d3 20-1000 0.9977 1000/100/20 9.1/8.7/12.8 17.7/6.7/10.8 
Citalopram Cocaine-d3 10-500 0.9973 500/50/10 8.7/10.3/14.1 17.2/-1.3/7.2 
Clomipramine Cocaine-d3 20-1000 0.9990 1000/100/20 9.0/9.2/11.2 9.7/1.7/5.6 
Dextropropoxyphene Cocaine-d3 20-1000 0.9999 1000/100/20 9.0/7.8/9.5 13.1/4.6/7.1 
Doxepin Cocaine-d3 20-1000 0.9985 1000/100/20 8.3/8.6/8.0 15.0/3.3/8.2 
Ecgonine methyl 
ester Cocaine-d3 20-1000 0.9981 1000/100/20 12.6/10.1/11.9 19.2/8.7/15.5 
Ethylmorphine Codeine-d6 5-250 0.9999 250/25/5 7.7/9.5/7.1 4.5/2.1/0.4 
Fluoxetine Codeine-d6 10-500 0.9994 500/50/10 15.9/13.8/15.8 13.5/-0.1/-5.6 
Hydroxyzine Cocaine-d3 5-250 0.9994 250/25/5 7.4/9.5/10.4 13.4/-1.7/2.9 
Levomepromazine Cocaine-d3 10-500 0.9993 500/50/10 7.9/7.1/7.2 11.3/2.9/5.1 
MBDB MDMA-d5 25-1250 0.9936 1250/125/25 6.9/11.4/11.7 -7.7/10.0/4.1 
Mianserine Cocaine-d3 10-500 0.9994 500/50/10 6.8/6.8/9.0 11.7/4.8/5.5 
Midazolam Midazolam-d4 0.5-25 0.9860 25/5/0.5 6.6/4.6/12.7 2.8/4.8/-8.8 
Mirtazapine Cocaine-d3 10-500 0.9988 500/50/10 9.2/8.1/8.5 15.4/3.9/9.9 
Nitrazepam Clonazepam
-d4 
0.5-25 0.9987 25/5/0.5 6.4/3.1/17.9 12.2/5.9/-10.6 
Norbuprenorphine Buprenorphine-d4 0.5-12.5 0.9881 12.5/2.5/0.5 16.4/12.1/15.8 8.4/-1.5/11.4 
Orphenadrine Cocaine-d3 10-500 0.9943 500/50/10 8.4/9.7/12.9 14.5/1.8/9.4 
PCP Cocaine-d3 5-250 0.9995 250/25/5 7.1/8.7/8.4 9.6/6.1/7.8 
Phenazepam Oxazepam-d5 1.25-25 0.9990 25/5/1.25 10.9/5.3/7.8 7.5/6.7/-0.8 
Promazine Cocaine-d3 10-500 0.9984 500/50/10 8.0/8.6/9.7 15.6/0.5/6.4 
Temazepam Temazepam-d5 0.5-25 0.9993 25/5/0.5 6.4/2.4/4.2 3.8/2.7/6.6 
Thioridazine Cocaine-d3 25-1250 0.9994 1250/125/25 7.9/15.1/8.2 13.0/-4.1/-0.1 
Tramadol Codeine-d6 10-500 0.9993 500/50/10 8.0/11.1/19.0 4.1/2.7/-4.4 
* linearity range is from LLOQ to ULOQ  
** ‰. 
 
1. Langel K, Engblom C, Pehrsson A, Gunnar T, Ariniemi K, Lillsunde P. Drug testing in oral fluid 
- Evaluation of sample collection devices. J Anal Toxicol. [Article]. 2008 Jul-Aug;32(6):393-401. 
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Annex 6.2 
 
To compare the sessions where most drivers participated in the study to those with a lower inclusion 
rate, refusal rates for individual sessions were grouped as high and low. The low and high refusal 
rates were determined as 0 – 47.9 % and 48.0 – 84.6 % respectively. The respective distributions of 
age groups according to the DRUID time codes are shown in table 1. Respective distributions 
according to gender are shown in table 2. Comparison was made by χ2-test for the cross tabulations. 
Statistically significant difference was seen for age groups in the time period Weekend 10:00-16:00 (χ2 
= 8.050, p= 0.045) (denoted 1) only and gender in the time period Weekday 04:00-10:00 (χ2 = 6.095 
p= 0.014) (denoted 2) only. 
 
Table 1. Distribution of age groups according to time period 
  Age group (years) 
Time code Refusal rate 18-24 25-34 35-49 50+ All 
Weekday 04.00-10.00 low high 
7.4 % 
3.8 % 
16.6 % 
17.4 % 
28.2 % 
36.9 % 
47.9 % 
41.9 % 
100 % 
100 % 
Weekday 10.00-16.00 low high 
9.5 % 
8.1 % 
14.7 % 
15.7 % 
25.9 % 
30.9 % 
49.9 % 
45.3 % 
100 % 
100 % 
Weekday 16.00-22.00 low high 
14.6 % 
13.0 % 
25.1 % 
24.2 % 
31.4 % 
32.7 % 
28.9 % 
30.0 % 
100 % 
100 % 
Weekday 22.00-04.00 low high 
23.4 % 
24.0 % 
27.7 % 
28.8 % 
25.5 % 
28.8 % 
23.4 % 
18.5 % 
100 % 
100 % 
Weekend 04.00-10.00 low high 
4.5 % 
6.7 % 
12.5 % 
15.6 % 
27.3 % 
35.2 % 
55.7 % 
42.5 % 
100 % 
100 % 
Weekend 10.00-16.001 low high 
8.9 % 
3.9 % 
18.6 % 
16.9 % 
33.5 % 
43.8 % 
39.1 % 
35.4 % 
100 % 
100 % 
Weekend 16.00-22.00 low high 
27.9 % 
17.9 % 
23.0 % 
23.9 % 
31.1 % 
29.3 % 
18.0 % 
28.8 % 
100 % 
100 % 
Weekend 22.00-04.00 low high 
38.4 % 
28.0 % 
28.3 % 
28.0 % 
20.2 % 
28.0 % 
13.1 % 
16.0 % 
100 % 
100 % 
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Table 2. Distribution of gender according to time code 
 
 
 
 
 
 
 
 
 
 
  Gender 
Time code Refusal rate male female All 
Weekday 04.00-10.002 low high 
77.9 % 
67.7 % 
22.1 % 
32.3 % 
100 % 
100 % 
Weekday 10.00-16.00 low high 
70.1 % 
67.1 % 
29.9 % 
32.9 % 
100 % 
100 % 
Weekday 16.00-22.00 low high 
63.6 % 
56.4 % 
36.4 % 
43.6 % 
100 % 
100 % 
Weekday 22.00-04.00 low high 
69.0 % 
74.0 % 
31.0 % 
26.0 % 
100 % 
100 % 
Weekend 04.00-10.00 low high 
78.2 % 
67.0 % 
21.8 % 
33.0 % 
100 % 
100 % 
Weekend 10.00-16.00 low high 
68.2 % 
63.7 % 
31.8 % 
36.3 % 
100 % 
100 % 
Weekend 16.00-22.00 low high 
65.6 % 
65.2 % 
34.4 % 
34.8 % 
100 % 
100 % 
Weekend 22.00-04.00 low high 
74.7 % 
64.0 % 
25.3 % 
36.0 % 
100 % 
100 % 
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7.1 Introduction: 
The traffic safety in Hungary was better in the middle of the decade compared to the catastrophic 
situation in 1990-91. In the year of 2000 the registered number of road accidents resulting in injuries 
was 17493, from which 1200 people died. The rate of accidents while driving under the influence of 
alcohol was 11.8 % (1). Since then, the accident-rate has somewhat stabilized. In 2007, 20635 road 
accidents occurred leading to injuries and 1232 people died. The rate of accidents while driving under 
influence of alcohol also increased moderately (13.8 %). As the result of law amendments introduced 
in 2009 and increased police enforcement the situation improved, the number of accident-related 
death reduced below 1000 in this year. 
 
The frequency of drunk-driving was examined in the south-east region of Hungary in the frame of a 
roadside survey in 1999. According to the results, 1.04% of the stopped drivers tested positive for 
alcohol. The frequency was two times higher in the night hours and on the weekends compared to the 
daylight hours and weekdays (2). The police regularly conduct two broad enforcement campaigns per 
year, on the Monday after Easter and in December. During these campaigns, the frequency of drunk-
driving was found to be 0.3 – 0.4 %. In case of blood alcohol concentration below 0.8 g/l, 12-14 
thousand civil offence procedures are conducted yearly. For blood alcohol concentration above 0.8 g/l 
10090 criminal procedures were conducted in 2009 (3). Driving under the influence of drugs and 
alcohol has been prohibited in Hungary since 1999 and 2865 procedures have been launched by the 
traffic safety authorities in the last 10 years; however, driving under influence of licit and illicit drugs 
could only be proved with toxicological analysis in 669 cases in the last decade (4). There was no 
examination targeting the frequency of occurrence of the driving under influence of licit and illicit drugs. 
 
7.1.1 Description of the roadside sampling 
The survey – acting upon a part of the territory of the culpability study – was conducted in a southern 
east Hungarian region, Csongrád County (population: 424849 persons, Fig. 7.1). The traffic safety of 
the county can be considered average. Due to its geographic location there is significant international 
transit traffic. During planning, the sampling locations both in urban and suburban areas were jointly 
appointed with the traffic safety authority on the basis of traffic density and accident frequency.  
 
 
Figure 7.1. The map of Hungary and Csongrád County  
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The sampling was done by a group of 4-5 persons. Two traffic policemen stopped the traffic, controlled 
the documents and determined the breath alcohol-level. Drivers were informed about the purpose and 
the procession of the examination. After obtaining informed consent, the interview, physical 
examination and oral fluid sampling were done by one or two MD(s). In all groups a university student 
was responsible for the actual traffic counting. An examination period lasted about 1 – 1.5 hours and 
15-30 samples were gathered. Depending on traffic density 2 (weekday, daytime, highway exit) to 68 
% (out of built-up area, night) of drivers were examined. Samplings took place, all together, on 101 
occasions. 
Although, the examinations were started on the 1st of February 2008, only a few cases were analyzed 
until 2009 due to the unpreparedness of the toxicology laboratory. In spite of ethic’s approval and 
expressed informed consent of participants, at the end of 2008, a nationwide newspaper alleged that 
illegal DNA sampling had occurred so examinations had to be suspended for approximately 2 months. 
After this, the purpose and the method of examinations were presented in a nationwide media 
campaign, after which we were permitted to continue sampling. Therefore, the sampling was not 
continuous and balanced with respect to the fourth quarter. 
In spite of these limitations the sample can be considered representative of the country – with 
exception of the capital. More than the two-thirds of the samples (2197, 72.89 %) were gathered on 
main roads, with the remainder gathered on side-roads.  
The distribution of responder drivers according to age, gender, road type, season, and DRUID time 
periods is presented in Table 7.1 to 7.4. There were 5 persons below the age of 18 - their data were 
excluded from the data processing.  
Traffic counting data did not allow to group data according to DRUID periods as we only had data in 
cases of peripheral and built-up areas. In respect of other altering the weighted statistical figures were 
calculated based on international data.  
 
 
Table 7.1. Distribution of responder drivers by gender and age  
Age Male Female Total 
18-24 188 84 272 
25-34 641 243 884 
35-49 690 238 928 
50+ 541 113 654 
Altogether 2060 678 2738 
Table 7.2. Distribution of responder drivers by road type 
 
 
 
Table 7.3. Distribution of responder drivers by season 
Season 
Dec.-Feb. 262 
March-May 1062 
June-Aug 1187 
Sept.-Nov 227 
Total 2738 
 
Road type Urban Rural Total 
  1966 772 2738 
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Table 7.4. Distribution of responder drivers by time period 
DRUID time period 
1 Weekday 04:00-09:59 299 
2 Weekday 10:00-15:59 1377 
3 Weekday 16:00-21:59 318 
4 Weekday 22:00-03:39 194 
5 Weekendday 04:00-09:59 102 
6 Weekendday 10:00-15:59 97 
7 Weekendday 16:00-21:59 212 
8 Weekendday 22:00-03:39 139 
Total 2738 
 
 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
7.2 Roadside data collection and analysis 
 
Before the start of the examination the permission of the Regional Research Ethics Committee was 
obtained what was indicated on the information leaflet given to the persons examined and also on the 
written consent form. 
 
Breath alcohol level was determined in all cases. The examination was carried out by a fuel cell device 
(LION 400 type), the control examination of the positive cases was carried out by a SERES 679TH 
ethylometer functioning on the principal of infrared spectrography. A conversion factor of 1:2100 was 
applied to express the results as g/l blood concentration.  
Following alcohol determination a short interview took place with the cooperating persons. The 
parameters examined are presented in Annex 7.1. After the examination of physical symptoms, the 
oral fluid sampling was done using a Statsure device. According to our experience in more than 90% 
of the cases the collection of the oral fluid sample exceeding 1 ml was obtained within 2 minutes 
(discolouration of the indicator). In a few cases sampling lasting 5 minutes did not result in the 
discolouration of the indicator and in these cases there was only about 0.7 ml oral fluid available for 
analysis. The samples were stored in cool bag on +4 C0 and delivered within an hour to the toxicology 
laboratory. 
 
The conditions of sample processing, GC-MS analyses, the validation procedure and its results are 
described in Annex 7.1. 
 
7.3 Non-response 
 
After police control and breath testing, 372 persons (12.28 %) refused cooperation in further 
examinations. Among these, the number of females was relatively higher (female 13.9 %, male 11.8 
%, of all cases). Among non-responders, the 35-49 age-group was over represented (64.4 %), and 
their rate was higher on weekdays and weekend afternoons (3. and 7. time periods). Cooperation was 
influenced by the weather as well. The rate of the non-responders during the winter months was 
between 17.6 – 42.9 %, and between 6.1 – 14.7 % in the spring and summer.. 
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Table 7.5. Distribution of non responders according by age and gender 
Age Male Female Total 
18-24 15 6 21 
25-34 54 23 77 
35-49 116 52 168 
50+ 82 24 106 
Altogether 267 105 372 
 
Table 7.5. Distribution of non responders according by age and gender 
DRUID time period 
1 38 
2 200 
3 54 
4 5 
5 12 
6 12 
7 40 
8 11 
Total 372 
  
 
As illicit drug consumption is most common below age 35, and as licit drug and alcohol consumption 
is more frequent over 50, we think that the number of non-responders does not have significant 
influence on the sample’s evaluation. It is worthwhile to note that there was no full street blockade 
during the sampling – vehicles were pulled over at random – which made it possible for a portion of 
drivers to avoid the control. Keeping this in mind, mostly with respect of alcohol, it is not possible to 
exclude underrepresentation in the sample.  
 
7.4 Results 
 
Analytical results of the core substance groups weighed for time period are presented in Table 7.6. 
Although 5 amphetamine group positive cases (2 males and 3 females) were found these data are 
excluded from the calculations as their concentration was below the recommended DRUID cut-off 
(Annex 2). 
 
Table 7.6. Adjusted general distribution of core substance categories (N=2738) 
Substance category Prevalence (%) Confidence interval (%) 
Negative 97.68 97.04 – 98.18 
Amphetamines - - 
Cocaine 0.04 0.01 – 0.21 
THC 0.19 0.08 – 0.44 
Illicit opiates - - 
Benzodiazepines 1.50 1.11 – 2.03 
Z-drugs 0.07 0.02 – 0.26 
Medicinal opioids 0.11 0.04 – 0.32 
Alcohol 0.15 0.06 – 0.38 
Alcohol – drugs - - 
Multiple drugs 0.27 0.13 – 0.54 
 
 
Distribution of core substance categories according to age, gender, and time period are shown in 
Tables 7.7 and 7.8.
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Table 7.7. Adjusted distribution of core substance categories by gender and age (N=2738) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 96.81 
93.10 - 98.55 
98.31 
97.00 – 99.05 
98.94 
97.86 – 99.47 
96.46 
94.52 – 97.73 
97.92 
97.21 – 98.45 
Amphetamine - - - - - 
Cocaine 0.00 
0.00 – 2.09 
0.08 
0.01 – 0.73 
0.07 
0.01 – 0.68 
0.00 
0.00 – 0.72 
0.05 
0.01 – 0.28 
THC 0.58 
0.11 – 3.13 
0.49 
0.17 – 1.39 
0.15 
0.03 – 0.82 
0.00 
0.00 – 0.72 
0.26 
0.11 – 0.59 
Illicit opiates - - - - - 
Benzodiazepines 2.61 
1.09 – 6.12 
0.96 
0.45 – 2.05 
0.41 
0.14 – 1.23 
3.06 
1.90 – 4.90 
1.46 
1.02 – 2.07 
Z-drugs 0.00 
0.00 – 2.09 
0.00 
0.00 – 0.58 
0.00 
0.00 – 0.55 
0.00 
0.00 – 0.72 
0.00 
0.00 – 0.19 
Medicinal opioids 0.00 
0.00 – 2.09 
0.08 
0.01 – 0.73 
0.05 
0.00 – 0.63 
0.19 
0.03 – 1.07 
0.09 
0.02 – 0.34 
Alcohol 0.00 
0.00 – 2.09 
0.00 
0.00 – 0.58 
0.38 
0.12 – 1.18 
0.28 
0.06 – 1.21 
0.20 
0.08 – 0.51 
Alcohol – drugs - - - - - 
Multiple drugs 0.00 
0.00 – 2.09 
0.08 
0.01 – 0.73 
0.00 
0.00 – 0.55 
0.00 
0.00 – 0.72 
0.02 
0.00 – 0.23 
 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 100.00 
95.10 – 100.00 
95.74 
92.40 – 97.65 
96.73 
93.66 – 98.34 
97.86 
93.44 – 99.32 
96.94 
95.35 – 97.99 
Amphetamine - - - - - 
Cocaine 0.00 
0.00 – 4.90 
0.00 
0.00 – 1.56 
0.00 
0.00 – 1.56 
0.00 
0.00 – 3.08 
0.00 
0.00 – 0.56 
THC 0.00 
0.00 – 4.90 
0.00 
0.00 – 1.56 
0.00 
0.00 – 1.56 
0.00 
0.00 – 3.08 
0.00 
0.00 – 0.56 
Illicit opiates - - - - - 
Benzodiazepines 0.00 
0.00 – 4.90 
1.46 
0.54 – 3.89 
2.05 
0.87 – 4.72 
2.14 
0.68 – 6.56 
1.63 
0.91 – 2.89 
Z-drugs 0.00 
0.00 – 4.90 
0.80 
0.21 – 2.92 
0.00 
0.00 – 1.56 
0.00 
0.00 – 3.08 
0.28 
0.08 – 1.05 
Medicinal opioids 0.00 
0.00 – 4.90 
0.21 
0.02 – 1.96 
0.21 
0.02 – 1.96 
0.00 
0.00 – 3.08 
0.15 
0.03 – 0.84 
Alcohol 0.00 
0.00 – 4.90 
0.00 
0.00 – 1.56 
0.00 
0.00 – 1.56 
0.00 
0.00 – 3.08 
0.00 
0.00 – 0.56 
Alcohol – drugs - - - - - 
Multiple drugs 0.00 
0.00 – 4.90 
1.79 
0.73 – 4.37 
1.01 
0.31 – 3.24 
0.00 
0.00 – 3.08 
1.00 
0.48 – 2.07 
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Total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 97.74 
95.08 – 98.98 
97.62 
96.39 – 98.43 
98.37 
97.34 – 99.00 
96.72 
95.05 – 97.84 
97.68 
97.04 – 98.18 
Amphetamine - - - - - 
Cocaine 0.00 
0.00 – 1.49 
0.06 
0.01 – 0.54 
0.05 
0.01 – 0.51 
0.00 
0.00 – 0.59 
0.04 
0.01 – 0.21 
THC 0.41 
0.08 –2.22 
0.36 
0.13 – 1.02 
0.11 
0.02 – 0.61 
0.00 
0.00 – 0.59 
0.19 
0.08 – 0.44 
Illicit opiates - - - - - 
Benzodiazepines 1.85 
0.77 – 4.35 
1.10 
0.59 – 2.02 
0.83 
0.42 – 1.64 
2.89 
1.85 – 4.48 
1.50 
1.11 – 2.03 
Z-drugs 0.00 
0.00 – 1.49 
0.22 
0.06 – 0.80 
0.00 
0.00 – 0.41 
0.00 
0.00 – 0.59 
0.07 
0.02 – 0.26 
Medicinal opioids 0.00 
0.00 – 1.49 
0.11 
0.02 – 0.63 
0.09 
0.01 – 0.57 
0.16 
0.03 – 0.87 
0.11 
0.04 – 0.32 
Alcohol 0.00 
0.00 – 1.49 
0.00 
0.00 – 0.43 
0.28 
0.09 – 0.88 
0.23 
0.05 – 0.99 
0.15 
0.06 – 0.38 
Alcohol – drugs - - - - - 
Multiple drugs 0.00 
0.00 – 1.49 
0.54 
0.23 – 1.28 
0.26 
0.08 – 0.84 
0.00 
0.00 – 0.59 
0.27 
0.13 – 0.54 
 
Table 7.8. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=2738) 
4 categories: weekdays. weekday nights. week-end days. week-end nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekend 
days 
04:00 – 21:59 
Weekend 
nights 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 97.39 
96.59 – 98.01 
97.42 
90.02 – 99.37 
98.38 
97.09 – 99.10 
100.00 
93.12 – 100.00 
97.68 
97.04 – 98.18 
Amphetamine - - - - - 
Cocaine 0.05 
0.01 – 0.29 
0.00 
0.00 – 5.75 
0.00 
0.00 – 0.59 
0.00 
0.00 – 6.88 
0.04 
0.01 – 0.21 
THC 0.11 
0.03 – 0.38 
0.00 
0.00 – 5.75 
0.48 
0.17 – 1.38 
0.00 
0.00 – 6.88 
0.19 
0.08 – 0.44 
Illicit opiates - - - - - 
Benzodiazepines 1.69 
1.21 – 2.36 
2.06 
0.44 – 9.20 
0.99 
0.47 – 2.09 
0.00 
0.00 – 6.88 
1.50 
1.11 – 2.03 
Z-drugs 0.10 
0.03 – 0.36 
0.00 
0.00 – 5.75 
0.00 
0.00 – 0.59 
0.00 
0.00 – 6.88 
0.07 
0.02 – 0.26 
Medicinal opioids 0.13 
0.04 – 0.41 
0.52 
0.04 – 6.69 
0.00 
0.00 – 0.59 
0.00 
0.00 – 6.88 
0.11 
0.04 – 0.32 
Alcohol 0.16 
0.06 – 0.46 
0.00 
0.00 – 5.75 
0.15 
0.03 – 0.85 
0.00 
0.00 – 6.88 
0.15 
0.06 – 0.38 
Alcohol – drugs - - - - - 
Multiple drugs 0.37 
0.18 – 0.75 
0.00 
0.00 – 5.75 
0.00 
0.00 – 0.59 
0.00 
0.00 – 6.88 
0.27 
0.13 – 0.54 
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Results for alcohol alone are presented in Tables 7.9-7.11. 
 
Table 7.9. Adjusted general distribution of alcohol by concentration class (N=2738) 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 0.05 0.01 – 0.24 
Alcohol 0.5 – 0.79 g/L 0.02 0.00 – 0.18 
Alcohol 0.8 – 1.19 g/L 0.00 0.00 – 0.14 
Alcohol 1.2+ 0.08 0.02 – 0.28 
In total 0.15 0.06 – 0.38 
 
Table 7.10 Adjusted distribution of alcohol alone by gender and age (N=2738) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L - - - 0.28 
0.06 – 1.21 
0.07 
0.02 – 0.31 
 0.5 – 0.79 g/L - - 0.07 
0.01 – 0.68 
- 0.02 
0.00 – 0.23 
 0.8 – 1.19 g/L - - - - 0.00 
0.00 – 0.19 
1.2+ - - 0.31 
0.09 – 1.07 
- 0.11 
0.03 – 0.37 
In total 0.00 
0.00 – 2.09 
0.00 
0.00 – 0.58 
0.38 
0.12 – 1.18 
0.28 
0.06 – 1.21 
0.20 
0.08 – 0.51 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L - - - - 0.00 
0.00 – 0.56 
 0.5 – 0.79 g/L - - - - 0.00 
0.00 – 0.56 
 0.8 – 1.19 g/L - - - - 0.00 
0.00 – 0.56 
1.2+ - - - - 0.00 
0.00 – 0.56 
In total 0.00 
0.00 – 4.90 
0.00 
0.00 – 1.56 
0.00 
0.00 – 1.56 
0.00 
0.00 – 3.08 
0.00 
0.00 – 0.56 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L - - - 0.23 
0.05 – 0.99 
0.05 
0.01 – 0.24 
 0.5 – 0.79 g/L - - 0.05 
0.01 – 0.51 
- 0.02 
0.00 – 0.18 
 0.8 – 1.19 g/L - - - - 0.00 
0.00 – 0.14 
1.2+ - - 0.23 
0.07 – 0.80 
- 0.08 
0.02 – 0.28 
In total 0.00 
0.00 – 1.49 
0.00 
0.00 – 0.43 
0.28 
0.09 – 0.88 
0.23 
0.05 - 0.99 
0.15 
0.06 – 0.38 
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Table 7.11. Adjusted distribution of alcohol alone by day of the week and time of the day (N=2738) 
4 categories: weekdays. weekday nights. week-end days. week-end nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekend days 
04:00 – 21:59 
Weekend nights 
22:00 – 03:59 
In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.03 
0.00 – 0.24 
- 0.15 
0.03 – 0.85 
- 0.05 
0.01 – 0.24 
 0.5 – 0.79 g/L 0.03 
0.00 – 0.24 
- - - 0.02 
0.00 – 0.18 
 0.8 – 1.19 g/L - - - - 0.00 
0.00 – 0.14 
1.2+ 0.11 
0.03 – 0.38 
- - - 0.08 
0.02 – 0.28 
In total 0.16 
0.06 – 0.46 
0.00 
0.00 – 5.75 
0.15 
0.03 – 0.85 
0.00 
0.00 – 6.88 
0.15 
0.06 – 0.38 
 
 
7.5 Discussion 
7.5.1Representative quality of the sample 
The sampling took place only in Csongrád County because the Hospital Study was planned also in 
this area, and the area of culpability study also encompasses it.  
The status of this region, with respect to chronic alcohol and illicit drug consumption is worse than the 
nationwide average. According to data from legal proceedings against illegal drug users, the 
nationwide average related to 100 000 inhabitants was 39.45 in 2008 and 47.45 in 2009, these values 
in Csongrád County were 63.23 and 60.94, respectively. 
This can be explained by the border proximal geographical location of the County and the presence of 
intermediate and advanced institutions which leads to the relatively high number of youth residing in 
Csongrád County. It is also possible that in Csongrád County police activity is more focused on illicit 
drugs than in other counties. The higher frequency of illicit drug consumption is also supported by the 
fact that illicit drug related mortality is the second highest in the country after Budapest.  
However, the traffic safety situation is better than the nationwide average which is demonstrated by 
lower frequency of traffic accidents and accidents resulting in death, and also the lower number of 
accidents that occurred under the influence of alcohol (Table 7.12).  
Summarizing the above mentioned for the whole country we must count on more cases driving under 
influence of alcohol and less under influence of illicit drugs than it is demonstrated by our data. Our 
results do not represent the situation in Budapest as significantly different traffic situation, alcohol and 
drug consumption habits exist there. 
As it has already been mentioned, according to our opinion the 12.28 % non-responders (primary 
female and of the 35-49 age-group) does not influence the results significantly.  
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Table 7.12.  The rate of traffic accidents, traffic fatalities, and the accidents caused by drunk drivers 
related to 100 000 inhabitants (2008). 
County Traffic accidents Traffic fatalities Accidents caused by 
drunk drivers 
Budapest 222.58 4.82 11,63 
Bács-Kiskun 166.57 11.62 24,92 
Baranya 171.96 8.83 27,48 
Békés 177.06 11.68 25,48 
Borsod 140.62 6.62 21,42 
Csongrád 161.75 6.37 19,33 
Fejér 198.55 10.50 27,30 
Győr-Sopron 193.29 12.60 20,70 
Hajdu-Bihar 223.98 9.38 25,01 
Heves 159.36 9.78 22,09 
Jász-Szolnok 181.86 12.53 20,29 
Komárom 210.74 11.76 34,65 
Nógrád 147.95 3.33 19,98 
Pest 191.21 9.12 27,78 
Somogy 205.85 12.00 36,31 
Szabolcs 185.29 8.06 31,17 
Tolna 170.72 13.84 23,49 
Vas 221.08 6.49 23,29 
Veszprém 214.88 10.79 26,27 
Zala 190.26 11.31 29,14 
All together 190.87 8.86 23,31 
 
7.5.2 Alcohol 
Information about the occurrence of drunk driving is only available from statistics derived from police 
investigations. According to these, in 2009 13.8 % of the parties at fault in an accident were drunk 
which is likely underrepresented as many accidents caused only property damage or resulted in slight 
injuries so no police measure took place. According to the data specifically on Csongrád County in 
1994-95, 56 % of accident victims who died within 6 hours and 34 % of the accident wounded who 
were treated at emergency departments were drunk. These rates of drunkenness among driver who 
died or were injured in a vehicle accident were 56 % and 38 %, respectively (5). These rates have not 
changed significantly in the last few years. Between 2000 and 2005, 39 % of the deceased in traffic 
accidents and 36 % of the drivers injured lethally were drunk. The average blood alcohol concentration 
was 2.09 g/l and 1.86 g/l respectively (6-7). 
 
No nationwide survey has been prepared concerning the frequency of driving under influence of 
alcohol. However, according to the criminal statistics, criminal procedures were launched against 
10090 persons in 2009 due to driving under the influence of alcohol (the blood alcohol concentration 
was higher than 0,8 g/l), while the detection of lower blood- or air alcohol concentration resulted in civil 
charges laid against 11925 vehicle drivers (12). In 1999 roadside survey was carried out solely in 
Csongrád County. Alcohol could be detected in 1.04 % of the examined drivers’ exhaled air (2). The 
frequency of occurrence was higher on weekends and at night, and was highest in males. The 
frequency was one of the lowest in Europe, with lower figures announced only in Scandinavian 
countries. According to nationwide statistical data, law amendments (zero tolerance) and increased 
police activity resulted in the decrease of drunk-driving over the last few years. During the Easter 
campaign of 2010, drunkenness could be proved in only 0.4% of the stopped drivers.  
 
Our results show comparably lower frequency of drunk-driving with respect to the last decades. The 
traffic safety measures introduced in the last years, the widespread use of air-alcohol determination 
and increased police activity likely have a role in this trend. It should be considered that present 
examinations were carried out on street passages showing increased traffic, however driving under 
alcohol influence typically occurs around pubs and on side-roads. During the campaign there was no 
full street cut-off, so drivers noticing the stoppage had the opportunity to avoid it. In spite of this, the 
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results suggest that the strict legal regulation was successful and driving under influence of alcohol 
has reduced among vehicle drivers.  
 
Trends found with time of the day, age and gender agree with former examination results and data in 
other states. The frequency of drunkenness is more frequent in males, over the age of 35, most 
common in suburban areas, on weekends and in the night hours. 
 
The air alcohol concentration we found was also really low (equal to 0,998 g/l blood concentration on 
average) which complies with the former data, as well. Although the blood alcohol concentration noted 
in cases of lethal traffic accidents was around 2.0 g/l (noted by road surveys in other states as well), 
the levels found in average drivers were significantly lower. These data show that only a small portion 
of drivers consume alcohol; however, this population is responsible for many fatal- and injurious motor 
vehicle accidents.  
 
7.5.3 Medicines  
A significant portion of the adult population in Hungary suffers from a psychological sickness, primary 
depression where the frequency of occurrence is around 10 % according to some surveys. There is no 
nationwide representative survey on the subject, however; the number of persons abusing medicine in 
Hungary was estimated around 100 thousand by Bauer 20 years ago (8). Based on statistical data of 
the amount of prescribed medicines (National Health Insurance Institution) it can be estimated that 
benzodiazepine derivatives were consumed regularly by 100-130 thousand people in 2009. 
Depression and different personality disorders occur with frequency of 6.8/10000 among persons sent 
for a disability examination (10). According to a survey of 14-16 year-olds, the life-time prevalence of 
medicine consumption without medical provision is 21.4 %, more than half the time medication was 
taken with alcohol (12).  
Previously, no representative survey has been conducted to determine the sedative consumption of 
drivers. Over the last decade, in Csongrád County, in 2.04 % of fatally injured traffic accident victims 
(5.3 % in drivers, 2.5 % in passengers) we detected the presence of sedatives, mainly benzodiazepine 
derivatives (7). These figures are slightly lower than data from West-European countries, however; in 
drivers suspected of driving under the influence of drugs, sedatives were only found in the blood and 
urine of 3.56 % (4). 
The low frequency reported in this population does not comply with the figures found in fatal accident 
victims and is much lower than the data stated in the bibliography. This can be explained by the fact 
that pre-screening of the samples was done using the FPIA method which employs a cut-off level (e.g. 
40 ng/ml benzodiazepines) that is above therapeutic range, so it is possible a significant number of 
impaired drivers were not recognized. 
The present examination showed benzodiazepines and Z-drugs in 0.71 % of oral fluid samples (the 
prevalence was 0.61 % in males and 1.12 % in females). The occurrence was higher in females and 
those over the age of 35. The frequency of consumption increased with age which corresponds with 
gender and age trends in psychiatric illness as well as sedative drug related-suicide. Occurrence was 
higher during the daylight hours on both weekdays and the weekend. This means – bearing in mind 
the occurrence rate of metabolites – that the observed medication found in our testing was due to the 
daytime use of these medications, taken in order to reduce stress, and not due to typical night time 
usage for the aid of relaxation or sleep. It can be recognized, from the interviews, that in most positive 
cases, consumption was not on medical provision and regularly; however, even a single instance of 
consumption significantly raises the risk of an accident.  
During examination of fatal accident victims, we recognized that benzodiazepines occurred with 
alcohol in two-thirds of the cases which significantly increases the risk of accident by synergist effect. 
However, in our present examinations, common presence of medicine and alcohol was found only in 
one case.  
 
7.5.4 Medicinal opiates  
These kinds of medications are indicated for those suffering from degenerative locomotor diseases, 
which occur more frequently with age. Diseases of the ICD XIII group occurred with a frequency of 
2.4/10000 among persons sent for a disability examination (10). With respect to usage of medical 
opiates by drivers, we have no previous data and neither was blood or urine level of medicinal opiates 
determined in our examinations of fatal accident victims.  
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In our current survey, the prevalence was 2.8 % and the frequency was almost the double in females 
compared to males. The frequency of consumption increased with age which corresponds with the 
occurrence of the degenerative locomotor diseases. The frequency – both on weekdays and 
weekends – was the highest before noon, which corresponds to consumption at the start of work and 
daily physical activity. 
 
7.5.5 Illicit Drugs 
Unfortunately, we only have a vague estimation with respect to the frequency of illicit drug usage. The 
number of regular drug users is estimated to be around 30-40 thousand; the amount of occasional 
users may be much higher than this.  
According to a survey of 14-16 year olds, the life-long prevalence of illicit drug usage among them is 
15.9 %, most frequently THC (14.1 %), followed by the consumption of amphetamine derivatives. The 
consumption of cocaine has grown over recent years and in the last 1-2 years the drugs GHB and 
mephedrone have become more common (11). 4317 new drug addicted persons were treated by 
healthcare institutions in 2009; however, mortality is quite low. Drug overdose resulted in death in less 
than 40 instances nationwide and there is a downward trend over the last decade (13). The presence 
of illicit drugs in fatal accident victims has been examined regularly in Csongrád County for 15 years. 
The frequency of occurrence is 0.56 % and the presence of illicit drug effect at the time of accident 
could be proved in 0.8 % of drivers lethally injured (7). Blood- and urine samples of 2865 drivers were 
examined who were suspected of driving under the influence of drugs between 2000 and 2009. The 
presence of illicit drugs or their decomposition elements could be proved from urine 2133 times and 
669 times from the blood. The drug most frequently found was THC; the next most frequent were 
amphetamine derivatives. Cocaine usage has increased in the last years, and the rate of 
politoxicomania is rather high (4). 
During our present examinations the presence of illicit drugs could be proved in 29 cases, which is 
1.06 % frequency. The most common is THC, followed by the consumption of cocaine. 
Politoxicomania was frequent, e.g. heroine consumption could be proved only together with other 
substances. Trends based on gender and age showed the consumption of illicit drugs is more frequent 
in young males. It deserves attention that during the interviews drug consumption before driving was 
admitted by only four persons who confessed using THC.  
 
In summary, our examinations executed during the roadside survey show that the formerly low alcohol 
consumption has decreased, and it is consumed primarily by males and over the age of 35. Compared 
with alcohol, one order of magnitude more medications (primarily benzodiazepines) could be 
identified, which indicates not only to the spread of consumption but also the fact that inhabitants do 
not recognize these medicines’ effects with reference to increased risk of accident. It deserves 
attention that - according to the interviews - most of the medicine-consumers use the medications 
occasionally and not regularly, based upon medical provision. The presence of illicit drugs – compared 
to frequency of alcohol consumption – is relatively high. The ratio of frequency, of the different various 
substances, agrees with the nationwide ratios of illicit drug consumption. Drug use was most frequent 
in young males, however in case of amphetamine derivatives there was no difference found between 
the genders. The higher use of illicit drugs by youth and compared to the frequency of driving under 
influence of alcohol corresponds with the high prevalence of illicit drug use noticed in youth by the 
ESPAD examinations. Besides the spread of illicit drug consumption, the high frequency of driving 
under the influence of illicit drugs can also be explained by the lack of roadside enforcement and by 
the fact that – as opposed to alcohol – only a small number of drivers consuming illicit drugs are 
recognized and punished.  
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Annex 7.1 
 
QUESTIONNAIRE FOR ROAD-SIDE SURVEY (USZ 34) 
 
         No:…………… 
 
 
Sex: male  female 
Age: ………..year 
Date and time: 200…year……month…....day…..hour……..minute 
Type of the road:   city   outskirts 
    main-road  side-road 
Type of vehicle:  car lorry bus motorbike. others 
Driving experience:………………..year 
Distance/year:………………km 
Distance of the previous drive:………..km 
 
Chronic illnesses:……………………………………………………………………... 
Regular medicine consumptions:…………………………………………………………… 
Date and type of the last medicine consumption…………………………............ 
………………………………………………………………………………………………….. 
Last alcohol consumption  date:…………………………………………………………….. 
    quantity:……..…dl beer,………….dl wine………..dl spirit  
Illegal drug consumption………………………………………………………………….... 
Last illegal drug consumption  date:………………………………………….................. 
     type………………………………………………. 
 
Clinical symptoms 
 Alcoholic odour   non  uncertain certain 
 Pupils:    narrow  normal  dilated 
 Reaction of pupils:  normal  damaged 
 Conjunctivae:   anaemic normal  red 
 Nystagmus:   non  horizontal vertical 
 Romberg-sign:   negative uncertain positive 
 Finger-nose probe:  negative uncertain positive 
 Orientation:   orientated uncertain disturbed 
 Memory:   normal  partly disturbed disturbed 
 Pulse: ………../min. 
 
Breath alcohol concentration: negative  positive (……. mg/l) 
 
 
 
………………………………… 
physician    
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Analysis of the oral fluid samples 
Materials All materials were analytical or HPLC grade: Na2HPO4, H3PO4, NaHCO3, KOH, CH2Cl2 – 
Merck; acetonitrile (ACN), butyl-acetate (BuOAc) – Scharlau, Germany; HFBA, MTBSTFA, MSTFA 
Sigma-Aldrich (USA); standards and deuterated analogs of 1 mg/ml or 0.1 mg/ml – Promochem 
(USA), except some non-deuterated standards of GC-MS grade which were the precious donation of 
the producers: Zopiclone, Zolpidem, Alprazolam (Sanofi-Aventis), Midazolam, Clonazepam (Roche), 
Tramadol (TEVA).  
 Sample collection: Oral fluid (OF) samples for the Road Side Survey (RSS) were collected by 
Statsure device. The average weight of the devices was calculated as the average of ten container + 
plug + stick without wrapper (7.93 ± 0.03). The buffer was separately stored at 4 oC and 1 ml was 
added into the container just before OF collection and the container was closed. The samples were 
kept in cool bag during collection, then in refrigerator until weighing and filtration (within 12 hours after 
collection). 200 µl of the filtered samples was stored in a 2 ml cryogenic tube (Brand Gmbh, Germany) 
for determination of amphetamines, the other part in another tube for determination of the other 
compounds. All samples were stored at - 80 oC until analysis. As the quantity of the OF collected 
generally differ from 1 ml (1 g), a correction factor was calculated for the positive samples by the 
formula: 
 F = 2/(weight of the sample in the container with sticker and plug - 7.93). 
Sample processing 
I. Amphetamines (AMF, MA, MDA, MDMA, MDEA) 
To 200 µl OF sample (containing Statsure) 50 µl bicarbonate buffer, 10 µl ISTD solution, and 0.5 ml 
extraction-derivatization reagent were added during mixing by Vortex. Mixing was continued for an 
additional 15 seconds and the samples were centrifuged (3000 rpm, 5 minutes). 50 µl from the upper 
phase was transferred into 32 x 11,6 mm GC vial with 200 µl insert (VWR Int., Germany ), capped, 
and measured by GC-MS in EI mode. 
Bicarbonate buffer: 8.5 ml cc NaHCO3 solution + 1.5 ml 10 M KOH (daily prepared); ISTD: mixture of 
D-5 analogs of AMF, MA, MDMA, and MDEA in a 5 µg/ml concentration each in methanol; Extraction-
derivatization reagent: 485 µl toluene + 15 µl HFBA (daily prepared)   
II. Other DRUID core substances, midazolam, temazepam, nitrazepam, 7-amino clonazepam, 
ketamine, and tramadol. 
To 1 ml OF sample 0.5 ml phosphate buffer (pH=9), 10 µl ISTD and 5 ml butyl-acetate were added in 
a 12 ml capped centrifuge tube (Brand, Germany), and extracted for 30 seconds with a Multi-Pulse 
Vortexer (Glas-Col, USA). After centrifuge (3000 rpm, 5 minutes) 4.5 ml organic phase was transferred 
into clean tubes and evaporated at 60 oC by pressed air in a TurboVap LV Concentration Workstation 
(Caliper LifeSci., USA). The samples were reconstituted with 75 µl acetonitrile (ACN), and 30 – 30 µl 
were measured into GC vials. To the first sample (S1, used to determine illicit drugs other than 
amphetamines, plus ketamine, zolpidem, oxazepam, temazepam, and tramadol) 15 µl MSTFA was 
added, capped, and analyzed by GC-MS in EI mode (on-line derivatization) within 16 hours after 
sample processing. The other (S2, for analysis of other benzodiazepines and zopiclone) was dried at 
room temperature with nitrogen stream, capped and stored under nitrogen at  –20 oC until 
derivatization and analysis.  
Following the extraction with butyl-acetate the lower phase (what still contained 0.5 ml butyl-acetate) 
was re-extracted with 4 ml CH2Cl2. After centrifuging (3000 rpm, 5 minutes) 3.5 ml of the lower phase 
was transferred to a clean tube and evaporated at room temperature by pressed air. The residue was 
dissolved in 75 µl ACN by vortex, 60 µl was transferred into a GC vial, 30 µl MSTFA was added, and 
capped. The samples were analyzed by GC-MS in EI mode (S3, benzoyl-ecgonine). 
The analysis for benzodiazepines and zopiclone was performed from the S2 samples. After warming 
to room temperature, 45 µl ACN : MTBSTFA = 2:1 solution was injected into the vials through the 
septum by a Hamilton syringe and vortexed six times for 2 seconds. Derivatization was effected at 80 
oC in a multi-block heater (Barnstead Int. USA) for 30 minutes. After cooling to room temperature the 
samples were analyzed by GC-MS in NCI mode within 8 hours after derivatization.  
When the concentration of a compound exceeded the upper limit of linearity, the ready GC sample 
was diluted up to 5-fold by acetonitrile and measured again. The results were multiplied by the degree 
of dilution. 
Standard stock solutions  
Separate stock solutions were used for amphetamines (AMF, MA, MDA, MDMA, and MDEA) and for 
the other substances. The amphetamine standards contained 1000, 750, 500, 250, 125, 100, 50, and 
20 ng in 20 μl volume (spiking volume) of each compound in methanol. Thus the concentration of the 
substances in the lowest concentration stock (Std 1) was equal to the DRUID cut off. The standard 
solutions for the other substances were prepared in similar way.  The highest standard (Std 8) 
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contained 2000 ng of morphine, codeine, methadone, and temazepam, 1000 ng of cocaine, BZE, 
nitrazepam, zolpidem, zopiclone, midazolam, and ketamine, 500 ng of 6-MAM, THC-COOH, tramadol, 
diazepam, oxazepam, and 7-amino-clonazepam, 100 ng of THC, alprazolam, clonazepam, 
nordiazepam, and lorazepam in 25 μl spiking volume in acetonitrile. As the presence of methanol 
promotes the decomposition of zopiclone, and as all compounds in the Promochem standards are 
dissolved in methanol, the adequate quantities of these components were measured into volumetric 
flask and evaporated with nitrogen stream at room temperature. The substances were resolved in 
acetonitrile (ACN), and the other components were added in ACN solution. Seven other calibration 
standards were prepared from Std 8 using the following dilution factors: 1.3, 2.0, 4.0, 8.0, 20, 40, and 
100.  
All calibration curves were calculated with the reciprocal concentrations of the substances. 
 
GC-MS analysis 
 
The analyses were performed with an apparatus consisting of a 6890N Network GC system, a 5975B 
inert XL MSD equipped with turbo pump, interchangeable EI and CI ion source, a 7683B autosampler 
(Agilent, Palo Alto CA, USA), and an Agilent MSD Chemstation data system (G 1701DA D.03.00.611).  
Amphetamines 
Analysis of amphetamines was performed in EI mode (EI, positive ions, 70 eV) using a DB-5MS 
column of 25 m x 0.25 mm x 0.25 μm (J & W Sci. Inc, USA), a glass wool packed liner (Agilent, Cat. 
No.5062-3587), and Helium 6.0 (Messer, Germany) as carrier gas. The temperature of inlet, transfer 
line, ion source, and quadrupole was adjusted to 250, 300, 230, and 150 oC, respectively. The initial 
temperature of the oven was 110 oC with a hold time of 2 minutes, and increased 45 oC/min to 320 oC 
with a final hold time of 1 minute. 2 µl sample was injected in splitless mode using a constant 1.5 
ml/min He flow rate. The run time was 7.67 min. The MS spectra and peak location of the HFB 
derivatives of each analyte were determined in full scan mode (50-550 amu), MS detection was 
performed in SIM (selected ion monitoring) mode. SIM ions and retention times are presented in Table 
1. 
 
S1 substances 
Illicit drugs (other than amphetamines), tramadol, zolpidem, temazepam, and oxazepam were also 
analyzed in EI mode using DB-5MS column of 15 m x 0.25 mm x 0.25 μm (J & W Sci. Inc, USA), and 
a double gooseneck liner (Agilent 5181-3315). The temperature of inlet, transfer line, ion source, and 
quadrupole was 280, 300, 230, and 150 oC, respectively. The initial temperature of the oven was 
adjusted to 120 oC with a 1 min. hold time, increased 60 oC/min to 220 oC, 20 oC/min to 290, then 40 
oC/min to 320 oC with a 1 min hold time and to 330 oC with a final hold time of 1 min. The total run time 
was 9.17 minutes. 2 µl sample was injected in pulsed splitless mode (injection pulse was 23 psi until 
0.2 min) with a constant 1.3 ml/min He flow rate. MS spectra, retention times, and SIM ions of the TMS 
derivatives and the non-derivatized compounds were determined as described for amphetamines 
(Table 1). 
 
S 2 Benzoyl-ecgonine (BZE) 
BZE was analyzed in the same way as S1 samples except the oven heating parameters. The initial 
temperature was 160 oC with a hold time of 0.5 minutes and was increased by 50 oC /min. to 220 oC, 
10 oC/min. to 236 oC, 50 oC/min. to 330 oC with a final holding time of 1 minute. The run time was 6.18 
min. 
 
S 3 Other benzodiazepines and zopiclone 
The analysis was performed on a 30 m x 0.32 mm x 0.10 μm DB-5HT (J & W Sci. Inc, USA) capillary 
column using a double gooseneck liner (Agilent 5181-3315) in negative chemical ionization (NCI) 
mode, adjusting the methane flow rate to 25 ml/min. The temperature of inlet, transfer line, ion source, 
and quadrupole was 250, 300, 200, and 150 oC, respectively. 2 µl sample was injected in pulsed 
splitless mode (30 psi, 0.8 min.) with a constant He flow rate of 2.4 ml/min. The initial oven 
temperature was 150 oC which was hold for 0.8 min, then increased 50 oC/min to 350 oC with a final 
hold time of 1 minute. The run time was 5.8 minutes. 
 
The cut-off values used for the GC-MS analysis are presented in Table 1. Due to comparison the data 
with those of the Hospital study and with the other National Reports the recommended cut-offs of the 
oral fluid samples were used for the evaluation and statistical analysis. 
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Table 1. Recommended equivalent cut-offs for DRUID core substances 
 
Substance Cut-off in 
whole blood 
(ng/mL) 
Cut-off in 
oral fluid 
(ng/mL) 
Recommended 
equivalent cut-off in 
oral fluid (ng/mL) 
Recommended  
equivalent cut-off in 
whole blood  (ng/mL) 
6-AM 10 5 161 10 
Alprazolam 10 1 3.5 10 
Amphetamine 20 25 360 20 
Benzoylecgonine 50 10 95 50 
Clonazepam 10 1 1.7 10 
Cocaine 10 10 170 10 
Codeine 10 20 94 10 
Diazepam 20 5 5.02 140 
Flunitrazepam 2 1 1.02 5.31 
Lorazepam 10 1 1.1 10 
MDA 20 25 2201 20 
MDEA 20 25 2703 20 
MDMA 20 25 2701 20 
Methadone 10 20 22 10 
Methamphetamine 20 25 410 20 
Morphine 10 20 95 10 
Nordiazepam 20 1 1.1 20 
Oxazepam 50 5 13 50 
THC 1 1 27 1.0 
Zolpidem 20 10 102 37 
Zopiclone 10 10 251 10 
Tramadol 50 50 480 50 
7-amino-
clonazepam 
10 1 3.11 10 
7-amino-
flunitrazepam 
2 1 1.02 8.51 
1  data based on less than 10 individual cases 
2 recommended cut-off for OF lower than the original DRUID cut-off in oral fluid, therefore the cut-off of 
blood hhas been raised 
3 no positive cases; cut-off of MDMA used for MDEA 
 
 
The Rts, SIM ions, and the linearity range of the substances are presented in Table 2.
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Table 2. Retention time, SIM ions and linearity range of the substances measured 
   SIM ions Lin. Range ISTD  
 Compound Rt T Q1 Q2 (ng/ml) (ng/ml) 
        
AMFs AMF-D5-HFB 3.700 244 123   50 
 AMF-HFB 3.710 240 118 169 20 - 500  
 MDA-HFB 4.830 135 162  20 - 500  
 MA-D5-HFB 4.130 258 213 169  50 
 MA-HFB 4.140 254 210 118 20 - 500  
 MDMA-D5-HFB 5.140 258 213 164  50 
 MDMA-HFB 5.150 254 210 162 20 - 500  
 MDEA-D5-HFB 5.232 273 408   50 
 MDEA-HFB 5.240 268 240 403 20 - 500  
S1 ketamine-D4 3.045  184 213 186  25 
 ketamine 3.050  180 209 182 10-1000  
 methadone-D9 3.743  78 303   50 
 methadone 3.764  72 294 165 20-2000  
 cocaine-D3 3.970  185 306   50 
 cocaine  3.976  182 303 272 10-1000  
 THC-D3 4.366  374 389   25 
 THC  4.375  371 386 387 1-100  
 codeine-D6-TMS 4.717  377 349   50 
 tramadol-TMS 3.258  58 245 335 5-500  
 codeine-TMS 4.735  196 178 343 20-2000  
 zolpidem 5.950  235 307 236 10-1000  
 morphine-D6-2TMS 4.873  435 420   50  
 morphine-2TMS 4.892 429 414 401 20-2000  
 6-MAM-D3-TMS 5.108 402 290 327  50 
 6-MAM-TMS 5.109 399 340 287 5-500  
 temazepam-D5-TMS 5.230 348 262   100 
 temazepam-TMS 5.238 343 257 357 20-2000  
 oxazepam-2TMS 4.448 429 430 431 5-500  
S2 BZE-D3 3.395  364 243 85  50 
 BZE 3.404  240 82 361 25-750  
S3 diazepam-d5 3.463  289 291   100  
 diazepam 3.468  284 285 286 5-375  
 nordiazepam 3.530  234 235 384 1-75  
 temazepam-d5 4.014  419 421 287  100  
 temazepam 4.020  414 416 282 20-1500  
 midazolam 3.739  325 326 327 20-1000  
 oxazepam 3.920  268 270 384 5-375  
 lorazepam 4.129  302 304  1-75  
 7-aminoclon-d4 4.054  253 367   50 
 7-aminoclonazepam 4.059  249 363  5-375  
 zopiclone 4.331  143 246  10-750  
 clonazepam-d4 4.149  433 435   50 
 clonazepam 4.151  429 431  1-75  
 nitrazepam 3.950  395 396  10-750  
 alprazolam-d5 4.313  313 315   50  
 alprazolam 4.312  308 309 310 1-75  
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Validation procedure 
 
 Linearity and intraday precision Using 8 calibration standard concentrations, five calibration curves 
were measured within one day for each group of substances. The linearity was checked by the R2 
value of their average curve calculated by a least squares regression model (criteria: R2 should be > 
0.98). Intraday precision was characterized by repeatability (RSD%) and accuracy (bias%) of the 
values re-calculated by the average curve related to the nominal concentrations. The limit of 
acceptability was 15% for accuracy and 20% for bias. 
 
Selectivity The peak areas of the SIM ions of all substances in Std 1 (cut off concentrations) were 
compared to that of the disturbing or overlapping matrix peaks of five blank samples. The limit of 
acceptability was an at least three times difference for the target, and at least a two times difference 
for the qualifier ions. 
 
Inter-day precision Triplicates of the highest, middle, and lowest concentration standards with daily 
calibration curves were measured in 5 separate days. The concentrations of the samples were always 
calculated against their daily calibration curves. Inter-day precision was characterized by the 
repeatability (RSD) and accuracy (bias). The limits of acceptability were 15% for bias and 20% for 
RSD. 
 
Extraction recovery 
1. Amphetamines Six OF samples (with matrix) were spiked with 20 μl 100 ng/ml concentration 
standard + 10 μl ISTD, processed and measured as described. To examine the effect of matrix on 
extraction recovery six other samples were prepared in which OF was replaced with distilled water (no 
matrix). Extraction recovery was calculated as percentage of the “no matrix” samples. 
2. Other substances Six OF samples were spiked with Std 4 standard and ISTD as described. 6 other 
empty samples were extracted with butyl-acetate and centrifuged. Then 4.5 ml organic phase was 
spiked with 90% quantity of Std 4 and ISTD (total). Recovery was calculated as percentage of the 
“total” samples. Recovery of BZE was determined in the same way spiking the methylene chloride 
phase before evaporation with 15,6 μl  Std 4 and 7.8 μl ISTD in the “total” samples. 
Stability The stability of the processed samples, containing matrix, was tested by analyzing 8 
replicates at the medium concentration level (Std 4). After derivatization the samples were combined, 
then divided into 7 vials and were injected in 4 hours intervals. The acceptable limit of degradation was 
a 20% decrease in the concentration of a substance. 
 
Validation results 
 
The linearity, selectivity, intra- and inter-day precision data fulfilled the validation criteria for all 
substances. The extraction recovery varied between 54.4 and 109 %, and was below 70% only for 
lorazepam, midazolam and benzoyl-ecgonine. All substances proved to be stable for 24 hours after 
sample processing except Zopiclone and Zolpidem (Table 3). As a consequence, the sample 
preparation and the measurement was timed in the way that all samples were analyzed within 8 
hours after processing. 
 
Table 3. Stability results of Zolpidem and Zopiclone 
 
Substances % of the 0 hours sample 
 4 8 12 16 20 24 
zolpidem 102.86 100.19 84.58 79.56 76.53 71.96 
zopiclone 93.02 87.92 31.06 12.74 16.19 21.13 
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8.1 Description of the roadside driver sampling 
 
8.1.1 Introduction and objectives 
The aim of the roadside survey was to assess prevalence of drivers who drive in the general traffic in 
the Veneto region (five different districts) within the North-East sector of Italy, which accounts for 
approximately 4.8 million people, under the influence of alcohol and/or other psychoactive substances. 
The survey was carried out in close co-operation with the local and state police. Briefly, the roadside 
protocol included: 
− Stopping the drivers at randomly selected sites and times; 
− Carrying out a breath-test for alcohol using a screening device (compulsory for all stopped 
drivers); 
− Administering (to the stopped drivers) a questionnaire on relevant socio demographic behavioural, 
physical and driving characteristics, skills 
− Applying a clinical protocol (elaborated by our group specifically) which included clinical 
anamnesis, psycho-behavioural examination based on the DSM IV – R, medical-physical 
examination (for signs of impairment); 
− Collecting: 
o A total of 1310 saliva samples were collected which were later analysed for 
prevalence of benzodiazepines, opiates, amphetamine, cannabis, cocaine, ecstasy 
and alcohol in our laboratory; 
o A total of 987 blood samples were collected which were later analysed for prevalence 
of benzodiazepines, opiates, amphetamine, cannabis, cocaine, ecstasy and alcohol in 
our laboratory. 
 
Originally we planned on obtaining approximately 3000 saliva samples with an additional 10% of blood 
samples (about 300) after the roadside stops. During the 3 year course of roadside sampling, and 
based on the various work package meetings held, we modified this to allow for a more appreciable 
sampling of blood thus allowing for a better standard of comparison between blood and saliva samples 
which would be indispensable for studying conversion factors between the diverse biological samples. 
Due to the increase of blood sampling (which took more time than saliva sampling) the total number of 
samples was lower than initially planned. It was considered very valuable to be able to compare blood 
samples of the controls to blood samples in the hospitals instead of saliva in the controls to blood in 
the hospitals for the case control study.  
The results of the survey will serve as reference data (controls) for the relative risk estimation (odds 
ratio calculation) of alcohol and other psychoactive substances in “case-control studies” i.e. hospital 
studies. In this population based case-control study, cases are formed by seriously injured car drivers 
and controls are representative samples of drivers from the driving population in the hospital's 
catchment area.  
 
The unweighted control sample could not be considered to be representative of all drivers who 
participated in road traffic in the five districts of Veneto Region at all days of the week and all times of 
the day, since the sample distribution over different times and days was not equal to the distribution of 
traffic volumes. The most probable cause was the regular sampling capacity of the research team, 
regardless of the traffic volumes that vary significantly by day of the week (weekdays versus weekend) 
and by time of the day. Furthermore, the police exhibited the preference for enforcement activities 
during high-risk hours, i.e. the night time hours with low traffic volumes. So, in order to ensure that the 
control sample was representative of the whole week, results have to be weighted based on traffic flow 
distribution over the various days of the week and times of the day. 
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8.1.2 Geographic distribution of drivers over the country 
Control drivers were stopped at random from moving traffic in five different districts of the Veneto 
region in North-East portion of Italy. Veneto is a large region of Italy that covers a total area of 
18,398.9 km2 that can be divided into four areas: the northern Alpine zone, the hill zone, the lower 
plain, and the coastal territory. The following specific districts were included in our survey: Padova, 
Rovigo, Treviso, Venice, and Vicenza, accounting for more than 8% of the entire population in Italy  
(see also Table 8.1). 
 
Figure 8.1 Survey regions 
 
The choice of these districts was based on the geographical distribution of population over the 
country. The five provinces cover all the geographical areas and reflect the Italian general topography. 
The social and economic structure of the region comprises agricultural, industrial and tourism activities 
thus representing a good model of the Italian socioeconomic configuration as well. Recently, 
epidemiological studies on the prevalence of drugs and alcohol in the Italian general population and 
driving population, has disclosed that approximately 10 % of the driving population has consumed 
alcohol before driving. The prevalence of drug use has been calculated to be in the range 4 - 6 %. 
These data are in agreement with the calculated  prevalence in our survey, allowing to infer that the 
survey region is reasonably representative for Italy as a whole. 
 
Table 8.1. Geographic distribution of drivers over the country 
Region Code Region count fraction 
03901 1-Padova 341 0,26 
03902 2-Venezia 319 0,24 
03903 3-Vicenza 224 0,17 
03904 4-Treviso 214 0,16 
03905 5-Rovigo 212 0,16 
Total  1310 1,00 
 
8.1.3 Distribution of drivers by road type 
In each district an average of 20 different research sites were selected, distributed over the different 
areas in the each district. The main selection criteria included:  
⇒ putative traffic flow,  
⇒ lack of possibilities for drivers to avoid the research site stop,  
⇒ enough room on the road for the research and police teams and their vehicles,  
⇒ safe working conditions.  
The research sites were selected among rural and urban roads.  
 110 
 
8.1.4 Distribution of drivers by season  
159 roadside survey sessions were conducted during the period February 2008 - August 2009. In 
each season of the DRUID time periods at least one roadside survey session took place. The 
distribution of sampled drivers in the different seasons is reported in Table 8.2.  As may be inferred, all 
seasons have a quite comparable distribution but in the autumn the number of samples is lower. This 
can be ascribed to the fact that in the period of the road survey (February 2008 - August 2009) autumn 
months (month 10 - 12) were sampled only once.  
 
Table 8.2. Distribution of drivers by season 
Season Count Fraction 
1 - month 1-3 (winter) 368 0,28 
2 - month 4-6 (spring) 373 0,28 
3 - month 7-9 (summer) 363 0,28 
4 - month 10-12 (autumn) 206 0,16 
 1310 1,00 
 
 
8.1.5 Distribution of drivers by day of the week and time of the day 
 
According to the DRUID definition of time periods (see Figure 8.2), Table 8.3 shows the distribution of 
drivers by day of the week and time of the day (8 DRUID Time Period categories).  
  Monday Tuesday 
Wednesd
ay Thursday Friday Saturday Sunday Monday 
04-
10 Period 1 Period 5   
10-
16 Period 2 Period 6   
16-
22 Period 3 Period 7   
22-
24   Period 4   Period 8 
  
00-
04       
Figure 8.2. Definition of time periods 
 
Table 8.3. Distribution of drivers by day of the week and time of the day (8 DRUID Time Period categories) 
Time period Count Fraction 
1 Weekday 04:00-09:59 71 0,05 
2 Weekday 10:00-15:59 113 0,09 
3 Weekday 16:00-21:59 87 0,07 
4 Weekday 22:00-03:39 329 0,25 
5 Weekendday 04:00-09:59 105 0,08 
6 Weekendday 10:00-15:59 17 0,01 
7 Weekendday 16:00-21:59 71 0,05 
8 Weekendday 22:00-03:39 517 0,39 
Total 1310 1,00 
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Categories 4 and 8 have a higher ratio of stops and sampling. As previously explained, the reason for 
this was that the police had a preference for enforcement activities during high-risk hours, i.e. the night 
time hours and the week-end period. Analogously, the low number of samples in period 6 can be 
ascribed to the scarce preference for enforcement activities during the low-risk periods such as 
Sunday mid-day hours. 
 
8.1.6 Distribution of drivers by gender and age  
According to the DRUID definition of the categories, Table 4 shows the distribution of drivers by 
gender and age. As may be seen, and as expected from the composition of the Italian driving 
population, the number of males is higher. The low numbers in both the 50+ groups could be 
considered as a selection issue (a higher risk population seems to have been preferred by the 
police enforcement activities) and not a representation of the distribution of traffic, considering 
that in the general driving population in Italy the percentage of drivers over 50 years old is about 
39 % (men) and 26 % (women). However, the number of travels/day in this group of drivers is 
lower than the other groups (data collected by ISTAT, the Italian National Institute of Statistics). 
 
 Table 8.4. Distribution of drivers by gender and age 
Gender – age Count Fraction 
F - 18-24 75 0,06 
F - 25-34 120 0,09 
F - 35-49 100 0,08 
F - 50+ 22 0,02 
M - 18-24 245 0,19 
M - 25-34 362 0,28 
M - 35-49 336 0,26 
M - 50+ 50 0,04 
Total 1310 1,00 
 
 
8.2 Roadside data collection and analysis 
 
8.2.1 Ethical approval 
The present study is conform the Italian Law and the rules of the Medical Ethical Committee.. 
 
8.2.2 Driver selection, interviews and medical examination 
Drivers were stopped by the police at the request of the acting research coordinator. All subjects were 
breath tested for alcohol by a police officer, using a screening breath test analyzer. Positive results 
were confirmed by a Breathalyzer “Draeger Alcotest 7410 Plus device”. The breath test was 
compulsory for all stopped drivers.  
As soon as a medical doctor was ready for interviewing and blood sampling a driver, the next car 
approaching the research site was stopped. The stopped drivers were asked to cooperate with the 
research team on a voluntary basis. The drivers who agreed to cooperate signed a written consensus 
form and were interviewed (gender and age of the subject, assumption of drugs and/or medicines). 
Besides the interview, a physical examination was performed with particular attention paid to clinical 
signs of drug use or abuse.  
The interviews and the medical examinations were conducted in a specially equipped mobile research 
unit with enough space to accommodate the research team and two subjects. The results for each 
driver, including breath test data, were entered on a uniquely numbered anonymous research form.  
 
8.2.3 Body fluid collection  
Subjects were requested to produce samples of blood and saliva, collected by a medical doctor. The 
most suitable arm for venipuncture was assessed and a tourniquet was applied to the upper arm. The 
skin at the puncture site was cleaned with a sterile non-alcoholic disinfectant wipe or swab and the 
needle was inserted into the antecubital vein. The tourniquet was removed and 3 mL of blood were 
collected in a 3.0 mL BD grey Vacutainer®. After withdrawing the needle from the arm, a pad was 
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placed over the puncture site and the subject was instructed to press firmly on the pad for 2 – 3 
minutes; samples were kept 2-8 °C until analysis. 
Saliva samples were collected using a Statsure device, as specified by the DRUID research protocol. 
The level of the buffer solution was checked against the line on the side of the tube before collection 
began. The collection pad was placed under the tongue and when the indicator window turned blue, 
the pad was removed from the mouth and placed into the collection/transport tube. If the driver was 
unwilling or unable to furnish a blood specimen, only a saliva sample was collected.  After collection 
the devices were weighted and stored at -20 °C until analysis. 
 
8.2.4 Toxicological analysis of body fluids  
The toxicological analysis (4 - 7) were performed at the TFA-UNIPD laboratory. Two in-house methods 
were developed, validated and used for the analysis of 31 drugs and metabolites in blood and saliva. 
The first method was used for the analysis of illicit drugs and medicines excluding THC and THC-
COOH. The second method was used for the analysis of THC and THC-COOH. Both methods are 
described in Annex I to this report.  
Blood alcohol concentration was determined by Breathalyzer “Draeger Alcotest 7410 Plus device” and 
a conversion factor of  1: 2100  has been applied to comply with the project guidelines. Saliva alcohol 
concentration was determined by a headspace gas-chromatography method, described in the Annex I 
as well. 
 
8.2.5 Statistical Analysis  
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
8.3 Non-response 
In Italy, legal regulations specify that, in order to assess DUI of alcohol and/or drug, drivers can be 
asked for medical examination (comprising an interview and a physical examination) and body fluid 
collection (saliva, blood or urine) that are performed by a physician in the presence of a Police Officer. 
Although the decision to participate to the control is voluntary strictly speaking, since the alternative is 
a formal admission of driving under the influence of drugs and/or alcohol with the consequent 
execution of the full sentence. participation is somewhat forced. 
In our survey, control drivers were stopped at random from moving traffic by a Police Officer. Due to 
the fact that refusing to participate to either the interview or the body fluid collection had legal 
consequences, we did not register any non-response. All the stopped drivers agreed to participate to 
the interview and to the withdrawal of one (blood or saliva) or two biological matrices (blood and 
saliva). Therefore no confounding effect due to non response was observed. 
 
8.4 Results   
In the following tables are reported the results obtained by the adjustment procedure, according to 
8.2.5. 
As may be inferred from Table 8.5, 84.99 % of stopped drivers tested negative for all substances, the 
prevalence for alcohol being 8.59% (alcohol only) and the use of drugs and/or medicinal drugs 
accounting for 5.41 %. Considering that benzodiazepines and medicinal opiates/opioids are not 
prohibited substances in Italy when used as prescription drugs, the use of illicit drugs accounts for 
nearly 3.9 %. Among drugs, the most represented is Cocaine, followed by THC and illicit opiates.  
Combination of alcohol with drugs exhibits a prevalence of 1.01 %, drug/drug combinations account 
for 1.22 %. 
 
 113 
Table 8.5. Adjusted general distribution of core substance categories (N=1310) 
Substance category Prevalence (%) Confidence interval 
(%) 
Negative 84.99 82.95 - 86.82 
Amphetamines - - 
Cocaine 1.25 0.78 - 2.01 
THC 1.15 0.70 - 1.89 
Illicit opiates 0.30 0.12 - 0.78 
Benzodiazepines 0.97 0.57 - 1.67 
Z-drugs - - 
Medicinal opiates and 
opioids 0.53 0.25 - 1.09 
Alcohol 8.59 7.19 - 10.23 
Alcohol+drugs 1.01 0.59 - 1.71 
Drugs-drugs combi 1.22 0.75 - 1.97 
 
 
Table 8.6. Adjusted distribution of core substance categories by gender and age (N=1310) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 
 
84.87 
79.91 – 88.77 
89.85 
86.23 – 92.60 
80.43 
75.99 – 84.22 
87.26 
74.30 – 94.19 
85.13 
82.79 – 87.21 
Amphetamines - - - - - 
Cocaine 
 
1.57 
0.61 – 3.99 
1.12 
0.43 – 2.87 
2.33 
1.20 – 4.49 
0.21 
0.00 – 8.47 
1.62 
1.01 – 2.61 
THC 
 
0.04 
0.00 – 1.58 
0.44 
0.10 – 1.86 
2.62 
1.40 – 4.86 
0.00 
0.00 – 8.08 
1.10 
0.61 – 1.96 
Illicit opiates 
 
0.04 
0.00 – 1.58 
0.00 
0.00 – 1.09 
1.08 
0.41 – 2.80 
0.00 
0.00 – 8.08 
0.39 
0.15 – 1.02 
Benzodiazepines 
 
2.38 
1.10 – 5.11 
0.00 
0.00 – 1.09 
0.42 
0.10 – 1.81 
0.00 
0.00 – 8.08 
0.75 
0.37 – 1.50 
Z-drugs - - - - - 
Medicinal opiates 
and opioids 
0.00 
0.00 – 1.51 
0.00 
0.00 – 1.09 
0.84 
0.29 – 2.45 
0.00 
0.00 – 8.08 
0.30 
0.10 – 0.88 
Alcohol 
 
9.48 
6.44 – 13.74 
5.38 
3.46 – 8.27 
10.08 
7.37 – 13.66 
12.32 
5.54 – 25.20 
8.39 
6.82 – 10.27 
Alcohol+drugs 
 
0.11 
0.01 – 1.72 
1.55 
0.69 – 3.48 
1.24 
0.50 – 3.01 
0.21 
0.00 – 8.47 
1.02 
0.56 – 1.86 
Drugs-drugs combi 
1.51 
0.58 – 3.91 
1.66 
0.75 – 3.63 
0.95 
0.34 – 2.60 
0.00 
0.00 – 8.08 
1.30 
0.76 – 2.21 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 
 
83.05 
71.87 – 90.39 
76.83 
66.79 – 84.54 
89.76 
83.65 – 93.75 
84.76 
66.45 – 93.98 
84.53 
80.11 – 88.12 
Amphetamines - - - -  -  
Cocaine 
 
0.15 
0.00 – 6.10 
0.11 
0.00 – 4.55 
0.00 
0.00 – 2.65 
0.00 
0.00 – 13.07 
0.06 
0.00 – 1.32 
THC 
 
2.71 
0.67 – 10.25 
2.83 
0.86 – 8.90 
0.03 
0.00 - 2.72 
0.00 
0.00 – 13.07 
1 32 
0.52 – 3.29 
Illicit opiates 
 
0.00 
0.00 – 5.82 
0.00 
0.00 – 4.35 
0.00 
0.00 – 2.65 
0.00 
0.00 – 13.07 
0.00 
0.00 – 1.21 
Benzodiazepines 
 
6.11 
2.35 – 14.99 
1.77 
0.41 – 7.32 
0.00 
0.00 – 2.65 
0.00 
0.00 – 13.07 
1.69 
0.74 – 3.81 
Z-drugs - - - - - 
Medicinal opiates 
and opioids 
0.00 
0.00 -5.82 
0.00 
0.00 – 4.35 
2.76 
1.07 – 6.96 
0.00 
0.00 – 13.07 
1.24 
0.48 – 3.19 
Alcohol 
 
7.98 
3.44 – 17.41 
18.35 
11.54 – 27.91 
3.21 
1.33 – 7.58 
15.24 
6.02 – 33.55 
9.22 
6.49 – 12.94 
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Alcohol+drugs 
 
0.00 
0.00 – 5.82 
0.11 
0.00 – 4.56 
2.12 
0.72 – 6.05 
0.00 
0.00 – 13.07 
0.99 
0.34 – 2.82 
Drugs-drugs combi 
0.00 
0.00 – 5.82 
0.00 
0.00 – 4.35 
2.12 
0.72 – 6.05 
0.00 
0.00 – 13.07 
0.95 
0.32 – 2.77 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 
 
84.51 
80.08 – 88.09 
87.31 
83.84 – 90.12 
83.08 
79.53 – 86.13 
86.34 
76.32 – 92.53 
84.99 
82.95 – 86.82 
Amphetamines - - - - - 
Cocaine 
 
1.29 
0.50 – 3.25 
0.92 
0.36 – 2.35 
1.67 
0.86 - 3.22 
0.13 
0.00 – 5.51 
1.25 
0.78 – 2.01 
THC 
 
0.57 
0.15 – 2.19 
0.91 
0.35 – 2.33 
1.89 
1.01 – 3.50 
0.00 
0.00 – 5.26 
1.15 
0.70 – 1.89 
Illicit opiates 
 
0.03 
0.00 – 1.27 
0.00 
0.00 – 0.88 
0.77 
0.30 – 2.01 
0.00 
0.00 – 5.26 
0.30 
0.12 – 0.78 
Benzodiazepines 
 
3.12 
1.69 – 5.69 
0.35 
0.08 – 1.49 
0,30 
0.07 – 1.30 
0.00 
0.00 – 5.26 
0.97 
0.57 – 1.67 
Z-drugs - - - - - 
Medicinal opiates 
and opioids 
0.00 
0.00 – 1.21 
0.00 
0.00 – 0.88 
1.39 
0.67 – 2.85 
0.00 
0.00 – 5.26 
0.53 
0.25 – 1.09 
Alcohol 
 
9.18 
6.46 – 12.89 
7.91 
5.72 – 10.84 
8.13 
6.03 – 10.87 
13.40 
7.28 – 23.37 
8.59 
7.19 – 10.23 
Alcohol+drugs 
 
0.09 
0.01 – 1.38 
1.27 
0.57 – 2.84 
1.49 
0.73 – 2.98 
0.13 
0.00 – 5.51 
1.01 
0.59 – 1.71 
Drugs-drugs combi 
1.21 
0.46 – 3.15 
1.34 
0.61 – 2.93 
1.28 
0.60 – 2.71 
0.00 
0.00 – 5.26 
1.22 
0.75 – 1.97 
 
 
When observing distribution by age, the general prevalence is to some extent higher in the group 35 – 
49, but the highest number of positives for alcohol only was found in the group 50 +. The group 35 - 49 
conversely exhibits the highest prevalence for drugs (cannabis, cocaine, opiates and their combination 
with alcohol). When observing distribution by gender, the highest prevalence of alcohol in women 25-
34 reflects a selection bias reasonably due to some pre-selection activity of the police. In the women 
group, the prevalence of cocaine and illicit opiates is zero, whereas the use of benzodiazepines is 
higher than in the male group, and, quite unexpectedly, more frequent in the youngest.  
 
 115 
Table 8.7. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=1310) 
4 categories: weekdays, weekday nights, week-end days, week-end nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Substance category Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 
85.23 
82.82 – 87.35 
85.41 
68.88 – 93.93 
84.18 
79.72 – 87.92 
85,49 
67.02 – 94.47 
84.99 
82.95 – 86.82 
Amphetamines - - - - - 
Cocaine 
1.63 
1.00 – 2.65 
0.91 
0.06 – 12.87 
0.14 
0.01 – 1.49 
1.16 
0.08 – 15.31 
1.25 
0.78 – 2.01 
THC 
0.00 
0.00 – 0.41 
0.30 
0.01 – 11.84 
4.72 
2.86 – 7.67 
1.16 
0.08 – 15.31 
1.15 
0.70 – 1.89 
Illicit opiates 
0.40 
0.15 – 1.05 
0.00 
0.00 – 11.31 
0.00 
0.00 – 1.22 
0.58 
0.02 – 14.36 
0.30 
0.12 – 0.78 
Benzodiazepines 
1.03 
0.56 – 1.91 
0.00 
0.00 – 11.31 
0.96 
0.33 – 2.79 
0.00 
0.00 – 13.37 
0.97 
0.57 – 1.67 
Z-drugs - - - - - 
Medicinal opiates and 
opioids 
0.73 
0.35 – 1.51 
0.00 
0.00 – 11.31 
0.00 
0.00 – 1.22 
0.00 
0.00 – 13.37 
0.53 
0.25 – 1.09 
Alcohol 
8.51 
6.89 – 10.46 
10.64 
3.81 – 26.37 
8.60 
5.97 – 12.24 
8.90 
2.62 – 26.17 
8.59 
7.19 – 10.23 
Alcohol+drugs 
1.03 
0.56 – 1.91 
1.82 
0.21 – 14.34 
0.77 
0.23 – 2.50 
2.13 
0.23 – 16.82 
1.01 
0.59 – 1.71 
Drugs-drugs combi 
1.44 
0.85 – 2.42 
0.91 
0.06 – 12.87 
0.62 
0.17 – 2.28 
0.58 
0.02 – 14.36 
1.22 
0.75 – 1.97 
 
When observing adjusted distribution of core substance categories by day of the week and time of the 
day, as shown in Table 8.7, it is interesting to note that driving under the influence of alcohol occurs in 
both day and night periods, but peaks at night. The prevalence of THC is the lowest during weekday, 
and the highest during weekend days and weekend nights; vice versa the use of cocaine appears 
evenly distributed along the week. However, it must be remembered that some time periods  (e.g. 
DRUID time period 6, corresponding to weekend day, period 7 and period 3) were underrepresented 
(n < 100). 
In Tables 8.8-8.10 are reported the results pertaining the use of alcohol according to concentration 
class, gender and age,  time day of the week and time of the day. 
 
Table 8.8. Adjusted general distribution of alcohol by concentration class (N=1310) 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 3.35 2.51 - 4.47 
Alcohol 0.5 – 0.79 g/L 2.02 1.39 - 2.94 
Alcohol 0.8 – 1.19 g/L 1.81 1.22 - 2.69 
Alcohol  ≥ 1.2 g/L 1.40 0.89 - 2.19 
In total 8.59 7.19 - 10.23 
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Table 8.9 Adjusted distribution of alcohol alone by gender and age (N= 1310) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 3.18 
1.62 - 6.15 
2.48 
1.30 - 4.71 
3,87 
2,31 - 6,42 
0,21 
0,00 – 8,47 
3,05 
2.15 – 4.31 
 0.5 – 0.79 g/L 1.82 
0.75 - 4.34 
0.75 
0.24 - 2.34 
2.40 
1.25 – 4.57 
8.69 
3.35 – 20.71 
1.96 
1.26 – 3.02 
 0.8 – 1.19 g/L 2.82 
1.38 - 5.68 
0.65 
0.19 - 2.19 
2.67 
1.43 – 4.91 
3.42 
0.79 – 13.58 
2.03 
1.32 – 3.11 
≥ 1.2 g/L 1.66 
0.66 - 4.13 
1.49 
0.65 - 3.39 
1.15 
0.45 – 2.89 - 
1.35 
0.79 – 2.27 
In total 9.48 
6.44 - 13.74 
5.38 
3.46 - 8.27 
10.08 
7.37 – 13.66 
12.32 
5.54 – 25.20 
8.39 
6.82 – 10.27 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 2.56 
0.62 – 10.03 
9.48 
4.89 – 17.61 - 
15.24 
6.02 – 33.55 
4.31 
2.56 – 7.17 
 0.5 – 0.79 g/L 0.08 
0.00 – 5.97 
8.19 
4.01 – 16.01 
0.03 
0.00 – 2.72 - 
2.24 
1.09 – 4.55 
 0.8 – 1.19 g/L 0.16 
0.00 – 6.11 
0.44 
0.04 – 5.16 
2.12 
0.72 – 6.05 - 
1.11 
0.40 – 2.99 
≥ 1.2 g/L 5.19 
1.84 – 13.75 
0.22 
0.01 – 4.76 
1.06 
0.24 – 4.47 - 
1.57 
0.67 – 3.64 
In total 7.98 
3.44 – 17.41 
18.35 
11.54 – 27.91 
3.21 
1.33 – 7.58 
15.24 
6.02 – 33.55 
9.22 
6.49 – 12.94 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 3.05 
1.64 – 5.60 
3.85 
2.41 – 6.11 
2.77 
1.65 – 4.62 
5.76 
2.26 – 13.91 
3.35 
2.51 – 4.47 
 0.5 – 0.79 g/L 1.47 
0.61 – 3.52 
2.21 
1.19 – 4.07 
1.73 
0.90 – 3.30 
5.48 
2.10 – 13.54 
2.02 
1.39 – 2.94 
 0.8 – 1.19 g/L 2.29 
1.12 – 4.61 
0.61 
0.19 – 1.90 
2.51 
1.46 – 4.29 
2.16 
0.50 – 8.85 
1.81 
1.22 – 2.69 
  ≥ 1.2 g/L 2.36 
1.17 – 4.71 
1.24 
0.55 – 2.79 
1.12 
0.50 – 2.50 - 
1.40 
0.89 – 2.19 
In total 9.18 
6.46 – 12.89 
7.91 
5.72 – 10.84 
8.13 
6.03 – 10.87 
13.40 
7.28 – 23.37 
8.59 
7.19 – 10.23 
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Table 8.10 Adjusted distribution of alcohol alone by day of the week and time of the day (N=1310) 
4 categories: weekdays. weekday nights. week-end days. week-end nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 2.98 
2.07 – 4.27 
2.43 
0.34 – 15.28 
4.72 
2.86 – 7.67 
1.55 
0.13 – 15.92 
3.35 
2.51 – 4.47 
 0.5 – 0.79 g/L 2.16 
1.40 – 3.29 
1.52 
0.15 – 13.85 
1.68 
0.73 – 3.80 
1.93 
0.20 – 16.53 
2.02 
1.39 – 2.94 
 0.8 – 1.19 g/L 1.85 
1.16 – 2.92 
2.74 
0.42 – 15.74 
1.58 
0.67 – 3.67 
2.13 
0.23 – 16.82 
1.81 
1.22 – 2.69 
  ≥ 1.2 g/L 1.52 
0.91 – 2.52 
3.95 
0.79 – 17.53 
0.62 
0.17 – 2.28 
3.29 
0.50 – 18.56 
1.40 
0.89 – 2.19 
In total 8.51 
6.89 – 10.46 
10.64 
3.81 – 26.37 
8.60 
5.97 – 12.24 
8.90 
2.62 – 26.17 
8.59 
7.19 – 10.23 
 
In total, alcohol prevalence is 8.59 % with confidence interval 7.19 – 10.,23; however it must be 
highlighted that the zero tolerance approach was not in force in Italy during DRUID roadside survey 
sampling period, and the legal limit for DUI was 0.5 g/L. Considering only the class ≥ 0.5 g/L, the total 
prevalence for DUI of alcohol according to Italian law is reduced to 5.24 %. The highest prevalence 
occur in the time period 22:00 – 03:59, either during week or weekend. In the same time period are the 
highest concentrations  (≥ 1.2 g/L) observed more frequently (3.95 and 3.29%). When observing 
distribution by age, the highest frequency is observed for the group ≥ 50; however, in this group no 
concentration  ≥ 1.2 g/L was observed in both the male and female groups. Conversely, the highest 
concentration category is mostly represented in the groups 18 – 24. 
 
8.5 Discussion 
8.5.1 Representativeness 
The Veneto region was chosen due to the vast number of rural, urban, provincial and state roads 
within the region. In total there are 7397 Km of state regional and provincial roads. It is important to 
note that, as previously stated, the police preferred to choose times of day and days that would be 
most dangerous. DUI of alcohol or drugs is according to Italian legislation, is a criminal offence and 
police, willing to enforce their prevention/repression activity, preferred to sample in time periods were a 
positive correlation between accident occurrence and use of alcohol/substances is known (Ferrara et 
al. 2000). As a matter of fact, in week night and weekend nights accidents are caused mainly by 
human factors, whereas in week day and weekend day heavy traffic conditions have the main impact 
on the frequency of accidents. This of course may have reduced the representativeness for the entire 
population, but, as stated in the Statistical section, correcting factors were applied for the traffic. As to 
the existence of bias, we must emphasize that police may have applied a pre-selection of people that 
were sent to the researchers for the DRUID protocol, based either on the use of presumptive tests for 
alcohol or physical signs of impairment, according to their standard protocols. However, the results 
obtained are in agreement with epidemiological studies on the use of alcohol and drugs in Italy (see 
8.5.3), evidencing that the sampled population can be considered a representative sample of Italy. 
 
8.5.2 Effects of non response  
There was no effect of non response, as detailed in section 3 above. 
 
8.5.3 Highlights  
A comparison between the results of DRUID roadside survey, Italian epidemiology data on use/abuse 
of substances, and available road side surveys was though of interest. Alcohol turned out to be the 
most prevalent substance in the sampled driving population: 8,59 %, with confidence interval 7.19 – 
10,23; this result is in good agreement with the most recent epidemiology studies on alcohol use in 
Italy (2 - 5). In 2008, 28.3% of the Italian population drank alcohol daily, 41.7 % drank occasionally 
(irregularly), 26.2 % drank between meals. 9.4% of Italians are considered heavy drinkers, consuming 
excessive daily amounts of alcohol (more than 20 g/day for women, 40 g/day for men).  A survey 
based on interviews in different Italian regions (either in the North, in the Middle or in the South of 
Italy) evidenced that about 14% of interviewed people admitted having driven a car or a motorcycle 
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after consuming 2 or more glasses of wine (10 – 12 g or more) in the previous 60 min. 14 % was the 
total prevalence for Italy, with regional distribution from 6 % in Campania (in the South)  to 16 % in Val 
d’Aosta (in the North). In the same survey, people aged 65-69 admitted driving when under the 
influence of alcohol in 12 % of cases. 
Considering the Italian law enforced during DRUID operations, the alcohol concentrations below 0,5 
g/L (3.35 % of the total sample, 38 % of positive for alcohol only) cannot be considered DUI offences. 
Only recently, in August 2010, a zero tolerance approach has been introduced for people aged below 
21 or during the first three years of driving license holding.  
Wishing to compare our results to data gathered in other roadside surveys, we could use the DRUID 
5.24 % prevalence of alcohol ≥ 0.5 g/L and compare it to 5.9 % of BAC ≥ 0.5 g/L (measured either by 
breathalyzers or “precursor tests”) obtained by Police and Carabinieri in their activity in 2007 (on 
790319 drivers stopped), or to 3.41 % obtained in 2008 on 1393467  drivers (6). The confidence 
intervals are not known. For the same year 2008, the Police obtained  9.33 %, of alcohol ≥ 0.5 g/L 
during weekend nights, whereas the DRUID weighted prevalence for the same time period is 7.35 %. 
As far as drugs, a clear distinction must be made between illicit and licit ones (benzodiazepines, 
medicinal opiates). For licit drugs, i.e. those that can be used  when a medical prescription is 
presented, no road side survey is available for comparison.  
For illicit drugs, recent surveys are only available for selected time periods, namely weekend nights, 
and for selected locations (e.g. streets near discos or pubs). In those cases, up to 47 % of positive for 
illicit drugs and/or alcohol was obtained (7, 8) with 27.8 % of positive for alcohol, 10.2 for illicit drugs 
only, and 8.7 % alcohol combination with drugs. Older data, given by Police and regarding 2004, 
reported 11481 positive drivers for drugs but no data on the whole number of stopped drivers was 
available and the prevalence was mathematically estimated to be 12.4 % (9). To get a more general 
view, we were able to compare our data to epidemiology studies. 
In DRUID roadside survey, the most prevalent illicit drug is cocaine (1.25 % total population), followed 
by THC (1.15 %) and illicit opiates (0.30 %). The same trend has been observed in the 2009 National 
report to the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) (10) presenting 
studies conducted in 2008 on the general population and providing information on trends in illegal drug 
use. Cocaine use in Italy, both occasional and frequent, seems to be considerably higher than the 
European average, and particularly prevalent in the male population between 15 and 34 years of age. 
For both genders, the youngest subjects, between 15-24 years of age, and those between 25-34, 
report having used cocaine over the course of the last year, in the highest percentages (15-24 years of 
age: m=3.27%; f=2,0%; 25-34 years of age: m=4.97%; f=2.14%). Prevalence of use decreases 
steadily in the older age groups, reaching 1.79% and 0.86% for men in the groups aged between 35-
44 and 45-55 respectively, and 0.43% and 0.17% for women.  For men aged between 55-64, the 
prevalence of use is 0.38% while for women it is near 0%. The trend that emerged confirm that there 
has been a steady increase in cocaine frequent use in the Italian population (1.6 % total prevalence) 
starting from 2001 to 2008, with men having a greater propensity for it than women. These data are in 
agreement with our results (1.15 %), when we consider that people under 18 was excluded in our 
study and that the 1.15 % value does not include cocaine in combination with alcohol or other drugs. 
According to the information gathered in population surveys conducted between 2001 and 2007/08, 
the use of cannabinoids has also risen steadily giving Italy one of the highest incidences of use among 
the European countries: 1.34% of the Italian population uses cannabis frequently. The highest 
prevalence is in subjects ranging between 15-24 years of age with similar incidence among women 
and men. The total prevalence in the DRUID roadside survey is comparable (1.15 % for cannabis 
alone, excluding combinations). 
Lastly, 0.15% of the Italian population sample reported frequent use of heroin, whereas 1.57% 
reported having tried heroin at least once in their lives, and 0.39% reported having used it in the 
course of the twelve months prior to completing the questionnaire. In the roadside data base a 0.30% 
prevalence was observed. 
The frequent use of stimulant drugs (amphetamines, ecstasy) was reported by 0.04% only of the 
Italian population sample, a much lower incidence in comparison to the European average; in the 
roadside survey the weighted incidence is, accordingly,  0 %.  
In the National Report to the EMCDDA, a strong tendency toward polydrug use was observed and a 
high incidence of combined use of alcohol and tobacco with all other drugs was reported; in DRUID 
roadside survey, alcohol plus drug and drug/drug combinations account for 1.01 and 1.22 % of the 
total population respectively, their incidence being comparable to those of cocaine or THC alone. 
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Annex 8.1. Methods of analysis 
 
Sample collection 
For the preparation of blanks, calibrators and quality control samples, a pool of drug-free OF was 
prepared from samples from 8 healthy volunteers. 
Method 1. Liquid chromatography/tandem mass spectrometry for the analysis of illicit drugs and 
medicines (excludingTHC and THC-COOH) 
Chemicals.  
The 30 target analytes and the internal standards are listed in Table 1. Stock solutions in methanol or 
acetonitrile at 1 g/L or 100 mg/L were supplied by Cerilliant (Round Rock, TX, USA) and Lipomed 
(Arlesheim, Switzerland).  
Standard solutions. 
From individual stock solutions mixed working solutions in methanol at 12.5 mg/L, 2.5 mg/L, 0.5 mg/L 
and 0.05 mg/L were prepared with the exception of zopiclone. The IS stock solutions were diluted in 
methanol to give a mixed working solution of 4 mg/L. Zopiclone working solution in acetonitrile at 10 
mg/L, 1 mg/L, 0.1 mg/L and 0.01mg/L were prepared weekly and not mixed with the other substances. 
Sample preparation.  
The samples were extracted by solid phase extraction (SPE) using Bond Elut Certify SPE (130 mg - 
10 mL; Varian Inc, Palo Alto, CA, USA) columns. 1 ml blood samples were diluted with 6 ml of 
phosphate buffer, spiked with 20 L of IS working solution, centrifuged and introduced into the SPE 
columns conditioned with methanol and phosphate buffer (0.1 M, pH 6). 500 L OF sample   
centrifuged, diluted with 2 mL of phosphate buffer, spiked with 20 L of IS solution, an  uced 
into conditioned SPE columns. The calibrators and quality control samples were prepared from 1 mL 
blank blood samples or 250 L blank oral f          
with working solutions. The columns were washed with purified water, HCl 0.1 N, and methanol. The 
elution was carried out by of dichloromethane/isopropanol 90:10 (v/v) containing 2% of NH4OH 
aqueous solution. Eluates were evaporated at room temperature under a stream of nitrogen and re-
dissolved in 50 L of 5 mM ammonium acetate buffer pH 5.0/acetonitrile (vol/vol, 10:90). 
HPLC Chromatographic conditions. 
An Agilent 1200 HPLC system (Agilent, Santa Clara, CA, USA) was used. The chromatographic 
separation was performed by a Waters Atlantis T3 (100 x 2.1 mm, 3 m particle size) column at 40 °C 
using gradient elution with 5 mM ammonium acetate buffer pH 5.0 (phase A) and acetonitrile (phase 
B) at a flow rate of 0.3 mL/min. A gradient was programmed by increasing % B as follows: from 10% B 
to 25 % B in 4 min, hold for 3 min, to  40 % B in 5 min, to 60% in 4 min, to 90 % B in 2 min, hold for 2 
min. An injection volume of 5 L was used. 
Mass spectrometry. 
The HPLC system was combined with an Agilent MSD ion trap mass spectrometer (Agilent, Santa 
Clara, CA, USA) fitted with an Electrospray (ESI) ionization source. The mass spectrometer was 
operated in positive ion mode and in the multiple reaction monitoring (MRM) mode. For collisionally 
induced dissociations helium was used as a target gas and appropriate tickle voltage, tickle time and 
qz values were determined for each substance. The MRM transitions with the corresponding collision 
voltage and retention time of the analytes and internal standards are presented in Table 1. 
Validation results. 
The method was validated in terms of specificity/selectivity, linearity, limits of quantitation (LOQ), intra-
assay precision, inter-assay precision and accuracy (bias). No interferences were detected by 
analyzing 20 drug-free OF and blood samples. The calibration curves, prepared with six points ranging 
from 1 to 200 g/L in spiked blood or OF, yielded r2 ≥0.9889. The LOQs, expressed as the lowest 
analyte concentration which could be determined with an acceptable level of precision and bias (≤ 20 
%), were in the range 1-50 g/L for all compounds. The intra- and inter-assay preci ion and accuracy 
were determined by measuring four replicates at two concentration levels (low and high) on four 
different days (n=16). Precision was expressed as the CV% of the measured values and was always < 
15% in both blood and OF, with the exception of zopiclone. Details are given for OF in Table 1. The 
accuracy, expressed as bias, was always in the range ± 15 % at the two levels. 
Method 2. Gas chromatography - mass spectrometry for the determination of THC and THC-COOH. 
Chemicals. 
Delta-9-tetrahydrocannabinol (THC),11-nor-9-carbooxy-tetrahydrocannabinol (THC-COOH) and the 
internal standards THC-d3 and THC-COOH-d3 in methanol at 100 mg/L were obtained from Cerilliant 
(Round Rock, TX, USA).  
Standard solutions. 
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From individual stock solutions at 100 mg/L, mixed working solutions in methanol at 5 mg/L, 1 mg/L, 
0.500 mg/L, 0.250 mg/L and 0.025 mg/L were prepared. The internal standard (THC-d3 and THC-
COOH-d3) stock solutions at 100 mg/L were diluted in methanol to give a mixed working solution of 
0.5 mg/L.  
Sample preparation. 
The samples were prepared by liquid-liquid extraction. To 2 ml blood. 5 mL of hexane/ethyl acetate 
(vol/vol, 90:10) containing 0.4% of glacial acetic acid and 40 L of IS workin      
500 l OF, 3 mL of hexane/e          id and 10 
L of IS working solution were added. The calibrators and quality control samples were prepared by 
spiking 2 mL blank blood or 250 L blank OF d          
solutions. The samples were mixed by inversion for 15 min. After centrifugation, the organic phase 
was transferred to conical tubes and evaporated to dryness at 40 °C under a stream of nitrogen. To 
the dried extracts were added 50 (blood) or 30 (OF) L of trimethylsylil-trifluoro acetamide contaning 
1% of trimethylchlorosylane as derivitizing agent. Derivatization was achieved by heating at 75 °C for 
20 min. 
Gas chromatography conditions. 
An Agilent 6890N gas chromatography (GC) system (Agilent, Santa Clara, CA, USA). The 
chromatographic separation was performed with an HP Ultra 1 Methyl Siloxane column (12 m x 200 
µm o.d., 0.33 µm film thickness). Helium at a constant flow of 0.8 mL/min was used as a carrier gas. 1 
(blood) or 2 (OF) L of derivatized extracts were injected by splitless injection at 250°C .  The initial 
oven temperature of 80 °C was held for 1 min, followed by an increase to 300°C at 25°C/min with 2 
min hold. 
Mass Spectrometry. 
All mass spectrometric measurements were performed on an Agilent 5973 MS single quadrupole 
mass spectrometer (Agilent, Santa Clara, CA, USA). The single quadrupole was operated in Electron 
Ionization (EI) conditions (70 eV, 200 A) and in sing         
monitored: for THC ions at m/z 303, 371 and 386; for THC-COOH ions at m/z 371, 473 and 488; for 
the IS THC-d3 ions at m/z 306, 374 and 389; for the IS THC-COOH-d3 ions at m/z 374, 476 and 491. 
Validation results. 
No interferences were detected by analyzing 20 drug-free oral fluid or blood samples. The calibration 
curves, prepared with six points ranging from 0.2 to 20.0 g/L THC and THC-COOH in spiked blood 
and OF, yielded r2 ≥0.999. The LOQs resulted to be 0.2 g/L for THC and THC-COOH in both fluids. 
The intra- and inter-assay precision and accuracy were determined by measuring four replicates at 
two concentration levels (1 g/L and 5 g/L) on four differe     -assay precision 
was found to be 3.2 and 1.9 % and the inter-assay precision 3.5 and 2.3 % for the lower and higher 
concentration levels, respectively. The accuracy (bias) was found to be +1.2 and +0.8% for the lower 
and higher concentration levels, respectively. 
Method 3. Saliva alcohol concentration by Headspace Gas Chromatography 
Chemicals. 
Absolute 200 proof ethanol, LC grade iso-propanol, sodium chloride, and sodium fluoride were 
obtained from Sigma Aldrich (Milan, Italy). Acetaldehyde, LC grade methanol, acetone, n-propanol, 
methyl,ethyl ketone and toluene were purchased from Merck Chemicals (Milan, Italy). Purified water 
was obtained with a Milli-Q system (Millipore).  
Standard solutions. Ethanol working solutions in purified water at 1, 2 and 5 g/L were prepared and 
used for the validation and preparation of calibration curves. Iso-propanol (IS) working solution was 
prepared in purified water at 0.5 g/L. Ethanol Standards (0.05%, 0.08%, 0.10%, 0.20% and 0.30% 
w/v) NIST traceable were purchased from Cerilliant (Round Rock, TX, USA) and used as quality 
controls. 
Sample preparation. 
To 0.1 mL oral fluid in a 20 mL glass headspace vial were added 750 mg sodium chloride, 40 mg 
sodium fluoride, 0.5 mL of IS working solution and water to a final volume of 1.5 mL. The calibrators 
and quality control samples were prepared by adding to 0.5 mL blank blood samples or to water the 
appropriate working solution volumes. To 0.1 mL of OF in a 20 mL glass headspace vial were added 
750 mg sodium chloride, 40 mg sodium fluoride, 0.1 mL of IS working solution and water to a final 
volume of 1.5 mL. The calibrators and quality control samples were prepared by adding to 0.1 mL 
water the appropriate working solution volumes.  
Headspace-Gas Chromatography (HS-GC) conditions. 
An Agilent 7694 gas chromatograph (GC) with flame ionization detector and a headspace autosampler 
was used. The chromatographic separation was performed on J&W DB-ALC1 (30 m x 0.534 µm x 
3.00 µm) column. The GC operational parameters were: oven 50º C isothermal, injector 250 ºC, 
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detector (FID) 250 ºC, hydrogen flow 35 mL/min, Air flow 450 mL/min, Make-up gas (nitrogen) flow 
22.6 ml/min. The injection was in split mode with a split ratio 1:50. The HS sampler parameters were: 
sample oven 75 ºC, sample equilibration 10 min, sample inject 1.00 min.  
Validation results. 
Volatiles were identified based on relative retention times compared to calibrators. Linearity was 
evaluated by the preparation of calibration curves with 5 points ranging from 0.01 to 0.05 % w/v. The r2 
value for the linear regression curve was always 0.997 or greater. A study was run to evaluate the 
interferences of other volatile substances (acetaldehyde, methanol, acetone, isopropanol, toluene and 
methyl ethyl ketone). The peaks were resolved with a resolution better than 1 and a peak-to-valley 
ratio better than 90%. The precision, accuracy, and limit of quantitation (LOQ) were determined by ten 
replicate measurements of ethanol at different concentrations; precision was defined as the coefficient 
of variation (CV%); accuracy was defined as the deviations from the actual concentration. The LOQ 
was determined to be 0.010%. .At concentrations of 0.010, 0.050, 0.100, 0.200 and 0.300 % 
precisions were 1.8%, 0.4%, 0.2%, 0.5%,0.2% respectively and accuracies were +13.0% +8.5% -1.8% 
+0.6% -1.6%. 
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Validation parameters for core drugs and additional substances in OF.  Low = LOQ, High = 5 x LOQ. 
Compound Rt (min) 
Fragmenta
tion 
amplitude 
(V) 
Transitions  
(m/z) IS 
LOQ 
g/L 
R2 
 
Intra-assay  
% CV 
Low      High  
Inter-assay 
%CV 
Low     High 
6-Acetylmorphine (6-MAM) 6.4 1.10 328  → 268 cocaine D3 5 0.9961 6.2 4.5 10,0 9,8 
7-aminoclonazepam 9.9 1.00 286 → 250 nordiazepam D5 1 0.9940 7.2 5.4 9.5 5.0 
7-aminoflunitrazepam 11.7 1.00 284 → 135 nordiazepam D5 1 0.9920 4.3 4.2 13.8 9.1 
alprazolam 17.2 1.20 309 → 281 nordiazepam D5 1 0.9889 8.5 9.8 14.8 13.0 
amitriptyline 17.0 1.10 278 → 233 cocaine D3 5 0.9940 5.4 2.2 9.3 8.5 
amphetamine 5.9 1.10 136 → 119 MDPA 25 0.9928 4.3 3.6 11.9 7.0 
benzoylecgonine 7.7 1.20 290 → 168 benzoylecgonine
D3 
10 0.9942 4.1 4.3 13.5 12.8 
bromazepam 14.7 1.00 316 → 182 nordiazepam D5 2 0.9918 3.7 3.2 14.1 10.5 
buprenorphine 15.4 1.00 468 → 414 buprenorphine 
D4 
5 0.9958 2.9 1.8 7.9 6.5 
clonazepam 17.5 0.90 316 → 270 nordiazepam D5 1 0.9989 3.8 2.6 14.1 12.5 
cocaine  9.9 1.00 304 → 182 cocaine D3 10 0.9928 4.6 5.4 10.7 5.9 
codeine 4.9 1.00 300 → 215 cocaine D3 10 0.9972 3.8 2.5 11.1 14.3 
diazepam 19.9 0.90 285 → 193 nordiazepam D5 5 0.9958 5.5 4.2 16.3 9.7 
flunitrazepam 18.3 1.10 314 → 268 nordiazepam D5 1 0.9930 6.1 5.3 11.5 9.8 
fluoxetine 17.3 1.20 310 → 148 cocaine D3 5 0.9990 3.5 2.9 12.4 8.7 
ketamine 8.1 0.90 238 → 220 MDPA 20 0.9978 4.5 4.0 14.3 10.3 
lorazepam 17.3 1.10 322 → 305 nordiazepam D5 1 0.9880 9.8 8.0 14.7 10.5 
metamphetamine 6.6 1.10 150 → 119 MDPA 25 0.9928 6.0 4.5 12.3 8.8 
methadone 17.2 1.20 310 → 265 cocaine D3 20 0.9989 3.1 2.8 8.5 6.5 
methylendioxyamphetamine 
(MDA) 
6.4 1.00 180 → 163 MDPA 25 0.9937 5.5 6.5 10.9 10.5 
methylendioxyethylampheta
mine (MDEA) 
7.7 1.00 208 → 163 MDPA 25 0.9962 4.8 4.1 9.9 8.5 
methylendioxymetampheta
mine (MDMA) 
6.9 0.90 194 → 163 MDPA 25 0.9948 5.9 4.2 8.0 6.6 
morphine 2.2 1.10 286 → 201 cocaine D3 10 0.9989 5.0 3.2 7.7 6.6 
norbuprenorphine 11.4 1.30 414 → 396 buprenorphine 
D4 
5 0.9995 3.9 2.4 7.0 5.4 
nordiazepam 18.5 0.90 271 → 208 nordiazepam D5 20 0.9943 5.5 4.9 9.1 8.7 
olanzapine 8.2 1.20 313 → 256 MDPA 5 0.9961 4.0 3.5 5.8 6.0 
oxazepam 16.9 0.80 288 → 241 nordiazepam D5 50 0.9921 3.7 2.9 8.1 7.2 
venlafaxine 11.5 1.10 278 → 260 cocaine D3 5 0.9989 3.5 1.9 6.0 5.3 
zolpidem 11.1 1.10 308 → 263 cocaine D3 20 0.9925 3.0 2.0 5.5 5.3 
zopiclone 8.8 0.80 389 → 345 MDPA 10 0.9918 10.5 9.3 16.2 14.8 
benzoylecgonine D3(IS) 7.6 1.00 293 → 171 -       
buprenorphine D4 (IS) 15.4 1.00 472 → 415 -       
cocaine D3 (IS) 9.9 1.00 307 → 185 -       
methylendioxypropylamfeta
mine (MDPA) (IS) 
9.0 0.90 222 → 163 -       
nordiazepam D5 18.4 0.90 276 → 213 -       
 
 
  124 
9 Country report Lithuania 
 
Authors: Marija Caplinskiene, Alvydas Pauliukevicius, Zita Minkuviene, Vaida Stankute 
 
State Forensic Medical Service under the Ministry of Justice, Didlaukio 86E, Vilnius, Lithuania 
 
9.1 Description of the roadside driver sample 
In the Lithuania roadside surveys (RSS) have been carried out from 10th of April 2008 until 12th of May 
2009 to assess the situation in Lithuania regarding the prevalence of alcohol and other psychoactive 
substances in drivers in the general traffic. The second objective of the roadside surveys was to collect 
control data for a case-control study to determine the risk of driving under the influence of 
psychoactive substances. In this case-control study cases are formed by seriously injured car drivers 
and controls are a representative sample of drivers from the driving population in the hospital's 
catchments area. For both the prevalence and the case-control calculations, the dataset has been 
weighed for the distribution of traffic by DRUID time period.   
 
All studies were approved by Lithuanian Bioethics Commission according to the code of ethics on 
human experimentation established by the declaration of Helsinki (1964) and amended in Edinburgh 
(2000).  
 
The uniform protocol on road side surveys and all procedures were prepared and adapted by the 
working paper "Uniform design and protocols for carrying out case-control studies" (revision date: 
29/06/2007) of the DRUID project and were set up in progress. Information and the design on uniform 
road side surveys were sent to the Lithuanian Police and other respective state institutions.  The 
uniform questionnaire forms in Lithuanian language for road side surveys were prepared. TMI DRUID 
researchers team for road side surveys appointed. Toxicological analyses protocol completed. The 
uniform protocol for road side surveys was sending for Lithuanian Bioethics Commission for approval.  
 
The meetings were organized with Lithuanian Police representatives on the uniform protocol for road 
side surveys, all details were discussed, the responsible persons were appointed. Dissemination 
activities carried out by information leaflet about the project and distributed during the road side 
survey. The continuing the DRUID advertising campaign via mass media (during project period) the 
information articles about the DRUID project were published in the public journals (“VEIDAS”, 
“MOKSLAS IR TECHNIKA”), information about the project were spread by LT-radio.  
 
9.2 Roadside data collection and analysis 
9.2.1 Characteristics of the roadside sample 
 
Both foreign and domestic drivers were included if they drove a passenger car or a van (domestic car 
drivers B category). The following information was collected for participants:  date, time, gender, age, 
road type, clinical signs of impairment, self-reported drug use and for refuses the reason of refusal. 
The type of body fluid that was collected was whole blood. 
 
12 different research sites were selected, distributed over the different areas in the research regions. 
The main selection criteria were: traffic flow, possibilities for drivers to avoid the research site, safe 
working conditions. Almost all sites were selected along main municipal and provincial roads. During 
the period 2005-2009, these road types accounted for approximately 90% of serious injury crashes in 
the Lithuania.  
Table 9.1 presents the distribution of the survey sample by road type. The roadside samples are 
almost evenly spread over the urban and rural roads. 
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Table 9.1. Distribution of the survey sample by road type 
Road type Road side sample 
Urban (52%) 
Rural (48%) 
Total (100%) 
  
As stated before, the roadside survey sessions have been distributed over all seasons of the year. 
This distribution is present in table 9.2. Almost three quarters of all samples have been collected in the 
second half of the year.  
 
Table 9.2. Distribution of the roadside sample by season 
Season of the year Roadside sample 
January- March (16%) 
April- June (10%) 
July- September (33%) 
October- December (41%) 
Total (100%) 
 
 
The distribution of the survey sample over the eight different time periods is presented in table 9.3. 55 
roadside survey sessions were conducted during the period from 10th of April 2008 until 12th of May 
2009. In each time of the DRUID time periods at least one roadside survey session took place, the 
period 5 was problematic as no samples were collected regarding a very low traffic during this time 
period.  
 
Table 9.3 Distribution of the roadside sample by DRUID time period 
DRUID time period Road side sample 
1 (3%) 
2 (14%) 
3 (30%) 
4 (2%) 
5 (0%) 
6 (32%) 
7 (18%) 
8 (1%) 
In total (100%) 
 
Most samples were collected in the afternoon (10-16) and evening (16-22) during both weekdays and 
the weekend. Only a small fraction of the total number of samples (6%) was collected in the other time 
periods with even no samples from time period five. The skiff sampling was due to a traffic volume.  
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Table 9.4 Distribution of the roadside sample by age and gender 
Age Male Female Total 
18-24 191 (16%) 23 (15%) 214 (16%) 
25-34 299 (25%) 43 (29%) 342 (25%) 
35-49 424 (35%) 34 (23%) 458 (34%) 
50+ 286 (24%) 50 (33%) 336 (25%) 
Unknown 12 (1%) 0 (0%) 12 (1%) 
Total 1200 (100%) 150 (100%) 1350 (100%) 
 
Most samples (89%) were collected from male drives. The distribution by age was quite comparable 
for males and females.  
  
9.2.2 Driver selection and data collection procedures 
Randomly selected drivers were stopped by the police at the request of the acting researcher. The 
interviewer and nurse were interviewing the driver and taking the blood sample. Participation was on a 
voluntary basis. Drivers, who agreed to cooperate, were interviewed on their drug and medicine use. 
The results for each driver were entered on a uniquely numbered research form. The same form was 
used for responders and non-responders. Subsequently, subjects were requested to produce a blood 
specimen. A trained research nurse performed the venapuncture. All specimens were numbered; the 
numbers corresponding with those of the subjects' research forms. The interviewing and sampling of 
blood took place in a specially equipped mobile research unit with enough space to accommodate the 
research team and two subjects or in stationary Lithuanian Police check point station. Breath testing 
was not performed during the RSS. Apart from self-reported drug use and time of administration, data 
collection also comprised date and time of selection, gender and age of the subject, and signs of 
impairment. For non-responders the unified protocol form was full filled, indicating the reason on 
rejecting. 
9.2.3 Description of method for toxicological analyses 
The blood samples were collected in 6 ml vacuum blood tubes, made by „Vacuette“ firm with Na+ 
fluoride and K+ oxalate. The sample shipping and storage were done by DRUID guidelines. All 
analyses on DRUID core substances were done in TMI Toxicology Lab in Vilnius. The toxicology Lab 
undergoes all proficiency tests (Round Robin test) for detection substances in blood. The samples 
storage was in TMI Toxicology Lab in -20°C.  
 
The methods used in TMI Toxicology Lab were following: for ethanol detection in blood was done 
using GC/HS method (the amount of blood used were 0,2 ml); for amphetamines, cocaine and 
opiates, cannabinoids detection in blood were done using GC-MS method (from 1 ml blood each); for 
benzodiazepines detection were used HPLC and GC-MS (from 1 ml of blood). All detailed information 
on toxicological methods is described in Annex 9.1. The methods used for toxicological analyze in 
TMI Toxicology Laboratory and Annex 9.2. The Validation data (reproducibility). 
 
9.2.3.1 Bioethical issues 
TMI submitted all the necessary documents required for receiving the permission for implementation of 
the DRUID project in Lithuania to the Lithuanian Bioethical Committee in November, 2007. The 
documents were prepared following the Committee's previous recommendations and remarks. 
 
The preliminary written consent (including some remarks) from the Committee was received at TMI on 
November 21, 2007 (Lithuania's Bioethical Committee's official letter No.6B-07-386 (Code 07-11-01). 
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9.2.3.2 Data and sample collection issues 
Data and sample collection in Task 2.2a, 2.2b, 2.3 has been started following the relative protocols, 
procedures and other requirements.  
 
9.2.3.3 Toxicological issues 
Toxicological methods regarding the sample analyses in the above tasks have been set up in the TMI 
Toxicology lab in Vilnius. During the joint workshop at LMU (Muenchen, February 18-22, 2008) TMI 
experts-toxicologists have undergone inter-lab quality control. The TMI Toxicology lab undergo Round 
Robin test - the proficiency testing to be performed by DRUID partners. 
  
  
9.2.3.4 Research area and selection of research sites 
 
The control drivers were taken at random from moving traffic in the following research regions of 
Lithuania – in Vilnius, Kaunas, Klaipeda and Alytus regions, in main urban and rural roads. These 
research regions of Lithuania were based on the geographical distribution of population over the 
country, accounting for 3,350 mln. Inhabitants (see picture No.1 Map LT – 4 RSS research regions in 
Lithuania). 
 
 
 
 
Figure 9.1 Map LT – 4 RSS research regions in Lithuania  
 
The survey was carried out during the four quarters of the year (winter – month 1-3, spring – 4-6, 
summer – month 7-9, autumn – month 10-12), during the daytime and night time on weekdays and 
weekends using time intervals of the week according to DRUID project time periods. The expected 
4 RSS research 
regions in LT: 
Vilnius, Kaunas, 
Klaip da, Alytus
Vilnius region
Klaip da region
Kaunas region
Alytus region
Map of RSS research regions in LT
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number of samples (whole blood) was approximately 1500.  The personnel in charge of stopping the 
vehicles at the check points were police staff, the personnel in charge of filling in the driver 
information/case study report were members of the researcher team and the personnel in charge of 
taking the blood samples were licensed nurses. 
 
9.2.3.5 Data collection procedure  
Car drivers were randomly selected and stopped by police officers at the check points. The researcher 
filled in the driver information/case study report and the nurses took the blood samples using vacuum 
tubes.  
   
The transportation and storage: the 5-10 mL whole blood was collected in vacuum tubes containing 
sodium fluoride and potassium oxalate, transportation at 4°C (max. 48 hours) to the Toxicology Lab of 
TMI, storage in laboratory at -20°C.  
 
9.3 Non-response 
The total number of randomly selected drivers (incl. refuses) - 1731. The total number of interviewed 
drivers performed – 1726. The total number of blood-sampled drivers was 1323. The response rate 
was 76%. The total number size of Data Base (DB) of Lithuanian RSS was 1318.  
 
Table 9.5 Distribution of drivers by gender non-response 
 
 
Refusals 
(non-response) 
Respondents 
(Volunteers) 
Total 
Gender Male 127 (33,3%) 1200 (88,9%) 1327 
 Female 254 (66,7%) 150 (11,1%) 404 
 Unknown 0 (0%) 0 (0%) 0 
Total 381 (100%) 1350 (100%) 1731 
 
The non-responses group were in age from 18-31, two third of this group were female. The main 
reason of rejection was the lack of time. No signs of impairment in this group were observed. 
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9.4 Results  
The analytical results for mutually exclusive substance groups weighted for time period for core 
substances are presented in Table 9.6. The results by age and gender are presented in Table 9.7 and 
by time period in Table 9.8.  A dummy variable has been included to create a better presentation of 
the results in SAS. 45 records have been deleted since they did not contain any substance values for 
blood. In total 1264 records were included.  A factor 1.04 was added to the traffic distribution per time 
period to correct for missing time period 5 that accounted for 4%.  
 
Table 9.6 Adjusted general distribution of core substance categories (N=1264) 
Substance percent lower upper 
00 negative 94,49 93,09 95,61 
01 amphetamines 0,22 0,07 0,66 
02 cocaine - - - 
03 THC - - - 
04 illicit opiates - - - 
05 benzodiazepines 1,41 0,90 2,23 
06 Z-drugs - - - 
07 medicinal opiates and opioids - - - 
08 alcohol 3,86 2,93 5,06 
09 alcohol-drugs combinations 0,03 0,00 0,36 
10 drug-drug combinations - - - 
 100,00   
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Table 9.7. Adjusted distribution of core substance categories by gender and age (N=1264) 
Male  18-24 25-34 35-49 50+ Total 
Negative 95,21 96,07 95,39 93,43 94,88 
  90,68 - 97,60 93,05 - 97,81 92,96 - 97,02 89,89 - 95,79 93,45 - 96,01 
Amphetamines 0,00 0,32 0,00 0,00 0,08 
  0,00 - 2,38 0,05 - 1,98 0,00 - 0,90 0,00 - 1,36 0,01 - 0,47 
Benzodiazepines 0,24 0,00 0,21 2,91 0,82 
  0,02 - 2,83 0,00 - 1,40 0,03 - 1,28 1,48 - 5,61 0,43 - 1,52 
Alcohol 4,54 3,60 4,40 3,52 4,20 
  2,24 - 9,01 1,96 - 6,55 2,82 - 6,80 1,91 - 6,40 3,18 - 5,52 
Alcohol-drugs combinations 0,00 0,00 0,00 0,14 0,03 
  0,00 - 2,38 0,00 - 1,40 0,00 - 0,90 0,01 - 1,62 0,00 - 0,40 
 
Female 18-24 25-34 35-49 50+ Total 
Negative 88,70 99,24 97,66 52,73 90,77 
  65,71 - 96,98 91,59 - 99,94 86,77 - 99,62 30,84 - 73,62 84,30 - 94,74 
Amphetamines 11,30 0,00 0,00 0,00 1,53 
  3,02 - 34,29 0,00 - 7,06 0,00 - 9,35 0,00 - 18,35 0,40 - 5,63 
Benzodiazepines 0,00 0,00 2,34 45,02 7,07 
  0,00 - 19,00 0,00 - 7,06 0,38 - 13,23 24,60 - 67,26 3,70 - 13,06 
Alcohol 0,00 0,76 0,00 2,25 0,64 
  0,00 - 19,00 0,06 - 8,41 0,00 - 9,35 0,19 - 21,84 0,09 - 4,21 
Alcohol-drugs combinations 0,00 0,00 0,00 0,00 0,00 
  0,00 - 19,00 0,00 - 7,06 0,00 - 9,35 0,00 - 18,35 0,00 - 3,07 
 
Total 18-24 25-34 35-49 50+ Total 
Negative 94,60 96,57 95,58 91,08 94,49 
  90,18 - 97,10 93,97 - 98,07 93,29 - 97,11 87,27 - 93,82 93,09 - 95,61 
Amphetamines 1,06 0,27 0,00 0,00 0,22 
  0,28 - 3,96 0,04 - 1,67 0,00 - 0,83 0,00 - 1,28 0,07 - 0,66 
Benzodiazepines 0,22 0,00 0,38 5,35 1,41 
  0,02 - 2,57 0,00 - 1,18 0,10 - 1,48 3,31 - 8,53 0,90 - 2,23 
Alcohol 4,12 3,16 4,04 3,45 3,86 
  2,02 - 8,19 1,73 - 5,69 2,59 - 6,26 1,89 - 6,20 2,93 - 5,06 
Alcohol-drugs combinations 0,00 0,00 0,00 0,13 0,03 
  0,00 - 2,16 0,00 - 1,18 0,00 - 0,83 0,01 - 1,53 0,00 - 0,36 
 
Table 9.8 Adjusted distribution of core substance categories by day of the week and time of the day 
(N=1264) 
Timeperiod 
weekday 
04:00-
21:59 
weekday 
22:00-
03:59 
weekend 
04:00-
21:59 
weekend 
22:00-
03:59 Total 
Negative 94,26 96,15 94,58 100,00 94,49 
  92,59 - 95,57 82,65 - 99,24 91,16 - 96,72 
86,63 - 
100,00 93,09 - 95,61 
Amphetamines 0,29 0,00 0,00 0,00 0,22 
  0,09 - 0,88 0,00 - 11,28 0,00 - 1,43 0,00 - 13,37 0,07 - 0,66 
Benzodiazepines 1,81 0,00 0,29 0,00 1,41 
  1,14 - 2,88 0,00 - 11,28 0,04 - 1,96 0,00 - 13,37 0,90 - 2,23 
Alcohol 3,64 3,85 4,99 0,00 3,86 
  2,62 - 5,03 0,76 - 17,35 2,95 - 8,31 0,00 - 13,37 2,93 - 5,06 
Alcohol-drugs combinations 0,00 0,00 0,15 0,00 0,03 
  0,00 - 0,40 0,00 - 11,28 0,01 - 1,70 0,00 - 13,37 0,00 - 0,36 
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The analytical results for alcohol by concentration class are presented in Table 9.9. The results by age 
and gender are presented in Table 9.10. and by time period in Table 9.11. 
 
Table 9.9 Adjusted general distribution of alcohol by concentration class (N=1264) 
BAC percent lower upper 
1 alcohol 0.1-0.49 1,55 1,00 2,39 
2 alcohol 0.5-0.79 0,43 0,19 0,97 
3 alcohol 0.8-1.19 0,41 0,18 0,94 
4 alcohol 1.2+ 1,47 0,94 2,29 
SUM 3,86 2,93 5,06 
 
Table 9.10 Adjusted distribution of alcohol alone by gender and age (N=1264)  
Male 18-24 25-34 35-49 50+ Total 
1 alcohol 0.1-0.49 2,89 1,39 1,63 0,80 1,68 
  1,19 - 6,82 0,53 - 3,61 0,79 - 3,34 0,23 - 2,71 1,08 - 2,61 
2 alcohol 0.5-0.79 0,31 0,46 0,76 0,17 0,47 
  0,03 - 2,94 0,10 - 2,22 0,27 - 2,14 0,02 - 1,69 0,21 - 1,07 
3 alcohol 0.8-1.19 0,24 0,32 0,50 0,31 0,45 
  0,02 - 2,83 0,05 - 1,98 0,14 - 1,75 0,05 - 1,93 0,19 - 1,03 
4 alcohol 1.2+ 1,11 1,43 1,51 2,23 1,59 
  0,28 - 4,26 0,55 - 3,66 0,71 - 3,18 1,04 - 4,73 1,01 - 2,49 
SUM 4,54 3,60 4,40 3,52 4,20 
  2,24 - 9,01 1,96 - 6,55 2,82 - 6,80 1,91 - 6,40 3,18 - 5,52 
 
Female 18-24 25-34 35-49 50+ Total 
1 alcohol 0.1-0.49 - - - 2,25 0,32 
  - - - - - - - - - 0,19 - 21,84 0,03 - 3,66 
2 alcohol 0.5-0.79 - - - - 0,00 
  - - - - - - - - - - - - 0,00 - 3,07 
3 alcohol 0.8-1.19 - - - - 0,00 
  - - - - - - - - - - - - 0,00 - 3,07 
4 alcohol 1.2+ - 0,76 - - 0,32 
  - - - 0,06 - 8,41 - - - - - - 0,03 - 3,66 
SUM 0,00 0,76 0,00 2,25 0,64 
  0,00 - 19,00 0,06 - 8,41 0,00 - 9,35 0,19 - 21,84 0,09 - 4,21 
 
Total 18-24 25-34 35-49 50+ Total 
1 alcohol 0.1-0.49 2,61 1,17 1,49 0,88 1,55 
  1,08 - 6,19 0,44 - 3,05 0,72 - 3,07 0,28 - 2,75 1,00 - 2,39 
2 alcohol 0.5-0.79 0,28 0,39 0,70 0,16 0,43 
  0,03 - 2,67 0,08 - 1,87 0,25 - 1,96 0,02 - 1,59 0,19 - 0,97 
3 alcohol 0.8-1.19 0,22 0,27 0,46 0,30 0,41 
  0,02 - 2,57 0,04 - 1,67 0,13 - 1,61 0,05 - 1,82 0,18 - 0,94 
4 alcohol 1.2+ 1,00 1,32 1,39 2,11 1,47 
  0,25 - 3,87 0,53 - 3,27 0,65 - 2,93 0,98 - 4,46 0,94 - 2,29 
SUM 4,12 3,16 4,04 3,45 3,86 
  2,02 - 8,19 1,73 - 5,69 2,59 - 6,26 1,89 - 6,20 2,93 - 5,06 
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Table 9.11 Adjusted distribution of alcohol alone by day of the week and time of the day (N=1264) 
Time period 
weekday 
04:00-
21:59 
weekday 
22:00-
03:59 
weekend 
04:00-
21:59 
weekend 
22:00-
03:59 Total 
1 alcohol 0.1-0.49 1,13 3,85 2,95 - 1,55 
  0,63 - 2,03 0,76 - 17,35 1,49 - 5,75 - - - 1,00 - 2,39 
2 alcohol 0.5-0.79 0,38 - 0,69 - 0,43 
  0,14 - 1,02 - - - 0,18 - 2,61 - - - 0,19 - 0,97 
3 alcohol 0.8-1.19 0,46 - 0,29 - 0,41 
  0,19 - 1,14 - - - 0,04 - 1,96 - - - 0,18 - 0,94 
4 alcohol 1.2+ 1,67 - 1,05 - 1,47 
  1,03 - 2,70 - - - 0,35 - 3,16 - - - 0,94 - 2,29 
SUM 3,64 3,85 4,99 0,00 3,86 
  2,62 - 5,03 0,76 - 17,35 2,95 - 8,31 0,00 - 13,37 2,93 - 5,06 
 
Results on the roadside survey in Lithuania show that the prevalence of alcohol was 3.86%. The 
higher prevalence was found among male 4.2 percent than female 0.64 percent; no difference was 
found for male age groups. For females alcohol prevalence was higher in the age group of 50+. The 
higher prevalence of alcohol was found at weekend nights than during other periods of the week. 
1.55% of the drivers were found to have alcohol concentrations 0.1-0.45 and 1.45% of the drivers BAC 
concentration of 1.2+.  The alcohol and drugs combination was only found among 0.03 percent of the 
drivers. 
 
The Benzodiazepines were detected in 1.41% of the samples and were thus the most prevalent 
medicinal drug group detected. The prevalence was higher among female drivers (7.07%) than among 
male drivers (0.82%). The prevalence was higher in age group 50+ for both genders. Benzodiazepines 
were commonly found during weekdays at daytime. During this time period the prevalence was 5.56 
%.  
 
Amphetamines were detected in 0.22% of the drivers. Among male drivers the prevalence was 0.08% 
but among female drivers the prevalence was much higher with 1.53%.  Most users were in age group 
18-24.  
 
No cocaine, THC, illicit opiates, Z-drugs, medicinal opiates and opioids were found in collected blood 
samples. 
9.5 Discussion 
Lithuanian roadside survey and national data was collected from 10th of April 2008 until 12th of May 
2009 assess the situation in country regarding the prevalence of alcohol and other psychoactive 
substances in drivers as control population. The research areas of Lithuania were based on the 
geographical distribution of population over the country, accounting for 3,350 mln. inhabitants in total. 
All collected blood samples were investigated in TMI Toxicology laboratory and the data was filled in a 
database. 
 
Such studies on roadside survey in Lithuania done first time so there are no data available to compare 
with situation of previous years on driving population. Till now the main problem in driving population in 
Lithuania is the use of alcohol and relatively in high concentrations. It’s critical important to use the 
DRUID project experience and data to do the future studies on driving population.  
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Annex 9.1  
 
THE METHODS USED FOR TOXICOLOGICAL ANALYSE IN TMI TOXICOLOGY LABORATORY 
FOR: 
 
AMPHETAMINES 
 
LLE 
1ml whole blood + 1ml H2O + 50μl IS + 200μl 8N NaOH + 5ml 1-chlorobutane. Vortex 1 min. Organic 
layer + 1ml 0,2N H
2
SO
4.
 Vortex 2 min.  
Aqueous layer + 100μl 8N NaOH + 1,2ml 1-chlorbutane.  Vortex 2 min.  
Organic layer +100μl tartaric acid in ethylacetate. Evaporate at 40°C, N
2 
Equipment: Caliper Turbo 
Vap LV 
Derivatisation 
+ 50µl ethylacetate + 50μg HFBA. 20min. at 70°C. Equipment: Pierce Reacti-Therm III 
+100μl tartaric acid in ethylacetateat. Evaporate at 
 
40°C, N
2 
  Equipment: Caliper Turbo Vap LV  
 Reconstitution:50µl ethylacetate. 
IS: 
Amfetaminas-D5 Cerilliant, 1mg/ml 1000 ng/ml 
Metamfetaminas-D5 Cerilliant, 1mg/ml 1000 ng/ml 
MDA-D5 Cerilliant, 1mg/ml 1000 ng/ml 
MDMA-D5 Cerilliant, 1mg/ml 1000 ng/ml 
MDEA-D5 Cerilliant, 1mg/ml 1000 ng/ml 
 
Chromatographic conditions: 
Chromatographic system: Agilent technologies 7890A 
Column: DB-5ms ( Agilent technologies, ID -0,25 mm, length – 30 m, 5% Phenyl Arylene polymer, non-
polar) 
Carrier gas: Helium 
Temperature gradient: 100°C(1,0)→20°C/min→200°C→30°C/min→300°C(7) 
Injection: 2μl  
Mass Spec conditions: 
MS system: Agilent technologies 5975C inert XL MSD with Triple Axis Detector; EI 70 V 
Compound Rt TIon (m/z) QIon (m/z) 
Amphetamine-D5 (IS) 5.11 244 123 
Amphetamine 5.13 240 91; 118 
Methamphetamine-D5(IS) 6.03 258 213 
Methamphetamine 6.06 254 118; 210 
MDA-D5(IS) 7.67 167 268 
MDA 7.69 162 240; 375 
MDMA-D5(IS) 8.25 258 213 
MDMA 8.27 254 162; 210 
MDEA-D5(IS) 8.43 273 408 
MDEA 8.45 268 240; 403 
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COCAINE and OPIATES 
 
SPE 
Columns: mixed mode, Grace 3 ml/200mg Drug-Clean, Alltech Associates 
Sample: 
1 ml whole blood + 4 ml H2O + 50 μl IS 
+ 2 ml phosphate buffer pH-6,2 (K2HPO4 x 3H2O) 
Column conditioning 3 ml Methanol 
3 ml  H2O 
1 ml phosphate buffer pH-6,2 
 
Washing:  2 ml H2O 
2 ml 0,1 N HCl 
3 ml Methanol 
 
Elution: 1 x 3 ml CH2 Cl2/IPA/NH4OH (78:20:2) 
40 ml 2-propanol + 4 ml NH4OH. Mix + 156 ml dichlormethane  
 Evaporate at
 
40°C, N
2  
Equipment: Pierce Reacti-Therm III  
Derivatisation 
+ 50 μl Ethylacetate + 40 μl BSTFA. 20min. at 100°C. Equipment: Pierce Reacti-Therm III   
IS: 
ME-D3 Cerilliant, 0,1mg/ml 1000 ng/ml 
Cocaine-D3 Cerilliant, 1mg/ml 1000 ng/ml 
BE-D Cerilliant, 1mg/ml 10 000 ng/ml 
Codeine-D3 Cerilliant, 1mg/ml 2000 ng/ml 
Morphine-D3 Cerilliant, 1mg/ml 2000 ng/ml 
6MAM-D3 Cerilliant, 1mg/ml 2000 ng/ml 
 
 
Chromatographic conditions: 
Chromatographic system: Agilent technologies 7890A 
Column: DB-5ms ( Agilent technologies, ID -0,25 mm, length – 30 m, 5% Phenyl Arylene polymer, non-
polar) 
Carrier gas: Helium 
Temperature gradient (opiates): 150C (3,0) → 10C/min. → 280C (0,0)  → 40C/min. → 300C (8,0) 
Temperature gradient (cocaine):  80C (4,0) → 40C/min. → 240C (6,0)  → 30C/min. → 290C (0,0) 
Injection: 2μl  
Mass Spec conditions: 
MS system: Agilent technologies 5975C inert XL MSD with Triple Axis Detector; EI 70 V 
Compound Rt TIon (m/z) QIon (m/z) 
ME-D3(IS) 6,98 85 185; 274 
ME 6,99 82 182; 271 
Cocaine-D3(IS) 8,87 185 201; 306 
Cocaine 8,88 182 198; 303 
BE-D3(IS) 9,07 243 364 
BE 9,08 240 256; 361 
Codeine-D3(IS) 15,09 374 346 
Diphenhydramine 9,62 58 152; 165 
Tramadol 10,52 58 245; 335 
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Methadone 12,37 72 165; 178 
Codeine 15,12 371 234; 343 
Morphine-D3(IS) 15,47 432 417 
Morphine 15,49 429 401; 414 
6-MAM-D3(IS) 16,02 402 343 
6-MAM 16,04 399 287; 340 
Zolpidem 17,9 235 219; 307 
Buprenorphine 23,44 450 482 
 
 
 
CANNABINOIDS 
 
SPE 
Columns: non-polar, Chromabond C8 1 ml/100 mg, Macherey-Nagel Gmbh & Co. 
Sample: 
1 ml whole blood + 1 ml IS + 2 ml  H2O 
Column conditioning 2x1ml Methanol 
2x1ml  H2O 
 
Washing:  1ml  H2O 
1ml 0,25M acetic acid 
1ml  H2O 
 
Elution: 2x1ml Acetone  
 
 Evaporate at
 
40°C, N
2  
Equipment:  Caliper Turbo Vap LV 
Derivatisation 
+ 150 μl DMSO/TBAH (1ml: 980 μl DMSO/ 20 μl TBAH)   
+ 50 μl Jodmethane, 25-30 min room temperature 
+ 350 μl 0,1 M HCl +  1 ml Isooctane 
Organic layer evaporate at 40°C, N2  Equipment:  Caliper Turbo Vap LV 
Reconstitute in 40 μl Ethylacetate  
IS: 
THC-D3 Cerilliant, 0,1mg/ml 30 ng/ml 
THC-OH-D3 Cerilliant, 0,1mg/ml 20 ng/ml 
THC-COOH-D3 Cerilliant, 0,1mg/ml 30 ng/ml 
 
Chromatographic conditions: 
Chromatographic system: Agilent technologies 7890A 
Column: DB-5ms ( Agilent technologies, ID -0,25 mm, length – 30 m, 5% Phenyl Arylene polymer, non-
polar) 
Carrier gas: Helium 
Temperature gradient: 150C (0,0) → 25C/min. → 280C (9,8) 
Injection: 2μl  
Mass Spec conditions: 
MS system: Agilent technologies 5975C inert XL MSD with Triple Axis Detector; EI 70 V 
Compound Rt TIon (m/z) QIon (m/z) 
THC-D3(IS) 6,03 316 248; 331 
THC 6,04 328 245; 285 
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THC-OH-D3(IS) 6,69 316 260; 361 
THC-OH 6,7 313 257; 358 
THC-COOH-D3(IS) 7,35 316 360; 375 
THC-COOH 7,36 313 357; 372 
 
 
 
BENZODIAZEPINES 
LLE 
200μl  whole blood + 100μl K2HPO4  (PBS pH-9,2) + 300μl organic mix from (n-Butylacetate and IS 
Flurazepam 200 ng/ml), 
Vortex 1 min.  
Derivatisation 
50μl Upper organic layer transfer to chromatography vials + 10μl (MTBSTFA)Vortex 0,1 min., 20min. 
at 90°C. Equipment: Pierce Reacti-Therm III 
IS: 
 Flurazepam  Lipomed 200 ng/ml 
 
Chromatographic conditions: 
GC/NICI-MS system, Agilent 5975C inert XL el/cl MSD GC System  
 Column: Agilent 123-5731 DB-5HT, max. 400 ºC, 30 m, 0,320 mm, 0,1 μm particle 
size.  
Carrier gas: Helium 
Chemical ionization gas – methan (purity 5,5) 
Temperature gradient: 180C (0) → 50ºC/min. → 325ºC → (2,0)     Run Time- 4,9 min 
Injection: 2μl  
Mass Spec conditions: 
Compound  Retention time (min) TIon (m/z) QIon (m/z) 
Flurazepam (IS) 2,57 387 389 
137Diazepam 2,05 284 286 
Flunitrazepam 2,32 313 314 
Oxazepam 2,49 268 270 
Lorazepam 2,70 302 304 
Alprazolam 2,84 308 310 
Zopiclone 3,03 143 246 
Nordazepam 2,11 234 384 
7-amino-clonazepam 2,62 249 363 
Clonazepam 2,73 429 431 
 
ETHANOL 
 
IS: 0,1 % 1-propanol 
Chromatographic conditions: 
Chromatographic system: Perkin Elmer Clarus 500 TurboMatrix110 
Column 1: Elite BAC1 ( PE: 0,18x10x1,0) 
Column 1: Elite BAC2 ( PE: 0,18x10x0,63) 
Carrier gas: Helium 
Temperature: 35C  
Injection: 2μl  
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Controls for: 
 
Benzodiazepines – Medidrug Benzodiazepine S, level 1 (serum cotrol). Remark: used serum control 
as not produsing the controls in blood. 
 
Other – Medidrug BTMF 2/---B, drugs of abuse, whole blood control with reference values. Remark: 
produced year 06; 07 ir 08: 2/06-B; 2/07-B ir 2/08-B.  
 
Alkohol – Medidrug Ethanol VB-plus, Blood alcohol- Whole blood control (human). Concentrations: 0,5 
g/L; 0,8 g/L ir 1,1 g/L. Folowing concentrations produced: 0,2 g/L ir 4,0 g/L 
 
Terms: 
 
Benzodiazepines – Nr.1- Nr.400 – from 2008.10.01 till 2009.03.06.; Nr.401- Nr.1323 – from 
2009.11.02. till 2009.12.02. 
 
Other – Nr.1- Nr.970 – from 2008.10.01 till 2009.05.31.; Nr.971- Nr.1323 – from 2009.09.15. till 
2009.11.01. 
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Annex 9.2 
 
VALIDATION DATA (REPRODUCIBILITY) 
Compound Calibration points, ng/ml Avg. ng/ml RSD, % Bias, % LOD, ng/ml 
LOQ, 
ng/ml 
Diazepam 0;10;20;30;50;70;100;120 10,34 /49,7/ 101,11 10,83 /4,67/ 4,48 3,4 /-0,6/ 1,11 1,4 4,2 
Flunitrazepam 0;10;20;30;50;70;100;120 11,8 /49,26/ 103,4 9,92 /10,90/ 4,46 18 /-1,5/ 3,4 1,2 3,6 
Oxazepam 0;10;20;30;50;70;100;120 10,93 /51,3/ 102,22 14,36 /5,54/ 7,15 9,3 /2,6/ 2,22 3,2 9,8 
Lorazepam 0;10;20;30;50;70;100;120 11,73 /50,4/ 102,91 14,66 /7,90/ 9,37 17,3 /0,8/ 2,91 2,3 7,0 
Alprazolam 0;10;20;30;50;70;100;120 12,38 /51,64/ 102,67 5,25 /4,45/ 5,07 23,8 /3,3/ 2,67 2,6 7,9 
Zopiclone 0;10;20;30;50;70;100;120 - /49,16/ 104,19 - /16,97/ 18,47 - /-1,7/ 4,19 6,1 18,4 
Nordazepam 0;10;20;30;50;70;100;120 9,32 /49,65/ 103,31 13,63 /9,73/ 10,75 -6,8 /-0,7/ 3,31 1,8 5,5 
7-amino-clonazepam 0;10;20;30;50;70;100;120 12,85 /51,8/ 95,43 22,18 /8,55/ 8,79 28,5 /3,6/ -4,57 3,8 11,4 
Clonazepam 0;10;20;30;50;70;100;120 11,87 /52,89/ 101,52 15,25 /7,83/ 11,14 18,7 /5,8/ 1,52 1,7 5,0 
Amphetamine 0;20;50;100;150;200;250;300 23,60/143,07/288,13 14,58/2,40/1,92 18/-5/-4 4,2 12,7 
Methamphetamine 0;20;50;100;150;200;250;300 21,93/139,26/289,14 7,48/4,72/4,05 10/-7/-4 5,24 15,9 
MDA 0;20;50;100;150;200;250;300 20,44/141,32/285,23 10,71/2,05/6,25 2/-6/-5 2,65 8,02 
MDMA 0;20;50;100;150;200;250;300 21,63/133,58/277,62 3,24/1,91/1,61 8/-11/-7 2,33 7,1 
MDEA 0;20;50;100;150;200;250;300 22,68/136,7/280,33 1,59/2,44/1,5 13/-9/-7 1,78 5,39 
THC 0;2;4;6;8;10;12;14 -/9,58/14.58 -/3,44/2,47 19,75/4,1 0,84 2,54 
THC-OH 0;2;4;6;8;10;12;14 2,08/8,61/13,70 4,33/3,14/14,45 4/7,63/-2,14 0,52 1,56 
THC-COOH 0;10;20;30;40;50;60;70 11,04/46,06/63,55 5,34/3,34/10,95 10,4/15,5/-9,21 2,39 7,15 
ME 0;10;20;30;40;50;60;70 -/35,93/59,18 -/6,74/14,26 -/-10,17/-15,46 4,56 13,82 
Cocaine 0;10;20;30;40;50;60;70 10,42/39,2/69,92 9,69/4,69/3,7 4,2/-2/-0,11 3,71 11,25 
BE 0;50;100;150;200;250;300;350 50,24/184,46/326.3 4,48/6,3/3,85 0,48/-7,77/-6,77 7,95 24,08 
Diphenhydramine 0;10;25;50;100;150;200;250 112,87/221,77 11,32/21,31 12,87/-11,29 7,11 21,55 
Tramadol 0;10;25;50;100;150;200;250 94,92/193,81 9,17/6,28 -5,08/-22,48 3,95 11,98 
Methadone 0;10;25;50;100;150;200;250 8,94/96,86/198,04 14,32/2,97/8,12 -10,6/-3,14/-20,78 3,21 9,72 
Codeine 0;10;25;50;100;150;200;250 10,79/99.36/251/83 1,76/2,21/3,37 7,9/-0,64/0,73 1,8 5,44 
Morphine 0;10;25;50;100;150;200;250 -/104,9/217,17 -/12,4/3,58 -/4,9/-13,13 5,01 15,18 
6MAM 0;10;25;50;100;150;200;250 10,94/95,14/248,02 4,94/1,32/3,12 9,4/-4,86/0,79 2,78 8,42 
Buprenorphine 0;10;25;50;100;150;200;250 87/7/266.05 13,61/5,59 -12,3/6,42 5,22 15,82 
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10.1 Description of the roadside driver sample 
10.1.1 Introduction 
In the Netherlands roadside surveys have been carried out from January 2007 until August 2009 to 
gain more insight in the prevalence of psychoactive substances among the driving population. A 
second objective of the roadside surveys is to collect control data for a case-control study to determine 
the risk of driving under the influence of psychoactive substances. In this case-control study cases are 
formed by seriously injured car drivers and controls are a representative sample of drivers from the 
driving population in the hospital's catchment area. 
For both the prevalence and the case-control calculations, the dataset has been weighed for the 
distribution of traffic by DRUID time period.  
72 roadside survey sessions were conducted, twelve in each of the six regions. In each time of the 
eight DRUID time periods at least one roadside survey session took place. The other four survey 
sessions were distributed according to the distribution of traffic or to the distribution of accidents and 
risk, depending whether the region was included in the DRUID hospital study or not. 
Drivers were stopped by the police at the request of the acting research coordinator. As soon as one 
of the two interviewers/nurses was ready for interviewing and blood sampling a driver, the next car 
approaching the research site was stopped. The stopped drivers were asked to cooperate with the 
research team on a voluntary basis. Drivers who agreed to cooperate, were interviewed on their drug 
and medicine use. The results for each driver were entered on a uniquely numbered research form; 
see Appendix A. Subsequently, subjects were requested to produce a blood specimen. If they were 
not able or willing to do so, they were requested to deliver a saliva specimen. A trained research nurse 
performed the venapuncture. Subjects who delivered a blood specimen, received a € 10 reward. For 
oral fluid, they received € 5. All specimens were numbered; the numbers corresponding with those of 
the subjects' research forms.  
Interviewing and sampling of body fluids took place in a specially equipped mobile research unit with 
enough space to accommodate the research team and two subjects. After the interview and the blood 
or saliva sampling, all subjects were breath-tested for alcohol by a police officer, using a Dräger 
Alcotest 7410 Plus com screening device. The breath test was compulsory for all stopped drivers. 
Breath test results were entered on the (anonymous) research form. Apart from self-reported drug use 
and time of administration, data collection also comprised date and time of selection, gender and age 
of the subject, and signs of impairment.  
 
10.1.2 Geographical distribution of drivers over the country 
Control drivers were selected at random from moving traffic in six different police regions. The choice 
of these districts was based on the geographical distribution of population over the country. 
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Figure 10.1 Geographical distribution of the roadside survey regions 
 
The following police regions (and one district) were included: Amsterdam Amstelland, Hollands-
Midden, Gelderland-Zuid, Twente, Groningen, and Tilburg, accounting for 3,7 million inhabitants in 
total. This is almost a quarter of the Dutch population. 
Per police region around 20 different research sites were selected, distributed over the different areas 
in the police region. The main selection criteria were: traffic flow, (lack of) possibilities for drivers to 
avoid the research site, enough room for the research and police teams and their vehicles, safe 
working conditions. Almost all sites were selected along main municipal and provincial roads. During 
the period 2006-2008, these road types accounted for approximately 80% of serious injury crashes in 
the Netherlands.  
In total 5064 drivers were asked to participate. 242 refused cooperation, and 4822 drivers were 
included.  
Table 10.1 presents the distribution of the samples by survey region. Most of the drivers were included 
in Twente and Gelderland-Zuid. The lowest number of drivers was included in the Tilburg Region. The 
different numbers of included drivers between regions were a result of differences in traffic. These 
differences were caused by several reasons, e.g. weather conditions, distribution of the sampling 
periods over time and day, locations, and the size of the participating policeteam. 
 
Table 10.1. Distribution of drivers by region (n=4822) 
Region Distribution of samples 
Hollands-Midden 16.1% 
Tilburg 15.2% 
Amsterdam Amstelland 16.6% 
Groningen 16.5% 
Twente 18.4% 
Gelderland-Zuid 17.3% 
 
Traffic distribution numbers were not available for all six regions. For the region that traffic distribution 
was available the representativeness of these figures for traffic distribution is not optimal since the 
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available data did not represent the vehicle kilometers that are driven in the region, but the number of 
trips that started in the region. 
 
10.1.3 Distribution by time period 
Table 10.2 presents the distribution of drivers by time period. Over 70% of all included drivers were 
sampled during daytime hours (4 AM-10PM), while during these hours around 95% of vehicle 
kilometers are driven. 
 
Table 10.2. Distribution of drivers by time period (n=4822) 
Timeperiod Distribution of samples Distribution of 
traffic 
Weekday 04:00-09:59 14.5% 22.0% 
Weekday 10:00-15:59 13.4% 23.6% 
Weekday 16:00-21:59 13.1% 26.9% 
Weekday 22:00-03:39 14.0% 3.0% 
Weekendday 04:00-09:59 8.2% 2.7% 
Weekendday 10:00-15:59 8.5% 11.1% 
Weekendday 16:00-21:59 15.2% 8.0% 
Weekendday 22:00-03:39 13.1% 2.7% 
 
Therefore, night time hours are overrepresented in the sample. The reason behind this is two-fold. The 
first reason is that police had a preference for roadside survey sessions during times and days where 
their normal alcohol enforcement would take place. The second reason for an overrepresentation of 
night time hours was to make sure that enough samples were gathered during times and days where 
the prevalence of psychoactive substances was expected to be high.  
 
10.1.4 Distribution by quarter of the year 
 
Table 10.3. Distribution of drivers by quarter of the year (n=4822) 
Substance category Distribution of samples 
1st quarter (Jan-Mar) 21.3% 
2nd quarter (Apr-Jun) 29.2% 
3rd quarter (Jul-Sep) 25.9% 
4th quarter (Okt-Dec) 23.6% 
 
The distribution of drivers by quarter of the year is presented in table 10.3. The sampling of drivers is 
quite evenly distributed over the four quarters of the year. The share of sampled drivers in the first 
quarter of the year is the lowest (21.3%) and in the second quarter the share of sampled drivers is the 
highest (29.2%). Both quarters are close to the mean though. 
 
10.1.5 Distribution by gender and age 
Table 10.4 presents the distribution of the samples by age (divided over 4 age groups) and gender. 
Around 70% of the included drivers were males. This share was more or less the same for every age 
group. The number of drivers between 18 and 24 is lower than drivers from other age groups. 
However, this age group contains 7 years, whereas the other groups contain at least 10 years. For 5 
drivers no age was recorded. 
 
Table 10.4. Distribution samples by gender and age (n=4817) 
Age group Distribution of male 
drivers 
Distribution of 
female drivers 
Total distribution 
of samples 
18-24 years old 68.5% 31.5% 13.0% 
25-34 years old 70.4% 29.6% 23.0% 
35-49 years old 69.0% 31.0% 34.3% 
50 years and older 73.1% 26.9% 29.7% 
Total ages 70.5% 29.5% 100% 
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10.2 Roadside data collection and analysis 
 
10.2.1 Ethical approval  
No ethical approval was needed in the Netherlands. After having been informed about the project, the 
Ethical Committee answered that “the project is not encompassed by the law on Ethical Committees 
and consideration regarding bio-medical research projects. Therefore, the project should not be 
announced to the ethical Committee”. Hence, no informed consent was requested. 
 
10.2.2 Samples 
Venous blood samples were collected from car drivers on a voluntary basis during a road side survey, 
and collected in glass tubes containing 20 mg sodium fluoride and 143 IU heparin sodium (BD 
Plymouth, UK). Oral fluid samples were taken by spitting into a polypropylene container (Deltalab, 
Spain).  
During the road side survey, blood samples and oral fluid samples were stored in solid carbon dioxide 
at about -80˚C (dry ice). After transportation to the Netherlands Forensic Institute (NFI) in The Hague, 
blood samples and oral fluid samples were stored at -20˚C until analysis. 
 
10.2.3 Analytical conditions 
LCMS analysis was performed on a Water Acquity UPLC®-system with a Waters Quatro premier XE 
triple quadrupole mass spectrometer. Chromatography employed a reversed-phase UPLC ® column 
(BEH C-18, 100 x 2.1-mm i.d., 1.7 µm particle diameter) and a 17-min gradient elution (methanol / 10 
mM ammonium bicarbonate pH 10.0, 5/95 to 95/5). The UPLC® injector was modified for on-line 
dilution of the injected sample to allow large injection volumes of acetone. The eluent was introduced 
to the electrospray source of the triple quadrupole MS instrument at a flow-rate of 500 μL/min. 
Molecular ions were fragmented using optimized collision-induced dissociation voltages for each 
compound (9 to 50 eV, positive ion mode). For each target-compound two MRM were monitored and 
for each deuterated internal standard one MRM was monitored. 
 
10.2.4 Method of BAC quantification  
BAC was measured in breath by means of hand hold alcolmetres of the police teams using a Dräger 
Alcotest 7410 Plus com screening device. The alcolmetres are calibrated to show a reading of 0.5 g/L 
ethanol when calibrated by means of breath containing 0.22 mg/L.  
1 permille BAC in the Netherlands is equivalent to a breath alcohol result of 440 microgram per liter. 
This conversion factor was not the same as the conversion factor used in the DRUID project (2100). 
Therefore, all BAC results were multiplied by a factor 2300/2100. 
 
10.2.5 Weighting factors for the control sample 
The unweighted control sample could not be considered to be representative of all drivers who 
participated in road traffic in the six police districts at all days of the week and all times of the day, 
since the sample distribution over different times and days was not equal to the distribution of traffic 
volumes. The reason for this was the more or less constant sampling capacity of the research team, 
regardless of the traffic volumes that are strongly varying by day of the week (weekdays versus 
weekend) and by time of the day. Furthermore, the police had a quite understandable preference for 
enforcement activities during high-risk hours, i.e. the nighttime hours with low traffic volumes. So, in 
order to make the control sample representative for the whole week, it had to be weighted, based on 
traffic flow distribution over the various days of the week and times of the day.  
In order to make the control sample representative of the general driving population in the Tilburg 
police district, it had to be weighted. The weighting procedure was based on 2007-2008 trip data 
collected by the Dutch Central Bureau of Statistics (CBS), following the weighting procedure that was 
applied in a previous case-control study by Mathijssen and Houwing (2005). 
Table 10.5 provides an overview of the sample distribution, the traffic distribution and the resulting 
weightfactor.  
Weekend nights and, to a lesser degree, weekday nights were strongly over-represented in the control 
sample. Drink driving is strongly concentrated in nighttime hours. As a consequence, drink driving was 
over represented in the unweighted control sample. Weighting the control sample solved this problem.  
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Table 10.5. Applied weighting factors 
Timeperiod Distribution of 
samples 
Distribution 
of traffic 
Weight factor 
Weekday 04:00-09:59 14.5% 22.0% 1.52 
Weekday 10:00-15:59 13.4% 23.6% 1.76 
Weekday 16:00-21:59 13.1% 26.9% 2.05 
Weekday 22:00-03:39 14.0% 3.0% 0.22 
Weekendday 04:00-09:59 8.2% 2.7% 0.33 
Weekendday 10:00-15:59 8.5% 11.1% 1.31 
Weekendday 16:00-21:59 15.2% 8.0% 0.53 
Weekendday 22:00-03:39 13.1% 2.7% 0.21 
 
 
10.2.6 Statistical analysis 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
10.3 Non-response 
In the Dutch roadside survey information on non respondents is available for the following 
characteristics: age, gender, passengers, BAC, and self reported use of psychoactive substances.  
Based on this information a comparison between respondents and non-respondents can be made in 
order to assess the possible size and nature of the non-response bias. The age and gender 
distribution for both the response and the non-response group is presented in table 10.6. 
 
Table 10.6. Distribution by age and gender for respondents and non-respondents 
 Respondents (n=4822) Non-respondents (n=242) 
 Male Female Total Male Female Total 
18-24 8.9% 4.1% 13.0% 12.0% 1.7% 13.6% 
25-34 16.2% 6.8% 22.9% 26.0% 5.0% 31.0% 
35-49 23.6% 10.6% 34.3% 26.9% 5.8% 32.6% 
50+ 21.7% 8.0% 29.7% 12.8% 4.6% 17.4% 
Unknown  0.1% -- 0.1% 5.4% -- 5.4% 
Total 70.5% 29.5% 100% 83.1% 16.9% 100% 
 
Males aged 25-34 years were overrepresented among the non-response group and females aged 35 
years and older, as well as males aged 50 years and older were underrepresented. The number of 
non-respondents in each of these groups were very low. Therefore, the possible effect of these biases 
is expected to be very limited.  
The share of drivers who were driving with passengers was almost identical. When adjusting for 
unknown passengers, 61.5% of the respondents were driving alone versus 62.2% of the non 
respondents.  
The distribution by BAC level is presented in table 10.7. All drivers, whether they participated in the 
study or not, were tested for alcohol. 
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Table 10.7. Distribution by BAC level for respondents and non-respondents 
BAC Respondents (n=4822) Non-respondents (n=242) Total (n=5064) 
0-0.1  95.8% 92.6% 95.6% 
0.1-0.5  3.1% 5.4% 3.2% 
0.5-0.8  0.5% 0.8% 0.5% 
0.8-1.3  0.4% 0.8% 0.4% 
>1.3 0.3% 0.4% 0.3% 
Total 100% 100% 100% 
 
The prevalence of alcohol is slightly higher for the non-response group than it is for the response 
group. However, the distribution over the BAC level is almost identical for the combination of both the 
respondent group and the non-respondent group as it is for the respondent group alone.  
The selfreported use of psychoactive substances was higher for the non-response group. After 
correction for the unknown answers, 6.5% of the non respondents reported the use of psychoactive 
substances in the past 12 hours versus 3.6% of the respondents. When correcting for this bias, the 
self reported use of the total study population would shift from 3.6% to 3.7%.  
Based on the comparison between the response and non-response group it can be assumed that 
there is a strong likelihood of difference in prevalence between both groups. However, the possible 
bias is tends to be very small due to the small size of the non-response group.  
 
10.4 Results  
In total 4822 drivers were included in the analysis. Table 10.8 provides a general overview of the use 
of psychoactive substances in Dutch Traffic. Alcohol and THC are by far the most commonly detected 
substances, followed by benzodiazepines, drug-drug combinations and cocaine.  
 
Table 10.8. Adjusted general distribution of core substance categories (N=4822) 
Substance category Prevalence (%) Confidence interval 
(%) 
Negative 94.49 93.81 - 95.10 
Amphetamine 0.19 0.10 - 0.36 
Cocaine 0.30 0.18 - 0.50 
THC 1.67 1.34 - 2.07 
Illicit opiates 0.01 0.00 - 0.09 
Benzodiazepines 0.40 0.25 - 0.62 
Z-drugs 0.04 0.01 - 0.15 
Medicinal opioids 0.16 0.08 - 0.32 
Alcohol 2.15 1.78 – 2.60 
Alcohol – drugs 0.24 0.13 - 0.42 
Multiple drugs 0.35 0.22 - 0.56 
 
Illicit drugs are commonly detected in drug-drug and drug-alcohol combinations as well. Cocaine was 
detected among 0.30% of the drivers as a single drug, but also present in combination with alcohol or 
other drugs in 0.36% of the drivers. The prevalence of amphetamines is doubled from 0.19% to 37% if 
combined use is taken into account. Medicinal drugs are less frequently used in combinations. 
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Table 10.9. Combined use of psychoactive substances 
Substance Prevalence (%) Total prevalence (%) 
amphetamines alone 0.19  
amphetamines in combination 0.18 0.37 
cocaine alone 0.30  
cocaine in combi 0.36 0.66 
THC alone 1.67  
THC in combi 0.43 2.10 
illicit opiates alone 0.01  
illicit opiates in combi 0 0.01 
benzodiazepines alone 0.40  
benzodiazepines in combi 0.04 0.44 
z-drugs alone 0.04  
z-drugs in combi 0.01 0.05 
opiates and opioids alone 0.16  
opiates and opioids in combi 0.05 0.21 
alcohol alone 2.10  
alcohol in combi 0.28 2.38 
 
Alcohol is the most commonly detected psychoactive substance in traffic in the Netherlands. In 
traffic, 2.15% of the drivers had a bac of 0.1g/L and 0.61% had a BAC above the 0.5 g/L. 
 
Table 10.10. Adjusted general distribution of alcohol by concentration class (N=4822) 
Alcohol alone Prevalence (%) Confidence interval 
(%) 
Alcohol 0.1 – 0.49 g/L 1.54 1.23 – 1.93 
Alcohol 0.5 – 0.79 g/L 0.26 0.15 – 0.44 
Alcohol 0.8 – 1.19 g/L 0.14 0.07 – 0.29 
Alcohol 1.2+ 0.21 0.12 – 0.39 
In total 2.15 1.78 – 2.60 
 
  
  147 
Table 10.11. Adjusted distribution of core substance categories by gender and age (N=4822) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 91.05 
87.61 – 93.61 
92.12 
89.93 – 93.83 
93.40 
91.82 – 94.70 
95.32 
93.93 – 96.40 
93.54 
92.66 – 94.32 
Amphetamine 0.18 
0.02 - 1.41 
0.13 
0.02 - 0.76 
0.55 
0.26 – 1.17 
0.00 
0.00 – 0.34 
0.23 
0.12 – 0.46 
Cocaine 0.86 
0.29 - 2.49 
0.91 
0.43 - 1.91 
0.23 
0.07 – 0.71 
0.00 
0.00 – 0.34 
0.36 
0.21 – 0.63 
THC 5.75 
3.76 - 8.69 
2.51 
1.60 - 3.91 
2.12 
1.43 – 3.13 
0.63 
0.31 – 1.28 
2.08 
1.65 – 2.62 
Illicit opiates 0.00 
0.00 - 1.08 
0.05 
0.00 - 0.61 
0.00 
0.00 – 0.33 
0.00 
0.00 – 0.34 
0.01 
0.00 – 0.13 
Benzodiazepines 0.00 
0.00 - 1.08 
0.00 
0.00 - 0.52 
0.45 
0.19 – 1.03 
0.34 
0.13 – 0.88 
0.27 
0.14 – 0.50 
Z-drugs 0.00 
0.00 - 1.08 
0.00 
0.00 - 0.52 
0.03 
0.00 – 0.34 
0.15 
0.04 – 0.61 
0.06 
0.02 – 0.22 
Medicinal 
opioids 
0.06 
0.00 - 1.20 
0.00 
0.00 - 0.52 
0.00 
0.00 – 0.33 
0.32 
0.12 – 0.85 
0.11 
0.04 – 0.30 
Alcohol 0.82 
0.27 - 2.42 
2.17 
1.34 - 3.51 
2.79 
1.98 – 3.91 
3.01 
2.17 – 4.18 
2.52 
2.04 – 3.11 
Alcohol – drugs 0.67 
0.20 - 2.20 
0.81 
0.37 - 1.77 
0.20 
0.06 – 0.67 
0.03 
0.00 – 0.39 
0.32 
0.18 – 0.58 
Multiple drugs 0.61 
0.17 - 2.11 
1.30 
0.70 - 2.42 
0.24 
0.08 – 0.74 
0.20 
0.06 – 0.68 
0.50 
0.31 – 0.80 
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Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 97.23 
93.29 – 98.88 
95.76 
92.75 – 97.55 
96.46 
94.63 – 97.69 
97.47 
95.52 – 98.58 
96.71 
95.66 – 97.51 
Amphetamine 0.00 
0.00 - 2.42 
0.46 
0.10 – 2.13 
0.00 
0.00 – 0.66 
0.00 
0.00 – 0.88 
0.09 
0.02 – 0.42 
Cocaine 0.34 
0.04 - 3.04 
0.53 
0.12 – 2.25 
0.04 
0.00 – 0.73 
0.00 
0.00 – 0.88 
0.15 
0.05 – 0.53 
THC 1.61 
0.50 – 5.07 
1.51 
0.61 – 3.69 
0.62 
0.23 – 1.66 
0.00 
0.00 – 0.88 
0.71 
0.39 – 1.30 
Illicit opiates 0.00 
0.00 - 2.42 
0.00 
0.00 – 1.33 
0.00 
0.00 – 0.66 
0.00 
0.00 – 0.88 
0.00 
0.00 – 0.26 
Benzodiazepines 0.00 
0.00 - 2.42 
0.53 
0.12 – 2.25 
1.09 
0.51 – 2.31 
0.55 
0.17 – 1.80 
0.70 
0.38 – 1.28 
Z-drugs 0.00 
0.00 - 2.42 
0.00 
0.00 – 1.33 
0.00 
0.00 – 0.66 
0.00 
0.00 – 0.88 
0.00 
0.00 – 0.26 
Medicinal 
opioids 
0.00 
0.00 - 2.42 
0.00 
0.00 – 1.33 
0.35 
0.10 – 1.26 
0.47 
0.13 – 1.68 
0.28 
0.11 – 0.71 
Alcohol 0.61 
0.10 – 3.50 
1.07 
0.37 – 3.07 
1.44 
0.74 – 2.78 
1.51 
0.72 – 3.15 
1.30 
0.83 – 2.02 
Alcohol – drugs 0.21 
0.02 – 2.82 
0.08 
0.00 – 1.47 
0.00 
0.00 – 0.66 
0.00 
0.00 – 0.88 
0.04 
0.00 – 0.33 
Multiple drugs 0.00 
0.00 - 2.42 
0.07 
0.00 – 1.46 
0.00 
0.00 – 0.66 
0.00 
0.00 – 0.88 
0.01 
0.00 – 0.29 
 
 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 92.94 
90.37 – 94.86 
93.14 
91.42 – 94.54 
94.43 
93.25 – 95.42 
95.91 
94.82 – 96.79 
94.49 
93.81 - 95.10 
Amphetamine 0.12 
0.02 – 0.98 
0.22 
0.07 – 0.76 
0.36 
0.17 – 0.78 
0.00 
0.00 – 0.24 
0.19 
0.10 - 0.36 
Cocaine 0.70 
0.26 – 1.88 
0.81 
0.41 – 1.57 
0.16 
0.05 – 0.49 
0.00 
0.00 – 0.24 
0.30 
0.18 - 0.50 
THC 4.49 
3.00 – 6.66 
2.22 
1.48 – 3.33 
1.62 
1.12 – 2.33 
0.45 
0.22 – 0.93 
1.67 
1.34 - 2.07 
Illicit opiates 0.00 
0.00-0.75 
0.03 
0.00 – 0.44 
0.00 
0.00 – 0.22 
0.00 
0.00 – 0.24 
0.01 
0.00 - 0.09 
Benzodiazepines 0.00 
0.00-0.75 
0.15 
0.03 – 0.64 
0.66 
0.37 – 1.17 
0.39 
0.18 – 0.85 
0.40 
0.25 - 0.62 
Z-drugs 0.00 
0.00-0.75 
0.00 
0.00 – 0.38 
0.02 
0.00 – 0.26 
0.11 
0.03 – 0.44 
0.04 
0.01 - 0.15 
Medicinal 
opioids 
0.04 
0.00-0.83 
0.00 
0.00 – 0.38 
0.12 
0.03 – 0.43 
0.36 
0.16 – 0.80 
0.16 
0.08 - 0.32 
Alcohol 0.75 
0.29 – 1.96 
1.86 
1.19 – 2.89 
2.33 
1.72 – 3.16 
2.60 
1.92 – 3.51 
2.15 
1.78 – 2.60 
Alcohol – drugs 0.53 
0.17 – 1.63 
0.60 
0.28 – 1.30 
0.13 
0.04-0.45 
0.02 
0.00 – 0.28 
0.24 
0.13 - 0.42 
Multiple drugs 0.42 
0.12 – 1.47 
0.96 
0.52 – 1.77 
0.16 
0.05 – 0.49 
0.15 
0.04 – 0.49 
0.35 
0.22 - 0.56 
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Table 10.11 presents the distribution of psychoactive substances by gender and age. 
 
Illegal drug use is mainly a problem among young male drivers. 
Young male drivers aged 18-24 have the highest prevalence of THC in traffic. Furthermore, the 
prevalence of cocaine, alcohol-drugs and drug-drug combinations is higher for males aged 18-34, than 
for males 35 years and older. The prevalence of medicinal drugs is very low among young male 
drivers.  
The prevalence of psychoactive substances among the youngest agegroup (18-24) of female drivers 
is lower than it is for the agegroup 25-35 years. Multi drug use is almost absent amongst female 
drivers, but alcohol, THC and cocaine are relatively frequently found among female drivers younger 
than 35 years old, when compared to older female drivers, 
The use of medicinal drugs in traffic is most often detected by female drivers 35 years and older. 
Young drivers (18-24) have lower BAC's than older drivers and male drivers have approximately a 
twice as high prevalence of alcohol, although the prevalence of high BAC levels (1.2g/L) is similar for 
female drivers as for male drivers. 
  
Table 10.11. Adjusted distribution of alcohol alone by gender and age (N=4822)  
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.60 
0.17 – 2.10 
1.34 
0.72 – 2.47 
1.98 
1.32 – 2.96 
2.40 
1.66 – 3.46 
1.83 
1.43 – 2.35 
 0.5 – 0.79 g/L 0.15 
0.02 – 1.37 
0.19 
0.04 – 0.86 
0.30 
0.11 – 0.82 
0.35 
0.14 – 0.90 
0.28 
0.15 – 0.52 
 0.8 – 1.19 g/L 0.06 
0.00 – 1.20 
0.34 
0.10 – 1.10 
0.12 
0.03 – 0.55 
0.18 
0.05 – 0.65 
0.18 
0.08 – 0.39 
1.2+ - 
 
0.30 
0.09 – 1.03 
0.39 
0.16 – 0.95 
0.08 
0.01 – 0.49 
0.22 
0.11 – 0.45 
In total 0.82 
0.27 – 2.42 
2.17 
1.34 – 3.51 
2.79 
1.98 – 3.91 
3.01 
2.17 – 4.18 
2.52 
2.04 – 3.11 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.14 
0.01 – 2.68 
1.07 
0.37 - 3.07 
0.85 
0.36 – 1.98 
1.00 
0.41 – 2.46 
0.86 
0.50 – 1.48 
 0.5 – 0.79 g/L 0.34 
0.04 – 3.04 
- 
 
0.11 
0.01 – 0.87 
0.41 
0.10 – 1.58 
0.20 
0.07 – 0.60 
 0.8 – 1.19 g/L - 
 
- 
 
0.04 
0.00 – 0.73 
0.10 
0.01 – 1.06 
0.04 
0.01 – 0.35 
1.2+ 0.13 
0.01 – 2.67 
- 
 
0.41 
0.20 – 0.84 
- 
 
0.19 
0.06 – 0.58 
In total 0.61 
0.10 – 3.50 
1.07 
0.37 - 3.07 
1.44 
0.74 – 2.78 
1.51 
0.72 – 3.15 
1.30 
0.83 – 2.02 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.46 
0.14 – 1.53 
1.26 
0.74 – 2.16 
1.60 
1.11 – 2.31 
2.01 
1.43 – 2.83 
1.54 
1.23 – 1.93 
 0.5 – 0.79 g/L 0.21 
0.04 – 1.13 
0.14 
0.03 – 0.62 
0.24 
0.09 – 0.60 
0.37 
0.17 – 0.81 
0.26 
0.15 – 0.44 
 0.8 – 1.19 g/L 0.04 
0.00 – 0.83 
0.24 
0.08 – 0.79 
0.09 
0.02 – 0.39 
0.16 
0.05 – 0.51 
0.14 
0.07 - 0.29 
1.2+ 0.04 
0.00 – 0.83 
0.21 
0.06 – 0.74 
0.41 
0.20 – 0.84 
0.06 
0.01 – 0.35 
0.21 
0.12 – 0.39 
In total 0.75 
0.29 – 1.96 
1.86 
1.19 – 2.89 
2.33 
1.72 – 3.16 
2.60 
1.92 – 3.51 
2.15 
1.78 – 2.60 
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Table 10.12. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=4822) 
4 categories: weekdays, weekday nights, weekend days, weekend nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 95.33 
94.58 – 95.98 
85.91 
79.30 – 90.65 
93.89 
92.28 – 95.19 
86.39 
79.45 – 91.25 
94.49 
93.81 - 95.10 
Amphetamine 0.15 
0.07 – 0.35 
0.45 
0.06 – 3.40 
0.22 
0.07 – 0.74 
0.63 
0.10 – 4.00 
0.19 
0.10 - 0.36 
Cocaine 0.25 
0.13 – 0.48 
0.15 
0.01 – 2.87 
0.42 
0.17 – 1.03 
0.95 
0.19 – 4.52 
0.30 
0.18 - 0.50 
THC 1.44 
1.10 – 1.89 
3.26 
1.37 – 7.58 
2.04 
1.34 – 3.09 
2.85 
1.08 – 7.32 
1.67 
1.34 - 2.07 
Illicit opiates 0.00 
0.00 – 0.11 
0.00 
0.00 – 2.59 
0.03 
0.00 - 0.42 
0.00 
0.00 – 2.87 
0.01 
0.00 - 0.09 
Benzodiazepines 0.48 
0.30 – 0.77 
0.00 
0.00 – 2.59 
0.21 
0.06 – 0.72 
0.16 
0.01 – 3.17 
0.40 
0.25 - 0.62 
Z-drugs 0.05 
0.01 – 0.20 
0.00 
0.00 – 2.59 
0.03 
0.00-0.42 
0.00 
0.00 – 2.87 
0.04 
0.01 - 0.15 
Medicinal opioids 0.20 
0.09 – 0.41 
0.15 
0.01 – 2.87 
0.08 
0.01 – 0.51 
0.00 
0.00 – 2.87 
0.16 
0.08 - 0.32 
Alcohol 1.59 
1.22 – 2.06 
9.20 
5.49 – 15.02 
2.51 
1.72 – 3.64 
6.65 
3.49 – 12.28 
2.15 
1.78 – 2.60 
Alcohol – drugs 0.19 
0.09 – 0.40 
0.74 
0.14 – 3.89 
0.24 
0.07 – 0.76 
0.95 
0.19 – 4.52 
0.24 
0.13 - 0.42 
Multiple drugs 0.32 
0.18 – 0.58 
0.15 
0.01 – 2.87 
0.33 
0.12 – 0.90 
1.42 
0.37 – 5.26 
0.35 
0.22 - 0.56 
 
The use of illicit drugs and alcohol in traffic is the highest in week and weekend nights. The use of 
medicinal drugs is the highest during daytime hours. Multi drug use was most prevalent in weekend 
nights and the lowest in week nights. 
 
Table 10.13. Adjusted distribution of alcohol alone by day of the week and time of the day (N=4822) 
4 categories: weekdays, weekday nights, week-end days, week-end nights 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 1.06 
0.77 – 1.46 
6.68 
3.63 – 11.97 
1.96 
1.28 – 2.98 
5.38 
2.63 – 10.69 
1.54 
1.23 – 1.93 
 0.5 – 0.79 g/L 0.22 
0.11 – 0.44 
1.04 
0.24 – 4.37 
0.24 
0.08 – 0.77 
0.47 
0.06 – 3.73 
0.26 
0.15 – 0.44 
 0.8 – 1.19 g/L 0.10 
0.04 – 0.28 
0.89 
0.19 – 4.13 
0.14 
0.03 – 0.62 
0.32 
0.03 – 3.45 
0.14 
0.07 - 0.29 
1.2+ 0.20 
0.10 – 0.42 
0.59 
0.09 – 3.65 
0.16 
0.04 – 0.65 
0.47 
0.06 – 3.73 
0.21 
0.12 – 0.39 
In total 1.59 
1.22 – 2.06 
9.20 
5.49 – 15.02 
2.51 
1.72 – 3.64 
6.65 
3.49 – 12.28 
2.15 
1.78 – 2.60 
 
Alcohol use was the highest during weeknights and not during weekend nights. The prevalence of 
drivers with a BAC above the legal limit of 0.5 g/L was around 0.5% during daytime in both week and 
weekend days, around 1.2% in weekend nights and approximately 2.55% in weeknights. 
10.5 Discussion  
The analysis of the roadside survey data show that alcohol and THC are by far the prevailing 
psychoactive substances among drivers of passenger cars in the Netherlands. 2.38% of the drivers 
were positive for alcohol (BAC ≥ 0.1 g/l); 2.10% was positive for alcohol alone and 0.28% was positive 
for alcohol in combination with other psychoactive substances. 2.10% of the drivers were positive for 
THC; 1.67 for THC alone and 0.43% for THC in combination with alcohol and/or other psychoactive 
substances. 
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Cocaine, benzodiazepines and amphetamines were the next most prevalent substances with 
prevalences of 0.66%, 0.44% and 0.37%, respectively. 
Illicit drugs, both alone and in combination with alcohol or other psychoactive substances are most 
prevalent among young male drivers aged 18-34. Medicinal drugs was mostly detected among female 
drivers aged 35 and older.  
Drug and alcohol use is most prevalent among night time hours, both during week and weekend 
nights. Medicinal drugs were most commonly detected among daytime drivers. 
Between 2000 and 2004 a roadside survey has been conducted in the Tilburg police district as part of 
the European IMMORTAL study (Impaired Motorists, Methods of Roadside Testing and Assessment 
for Licensing), which is also one of the participating police districts in the present study. Drivers in the 
IMMORTAL study where tested on blood or urine though and the applied cut-off levels were in general 
higher than they were in the DRUID study for blood.  
The prevalence of drugs was higher in the IMMORTAL study than it is in the DRUID study. This 
difference could partly be explained by the use of urine as body fluid in the IMMORTAL study, since 
drugs are longer detectable in urine than in oral fluid. Furthermore, for oral fluid equivalent cut-offs 
have been used in the DRUID roadside survey which are higher than the limits of quantitation that 
were used for the cut-offs for blood.  
On the other hand, the IMMORTAL cut-offs in serum were (after correction for the conversion) higher 
than the DRUID cut-offs in blood, which would likely have lead to relatively higher prevalence results in 
the DRUID study.  
Due to the design differences in the two studies it is better to focus on the ranking of substances and 
the relative differences in prevalence between groups, rather than comparing the actual figures.  
The DRUID and IMMORTAL study both have found a relatively high prevalence for alcohol and THC. 
Furthermore, the prevalence of alcohol and drugs was strongly concentrated in night time hours and 
medicinal drug use was more prevalent during daytime hours in both studies.  
There are also some differences: Benzodiazepine use was one of the prevailing substances in the 
IMMORTAL study, whereas in the DRUID study the prevalence is not that high anymore. Furthermore, 
not only the youngest group of male drivers is overrepresented among drug drivers, also young male 
drivers aged 25-34 are overrepresented. In the DRUID project, medicinal drugs is not only prevailing 
among female drivers aged 50+, but also among female drivers aged 35-49. 
More research is needed to get a better idea whether these differences are artificial or real. 
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11.1 Description of the roadside driver sample 
The main objective for the Norwegian DRUID roadside survey was to study the prevalence of drug and 
alcohol use among drivers in representative areas of the country, covering north, middle, south-west 
and south-east, including the capital. The drivers included in the roadside survey were also intended 
to be used as control population in a case-control study of fatal accidents.  
 
The study was performed as described in Annex 1 of the Summary Report, except that the Regional 
Committee for Medical and Health Research Ethics did not allow the recording of information about 
refusers.  
 
For practical and economical reasons, we could not perform roadside sampling completely by random 
in such a sparsely populated country as Norway, which covers an area of 385 252 square kilometres, 
and has 93 247 km of public roads, but a population of only 4.8 millions. Therefore, six representative 
areas were selected: two areas in south-eastern Norway (Hedmark & Romerike and Buskerud & 
Asker-Bærum, both areas included parts of Oslo), two areas in south-western Norway (Hordaland and 
Haugaland), and two areas in middle and northern Norway (Trøndelag and Troms), see Figure 1. The 
selected areas constituted parts of five of Norway’s 10 Mobile Police Service districts. Oslo Police 
gave the Mobile Police Service of surrounding districts permission to stop drivers within Oslo.   
 
Drivers were selected from April 2008 to March 2009 using a stratified multi-stage cluster sampling 
procedure. In the first stage, representative police districts were selected. In the second stage, random 
road sites and time intervals were selected according to a table of random sampling numbers (1). The 
third state consisted of randomly stopping drivers. The data collection was carried out in cooperation 
with the National Mobile Police Service of Norway, which has the right to stop vehicles without any 
particular suspicion. 
 
Roads were chosen by first randomly selecting map co-ordinates within the study areas, weighted 
according to the population in the area, and then choosing the roads closest to the selected map 
coordinates. Sites included both urban and rural roads, but only within about 120 km from the Mobile 
Police Service headquarters in the following cities: Haugesund, Bergen, Trondheim and Tromsø, and 
in south-eastern Norway within about 200 km from the laboratories of the Norwegian Institute of Public 
Health in Oslo. 
 
Time intervals were chosen by first randomly selecting a period of 3-5 consecutive days for each 
police district for each season of the year. For each day, the starting time for roadside sampling was 
randomly selected. However, some of the selected time periods had to be changed to comply with 
working time regulations for police officers. 
 
For each day the police chose two road sites that were suitable as checkpoints located within about 
30-45 minutes’ drive from each other. After stopping drivers by random for two hours at the first site, 
the personnel had a one hour break where they moved to the second sampling site, and continued 
sampling for two hours. If more cars passed the site than the police or the research team could 
handle, the police were instructed to stop cars at random, rather than stopping old cars, young drivers 
or other possible suspects of drugged driving.   
 
Oral and written information about the project was given to each driver; leaflets were available in 12 
languages. If informed consent was given, a sample of oral fluid was taken and a questionnaire filled 
in. Participating drivers did not receive any reward for taking part in the survey. 
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Figure 11.1. Map showing the study areas. 1: Hedmark & Romerike, 2: Buskerud & Asker-Bærum, 3: 
Hordaland, 4: Haugaland, 5: Trøndelag, and 6: Troms. 
 
Altogether 184 roadside survey sessions were conducted, and 10 004 drivers were asked to provide a 
voluntary and anonymous sample of oral fluid. A total of 5.8% (583 drivers) refused to participate; 
thus, a total of 9 421 samples were taken. Samples from 69 motorcyclists and 80 truck drivers were 
excluded from this study in addition to samples from six car drivers below 18 years of age. Thirty 
samples contained less than 0.2 ml of oral fluid and could therefore not be analysed for both alcohol 
and drugs; those 30 drivers were also excluded. Thus, data from a total of 9 236 van and car drivers 
are included in this report.  
 
About 58% of the included drivers were from south-eastern Norway, 19% from south-west, and 23% 
from middle/north. As comparison, in December 2008 about 54% of all cars and vans were owned by 
drivers living in south-east, 23% in south-west, and 23% in middle/north according to Statistics Norway 
(http://www.ssb.no). 
 
11.1.1 Distribution of drivers by road type 
Practical sites for the roadside study were chosen by the Mobile Police Service at the roads that were 
selected by the random procedure described above. The distribution of drivers included from urban 
and rural roads are presented in Table 11.1. The number of respondents was quite evenly distributed 
over rural and urban roads. However, in south-eastern Norway a larger proportion of the drivers were 
selected from urban roads than in other parts of the country due to higher population density. 
 
Table 11.1: Distribution of drivers included in urban and rural roads from the three regions of Norway 
Road type South-east South-west Middle/north Total 
Urban 61.5% 48.1% 44.4% 55.0% 
Rural 38.5% 51.9% 55.6% 45.0% 
Total 100.0% 100.0% 100.0% 100.0% 
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11.1.2 Distribution of drivers by season, day of the week and time of the 
day 
The time periods were initially selected by random as described above. However, the Mobile Police 
Service had to move some time periods because these periods did not comply with their working hour 
regulations. In addition, some sampling days were cancelled due to illness or extreme weather 
conditions, and one sampling period of five consecutive days had to be moved from the holiday 
season to a later month. Therefore, drivers for the period July – September are over-represented, 
while drivers in October – December are under-represented (Table 11.2). The distribution by time 
period was also somewhat affected (Table 3); the largest under-representation was for weekday 
evening and weekend early morning, while the largest over-representation was for weekend daytime.   
 
 
Table 11.2. Distribution of drivers by season 
January - March April - June July - September October - December 
28.3% 25.2% 30.0% 16.5% 
 
Table 11.3. Distribution of drivers by the eight time periods 
Time period no. Day and time Normal traffic Roadside survey 
1 Mon-Fri, 04.00-9.59 15.0 10.0 
2 Mon-Fri , 10.00-15.59 26.6 25.2 
3 Mon-Thu, 16.00-21.59 23.1 14.3 
4 Mon-Thu, 22.00-23.59 5.9 8.1 
 + Tue-Fri, 00.00-03.59   
5 Sat-Sun, 04.00-9.59 1.5 4.1 
6 Sat-Sun, 10.00-15.59 8.0 17.7 
7 Fri-Sun, 16.00-21.59 15.3 15.1 
8 Fri-Sun, 22.00-23.59 4.6 5.5 
 
 
 + Sat-Mon, 00.00-03.59   
Total  100.0 100.0 
 
 
11.1.3 Distribution of drivers by gender and age 
The inclusion of drivers was random as far as gender and age was concerned. The distribution by age 
and gender is presented in Table 4. The percentage of males was higher than females, and only about 
28% were below 35 years of age. These percentages correspond to the distribution of km driven by 
gender and age among drivers in the Norwegian Travel Survey (2).  
 
Table 11.4. Distribution of drivers by age and gender 
Gender 18-24 years 25-34 years 35-49 years 50+ years Unknown Total 
Female 3.3% 5.5% 11.0% 9.1% 0.0% 28.8% 
Male 7.1% 12.4% 24.1% 27.5% 0.1% 71.1% 
Total 10.4% 17.9% 35.1% 36.6% 0.1% 100.0% 
 
 
11.2 Roadside data collection and analysis 
Oral fluid was collected using the Statsure Saliva Sampler™ (see Annex 2 of the Summary Report). 
The oral fluid sampling kits were inspected visually, and kits that did not contain any buffer, or 
contained too small volume of buffer as observed visually, were discarded (about 5%). When sampling 
oral fluid, the collection pad was placed under the tongue until the indicator turned blue, or until five 
minutes had passed. The vial was then capped and labelled with a bar code label identical to the bar 
code of the questionnaire. The sample was kept in a bag at a temperature of approximately 5°C for a 
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maximum of 6 hours, and then frozen at about -20°C. Frozen samples from south-western, middle and 
northern Norway were transported to Oslo by airplane in well-insulated containers preventing the 
frozen samples from thawing during transport. 
 
One day before the analysis of oral fluid started, samples were thawed and weighed to determine the 
total amount of oral fluid collected, and aliquots were pipetted into separate tubes for analysis of 
alcohol and drugs. The concentrations of alcohol and drugs in undiluted oral fluid were calculated 
based on the weight of oral fluid collected, assuming that 1.0 ml buffer was present in the collection 
device.  
 
Drug concentrations in oral fluid-buffer mixtures were analysed by the Division of Forensic Toxicology 
and Drug Abuse at the Norwegian Institute of Public Health using liquid chromatography – tandem 
mass spectrometry (3) and concentrations in un-diluted oral fluid were calculated. 
In addition to the common list of drugs analysed, we analysed for nitrazepam, 7-aminonitrazepam, 7-
aminoclonazepam, 7-aminoflunitrazepam, carisoprodol and meprobamate. 
 
Three-point calibration was used. Upper and lower calibrator and upper limit of linearity are presented 
in Table 11.5. Cutoff concentrations are presented in Annex 2 of the Summary Report. 
 
Table 11.5. Lowest and highest calibration standard, and limit of linearity (ng/ml) 
Analyte Lowest standard Highest standard Limit of linearity 
6-MAM 1.25 12.5 124.9 
7-Aminoclonazepam 1.25 12.5 125.2 
7-Aminoflunitrazepam 0.25 2.5 25.1 
7-Aminonitrazepam 1.25 12.5 124.5 
Alprazolam 0.75 7.5 75.2 
Amphetamine 88.6 886 8860 
Benzoylecgonine 12.5 125 1250 
Diazepam 0.65 6.50 65.0 
Carisoprodol 50.3 503 503 
Clonazepam 0.76 7.56 75.6 
Cocaine 3.00 30.0 90.0 
Codeine 12.5 125 1250 
Flunitrazepam 0.51 5.14 51.4 
Lorazepam 1.52 15.2 152 
MDA 50.7 507 1520 
MDEA 50.2 502 502 
MDMA 9.88 98.8 988 
Meprobamate 20.0 200 2000 
Metamphetamine 50.7 507 5070 
Methadone 12.5 125 375 
Morphine 12.5 125 1250 
Nitrazepam 0.75 7.47 74.7 
Nordiazepam 1.25 12.5 125 
Oxazepam 8.54 85.4 854 
THC 0.99 16.7 167 
Zolpidem 0.25 2.5 25.0 
Zopiclone 1.25 12.5 125 
 
Samples with higher concentrations than the limit of linearity were diluted with sampling kit buffer and 
re-analysed. In cases where no sample was left for diluting and re-testing, concentrations were 
extrapolated. 
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The alcohol concentration in oral fluid was analysed by an automated enzymatic method using alcohol 
dehydrogenase (4). The method was initially developed for the analysis of alcohol in blood and urine. 
Before we used it in this study, the method was validated for the analysis of alcohol in saliva diluted 
with buffer from the Statsure sampling kit. The validated upper limit of linearity was 3 g/l in the oral 
fluid – buffer mixture. The BAC was estimated by multiplying the alcohol concentration in oral fluid by 
1.22.  
 
We recorded the driver’s gender, age group and nationality, in addition to the month, day of the week, 
time interval (2h intervals), site, and type of vehicle. 
 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
The study was approved by the Regional Committee for Medical and Health Research Ethics. 
 
 
11.3 Non-response 
A total of 5.8% refused to provide a sample of oral fluid. The refusal rate varied between different 
regions; in south-east 6.2%, in south-west 6.7%, and in middle/north 3.9%. We were not allowed to 
collect any data on the refusers. 
 
We requested a voluntary sample of oral fluid after the Mobile Police Services had performed their 
mandatory control. Six drivers whom the police officers suspected of driving while drunk refused to 
provide a sample of oral fluid before they were transported to a different site for evidential breath 
testing or blood sampling for legal purposes. Thus, the prevalence of BACs above the legal limit of 0.2 
g/kg might have been about 1% among the refusers, and the total prevalence of drunken driving was 
about 0.06% higher than the value presented in this report. We assume that the prevalence of drugs 
might also have been higher among the refusers than among those who decided to participate in the 
study, because some drivers were not convinced that the study was absolutely anonymous. 
 
 
11.4 Results 
The weight of 50 samples were lower than the weight for non-used sampling kits (containing buffer), in 
spite of the fact that we were able to pipette at least 0.1 ml oral fluid-buffer mixture from these vials. 
This fact indicated that the original volume of buffer in these samples was significantly lower than 1.0 
ml. Alcohol or drugs were found in 10 of these samples. The exact concentration of drugs in undiluted 
oral fluid could not be calculated for these samples. Instead we used the average weight for all 
received samples for calculation purposes. 
 
Analytical results for mutually exclusive substance groups (weighted for time period) for core 
substances are presented in Table 6. Results by age and gender are presented in Table 7 and by time 
period in Table 11.8. The total findings for each substance groups are not presented. Results for 
alcohol alone are presented in Tables 11.9-11.11. Results for additional substances are presented in 
Table 12. 
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Table 11.6. Adjusted general distribution of core substance categories (N=9236) 
Substance category Prevalence (%) Confidence interval (%) 
Negative 97.03 96.67 – 97.36 
Alcohol 0.32 0.23 – 0.46 
Amphetamines 0.06 0.02 – 0.13 
Cocaine 0.06 0.03 – 0.14 
THC 0.48 0.36 – 0.64 
Illicit opiates 0.00 0.00 – 0.04 
Benzodiazepines 0.84 0.67 – 1.05 
Z-drugs 0.69 0.54 – 0.88 
Medicinal opioids 0.16 0.10 – 0.27 
Alcohol – drugs 0.07 0.03 – 0.15 
Multiple drugs 0.28 0.19 – 0.42 
 
Table 11.7. Adjusted distribution of core substance categories by gender and age (N=9228) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 96.74 
95.11 – 97.83 
96.99 
95.83 – 97.83 
97.80 
97.10 – 98.33 
96.85 
96.09 – 97.47 
97.17 
96.74 – 97.55 
Alcohol 0.44 
0.15 – 1.29 
0.06 
0.01 – 0.45 
0.29 
0.14 – 0.62 
0.43 
0.24 – 0.77 
0.34 
0.22 – 0.51 
Amphetamines 0.14 
0.02 – 0.81 
0.19 
0.05 – 0.66 
0.05 
0.01 – 0.27 
0.00 
0.00 – 0.15 
0.06 
0.03 – 0.16 
Cocaine 0.00 
0.00 – 0.56 
0.15 
0.04 – 0.59 
0.08 
0.02 – 0.32 
0.04 
0.01 – 0.22 
0.07 
0.03 – 0.17 
THC 1.54 
0.85 – 2.78 
1.34 
0.81 – 2.18 
0.41 
0.22 – 0.78 
0.16 
0.06 – 0.42 
0.59 
0.43 – 0.81 
Illicit opiates 0.00 
0.00 – 0.56 
0.00 
0.00 – 0.34 
0.00 
0.00 – 0.17 
0.00 
0.00 – 0.15 
0.00 
0.00 – 0.06 
Benzodiazepines 0.55 
0.21 – 1.46 
0.39 
0.16 – 0.95 
0.56 
0.33 – 0.97 
1.09 
0.75 – 1.58 
0.73 
0.55 – 0.97 
Z-drugs 0.00 
0.00 – 0.56 
0.22 
0.07 – 0.70 
0.17 
0.06 – 0.44 
0.95 
0.64 – 1.42 
0.46 
0.32 – 0.66 
Medicinal opioids 0.00 
0.00 – 0.56 
0.00 
0.00 – 0.34 
0.26 
0.12 – 0.58 
0.23 
0.10 – 0.50 
0.18 
0.10 – 0.31 
Alcohol – drugs 0.11 
0.02 – 0.77 
0.18 
0.05 – 0.64 
0.04 
0.01 – 0.25 
0.06 
0.01 – 0.26 
0.08 
0.03 – 0.18 
Multiple drugs 0.49 
0.17 – 1.36 
0.49 
0.22 – 1.10 
0.33 
0.16 – 0.67 
0.18 
0.08 – 0.44 
0.32 
0.21 – 0.49 
 
(Table 7 continues on next page) 
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Table 11.7. (continued) Adjusted distribution of core substance categories by gender and age (N=9228) 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 99.15 
97.38 – 99.73 
98.29 
96.76-99.11 
97.52 
96.38-98.31 
93.92 
92.11-95.33 
96.72 
95.98-97.33 
Alcohol 0.29 
0.05 – 1.74 
0.27 
0.06 – 1.22 
0.30 
0.10 – 0.87 
0.30 
0.09 – 0.95 
0.29 
0.15 – 0.58 
Amphetamines 0.24 
0.03 – 1.65 
0.00 
0.00 – 0.75 
0.02 
0.00 – 0.42 
0.00 
0.00 – 0.45 
0.04 
0.01 – 0.21 
Cocaine 0.00 
0.00 – 1.21 
0.00 
0.00 – 0.75 
0.16 
0.04 – 0.64 
0.00 
0.00 – 0.45 
0.06 
0.01 – 0.25 
THC 0.32 
0.06 – 1.78 
0.43 
0.12 – 1.47 
0.20 
0.06 – 0.71 
0.00 
0.00 – 0.45 
0.19 
0.08 – 0.44 
Illicit opiates 0.00 
0.00 – 1.21 
0.00 
0.00 – 0.75 
0.00 
0.00 – 0.37 
0.00 
0.00 – 0.45 
0.00 
0.00 – 0.14 
Benzodiazepines 0.00 
0.00 – 1.21 
0.09 
0.01 – 0.91 
0.88 
0.47 – 1.66 
2.37 
1.54 – 3.62 
1.10 
0.77 – 1.57 
Z-drugs 0.00 
0.00 – 1.21 
0.61 
0.21 – 1.74 
0.74 
0.37 – 1.48 
2.62 
1.74 – 3.92 
1.22 
0.87 – 1.71 
Medicinal opioids 0.00 
0.00 – 1.21 
0.00 
0.00 – 0.75 
0.10 
0.02 – 0.56 
0.30 
0.09 – 0.95 
0.13 
0.05 – 0.36 
Alcohol – drugs 0.00 
0.00 – 1.21 
0.00 
0.00 – 0.75 
0.00 
0.00 – 0.37 
0.13 
0.02 – 0.67 
0.04 
0.01 – 0.21 
Multiple drugs 0.00 
0.00 – 1.21 
0.31 
0.08 – 1.29 
0.07 
0.01 – 0.50 
0.36 
0.13 – 1.04 
0.20 
0.09 – 0.45 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 97.50 
96.33 – 98.31 
97.39 
96.51 – 98.06 
97.71 
97.14 – 98.17 
96.09 
95.38 – 96.70 
97.03 
96.67 – 97.36 
Alcohol 0.39 
0.15 – 1.02 
0.12 
0.03 – 0.45 
0.30 
0.16 – 0.55 
0.39 
0.23 – 0.67 
0.32 
0.23 – 0.46 
Amphetamines 0.17 
0.04 – 0.68 
0.13 
0.04 – 0.45 
0.04 
0.01 – 0.20 
0.00 
0.00 – 0.11 
0.06 
0.02 – 0.13 
Cocaine 0.00 
0.00 – 0.39 
0.10 
0.02 – 0.41 
0.11 
0.04 – 0.29 
0.03 
0.00 – 0.16 
0.06 
0.02 – 0.14 
THC 1.15 
0.65 – 2.03 
1.06 
0.66 – 1.67 
0.34 
0.19 – 0.61 
0.12 
0.05 – 0.16 
0.48 
0.36 – 0.64 
Illicit opiates 0.00 
0.00 – 0.39 
0.00 
0.00 – 0.23 
0.00 
0.00 – 0.12 
0.00 
0.00 – 0.11 
0.00 
0.00 – 0.04 
Benzodiazepines 0.38 
0.14 – 1.00 
0.29 
0.12 – 0.69 
0.66 
0.44 – 1.01 
1.42 
1.07 – 1.88 
0.84 
0.67 – 1.05 
Z-drugs 0.00 
0.00 – 0.39 
0.34 
0.15 – 0.76 
0.35 
0.20 – 0.62 
1.39 
1.05 – 1.85 
0.69 
0.54 – 0.88 
Medicinal 
opioids 
0.00 
0.00 – 0.39 
0.00 
0.00 – 0.23 
0.21 
0.10 – 0.44 
0.25 
0.13 – 0.48 
0.16 
0.10 – 0.27 
Alcohol – drugs 0.08 
0.01 – 0.53 
0.12 
0.03 – 0.45 
0.03 
0.00 – 0.17 
0.08 
0.02 – 0.24 
0.07 
0.03 – 0.15 
Multiple drugs 0.33 
0.12 – 0.93 
0.44 
0.22 – 0.89 
0.25 
0.13 – 0.49 
0.23 
0.11 – 0.46 
0.28 
0.19 – 0.42 
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Table 11.8. Adjusted distribution of core substance categories by day of the week and time of the day 
(N=9236) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekendday
s 
04:00 – 21:59 
Weekendnigh
ts 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Negative 96.75 
96.27 – 97.17 
97.59 
95.94 – 98.57 
97.95 
96.27 – 98.46 
95.64 
93.37 – 97.16 
97.03 
96.67 – 97.36 
Alcohol 0.34 
0.22 – 0.52 
0.00 
0.00 – 0.69 
0.27 
0.12 – 0.58 
0.79 
0.30 – 2.10 
0.32 
0.23 – 0.46 
Amphetamine 0.04 
0.01 – 0.13 
0.13 
0.02 – 0.94 
0.02 
0.00 – 0.21 
0.40 
0.10 – 1.51 
0.06 
0.02 – 0.13 
Cocaine 0.04 
0.01 – 0.14 
0.27 
0.06 – 1.16 
0.00 
0.00 – 0.17 
0.40 
0.10 – 1.51 
0.06 
0.03 – 0.14 
THC 0.39 
0.26 – 0.58 
0.80 
0.33 – 1.96 
0.45 
0.25 – 0.83 
1.39 
0.65 – 2.92 
0.48 
0.36 – 0.64 
Illicit opiates 0.00 
0.00 – 0.06 
0.00 
0.00 – 0.69 
0.00 
0.00 – 0.17 
0.00 
0.00 – 0.83 
0.00 
0.00 – 0.04 
Benzodiazepin
es 
1.02 
0.80 – 1.31 
0.13 
0.02 – 0.94 
0.49 
0.27 – 0.88 
0.99 
0.41 – 2.38 
0.84 
0.67 – 1.05 
Z-drugs 0.92 
0.71 – 1.19 
0.13 
0.02 – 0.94 
0.35 
0.18 – 0.70 
0.00 
0.00 – 0.83 
0.69 
0.54 – 0.88 
Medicinal 
opioids 
0.21 
0.12 – 0.36 
0.00 
0.00 – 0.69 
0.11 
0.03 – 0.35 
0.00 
0.00 – 0.83 
0.16 
0.10 – 0.27 
Alcohol – drugs 0.06 
0.02 – 0.17 
0.13 
0.02 – 0.94 
0.04 
0.01 – 0.25 
0.20 
0.03 – 1.19 
0.07 
0.03 – 0.15 
Multiple drugs 0.23 
0.13 – 0.38 
0.80 
0.33 – 1.96 
0.33 
0.16 – 0.67 
0.20 
0.03 – 1.19 
0.28 
0.19 – 0.42 
 
Table 11.9. Adjusted general distribution of alcohol by concentration class (N=9227) 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 0.26 0.17 – 0.38 
Alcohol 0.5 – 0.79 g/L 0.04 0.02 – 0.11 
Alcohol 0.8 – 1.19 g/L 0.02 0.00 – 0.07 
Alcohol 1.2+ 0.01 0.00 – 0.06 
In total 0.32 0.23 – 0.46 
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Table 11.10. Adjusted distribution of alcohol alone by gender and age (N=9219)  
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.37 
0.12 – 1.19 
0.06 
0.01 – 0.45 
0.18 
0.07 – 0.46 
0.40 
0.22 – 0.73 
0.28 
0.18 – 0.44 
 0.5 – 0.79 g/L 0.07 
0.01 – 0.69 
0.00 
0.00 – 0.34 
0.12 
0.04 – 0.37 
0.03 
0.00 – 0.21 
0.06 
0.02 – 0.15 
 0.8 – 1.19 g/L 0.00 
0.00 – 0.56 
0.00 
0.00 – 0.34 
0.00 
0.00 – 0.17 
0.00 
0.00 – 0.15 
0.00 
0.00 – 0.06 
1.2+ 0.00 
0.00 – 0.56 
0.00 
0.00 – 0.34 
0.00 
0.00 – 0.17 
0.00 
0.00 – 0.15 
0.00 
0.00 – 0.06 
In total 0.44 
0.15 – 1.29 
0.06 
0.01 – 0.45 
0.29 
0.14 – 0.62 
0.43 
0.24 – 0.77 
0.34 
0.22 – 0.51 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.29 
0.05 – 1.74 
0.09 
0.01 – 0.91 
0.16 
0.04 – 0.64 
0.30 
0.09 – 0.95 
0.20 
0.09 – 0.46 
 0.5 – 0.79 g/L 0.00 
0.00 – 1.21 
0.00 
0.00 – 0.75 
0.00 
0.00 – 0.37 
0.00 
0.00 – 0.45 
0.00 
0.00 – 0.14 
 0.8 – 1.19 g/L 0.00 
0.00 – 1.21 
0.00 
0.00 – 0.75 
0.15 
0.03 – 0.63 
0.00 
0.00 – 0.45 
0.06 
0.01 – 0.24 
1.2+ 0.00 
0.00 – 1.21 
0.18 
0.03 – 1.07 
0.00 
0.00 – 0.37 
0.00 
0.00 – 0.45 
0.03 
0.01 – 0.20 
In total 0.29 
0.05 – 1.74 
0.27 
0.06 – 1.22 
0.30 
0.10 – 0.87 
0.30 
0.09 – 0.95 
0.29 
0.15 – 0.58 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.35 
0.13 – 0.95 
0.07 
0.01 – 0.36 
0.17 
0.08 – 0.38 
0.37 
0.22 – 0.65 
0.26 
0.17 – 0.38 
 0.5 – 0.79 g/L 0.05 
0.00 – 0.47 
0.00 
0.00 – 0.23 
0.08 
0.03 – 0.25 
0.02 
0.00 – 0.15 
0.04 
0.02 – 0.11 
 0.8 – 1.19 g/L 0.00 
0.00 – 0.39 
0.00 
0.00 – 0.23 
0.05 
0.01 – 0.20 
0.00 
0.00 – 0.11 
0.02 
0.00 – 0.07 
1.2+ 0.00 
0.00 – 0.39 
0.06 
0.01 – 0.33 
0.00 
0.00 – 0.12 
0.00 
0.00 – 0.11 
0.02 
0.00 – 0.06 
In total 0.39 
0.15 – 1.02 
0.12 
0.03 – 0.45 
0.30 
0.16 – 0.55 
0.39 
0.23 – 0.67 
0.32 
0.23 – 0.46 
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Table 11.11. Adjusted distribution of alcohol alone by day of the week and time of the day (N=9227) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekendday
s 
04:00 – 21:59 
Weekendnigh
ts 
22:00 – 03:59 
In total 
Alcohol alone Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
Prevalence 
(%) 
C.I. (%) 
 0.1 – 0.49 g/L 0.28 
0.17 – 0.44 
0.00 
0.00 – 0.69 
0.19 
0.08 – 0.48 
0.59 
0.19 – 1.81 
0.26 
0.17 – 0.38 
 0.5 – 0.79 g/L 0.04 
0.01 – 0.13 
0.00 
0.00 – 0.69 
0.07 
0.02 – 0.30 
0.00 
0.00 – 0.83 
0.04 
0.02 – 0.11 
 0.8 – 1.19 g/L 0.03 
0.01 – 0.11 
0.00 
0.00 – 0.69 
0.00 
0.00 – 0.17 
0.00 
0.00 – 0.83 
0.02 
0.00 – 0.07 
1.2+ 0.00 
0.00 – 0.06 
0.00 
0.00 – 0.69 
0.00 
0.00 – 0.17 
0.20 
0.03 – 1.19 
0.01 
0.00 – 0.06 
In total 0.34 
0.22 – 0.52 
0.00 
0.00 – 0.69 
0.27 
0.12 – 0.58 
0.79 
0.30 – 2.10 
0.32 
0.23 – 0.46 
 
 
Table 11.12. Adjusted general distribution of additional substances (N=9236) 
Substance Prevalence (%) Confidence interval (%) 
Nitrazepam 0.06 0.03 – 0.14 
7-aminonitrazepam 0.22 0.14 – 0.34 
7-aminoclonazepam 0.08 0.04 – 0.16 
7-aminoflunitrazepam 0.05 0.02 – 0.12 
Carisoprodol 0.00 0.00 – 0.04 
Meprobamate 0.00 0.00 – 0.04 
 
 
Benzodiazepines were detected in 0.84% of the samples and were thus the most prevalent medicinal 
drug group detected. The prevalence was higher among women (1.10%) than men (0.73%), but the 
difference was not statistically significant. The prevalence increased with age for both genders. 
Benzodiazepines were most commonly found during weekdays at daytime and weekend nights. Z-
drugs, which are sleeping agents, were also highly prevalent (0.69%). The prevalence was 
significantly higher among women (1.22%) than men (0.46%), and increased with age for both 
genders. Z-drugs were most commonly found during weekdays at daytime. 
 
THC was the most commonly found illegal drug, and was found in 0.48% of the samples. The 
prevalence was higher among men (0.59%) than women (0.19%), and the prevalence was highest 
among drivers below 35 years for both genders. The prevalence was highest during weekend nights 
and lowest during weekdays at daytime. The prevalence of amphetamines and cocaine was similar for 
men and women with averages of 0.6% for both substance groups, and were most commonly found in 
samples from weekend nights.  
 
The prevalence of alcohol was low, only 0.32%; slightly higher among men than women, and higher at 
weekend nights than during other periods of the week. Combinations of alcohol and drugs were found 
in only 0.07%, while multiple drugs were found in 0.28% of the samples. 
 
The prevalence of additional substances was fairly low. The sleeping agent nitrazepam and its 
metabolite 7-aminonitrazepam were the most commonly detected substances, and reflect that 
nitrazepam is fairly frequently used in Norway; less frequently than the z-drugs, but more frequently 
than flunitrazepam. Carisoprodol and its metabolite meprobamate were not detected in concentrations 
above the cut-off thresholds in any sample, reflecting a large decline in use after carisoprodol was 
withdrawn from the Norwegian market in 2008. 
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11.5 Discussion 
The incidence of drunken driving has decreased and drugged driving increased in Norway during the 
recent decades. In the 1980s, 0.27% of the motor vehicle drivers had blood alcohol concentration 
above 0.5‰ (5), while in 2005-6, about 0.1% of the drivers had alcohol concentrations in oral fluid 
above 0.5‰ and 0.3% above 0.2‰ (6). On the other hand, the number of blood samples from 
suspected drugged drivers submitted for drug analysis by the police increased from about 2 076 in 
1989 to 4 525 in 2008 (7). In the late 80-ies about 80% of the drivers were positive for at least one 
drug, whereas in 2008 more than 90% of the suspected drivers were drug positive. 
 
In the present study, 0.32% of the drivers were found to have alcohol concentrations above 0.1 g/l. 
This is similar to the results of our roadside survey performed in 2005-6 (6). Alcohol above 0.1 g/l was 
in that study found in samples from 0.4% of the drivers. A study performed by TISPOL found that 0.3% 
had blood alcohol concentrations above the legal limit in Norway (8). 
 
The prevalences of illegal drugs and psychoactive medicinal drugs were higher than for alcohol, 
confirming the results of our roadside survey performed in 2005-6 (6). The prevalences of different 
substances cannot be directly compared with the previous study, primarily because significantly lower 
cut-off thresholds were used in that study and because total substance findings were presented and 
not mutually exclusive substance groups which are presented in this report. In addition, oral fluid was 
collected using a different collection device which may affect the results for THC, zopiclone, and 
possibly also other substances. However, our current findings in relation to gender and age are similar 
to those found in our previous study (6).  
 
We have previously found that the use of illegal drugs was most commonly found in samples taken 
during weekends, while medicinal drugs were most commonly found during working days (6). The 
results from this study confirms those findings, but additionally indicate that illegal drugs were more 
common at weekends during the night than at daytime, and medicinal drugs were more common 
during weekdays at daytime than during the night. 
 
The prevalence of drugs does not directly reflect the prevalence of impairment because the drug 
concentration in oral fluid cannot be used to accurately estimate the drug concentration in blood (9), 
and because individual assessments of impairment were not performed. To determine whether a 
driver is impaired by one or more drugs, a blood sample must be analysed, and an expert evaluation 
of the analytical results must be done according to the current legislation in Norway. However, a 
process of establishing legislative blood drug concentration limits for driving under influence for 20 
drugs started in 2010 (10), and the new limits will reduce the need for expert assessments.  
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12 Country report Poland 
 
Authors:  
12.1 Description of the roadside driver sample 
The objective of the survey was to identify the scale of alcohol, medication and drugs use by drivers in 
Poland and compare the Polish results with those collected in other countries participating in the 
DRUID survey. 
 
It was Poland’s first study of prevalence of psychoactive substance use by drivers. The method for the 
research was developed in Poland in September 2007 (“Guidelines for roadside survey in Poland”) 
and subsequently approved by the coordinators. The procedure of research differed slightly from the 
DRUID guidelines adopted later. Thus, at some points it was necessary to adapt Polish results to the 
DRUID guidelines. 
 
During the Druid survey in Poland 4327 drivers were stopped. 51 people did not agree to take part in 
the survey. More than 251 people did not give enough saliva and the sobriety test could not be taken 
in the case of 19 people. As a result, 4005 people qualified for further analysis.  
 
12.1.1 Geographic distribution of drivers over the country 
The survey covered all of Poland. The country was divided into 6 sub-regions: central Poland 
(Mazowieckie, Lodzkie), the south (Malopolskie, Slaskie), the east (Lubelskie, Podkarpackie, 
Podlaskie, Swietokrzyskie), the north-west (Lubuskie, Wielkopolskie, Zachodniopomorskie), the south-
west (Dolnoslaskie, Opolskie), and the north (Kujawsko-Pomorskie, Pomorskie, Warminsko-
Mazurskie).  This was in line with the Nomenclature of Territorial Units for Statistics (NUTS 1) 
developed by the Polish Central Statistical Office, a division also used by  Eurostat.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.1. The division of Poland into sub-regions  
The number of drivers tested in the sub-regions differed depending on the population density. That 
was the only condition that determined the number of drivers surveyed across Poland. Because we did 
not have traffic volume studies13 we could use for the selection, we decided to survey the same 
number of drivers on urban and regional roads during the day, night, on weekdays and weekends and 
in all seasons. Table 1 presents the distribution of drivers by sub-region. 
 
                                                 
13 Every 5 years the General Directorate for National Roads and Motorways carries out a traffic survey but it 
only covers national roads that are within the Directorate’s remit.  
Central
East
North - west
South - west
South
North
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Table 12.1. Distribution of drivers by sub-region 
 Sub-region 
 Central 
(1) 
South 
(2) 
East (3) North-
west (4) 
South-
west (5) 
North 
(5) 
 
% of Poland’s population  
 
 
20.3 % 
 
20.8 % 
 
17.7 % 
 
15.9 % 
 
10.3 % 
 
14.9 % 
  
Number of drivers tested 
781 
(19.5 %) 
799 
(19.9 %) 
684  
(17.1 %) 
636  
(15.9 %) 
479 
(12.0 %) 
626 
(15.6 %) 
 
It is clear that the distribution of the roadside survey sample over the six different survey regions was 
almost the same as the distribution of the population of Poland.  
 
12.1.2 Distribution of drivers by road type 
There were 4 check points in each sub-region:  one in the sub-region’s biggest town,  one in a town 
with a population of 20,000 – 100,000, one on a national road and one on a regional road. The 
selection of the specific check points was made in cooperation with regional coordinators. The site for 
a check point was on a straight stretch of road, with no exits or access roads, at some distance from 
junctions, etc. Efforts were made to ensure that the checks and tests did not obstruct traffic as drivers 
pulled over and stopped for ten minutes or so. The check points were equally distributed as much as 
possible across the sub-region. 
 
In order to improve comparability with the other countries, the Polish survey results were recorded 
according to the DRUID guidelines. This was possible because the different checkpoints could be 
aggregated into a binary urban and rural code. 
 
Table 12.2. Distribution of drivers by road type 
 
 
 
 
 
The drivers were distributed more or less equally over the two road types.  
 
12.1.3 Distribution of drivers by season 
The survey began in the autumn of 2007 and continued for two years. The survey was carried out 
during the four seasons: in the summer (22 June – 22 September), autumn (23 September – 21 
December), winter (22 December – 20 March) and spring (21 March – 21 June). Table 12.3 presents 
the distribution of the drivers by season. 
 
Table 12.3. Distribution of drivers by season 
1. Winter   
(22 December – 
20 March) 
2. Spring 
 (21 March – 21 
June) 
3. Summer  
(22 June – 22 
September) 
4. Autumn  
(23 September – 
21 December) 
Total 
 
1034 ( 25.8 %) 
 
1035 (25.8 %) 
 
986  (24.6 %) 
 
950  (23.7 %) 
 
4005 (100 %) 
 
The samples are well distributed over the seasons.  
 
12.1.4 Distribution of drivers by day of the week and time of the day 
The roadside surveys were conducted during daytime (from 7:00 to 21:00) and night-time (from 21:00 
to 7:00), on weekdays (Monday from 7:00 to Friday to 21:00) and weekends (Friday from 21:00 to 
Monday to 7:00).  
 
Type of road Number 
Urban roads (1) 1966  (49 %) 
Rural roads (2) 2039 (51 %) 
Total 4005 (100 %) 
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Table 12.4. Distribution of drivers by day of week and time of day 
Time of week Time of day Number 
Week days (Monday 07-Friday 21) Day (07-21) 1032  (25.8 %) 
Night (21-07) 1021  (25.5 %) 
Weekends (Friday 21- Monday 07) Day (07-21) 967  (24.1 %) 
Night (21-07) 985  (24.6 % 
 
The Polish survey consisted of four different days of the week and time of the day periods and the 
distribution of the study population is almost evenly distributed over each of the four periods. The way 
the Polish survey was organised is different from the guidelines the DRUID adopted later. The 
difference is that the survey was carried out during the day and night only rather than during the 8 
periods the DRUID checked. Since the exact time and day of the sampling were recorded, for each 
sample the data for time could be converted into the DRUID day and time periods. This distribution is 
presented in Table 12.5. 
 
Table 12.5. Distribution of drivers by DRUID time periods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All DRUID time periods are covered. The distribution over the DRUID time periods in the morning (04-
10) is relatively lower than the six other DRUID time periods.  
 
12.1.5 Distribution of drivers by gender and age 
The survey covered Polish and foreign drivers of passenger cars, delivery vans (up to 3500 kg) and 
taxi cabs, aged 18 and more, stopped at random by road police at selected check points. From among 
4005 drivers 3612 (90.2%) were passenger car drivers and 364 delivery van drivers (9.1%)14. While 
some of the drivers were lorry drivers, when the police stopped them they were driving a passenger 
car. The group included 38 foreign nationals from 15 different countries (most were from Ukraine – 12, 
Lithuania – 7 and Germany - 4). Table 6 presents some more demographic data. 
 
Table 12.6. Distribution of drivers by gender and age 
Age Women Men Data not available Total 
18 - 24 133 589 0 722  (18.0 %) 
25 - 34 252 1075 3 1330  ( 33.2 %) 
35 - 49 224 970 0 1194  (29.8 %) 
50 + 76 680 2 758  (18.9 %) 
Data not available 1 0 0 1 ( %) 
Total 686  (17.1 %) 3314  (82.8 %) 5  (0.1 %) 4005  (100 %) 
 
The average age of women surveyed was 34.3 years with 37.1 for men. In 2005 the average age of 
women drivers was 37. For men it was 42. In 2010 SARTRE 4, an EU funded programme, studied the 
                                                 
14   No data is available about the type of vehicle for 29 of the drivers. 
DRUID  
time period Frequency Per cent 
1 Weekday 04:00-09:59 86 2,2 
2 Weekday 10:00-15:59 826 20.6 
3 Weekday 16:00-21:59 406 10.1 
4 Weekday 22:00-03:39 696 17.4 
5 Weekendday 04:00-09:59 294 7.3 
6 Weekendday 10:00-15:59 674 16.8 
7 Weekendday 16:00-21:59 439 11.0 
8 Weekendday 22:00-03:39 584 14.6 
Total 4005 100 
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age and gender structure of Polish passenger car drivers. The percentage of people who have a 
driving license and drove a car at least once in the recent year was as follows: aged 18 to 24  – 15 %, 
aged 25 to 34 – 30 %, aged 35 to 49 – 33 %, aged 50+ – 22 %. The distribution of drivers participating 
in DRUID is similar to the distribution established in the omnibus study.  
 
The relatively low percentage of women drivers is somewhat surprising. The official 2009 statistics of 
the Ministry of the Interior and Administration shows that in Poland 37 % of all individual driving 
licenses were held by women. The results of the omnibus study showed that women drivers make up 
34 % of all drivers. Consequently, the gender structure of drivers randomly stopped for the check did 
not fit the actual gender structure of Polish drivers, a fact that cannot be reliably explained at this point 
in time.  
 
12.2 Roadside data collection and analysis  
12.2.1 Ethical approval 
The procedure for the Polish survey was approved by the Bioethics Commission at the District 
Doctors’ Chamber in Krakow (no. 39/KBL/OIL/2006 of 17 May 2006).  
 
12.2.2 Body fluid collection 
There were two ITS employees and a traffic police patrol for each survey. The following was the 
survey procedure: 
 
• A police officer randomly motions a vehicle to pull over, walks up to the driver and asks to see the 
documents: registration documents, driving license, etc. As he talks to the driver he checks for 
external symptoms of alcohol or substance use and if observed the changes are recorded in a 
special form developed by the National Police. 
• The police officer informs the driver about why the ITS employee is there and asks if they can 
have a few questions before he carries out the routine sobriety check. If the driver accepts that, 
the police officer is joined by an employee of the Motor Transport Institute (ITS).  
• The ITS employee introduces himself and informs the driver about DRUID objectives. He then 
asks the driver if he agrees to take part in the anonymous survey. If the driver accepts that, he 
talks the driver through the test, hands him a short DRUID leaflet and begins the test (collects a 
saliva sample and conducts a short interview). Next the driver walks over to the police officer for a 
regular roadside check.  
• If the driver refuses to participate in the DRUID, the ITS employee asks about the reason for the 
decision and does not proceed with the test. This has no influence on police work at the site. The 
police officer tests the driver for alcohol and substances (psychoactive substances). For the latter 
he uses the drug tester. If both tests are negative, the police officer completes the check and the 
driver is free to go. 
• After the driver has left the checkpoint, the police officer gives the results of alcohol and 
psychoactive substance tests to the ITS employee who records them in the questionnaire.  
• When all the activities are completed, the police officer stops the next driver for a test.  
 
Saliva samples were collected as part of the DRUID survey (from all drivers who agreed to take part). 
Samples (1 ml) were collected by ITS employees using the device called Statsure Saliva Sampler. The 
procedure followed the guidelines of the manufacturer. Samples of saliva were stored in a special 
portable fridge. The fridges were brought to the checkpoint by ITS employees. Once collected, saliva 
samples were transported in the fridges by courier to the Institute of Forensic Research in Krakow.  
 
12.2.3 Toxicological analysis of body fluid  
Weighting procedure of Statsure was conducted after tubes were delivered to the laboratory. Stick with 
indicator was removed from device just after saliva collected to approach real saliva volume. 
Appropriate formula was applied for volume calculation.  Before analyses samples were stored for 
25.2 days (mean) or 18 days (median) in freezer at –20oC.  
 
For extraction 1 ml mixture of buffer/saliva (1:1,v/v) from transportation tube (0,5 ml) and saliva (0,5 
ml) or if less as much as possible (weight recorded). Samples were extracted with SPE cartridge 
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Oasis HLB 30 mg (hydrophylic/lipophilic bonds) for up to 1 ml volume sample. Elution solvent was a 
mixture of methanol, isopropanol and acetic acid (7.5:2.5:0.1, v/v) . Evaporation at 40oC (Pierce 
Thermo block) under nitrogen and reconstitution solution was 70 l (mixture of acetonitrile, water and 
formic acid (3:7:0.01) ). 
 
Internal standards were purchased from LGC Promochem. For quantitation deuterated standards for 
all analytes except for carbamazepine and zopiclone (used zolpidem-d6) applied. IS concentrations 
were the same (50 ng/ml) in net saliva. Country drugs were carbamazepine and imipramine. Additional 
drugs included in screening were 7-aminoclonazepam and 7-aminoflunitrazepam. 
 
The exact description of procedure See Annex 2: Chromatographic and mass spectrometry conditions. 
 
12.2.4Method of BAC quantification 
Sobriety was tested by road police. All drivers stopped under the DRUID project had to take the test. 
The road police used breathalysers to test for alcohol. Polish police used two devices: Alkomat 7410 
PLUScom by DRAGER  and Alco-sensor IV M by L. Tech. The results from both devices are given as 
mg/l and converted to %o  using a factor of 2100.  
 
12.2.5 Interviews 
ITS staff also recorded the details of the check point, date and time of day and driver’s reference 
number in a special questionnaire. During short interviews the following data were  collected: gender 
and age, type of vehicle, occupants in the vehicles, years of driving experience, number of kilometres 
annually, reasons for refusing to take part in DRUID project, what the driver declared in terms of 
alcohol, medication and drugs consumption, results of police tests for presence of psychoactive 
substances in the subject’s system and alcohol in the driver’s breath. Due to lack of experience the 
ITS team did not check for clinical signs of disorder. 
 
12.2.6 Statistical analysis 
The unweighted control sample could not be considered to be exact representative of all drivers who 
participated in road traffic in the six police districts during the 8 DRUID time periods, since the sample 
distribution over different times and days was not equal to the distribution of traffic volumes. So, in 
order to make the control sample representative for the whole week, it had to be weighted, based on 
traffic flow distribution over the various days of the week and times of the day. More information on the 
weighting procedure is available in annex 2 of this report. 
 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS. Tables have been created by using the "proc freq statement", including a statement on 
the weight factors to be used. The weighted prevalence of the substance under scrutiny is calculated 
by dividing the weighted number of positives for this substance by the weighted total of samples. 
Because lower and upper confidence limits calculated using traditional approximations may result in 
limits outside the (0,1) interval, a more elaborate approximation is used. To that end, the Wilson 
confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
12.3 Non-response 
51 people (1.3 % of all drivers stopped) did not agree to take part in the DRUID survey. The reasons 
varied but most people would say they were in a hurry, disliked surveys in general, were tired and 
concerned that the survey would extend the time of the police check. Some drivers said they had 
concerns about catching an infection, having their personal data put in a DNA database or being 
accused of committing other crimes. Table 7 presents the basic demographics of these respondents. 
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Table 12.7.  Distribution of drivers by gender and age for non-response 
 Age Refusals (non-
response) 
Respondents 
(Volunteers) 
Total 
 
 
Men 
18 - 24 5  (9.8 %) 589  (14.7 %) 594 
25 - 34 9  (17.6 %) 1075  (26.8 %) 1084 
35 - 49 14  (27.5 %) 970  (24.2 %) 984 
50 + 14  (27.5 %) 680  (17.0 % 694 
Data not available 1  (2.0 %) 0  (0 %) 1 
 
 
Women 
18 - 24 1  (2.0 %) 133  (3.3 %) 134 
25 - 34 0  (0 %) 252  (6.3 %) 252 
35 - 49 4  (7.8 %) 224  (5.6 %) 228 
50 + 1  (2.0 %) 76  (2.0 % 77 
Data not available 0  (0 %) 1  (0 %) 1 
Data not 
available 
 2  (2.0 %) 5  (0.1 %) 7 
Total  51  (100 %) 4005 (100 %) 4056 
 
 
The age of those refusing to take part differed (from 20 to 79, average age 40.5), they were mostly 
men (84.3 % of the entire group) and drivers of passenger cars (78.4 %). Only one of those people 
tested positive for alcohol later (1.5 %o). In general the average age of those refusing to do the DRUID 
survey was higher than the average age of those who did the survey (average age of women was 38.5 
and 41.1 of men). 
 
Table 12.8.  Distribution of drivers by region, road type, and season for non-response 
 1 2 3 4 5 6 
Region 9 11 6 11 7 7 
Road type 24 27     
Season 12 8 6 25   
 
The data show that neither the number of drivers refusing to take part nor their characteristics should 
have any effect on the results and how they were interpreted. In fact, the non response percentage is 
so small that even if the non response group would be selective the effect on the prevalence would be 
minimal. 
  
 
12.4 Results 
This section of the report presents the basic results of the study of prevalence of psychoactive 
substance use by Polish drivers of passenger and delivery cars. This, however, will be preceded with 
a short overview of Poland’s road traffic law. 
 
 Since 1963 Poland has had a very strict BAC of 0.2 g/L. The limit applies to everyone – adult drivers, 
young and professional drivers and bicyclists. There have never been any serious attempts to change 
the limit. All drivers  stopped by the police because of alcohol are obligatory sent to court. In 2001 
Poland introduced two systems for penalising drink driving. If the BAC is between 0.2 and 0.5 g/L, the 
case is referred to a court of first instance, and considered an offence. If the BAC is above 0.5 g/L the 
case is handled by the criminal courts and considered a crime. This means more severe penalties. 
Almost every single day the results of roadside sobriety checks or information about unusual accidents 
caused by drunk drivers are reported in the news media. There are numerous public campaigns and 
political and social statements on the negative effects of drink driving. This shows that Poland has had 
a consistent drink driving policy for years and that it has strong public support. This cannot be said, 
however, about other psychoactive substances. The first regulations were introduced in 1997, but it 
was not until six years later that the government published a list of psychoactive substances that 
cannot be taken when driving. At present, the following substances are banned: opiates, amphetamine 
and its derivatives, cocaine, THC and medication based on benzodiazepines such as diazepam, 
estazolam and clonazepam. The regulations do not make it clear whether any traces of a psychoactive 
substances make the driver liable (“zero tolerance”) or whether it must be proved that the substance 
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affects the driver’s mental and physical ability to drive. This lack of clarity makes enforcement more 
difficult and inconsistent. In addition the risks caused by psychoactive substances if used by drivers 
have only been addressed recently with much less intensity compared to alcohol. 
 
Table 112.9 shows the prevalence of psychoactive substances among the general driving population 
of Polish drivers. 
 
Table 12.9. Adjusted general distribution of core substance categories (N = 4005) 
 
Substance category Prevalence (%) Confidence interval (%) 
Negative 97.63 97.11 – 98.05 
Alcohol 1.47 1.14 – 1.90 
Amphetamine 0.05 0.01 – 0.18 
Cocaine - - 
THC 0.57 0.38 – 0.85 
Illicit opiates 0.09 0.04 – 0.25 
Benzodiazepines 0.14 0.08 – 0.31 
Z-drugs - - 
Medicinal opioids 0.03 0.01 – 0.15 
Alcohol – drugs - - 
Multiple drugs 0.02 0.00 – 0.14 
 
As you can see from the data, among all drivers 2.4 % tested positive for one or more of the 
psychoactive substances included in the study. The most common psychoactive substance in the 
population of Polish drivers is alcohol (1.47 % of all drivers tested) followed by THC (0.57 %) and 
benzodiazepines (0.14 %). This is no surprise. A recent representative survey of Poles conducted in 
2009 showed that the most prevalent substance was THC with about 2% of the population admitting to 
having taken it in the last 12 months. The relatively popular benzodiazepines are no surprise either. 
Poland has one of the highest consumption of over-the-counter sedatives and sleeping pills and Poles 
are known for their propensity for taking pain killers. The last two ESPAD surveys from 2007 (Ahlström 
et al. 2009) and a survey conducted by CINN KBPN in 2002 and 2006 (Sierosławski 2006) showed 
that Poles take more medication than THC. But the problem is that most people using the drugs are 
unaware of how they affect their mental and physical abilities with ¼ of users not knowing the name of 
the drug they take. 
 
What came as some surprise is the relatively low prevalence of amphetamine. Poland together with 
the Netherlands and Belgium is one of Europe’s leading producers of amphetamine (EMCDDA 2009). 
Population surveys show that the number of amphetamine users, including experimental users has 
been steadily rising since the 1990s. Since then amphetamine has become the second most prevalent 
drug after cannabis. The results of the previous surveys showed that in the last 12 months 1% of the 
respondents had taken amphetamine. Roadside surveys in Poland showed that almost equal numbers 
of drivers used amphetamine and THC, but in the majority of the cases amphetamine levels were 
below the cut-off point used in DRUID and these people were not included in further analyses. The 
evidence, however, suggests that amphetamine use in Poland should be further investigated. 
 
Table 12.10 shows the distribution of core substance categories by gender and age. 
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Table 12.10. Adjusted distribution of core substance categories by gender and age (N = 4005) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 96.93 
95.01 – 98.13 
96.18 
94.87 – 97.17 
96.71 
95.40 – 97.65 
99.52 
98.72 – 99.82 
97.21 
96.60 – 97.72 
Alcohol 0.54 
0.17 – 1.68 
2.61 
1.82 – 3.73 
2.41 
1.62 – 3.57 
0.45 
0.16 – 1.23 
1.75 
1.35 – 2.25 
Amphetamine 0.15 
0.02 – 1.04 
0.04 
0.00 – 0.42 
0.00 
0.00 – 0.39 
0.02 
0.00 – 0.53 
0.04 
0.01 – 0.18 
Cocaine - - - - - 
THC 1.85 
0.98 – 3.46 
1.05 
0.59 – 1.84 
0.23 
0.07 – 0.78 
0.00 
0.00 – 0.50 
0.68  
0.46 – 1.03 
Illicit opiates 0.00 
0.00 – 0.77 
0.11 
0.02 – 0.56 
0.25 
0.08 – 0.82 
0.00 
0.00 – 0.50 
0.11 
0.04 – 0.30 
Benzodiazepines 0.38 
0.10 – 1.43 
0.00 
0.00 – 0.35 
0.36 
0.13 – 0.97 
0.02 
0.00 – 0.53 
0.16 
0.07 – 0.37 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 – 0.77 
0.00 
0.00 – 0.35 
0.05 
0.01 – 0.48 
0.00 
0.00 – 0.50 
0.01 
0.00 – 0.14 
Alcohol – drugs - - - - - 
Multiple drugs 0.15 
0.02 – 1.05 
0.01 
0.00 – 0.37 
0.00 
0.00 – 0.39 
0.00 
0.00 – 0.50 
0.03 
0.00 – 0.16 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 99.87 
96.26- 100.00 
99.52 
97.64 – 99.90 
99.59 
97.69 – 99.93 
100.00 
95.12 – 100.00 
99.65 
98.85 – 99.90 
Alcohol 0.13 
0.00 – 3.74 
0.20 
0.02 – 1.87 
0.11 
0.01 -1.78 
0.00 
0.00 – 4.88 
0.13 
0.02 – 0.81 
Amphetamine 0.00 
0.00 – 3.51 
0.29 
0.04 – 2.03 
0.00 
0.00 – 1.57 
0.00 
0.00 – 4.88 
0.11 
0.01 – 0.77 
Cocaine - - - - - 
THC 0.00 
0.00 – 3.51 
0.00 
0.00 – 1.51 
0.00 
0.00 – 1.57 
0.00 
0.00 – 4.88 
0.00 
0.00 – 0.57 
Illicit opiates 0.00 
0.00 – 3.51 
0.00 
0.00 – 1.51 
0.00 
0.00 – 1.57 
0.00 
0.00 – 4.88 
0.00 
0.00 – 0.57 
Benzodiazepines 0.00 
0.00 – 3.51 
0.00 
0.00 – 1.51 
0.00 
0.00 – 1.57 
0.00 
0.00 – 4.88 
0.00 
0.00 – 0.57 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 – 3.51 
0.00 
0.00 – 1.51 
0.30 
0.0.4 – 2.12 
0.00 
0.00 – 4.88 
0.11 
0.01 – 0.77 
Alcohol – drugs - - - - - 
Multiple drugs 0.00 
0.00 – 3.51 
0.00 
0.00 – 1.51 
0.00 
0.00 – 1.57 
0.00 
0.00 – 4.88 
0.00 
0.00 – 0.57 
 
Table 12.10 continues on the next page.
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Tab. 12.10 continued. Adjusted distribution of core substance categories by gender and age (N = 4005) 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 97.45 
95.86 – 98.44 
96.81 
95.73 – 97.62 
97.27 
96.20 – 98.05 
99.56 
98.84 – 99.84 
97.63 
97.11 – 98.05 
Alcohol 0.47 
0.15 – 1.42 
2.16 
1.50 – 3.08 
1.95 
1.31 – 2.89 
0.41 
0.15 – 1.12 
1.47 
1.14 – 1.90 
Amphetamine 0.12 
0.02 – 0.86 
0.08 
0.02 – 0.43 
0.00 
0.00 – 0.31 
0.02 
0.0 - 049 
0.05 
0.01 – 0.18 
Cocaine - - - - - 
THC 1.52 
0.81 – 2.86 
0.85 
0.48 – 1.50 
0.18 
0.05 – 0.62 
0.00 
0.00 – 0.45 
0.57 
0.38 – 0.85 
Illicit opiates 0.00 
0.00 – 0.64 
0.09 
0.02 – 0.45 
0.20 
0.06 – 0.66 
0.00 
0.00 – 0.45 
0.09 
0.04 – 0.25 
Benzodiazepines 0.31 
0.08 – 1.18 
0.00 
0.00 – 0.28 
0.29 
0.10 – 0.78 
0.02 
0.00 – 0.49 
0.14 
0.06 – 0.31 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 – 0.64 
0.00 
0.00 – 0.28 
0.10 
0.02 – 0.49 
0.00 
0.00 – 0.45 
0.03 
0.01 – 0.15 
Alcohol – drugs - - - - - 
Multiple drugs 0.12 
0.02 – 0.86 
0.01 
0.00 – 0.30 
0.00 
0.00 – 0.31 
0.00 
0.00 – 0.45 
0.02 
0.00 – 0.14 
 
 
Analysis of the data suggests several conclusions:  
 
1. Prevalence of psychoactive substances is the highest among drivers aged 25 to 34 and 35 to 
49 and next 18 to 24. 
2. Practically in all of the age groups (except 18 to 24) alcohol is the most common psychoactive 
substance. The degree of prevalence is quite alarming among male drivers aged 25 to 34 and 
35 to 49  (2.61 % and  2.41 % respectively tested positive). 
3. Drivers aged 18 to 24 use less alcohol compared to other psychoactive substances (primarily 
THC – 1.52 % were positive). 
4. In all age groups consumption of psychoactive substances is distinctly higher among men 
than women (2.79 % of men were positive versus 0.35 % women). The most common 
substance among men is alcohol with other psychoactive substances (especially 
amphetamine and medical opioids) prevailing in women. This needs further verification 
because women were not well represented in the survey. 
 
Table 12.11 shows the distribution of psychoactive substances by day of the week and time of the day.  
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Table 12.11. Adjusted distribution of core substance categories by day of the week and time of the day (N 
= 4005)   
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekend days 
04:00 – 21:59 
Weekend nights 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Negative 97.81 
97.21 – 98.29 
96.41 
90.39 – 98.71 
97.20 
95.95 – 98.08 
97.26 
90.75 – 99.23 
97.63 
97.11 – 98.05 
Alcohol 1.41 
1.04 – 1.91 
1.72 
0.41 – 6.90 
1.70 
1.05 – 2.73 
0.86 
0.11 – 6.32 
1.47 
1.14 – 1.90 
Amphetamine 0.00 
0.00 – 0.13 
0.29 
0.02 – 4.54 
0.15 
0.03 – 0.67 
0.34 
0.02 – 5.44 
0.05 
0.01 – 0.18 
Cocaine - - - - - 
THC 0.52 
0.31 – 0.85 
0.86 
0.13 – 5.53 
0.61 
0.28 – 1.34 
1.54 
0.30 – 7.44 
0.57 
0.38 – 0.85 
Illicit opiates 0.13 
0.05 – 0.34 
0.00 
0.0 – 4.00 
0.00 
0.00 – 0.40 
0.00 
0.00 – 4.81 
0.09  
0.04 – 0.25 
Benzodiazepines 0.13 
0.05 – 0.34 
0.57 
0.06 – 5.04 
0.13 
0.03 – 0.63 
0.00 
0.00 – 4.81 
0.14 
0.06 – 0.31 
Z-drugs - - - - - 
Medicinal opioids 0.00 
0.00 – 0.13 
0.00 
0.00 – 4.00 
0.13 
0.03 – 0.63 
0.00 
0.00 – 4.81 
0.03 
0.01 – 0.15 
Alcohol – drugs - - - - - 
Multiple drugs 0.00 
0.00 – 0.13 
0.14 
0.00 – 4.27 
0.08 
0.01 -0.54 
0.00 
0.00 – 4.81 
0.02 
0.00 – 0.14 
 
Analysis of the data in Table 12.11 usually helps with a more accurate determination of the times of 
the week and day when drivers are most likely to have taken psychoactive substances.  In many of the 
previous surveys driving under the influence of psychoactive substances was associated with night 
time and weekend driving. This cannot be corroborated by the results of the Polish survey. As regards 
alcohol drunk drivers were caught during the day, night, on weekdays and over the weekend. With no 
distinct lines drawn between the times of day and week, fewer people in Poland are asked to take the 
alcohol test during night time. Another explanation could be that there is some diversity among drunk 
drivers. The experience from the survey shows many drivers tested in the morning hours were 
surprised that they tested positive for alcohol. While they admitted drinking alcohol the day before, 
they were certain that having rested at home they were safe to drive. Night time checks offered similar 
results. Many drivers were certain that by drinking a small amount of alcohol they were not breaking 
the traffic law. Alcohol concentration data suggest that this is a plausible explanation. Alcohol 
concentration in nearly half of the drunk drivers did not exceed 0.5 g/L (Table 12.12). 
 
Table 12.12.  Adjusted general distribution of alcohol by concentration class (N = 4005) 
Alcohol alone Prevalence (%) Confidence interval (%) 
Alcohol 0.1 – 0.49 g/L 0.89 0.64 – 1.23 
Alcohol 0.5 – 0.79 g/L 0.18 0.09 – 0.36 
Alcohol 0.8 – 1.19 g/L 0.27 0.15 – 0.48 
Alcohol 1.2+ 0.14 0.06 – 0.31 
In total 1.47 1.14 – 1.90 
 
The distribution of other psychoactive substances by day of the week and time of the day was closer 
to the expectations (Table 15). People driving under the influence of amphetamine and 
benzodiazepines tend to do it at night but when it comes to THC (the most common illicit psychoactive 
substance) the results are not clear cut. This could be because of varying availability of the 
substances and when they are usually consumed. 
 
The following tables (12.13 – 12.14) show the details of alcohol distribution in road traffic in Poland. 
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Table 12.13. Adjusted distribution of alcohol alone by gender and age (N = 4005) 
Men 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
0.1 – 0.49 g/L 0.34 
0.09 – 1.37 
1.26 
0.75 – 2.11 
1.90 
1.22 – 2.97 
0.09 
0.01 – 0.67 
1.05 
0.75 – 1.45 
0.5 – 0.79 g/L 0.17 
0.03 – 1.09 
0.30 
0.10 – 0.83 
0.10 
0.02 – 0.57 
0.26 
0.07 – 0.95 
0.21 
0.10 – 0.43 
0.8 – 1.19 g/L - 
 
0.91 
0.49 – 1.67 
0.07 
0.01 – 0.53 
- 
 
0.32 
0.18 – 0.58 
1.2+ 0.03 
0.00 – 0.82 
0.15 
0.03 – 0.61 
0.33 
0.12 – 0.93 
0.09 
0.01 – 0.67 
0.17 
0.08 – 0.38 
In total 0.54 
0.17 – 1.68 
2.61 
1.82 – 3.73 
2.41 
1.62 – 3.57 
0.45 
0.16 – 1.23 
1.75 
1.35 – 2.25 
Women 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
0.1 – 0.49 g/L 0.13 
0.00 – 3.74 
0.20 
0.02 – 1.87 
0.11 
0.01 – 1.78 
- 
 
0.13 
0.02 – 0.81 
0.5 – 0.79 g/L - 
 
- 
 
- 
 
- 
 
0.00 
0.00 - 057 
0.8 – 1.19 g/L - 
 
- 
 
- 
 
- 
 
0.00 
0.00 - 057 
1.2+ - 
 
- 
 
- 
 
- 
 
0.00 
0.00 - 057 
In total 0.13 
0.00 – 3.74 
0.20 
0.02 – 1.87 
0.11 
0.01 – 1.78 
0.00 
0.00 – 4.88 
0.13 
0.02 – 0.81 
In total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
0.1 – 0.49 g/L 0.31 
0.08 – 1.16 
1.06 
0.63 – 1.76 
1.55 
0.99 – 2.41 
0.09 
0.01 – 0.61 
0.89 
0.64 – 1.23 
0.5 – 0.79 g/L 0.14 
0.02 – 0.90 
0.24 
0.08 – 0.68 
0.08 
0.01 – 0.46 
0.24 
0.06 – 0.86 
0.18 
0.09 – 0.36 
0.8 – 1.19 g/L - 
 
0.74 
0.40 – 1.36 
0.06 
0.01 – 0.42 
- 
 
0.27 
0.15 – 0.48 
1.2+ 0.02 
0.00 – 0.68 
0.12 
0.03 – 0.49 
0.26 
0.09 – 0.75 
0.09 
0.01 – 0.61 
0.14 
0.06 – 0.31 
In total 0.47 
0.15 – 1.42 
2.16 
1.50 – 3.08 
1.95 
1.31 – 2.89 
0.41 
0.15 – 1.12 
1.47 
1.14 – 1.90 
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Table 12.14 Adjusted distribution of alcohol alone by day of the week and time of the day (N = 4005) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekend days 
04:00 – 21:59 
Weekend nights 
22:00 – 03:59 
In total 
Alcohol alone Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
Prevalence (%) 
C.I. (%) 
0.1 – 0.49 g/L 0.85 
0.58 – 1.26 
1.15 
0.21 – 6.00 
1.01 
0.54 – 1.87 
0.51 
0.04 – 5.74 
0.89 
0.64 – 1.23 
0.5 – 0.79 g/L 0.13 
0.05 – 0.34 
0.14 
0.00 – 4.27 
0.31 
0.10 – 0.91 
0.34 
0.02 – 5.44 
0.18 
0.09 – 0.36 
0.8 – 1.19 g/L 0.34 
0.18 – 0.63 
0.14 
0.00 – 4.27 
0.08 
0.01 – 0.54 
- 
 
0.27 
0.15 – 0.48 
1.2+ 0.09 
0.03 – 0.28 
0.29 
0.02 – 4.54 
0.31 
0.10 – 0.91 
- 
 
0.14 
0.06 – 0.31 
In total 1.41 
1.04 – 1.91 
1.72  
0.41 – 6.90 
1.70 
1.05 – 2.73 
0.86 
0.11 – 6.32 
1.47 
1.14 – 1.90 
 
It is quite clear from the data that drink driving is a male problem in Poland. Women are not very likely 
to drink and drive and their blood alcohol levels are low. Drink driving is less common among young 
and novice drivers (aged 18 to 24) compared to older drivers. What is more their blood alcohol levels 
are lower than those of older drivers. There is a great deal of concern in the case of drivers aged 25 to 
34 and 35 to 49 driving with high alcohol levels. It may be that some of them are alcoholics. This could 
explain to some extent why the reduction in drink driving has been so slow in Poland because 
traditional methods do not appeal to these groups. If confirmed in more in-depth studies, this 
hypothesis means that Poland must urgently diversify its drink driving policy. Finally, the survey has 
established that older drivers aged 50+ also drink and drive.   
 
12.5 Discussion of results 
What we know about the use of psychoactive substances by Polish drivers has so far been based on a 
few public opinion polls. In a survey in 2002 dr Janusz Sierosławski from the Warsaw based Institute 
of Psychiatry and Neurology found that 4.4 % of the drivers admitted to drink driving in the last year 
and 1.2 % said that they had driven after consuming other psychoactive substances. Similar results 
were obtained in 2006 in the last survey of the prevalence of psychoactive substances in road traffic. 
The DRUID survey was Poland’s special opportunity for filling the gaps.  
 
The survey found that alcohol was detected in 1.47 % of the drivers and other psychoactive 
substances were detected in 0.9 % of the drivers. In the case of Poland what seems like a low 
percentage is actually a high number: 174,000 drivers who drink and drive at least once a year, 
64,000 use THC, 15,000 take benzodiazepines and 9,000 take amphetamine. To compare – Polish 
police detect about 80,000 drunk drivers and about 1500 drivers who have taken other psychoactive 
substances15. 
 
While the data collected under DRUID suggest some improvement and levelling off of drink and drug 
driving, it must be treated with a certain degree of caution due to the different methods of estimating 
the prevalence. It was only recently, i.e. in October 2010 when Poland was running SARTRE 4 (Social 
Attitudes To Road Traffic Risk In Europe, an EU programme) that public opinion polls data were 
verified. It was established that 3.3 % of drivers admitted to driving in the last year having consumed 
even very small amounts of alcohol with 1.5 % in the last month and 1 % in the last week. The results 
for other psychoactive substances were 0.7 %, 0.6 % and 0.4 % respectively. Among drivers who 
admitted to driving under the influence of psychoactive substances other than alcohol 54.6 % had 
taken THC and 9.1 % had taken amphetamine. This shows that there has been some improvement in 
Poland in recent years and that DRUID results give a relatively true picture of the trends in Poland. 
The use of alcohol and amphetamine may be underestimated for various reasons.  
 
Over the last twenty years Poland’s prevention policy has achieved some success in reducing drink 
driving but recent results show that progress is now slower. There is an urgent need for a modified 
policy. Effective drink driving detection should be a priority. Any recommendations regarding other 
psychoactive substances are a more difficult task. DRUID results from other countries suggest that the 
                                                 
15 No data are available about the breakdown of psychoactive substances.  
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situation is not so bad in Poland but experience shows that many of the new traffic risks appear even if 
a little late. It can be expected that psychoactive substances other than alcohol are going to become a 
growing problem in Poland. This claim can be corroborated with the results of surveys of psychoactive 
substances use by youth. On the other hand, recommending a more intensive police enforcement now 
is not a very good option. The use of psychoactive substances by drivers is a relatively new problem in 
Poland and cannot be addressed effectively due to inadequate legal regulations, lack of trained police 
officers or specialist equipment for police patrols. What is more the experience from the survey shows 
that none of the methods used by Polish police (watching for external symptoms, use of devices) are a 
guarantee of effective detection of illicit substance driving.  Changes may also be required in 
toxicology testing and within the justice system as well. Because of this, any recommendations to step 
up police checks are a bit too early. Instead Poland should urgently revise its legal regulations (e.g. 
allow saliva test results as evidence in court), introduce continuous education training for police 
officers, toxicology lab staff and the justice system, provide the necessary equipment for toxicology 
labs and the police and finally raise public awareness. Based on DRUID results it seems a plausible 
recommendation to target police checks (and the work of the entire system) on detecting drivers who 
have consumed alcohol, THC and perhaps amphetamine. Another area is the inclusion of the medical 
community in prevention policies. Finally, because we still have a limited understanding of the problem 
in Poland, we need a system of regular (e.g. once every 2-3 years) checks to monitor the scale of 
psychoactive substances use in road traffic. Of the two methods (public opinion polls vs. roadside 
surveys) the first is clearly the easier and cheaper option. Roadside surveys, however, offer an insight 
into police work and the entire system for eliminating dangerous drivers. This information can be a 
point of reference for evaluating the effectiveness and efficiency of the policies. While a repeat survey 
of DRUID would probably be beyond the capacity of many countries, they can use it to formulate a set 
of minimum requirements for similar surveys in the future. 
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Annex 12.1 Chromatographic and mass spectrometry conditions 
 
Chromatographic conditions 
 
Two chromatographic systems were applied: Waters Sep. module and Agilent HP1100. Separations 
were performed on Merck KGaA columns 125 mm Superspher 60 RP-select B (C-8), 2 mm id. and 55 
mm Purospher STAR RP-18e (C-18), 4 mm id., 3 m particle si       
consisted of acetonitryle (A) and water (B), formic acid 1% in final mixture: 
gradient (I Waters; II Agilent) 
• I gradient. 0 min. 35% (A), 1 min 35% (A), 10 min 80% (A), 15 min 80%(A), 15.2 min 35% (A), 20 
min. 35% (A); 0,3 ml/min; 40oC 
• II gradient 0 min 5% (A), 9 min 65%, 10 min 5%, 13 min 5%; 0,8 ml/min; 25oC 
• injection volume: appropriate 30 and 20 l 
 
Mass spectrometry conditions and monitored drugs 
 
Micromass Quattro micro MS System and Agilent HP1100 MSD with ES+ ionisation for both 
 
Table 1.  Retention times, monitored m/z of SRM/MRM for all the included drugs 
      
 Drug Parent Daughte
r 
Drug Parent Daughte
r 
 Morphine 286 201 Carbamazepine 237 194 
 Morphine-D3 289 201 Oxazepam-D3 292 292 
 Codeine 300 165 Oxazepam 287/9 287/9 
 Codeine-D3 303 165 Zopiclone 277 245 
 6-acetylmorphine 328 165 Lorazepam-D4 325 325 
 6-acetylmorphine-D3 331 165 Lorazepam 321/3 321/3 
 Benzoylecgonine 290 168 Nordiazepam-D5 276 276 
 Benzoylecgonine-D3 293 171 Clonazepam-D4 320 320 
 7-Aminoclonazepam-D4 290 290 Clonazepam 316/8 316/8 
 7-Aminoclonazepam 286/8 286/8 Nordiazepam 271/3 271/3 
 MDA-D5 185 168 Alprazolam-D5 314 314 
 MDA 180 163 Alprazolam 309/11 309/11 
 Amphetamine 136 91 Flunitrazepam-
D7 
321 321 
 Amphetamine-D5 141 124 Flunitrazepam 314/5 314/5 
 7-Aminoflunitrazepam-
D7 
291 291 Diazepam-D5 290 290 
 MDMA 194 163 Diazepam 285/7 285/7 
 MDMA-D5 199 165 Imipramine-D3 284 89 
 7-Aminoflunitrazepam 284/6 284/6 Imipramine 281 86 
 Methamphetamine 150 91 Methadone-D3 313 268 
 Methamphetamine-D5 155 91 Methadone 310 265 
 MDEA-D5 213 163 THC-D3 318 196 
 MDEA 208 163 THC 315 193 
 Tramadol-D3 268 58    
 Tramadol 264 58    
 Cocaine-D3 307 185    
 Cocaine 304 182    
 Zolpidem-D6 314 235    
 Zolpidem 308 235    
 
  179 
Time
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00 6.20 6.40 6.60 6.80 7.00
%
0
100
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00 6.20 6.40 6.60 6.80 7.00
%
0
100
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00 6.20 6.40 6.60 6.80 7.00
%
0
100
2: MRM of 17 Channels ES+ 
320 > 320
1.46e54.97
2: MRM of 17 Channels ES+ 
318 > 318
6.87e3
5.05
2: MRM of 17 Channels ES+ 
316 > 316
2.33e45.05
Validation 
 
Freeze and thaw than centrifuged real saliva with addition of 0, 1, 5, 10, 20, 50, 100, 200 ng/ml seven 
levels calibration and negative each four repetitions. Additional levels 500 and 1000 ng/ml for high 
concentrations. 
 
Quality control samples 
 
Intensity of signal from mobile phase components before analysis UTAK 100% cut-off synthetic saliva, 
internal standards signals. Samples are not diluted, results are extrapolated because research is 
performed only for prevalence not for correlation. Additional levels 500 and 1000 ng/ml gave similar 
results as extrapolation. 
 
Figure 1. Chromatogram of a positive sample THC and clonazepam both 1 ng/ml 
 
Validation parameters: Calibration model used was linear with zero excluded 
 
Table 2. Accuracy and precision for reference material UTAK 
 
Compund 
UTAK 100% 
cut-off 
 
Measured 
 
Accuracy 
 
Precision (n=12) 
Amphetamine 100 87 87% 12% 
Metamphetamine 100 103 103% 17% 
Benzoylecgonine 40 43 108% 13% 
Methadone 10 11.5 115% 13% 
Oxazepam 100 86 86% 12% 
 
 
Time
12.00 12.25 12.50 12.75 13.00 13.25 13.50 13.75 14.00 14.25 14.50 14.75 15.00 15.25 15.50 15.75 16.00
%
0
100
12.00 12.25 12.50 12.75 13.00 13.25 13.50 13.75 14.00 14.25 14.50 14.75 15.00 15.25 15.50 15.75 16.00
%
0
100
4: MRM of 3 Channels ES+ 
318 > 196
2.35e4
13.64
4: MRM of 3 Channels ES+ 
315 > 193
913
S/N:PtP=5.65
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Table 3.   LOQ (CV<30%), for SRM or SIR method of ion recording 
 
Compound 
 
LOD 
 
LOQ 
 
Calibration equation 
Determination 
coefficient R2 (n=7) 
Amphetamine <1 5 Y = 0.042 * X - 0.033 0.997 
Metamphetamina <1 5 Y = 0.056 * X - 0.035 0.998 
MDA <1 5 Y = 0.020 * X + 0.024 0.998 
MDMA <1 5 Y = 0.020 * X + 0.008 1.000 
MDEA <1 5 Y = 0.020 * X + 0.038 1.000 
Tramadol <1 5 Y = 0.022 * X + 0.003 0.988 
Morphine 1 5 Y = 0.034 * X + 0.000 0.997 
Benzoylecgonine <1 5 Y = 0.023 * X – 0.015 0.999 
Codeine 1 5 Y = 0.020 * X + 0.064 0.996 
6-acetylmorphine 2 5 Y = 0.022 * X + 0.073 0.972 
7-aminoclonazepam 5 20 Y = 0.034 * X + 0.000 0.976 
7-aminoflunitrazepam 1 5 Y = 0.444* X + 0.000 0.986 
Zopiclon <1 1 Y = 0.026 * X - 0.013 0.984 
Carbamazepine <1 1 Y = 0.075 * X - 0.008 0.996 
Nordiazepam <1 1 Y= 0.020 * X - 0.011 0.999 
Oxazepam <1 2 Y = 0.022 * X - 0.007 0.999 
Cocaine <1 2 Y = 0.021 * X + 0.040 0.987 
Zolpidem <1 1 Y = 0.025 * X + 0.089 0.991 
Clonazepam <1 1 Y = 0.020 * X - 0.007 0.999 
Lorazepam <1 1 Y = 0.014 * X + 0.020 0.999 
Imipramine <1 1 Y = 0.022 * X - 0.027 0.987 
Diazepam <1 1 Y = 0.019 * X - 0.014 0.988 
Alprazolam 1 3 Y = 0.026 * X - 0.025 0.999 
Methadon <1 1 Y = 0.020 * X + 0.010 0.992 
Flunitrazepam <1 1 Y = 0.019 * X - 0.019 0.986 
THC 1 2 Y = 0.022 * X - 0.029 0.999 
 
Interference from blue indicator – collecting pad is tear off indicator stick and placed in transportation 
tube. Method was published in proceedings of SOFT/TIAFT Meeting in Seattle 2007 16 
 
                                                 
16  Wojciech Lechowicz, Maria Kala, Joni Walker (2007):  Screening and quantification of the twenty-four 
drugs in oral fluid relevant for road traffic safety by means of LC-MS-MS/ESI 
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13.1 Description of roadside driver sample 
It is well established that alcohol impairs driving ability and increases the accident risk. In recent years 
driving under influence of psychoactive substances other than alcohol has gained considerable 
attention. Although alcohol is the single compound most frequently detected among accident drivers, 
the role of drugs and medicines concerning the incidence in driving and their contribution for road 
traffic accidents has been a subject of increasing interest. 
In order to target strategies to better manage driving under influence (DUI), epidemiological data are 
necessary to document the scope of the problem. Most epidemiological studies on illicit drugs and 
medicines among drivers have been difficult to compare due to the lack of standardized protocols, e.g. 
selection of subjects, biological matrix used, different compounds included in the analytical protocol 
and their cut-off limits. One of the main purposes of DRUID project (Driving Under the Influence of 
Drugs, Alcohol and Medicines) is to study the prevalence of psychoactive drugs in the driving 
population. 
The Portuguese participation in this study allowed, for the first time, to obtain relevant information 
about the situation in Portugal regarding the prevalence of driving under the influence of alcohol and 
psychotropic substances among drivers not involved in accidents. The Portuguese Centre of Post-
Graduated Studies in Legal Medicine of the National Institute of Legal Medicine (CPS-NILM) has 
participated in the DRUID project integrating Task 2.2.a (Road Side Survey) as part of Work Package 
2 – Epidemiology. The CPS-NILM was responsible for planning, collecting and analyse about 4000 
samples of oral fluid from drivers whose participation was voluntary and anonymous. The selection 
was made randomly in sessions geographically distributed to ensure the representativeness of the 
Portuguese drivers. In order to allow comparability of results between different countries, several 
criteria were established in Deliverable D 2.1.2 (Uniform design and protocols for carrying out case-
control studies). Those criteria were related to the geographical distribution of sessions over different 
time periods (month, days and time of day).  
The type of device used for the collection of oral fluid samples was the same for all participant 
countries and was approved in the initial phase of the project. 
The toxicological analysis was performed using an analytical methodology for screening and 
quantification of 26 substances, 23 of which were common to all participant countries. A minimum 
analytical limit of detection (Analytical Cut-Off) was established for all substances. All laboratories that 
participated had to prove ability to achieve these values through participation in a previous program of 
proficiency. 
 
13.1.1 Geographical distribution 
The administrative division of Portugal Continental comprises 308 municipalities spread over 18 
districts in 5 regions. Considering the geographical distribution of the population, the number of driving 
licenses and the number of road accidents with victims in year 2006, 5 municipalities were selected in 
the district of Porto (Porto, Vila Nova de Gaia, Matosinhos, Gondomar and Valongo), 5 municipalities 
in the district of Coimbra (Coimbra, Figueira da Foz, Cantanhede, Penacova and Montemor-o-Velho) 
and 5 municipalities in the district of Lisboa (Lisboa, Sintra, Cascais, Oeiras and Loures). 
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Figure 13.1 Geographical distribution of roadside survey regions 
According to the official statistics of 2006, about 44% of the Portuguese population resided in the 
geographical area included in the study, and 49% of driving licences as well as 40% of road accidents 
with victims were there registered. Table 13.1 presents the distribution of population and drivers by 
Region, District and Municipality and the number of samples collected in the 3 Districts included in the 
study.  
 
Table 13.1. Distribution of population, driving licenses and number of samples collected by District 
Portugal Continental 
(5 Regions/ 18 Districts/ 308 Municipalities) 
10110271 inhabitants (*) 
5396647 driver licences (**) 
North Region Center Region Lisbon Region 
(8 Districts/ 86 Municipalities) (7 Districts/ 100 Municipalities) (3 Districts/ 51Municipalities) 
3744341 inhabitants (*) 2385891 inhabitants (*) 2794226 inhabitants (*) 
District of Porto District of Coimbra District of Lisboa 
(18 Municipalities) (17 Municipalities) (16 Municipalities) 
1805015 inhabitants (*) 437642 inhabitants (*) 2203503 inhabitants (*) 
Municipalities Inhabitants(*) 
Number 
of 
Samples 
Municipalities Inhabitants(*) 
Number 
of 
Samples 
Municipalities Inhabitants(*) 
Number 
of 
Samples 
V.N. Gaia 300868 
1374 
Coimbra 135314 
1345 
Lisboa  489562 
1302 
Porto 238954 Figueira Foz 63135 Sintra 445872 
Gondomar  169239 Cantanhede 38920 Loures 195035 
Matosinhos 168451 
Montemor-o-
Velho 24766 Cascais 188244 
Valongo 91274 Penacova 16857 Oeiras 172021 
* Year 2006 (Source: Instituto Nacional de Estatística)           
** Year 2006 (Source: Autoridade Nacional de Segurança 
Rodoviária)         
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13.1.2 Distribution by road type 
A total of 117 sessions were carried out on urban and inter-urban roads, in the 15 municipalities 
included in the study. The locations of the sessions were established according to the traffic flow and 
safety conditions for the DRUID working teams. In Table 13.2 it is represented the distribution of 
drivers by road type. 
 
Table 13.2. Distribution of drivers by road type 
District 
Drivers 
Urban Inter-Urban  (EN;EM; IP/IC) Total 
Porto 1132 242 1374 
Coimbra 796 549 1345 
Lisboa  1030 272 1302 
Total 2958 1063 4021 
EN – national road; EM – municipal road; IP/IC inter-regional road 
 
13.1.3 Distribution by month, day and time period 
Traffic exposure and prevalence of psychoactive substances used by drivers may vary considerably 
by time (month, day of the week and time of the day). The sessions were distributed evenly for the 
different seasons. The districts and municipalities included in this study had a monthly identical volume 
of traffic throughout the year.  
To ensure comparability of the results eight time periods were defined (day and time of day) and the 
planning was made to include more than one session in each of those periods. The sessions were 
conducted in different time periods according to the availability of police resources. Table 13.3 and 
13.4 presents the distribution of drivers with final valid sample by season and time period, respectively. 
In time period 5 the police forces concentrate their activity in specific operations which partly 
conditioned the planned sessions during this period. The availability of police resources in time period 
2 and the largest volume of traffic during this period, allowed the collection of a higher number of 
samples. 
 
Table 13.3. Distribution of drivers by season 
Season Drivers 
Winter (month 1-3) 1300 (32.78%) 
Spring (month 4-6) 959 (24.18%) 
Summer (month 7-9) 769 (19.39%) 
Autumn (month 10-12) 937 (23.63%) 
 
Table 13.4. Distribution of drivers by time period* 
 
 
 
 
 
 
 
 
 
 
 
*Weekday: 1- Monday to Friday 04:00 to 10:00  2 - Monday to Friday 10:00 to 16:00  
3 - Monday to Thursday 16:00 to 22:00  4 - Monday to Thursday 22:00 to 
04:00 
 
Weekend:  5 – Saturday and Sunday 04:00 to 10:00  6 – Saturday and Sunday 10:00 to 16:00 
7 – Friday to Sunday 16:00 to 22:00  8 – Friday to Sunday 22:00 to 04:00 
Time period Drivers 
1 483 (12.18%) 
2 892 (22.50%) 
3 489 (12.33%) 
4 485 (12.23%) 
5 222 (5.60%) 
6 418 (10.54%) 
7 518 (13.06%) 
8 458 (11.55%) 
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13.1.4 Distribution by gender and age 
  
Table 13.5 presents the distribution of drivers by gender and age group. 
 
Table 13.5. Distribution of drivers by gender and age group 
Age group Gender 
male female 
18-24 385 218 
25-34 802 455 
35-49 833 378 
≥ 50 690 146 
Note: In 53 questionnaires information about age or gender 
was missing. 
 
In this study female drivers represent 30.6% of all drivers. This may be partly justified by the fact that 
the number of women with driving licenses is lower than male. According to 2006 official data only 
37.2% of all driving license holders were female17. According to the same official data, about 47% of 
drivers were between 25 and 44 years. In our study the percentage of drivers between 25 and 49 
years old is higher. One reason may be attributed to the fact that the municipalities included in this 
study are part of large metropolitan areas where the majority of the active population lives. In fact, 
almost 40% of the Portugal inhabitants live in the districts of Lisboa and Porto (see Table 13.1).  
 
13.2 Roadside data collection and analysis 
Following the approval by the Ethic Committee of the Faculty of Medicine of the University of Coimbra, 
the roadside sessions were performed by teams of Police and researchers of the National Institute of 
Legal Medicine (INML, IP), between January 2008 and June 2009, in selected locations in accordance 
with the flow of traffic and security conditions for the teams. The first car approaching the research site 
was ordered to stop by the police as soon as one of the researchers was available to collect the 
sample and conduct the interview.  
Drivers stopped were informed about the aims of the DRUID project and invited to cooperate with the 
research team on a voluntary and anonymous basis. Drivers who agreed to cooperate, were 
interviewed about their drug and medicine use, and time of its administration. Apart from this, data 
collection also comprised date, time, gender and age of the subject, and signs of impairment. The 
results for each driver were entered on a uniquely anonymous numbered research form. 
After the interview and oral fluid sampling, all subjects were breath-tested for blood alcohol 
concentration (BAC) by a police officer using a Dräger Alcotest 7810 screening device. When the 
result obtained was ≥ 0.5 g/l, a Dräger Alcotest 7410 was used to obtain a quantitative result. In 
accordance with the Portuguese law, BAC is obtained through the concentration of alcohol in the 
breath using a conversion factor of 2.3. The breath test was compulsory for all drivers stopped and the 
results entered on the research form. 
For the oral fluid collection Statsure Saliva Sampler device was used. It consists of a tube 
containing 1 ml of buffer and a collector equipped with a volume adequacy indicator which 
changes colour when 1 ml is collected. In order to calculate the precise amount of collected oral fluid 
all the devices were weighed with and without sample thus allowing to determine the exact volume of 
each oral fluid sample collected. All samples were preserved at -20 ºC until toxicological analysis. 
All the samples were analyzed by the Department of Forensic Toxicology of the South Branch of the 
INML I.P., between March 2008 and July 2009, using a methodology developed for screening and 
quantification of the core substances (Deliverable D 2.1.2). Samples were prepared by liquid-liquid 
extraction followed by liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis [1]. 
The method was fully validated, including specificity and capacity of identification, limit of detection 
(0.2-2.1 µg/l), limit of quantification (0.8-6.4 µg/l), recovery (34-98%), carryover, linearity (1-200 µg/l), 
intra-assay precision (coefficient of variance (CV) <20% for 20 µg/l and CV <10% for 100 µg/l) and 
inter-assay accuracy (mean relative error <15%) and precision (CV <20%). For some substances the 
                                                 
17 Sinistralidade Rodoviária 2006 – Elementos Estatísticos – Observatório de Segurança Rodoviária (2007) 
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limit of detection and the limit of quantification of the method were below the DRUID cut-off. Detailed 
information on the toxicological analyses can be found in annex. 
 
13.3 Non -response  
The rate of drivers who refused to participate was only 3%. In such cases no sample was collected 
and in most of them it was not possible to obtain information for the questionnaire. 
 
13.4 Results  
The core substances and the analytical cut-offs used in this study were established in Deliverable 
D.2.1.2. For prevalence calculation the cut-off value (DRUID cut-off) was redefined considering the 
DRUID cut-off values established for blood analyzes in prevalence study of alcohol and other 
psychoactive substances in injured and killed drivers (Deliverable D.2.2.5). The core substances 
categories and the DRUID cut-off in oral fluid and whole blood are presented in Tables 13.6 and 13.7.  
 
Table 13.6. Core substances categories 
Type Group Analytical findings 
Negative Negative  
Illicit Drugs 
Amphetamines Amphetamine; Methamphetamine; MDMA; MDEA; MDA 
Cocaine Cocaine; benzoylecgonine 
THC THC 
Illicit Opiates 6-acetylmorphine; morphine;  morphine + codeine  (morphine>= codeine) 
Medicinal Drugs 
Benzodiazepines 
diazepam; nordiazepam; oxazepam; 
lorazepam; alprazolam; flunitrazepam; 
7-aminoflunitrazepam; clonazepam; 7-
aminoclonazepam 
Z-Drugs Zolpidem; Zopiclone 
Opiates and 
opioids 
Morfine + codeine (morphine < codeine); 
methadone; tramadol 
Alcohol Ethanol  
Various 
combinations 
Drug-Alcohol  
Drug-Drug  
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Table 13.7. DRUID cut-off in oral fluid and whole blood for core substances 
Substance Cut-off in oral fluid (ng/ml) 
Cut-off in whole 
blood (ng/ml) 
6-AM 16 10 
Alprazolam 3.5 10 
Amphetamine 360 20 
Benzoylecgonine 95 50 
Clonazepam 1.7 10 
Cocaine 170 10 
Codeine 94 10 
Diazepam 5.0 140 
Flunitrazepam 1.0 5.3 
Lorazepam 1.1 10 
MDA 220 20 
MDEA 270 20 
MDMA 270 20 
Methadone 22 10 
Methamphetamine 410 20 
Morphine 95 10 
Nordiazepam 1.1 20 
Oxazepam 13 50 
THC 27 1.0 
Zolpidem 10 37 
Zopiclone 25 10 
Tramadol 480 50 
7-amino-clonazepam 3.1 10 
7-amino-flunitrazepam 1.0 8.5 
 
The prevalence of drivers by type of substance is presented in table 13.8. The presence of at least 
one psychoactive substance was detected in almost 10% of drivers. Alcohol alone was detected in 
4.93% of the cases. Benzodiazepines and THC with a prevalence of 2.73% and 1.38%, respectively, 
were the substances most prevalent after alcohol. 
Table 13.8. Total drivers: Adjusted general distribution of core substance categories (n=3965) 
Substance category Prevalence (%) 95% Confidence interval  
Negative 90.01 84.04 – 90.91 
Alcohol 4.93 4.29 – 5.64 
Amphetamine --- -- 
Cocaine 0.03 0.01 – 0.16 
THC 1.38 1.07 – 1.80 
Illicit opiates 0.15 0.07 – 0.33 
Benzodiazepines 2.73 2.27 – 3.29 
Z-drugs --- -- 
Medicinal opioids 0.11 0.04 – 0.27 
Alcohol – drugs 0.42 0.26 – 0.67 
Multiple drugs 0.23 0.12 – 0.44 
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Drivers with amphetamine alone or Z-drugs alone or in combination were not detected. 
In 0.65% of drivers there was an association of at least two substances (Table 13.9). The prevalence 
of cases with alcohol-drugs combination (0.42%) was approximately twice of the multiple drugs 
(0.23%). THC was present in more than half of the cases with alcohol-drug combination, while cocaine 
or its metabolite was present in all cases of multiple drugs involving illicit drugs. 
 
Table 13.9. Combinations of alcohol–drugs and multiple drugs (n=3965) 
Various combinations Prevalence (%) 95% Confidence interval  
Alcohol + amphetamine 
0.42 0.26 – 0.67 
Alcohol + cocaine 
Alcohol + THC 
Alcohol + cocaine + THC 
Alcohol + benzodiazepines 
Illicit opiates + Benzoilecgonine 
0.23 0.12 – 0.44 
Illicit opiates + cocaine 
Illicit opiates + cocaine + THC 
Cocaine + THC + benzodiazepines 
Benzodiazepines + medicinal opiates 
 
In all illicit opiates positive cases, a direct marker of recent use of heroin, 6-acetylmorphine, was 
detected. Methadone was detected in 80% of the positive cases for medicinal opioids. No positive 
cases were detected for zolpidem, flunitrazepam and zopiclone. Benzodiazepines detected with the 
highest prevalence were nordiazepam (59%) and alprazolam (26%). In most cases where 
nordiazepam was detected, it was found in association with other benzodiazepines with common 
metabolism (diazepam and oxazepam). In contrast, only 14% of the alprazolam positive cases were in 
association with others benzodiazepines. 
The prevalence of positive cases in the districts of Porto (9.87%), Coimbra (9.63%) and Lisboa 
(10.24%) was similar (Tables 13.10, 13.11 and 13.12). 
Drivers who tested positive for cocaine alone (0.06%) were only detected in the district of Lisboa, 
where benzodiazepines prevalence is also greater (3.25%) than in districts of Coimbra (2.16%) and 
Porto (1.94%). The opposite was observed for alcohol with a prevalence of 6.8% in Porto, 5.32% in 
Coimbra and 4.46% in Lisbon.  
 
Table 13.10. District of Porto: Adjusted general distribution of core substance categories  (n=1324) 
Substance category Prevalence (%) 95% Confidence interval 
Negative 90.13 86.86 – 92.66 
Alcohol 6.08 4.15 – 8.83 
Amphetamine --- --- 
Cocaine --- --- 
THC 1.10 0.45 – 2.66 
Illicit opiates 0.15 0.02 – 1.21 
Benzodiazepines 1.94 0.98 – 3.79 
Z-drugs --- --- 
Medicinal opioids 0.15 0.02 – 1.21 
Alcohol – drugs 0.40 0.10 – 1.63 
Multiple drugs 0.04 0.00 – 1.00 
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Table 13.11. District of Coimbra: Adjusted general distribution of core substance categories 
                  (n=1348) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13.12. District of Lisboa: Adjusted general distribution of core substance categories 
                   (n=1293) 
Substance category Prevalence (%) 95% Confidence interval 
Negative 89.76 88.42 – 90.97 
Alcohol 4.46 3.67 – 5.41 
Amphetamine --- --- 
Cocaine 0.06 0.01 – 0.29 
THC 1.63 1.17 – 2.25 
Illicit opiates 0.19  0.07 – 0.48 
Benzodiazepines 3.25 2.58 – 4.08 
Z-drugs --- --- 
Medicinal opioids 0.00 0.00 – 0.18 
Alcohol – drugs 0.29 0.14 – 0.62 
Multiple drugs 0.36 0.18 – 0.71 
 
Distribution of core substance categories by gender and age is shown in Table 13.13. The prevalence 
of alcohol in male (6.21%) was more than two times higher than among female drivers (2.59%). In 
both groups, the age group 18-24 showed a higher prevalence, 9.76% in male and 8.00% in female 
drivers (Figure 13.2). 
Substance category Prevalence (%) 95% Confidence interval 
Negative 90.37 88.69 -91.82 
Alcohol 5.32 4.25 – 6.64 
Amphetamine --- --- 
Cocaine --- --- 
THC 1.09 0.66 – 1.79 
Illicit opiates 0.10 0.02 – 0.45 
Benzodiazepines 2.16 1.51 – 3.07 
Z-drugs --- --- 
Medicinal opioids 0.26 0.10 – 0.71 
Alcohol – drugs 0.62 0.32 – 1.20 
Multiple drugs 0.09 0.02 -0.44 
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Table 13.13.  Adjusted distribution of core substance categories by gender and age (n=3912) 
Male 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Negative 84.21 79.79 – 87.82 
86.68 
83.96 – 88.99 
89.92 
87.56 – 91.71 
91.67 
89.39 – 93.49 
88.67 
87.39 – 89.84 
Alcohol 9.76 6.95 – 13.53 
5.99 
4.47 – 8.00 
6.37 
4.89 – 8.26 
4.47 
3.17 – 6.26 
6.21 
5.34 – 7.21 
Amphetamine --- --- --- --- --- 
Cocaine 0 
0.00 – 1.20 
0.15 
0.03 – 0.82 
0.03 
0.00 – 0.53 
0.00 
0.00 – 0.54 
0.05 
0.01- 0.24 
THC 2.23 
1.09 – 4.52 
4.50 
3.20 – 6.29 
1.03 
0.53 – 1.98 
0.67 
0.28 – 1.59 
2.08 
1.60 – 2.71 
Illicit opiates 0.00 
0.00 – 1.20 
0.36 
0.11 – 1.15 
0.39 
0.14 – 1.11 
0.00 
0.00 – 0.54 
0.23 
0.11 – 0.51 
Benzodiazepin
es 
0.67 
0.19 – 2.33 
0.93 
0.44 – 1.95 
1.53 
0.89 – 2.63 
3.07 
2.03 – 4.62 
1.68 
1.25 – 2.25 
Z-drugs --- --- --- --- --- 
Medicinal 
opioids 
0.00 
0,00 – 1.20 
0.00 
0.00 – 0.54 
0.30 
0.09 – 0.97 
0.09 
0.01 – 0.71 
0.12 
0.04 – 0.35 
Alcohol – drugs 2.05 
0.97 – 4.28 
1.28 
0.68 – 2.42 
0.04 
0.00 - 0.54 
0.03 
0.00 – 0.61 
0.64 
0.39 – 1.03 
Multiple drugs 1.08 
0.39 – 2.94 
0.11 
0.02 – 0.74 
0.49 
0.19 – 1.25 
0.01 
0.00 – 0.56 
0.32 
0.16 – 0.62 
Female 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Negative 90.91 
86.26 – 94.09 
93.67 
91.16 – 95.50 
94.01 
91.49 – 95.82 
85.92 
79.89 – 90.36 
92.38 
90.86 – 93.67 
Alcohol 8.00 
5.05 – 12.46 
2.44 
1.40 – 4.22 
0.29 
0.06 – 1.33 
3.14 
1.38 – 6.97 
2.59 
1.88 – 3.58 
Amphetamine --- --- --- --- --- 
Cocaine 0.00 
0.00 – 1.79 
0.00 
0.00 – 0.77 
0.00 
0.00 – 0.81 
0.00 
0.00 – 2.21 
0.00 
0.00 – 0.28 
THC 0.09 
0.00 – 1.96 
0.24 
0.05 – 1.21 
0.00 
0.00 – 0.81 
0.00 
0.00 – 2.21 
0.10 
0.02 – 0.46 
Illicit opiates 0.00 
0.00 – 1.79 
0.00 
0.00 – 0.77 
0.00 
0.00 – 0.81 
0.00 
0.00 – 2.21 
0.00 
0.00 – 0.28 
Benzodiazepin
es 
1.00 
0.28 – 3.47 
3.65 
2.32 – 5.69 
5.44 
3.73 – 7.87 
10.83 
6.99 – 16.40 
4.75 
3.74 – 6.00 
Z-drugs --- --- --- --- --- 
Medicinal 
opioids 
0.00 
0.00 – 1.79 
0.00 
0.00 – 0.77 
0.25 
0.05 – 1.26 
0.00 
0.00 – 2.21 
0.09 
0.02 – 0.43 
Alcohol – drugs 0.00 
0.00 – 1.79 
0.00 
0.00 – 0.77 
0.00 
0.00 – 0.81 
0.11 
0.01 – 2.43 
0.01 
0.00 – 0.31 
Multiple drugs 0.00 
0.00 – 1.79 
0.00 
0.00 – 0.77 
0.00 
0.00 – 0.81 
0.00 
0.00 – 2.21 
0.08 
0.01 – 0.42 
 
 
Table 13.13 continues on the next page. 
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Table 13.13. continued.  Adjusted distribution of core substance categories by gender and age (n=3912) 
Total 
Age group 18-24 25-34 35-49 50+ In total 
Substance 
category 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Prevalence (%) 
 95% C.I. 
Negative 87.01 
83.89 – 89.61 
89.63 
87.78 – 91.23 
91.35 
89.69 – 92.76 
90.55 
88.43 – 92.32 
90.01 
89.04 – 90.91 
Alcohol 8.97 
6.83 – 11.70 
4.50 
3.46 – 5.82 
4.16 
3.19 – 5.39 
4.21 
3.07 – 5.75 
4.93 
4.29 – 5.64 
Amphetamine --- --- --- --- --- 
Cocaine 0.00 
0.00 – 0.72 
0.09 
0.02 -0.48 
0.02 
0.00 – 0.34 
0.00 
0.00 – 0.44 
0.03 
0.01 – 0.16 
THC 1.36 
0.67 -2.75 
2.72 
1.94 -3.80 
0.65 
0.34 -1.26 
0.54 
0.22 – 1.28 
1.38 
1.07 – 1.80 
Illicit opiates 0.00 
0.00 – 0.72 
0.21 
0.07 – 0.68 
0.25 
0.09 – 0.71 
0.00 
0.00 – 0.44 
0.15 
0.07 – 0.33 
Benzodiazepin
es 
0.08 
0.32 -1.98 
2.03 
1.37 -3.00 
2.96 
2.16 -4.03 
4.58 
3.38 – 6.17 
2.73 
2.27 – 3.29 
Z-drugs --- --- --- --- --- 
Medicinal 
opioids 
0.00 
0.00 – 0.72 
0.00 
0.00 – 0.32 
0.28 
0.11 – 0.75 
0.07 
0.01 – 0.57 
0.11 
0.04 – 0.27 
Alcohol – drugs 1.22 
0.58 -2.56 
0.75 
0.39 – 1.42 
0.03 
0.00 – 0.35 
0.05 
0.00 – 0.53 
0.42 
0.26 – 0.67 
Multiple drugs 0.64 
0.23 – 1.76 
0.06 
0.01 – 0.43 
0.31 
0.12 – 0.79 
0.01 
0.00 – 0.45 
0.23 
0.12 – 0.44 
 
 
 
 
Figure 13.2. Adjusted distribution of alcohol by gender and age 
 
The prevalence of THC in male (2.08%) is higher than that found among female drivers (0.10%). The 
age groups 18-24 and 25-34 are those with higher prevalence of THC and the only ones where the 
presence of THC was detected among female drivers (Figures 13.3 and 13.4). 
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Figure 13.3. Adjusted distribution of drugs by age (male) 
 
 
 
Figure 13.4. Adjusted distribution of drugs by age (female)  
 
Benzodiazepines use was significantly higher among females (4.75%) than among males (1.68%). 
Drivers in the age group 50+ showed a higher prevalence of benzodiazepines (4.58%). The use of 
these medicines was concentrated among females age 50 and older, (10.83%) (Table 13.13 and 
Figures 13.3 and 13.4). 
 
Prevalence of alcohol-drugs and multiple drugs is much higher among male (0.64% and 0.32% 
respectively), than in female drivers (0.01% and 0.08%) (Figure 13.5). 
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Figure 13.5. Adjusted distribution of alcohol-drug and multiple drugs by gender 
 
Distribution of core substance categories by day of the week and time of the day are presented in 
Table 13.14 and Figures 13.6 and 13.7. With the exception of medicinal opioids, all substance groups 
showed a higher prevalence at night-time (22:00 to 3:59), being alcohol (9.00%), cocaine (0.37%), 
THC (3.25%) and illicit opiates (0.37%) more prevalent on weekend nights and benzodiazepines 
(4.58%), alcohol-drugs (0.51%) and multiple drugs (0.53%), on week nights. The prevalence of alcohol 
on weekend nights (9.00%) is about three times higher than on the week nights (3.06%), being the 
prevalence during the daytime (4:00 to 21:59) similar on week (5.08%) and weekend (4.24%) (Figures 
13.6 and 13.7). 
The prevalence of THC on weekend (3.25%) and week (2.4%) night-time was higher than during 
daytime (Figures 13.6 and 13.7). 
Benzodiazepines have a similar prevalence at daytime during the week (2.73%) and weekend 
(2.71%), being the prevalence on week nights (4.58%) 3.4 times greater than on weekend nights 
(1.56%) (Figures 13.6 and 13.7). 
The prevalence of drivers with alcohol-drugs and multiple drugs was greater at night-time than during 
day time. In cases of multiple drugs, the prevalence at night-time was more than double than during 
the daytime (Figures 13.6 and 13.7). 
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Table 13.14. Adjusted distribution of core substance categories by day of the week and time of the  
                 day (n=3965) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnights 
22:00 – 03:59 
In total 
Substance 
category 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Negative 89.84 
88.68 – 90.88 
88.90 
79.69 – 94.24 
91.11 
89.09 – 92.80 
84.52 
74.66 – 91.01 
90.01 
89.04 – 90.91 
Alcohol 5.08  
4.34 – 5.94 
3.06 
0.90 – 9.90 
4.24 
3.11 – 5.76 
9.00 
4.37 – 17.64 
4.93 
4.29 – 5.64 
Amphetamine ---- ---- ---- ---- ---- 
Cocaine 0.00 
0.00 – 0.13 
0.00 
0.00 – 4.98 
0.12 
0.02 – 0.64 
0.37 
0.02 – 5.56 
0.03 
0.01 – 0.16 
THC 1.44 
1.07 – 1.94 
2.42 
0.62 – 8.96 
0.96 
0.50 – 1.84 
3.25 
1.00 – 10.08 
1.38 
1.07 – 1.80 
Illicit opiates 0.15 
0.06 – 0.38 
0.00 
0.00 – 4.98 
0.14 
0.03 -0.68 
0.37 
0.02 – 5.56 
0.15 
0.07 -0.33 
Benzodiazepin
es 
2.73 
2.19 – 3.38 
4.58 
1.66 – 12.02 
2.71 
1.84 – 3.99 
1.56 
0.31 – 7.54 
2.73 
2.27 – 3.29 
Z-drugs --- --- --- --- --- 
Medicinal 
opioids 
0.08 
0.03 – 0.27 
0.00 
0.00 – 4.98 
0.20 
0.05 – 0.77 
0.00 
0.00 – 4.89 
0.11 
0.04 – 0.27 
Alcohol – drugs 0.45 
0.26 -0.76 
0.51 
0.04 – 5.90 
0.31 
0.10 – 0.94 
0.50 
0.04 – 5.80 
0.42 
0.26 – 0.67 
Multiple drugs 0.23 
0.11 – 0.49 
0.53 
0.05 – 5.95 
0.19 
0.05 – 0.74 
0.43 
0.03 – 5.67 
0.23 
0.12 – 0.44 
 
 
 
 
Figure 13.6. Adjusted distribution of core substance categories by daytime (4:00 – 21:59) 
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Figure 13.7. Adjusted distribution of core substance categories by night-time (22:00 – 3:59) 
 
Table 13.15 shows the distribution of alcohol positive cases (≥ 0.1 g/l) by level of blood alcohol 
concentration (BAC). Only 1.22% of positive cases showed a value of BAC at or above the legal limit 
(0.5 g/l). In male drivers, the prevalence rate of BAC at or above de legal limit (1.53%) was more than 
double than that in women (0.65%) (Table 13.16 and Figure 13.8). 
 
Table 13.15. Adjusted general distribution of alcohol by concentration class (n=3965) 
Alcohol alone Prevalence (%) 95% Confidence interval  
Alcohol 0.1 – 0.49 g/l 3.71 3.17 – 4.35 
Alcohol 0.5 – 0.79 g/l 0.44 0.27 – 0.69 
Alcohol 0.8 – 1.19 g/l 0.47 0.30 – 0.74 
Alcohol 1.2+ 0.31 0.18 – 0.53 
In total 4.93 4.29 – 5.64 
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Table 13.16. Adjusted distribution of alcohol alone by gender and age (n=3912) 
Male 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
 0.1 – 0.49 g/l 8.39 
5.81 – 11.97 
4.06 
2.83 – 5.79 
4.41 
3.20 – 6.04 
4.01 
2.79 – 5.72 
4.69 
3.93 – 5.57 
 0.5 – 0.79 g/l 0.66 
0.18 – 2.31 
0.78 
0.35 – 1.75 
1.10 
0.58 – 2.07 
0.01 
0.00 – 0.56 
0.65 
0.40 – 1.04 
 0.8 – 1.19 g/l 0.33 
0.06 – 1.80 
0.18 
0.04 – 0.87 
0.66 
0.29 – 1.50 
0.46 
0.16 – 1.29 
0.43 
0.24 – 0.76 
1.2+ 0.38 
0.08 – 1.87 
0.96 
0.46 – 2.00 
0.20 
0.05 – 0.82 
--- 0.45 
0.25 – 0.79 
In total 9.76 
6.95 – 13.53 
5.99 
4.47 – 8.00 
6.37 
4.89 – 8.26 
4.47 
3.17 – 6.26 
6.21 
5.34 – 7.21 
Female 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
 0.1 – 0.49 g/l 7.43 
4.60 – 11.79 
0.91 
0.37 – 2.20 
0.25 
0.05 – 1.26 
3.14 
1.38 – 6.97 
1.94 
1.33 – 2.82 
 0.5 – 0.79 g/l --- 0.14 
0.02 -1.03 
--- --- 0.05 
0.01 – 0.37 
 0.8 – 1.19 g/l 0.57 
0.11 – 2.79 
1.28 
0.60 – 2.72 
0.04 
0.00 – 0.89 
--- 0.56 
0.28 – 1.12 
1.2+ --- 0.12 
0.01 -0.99 
--- --- 0.04 
0.00 – 0.36 
In total 8.00 
5.05 – 12.46 
2.44 
1.40 – 4.22 
0.29 
0.06 – 1.33 
3.14 
1.38 – 6.97 
2.59 
1.88 – 3.58 
Total 
Age group 18-24 25-34 35-49 50+ In total 
Alcohol alone Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
 0.1 – 0.49 g/l 7.93 
5.93 – 10.54 
2.74 
1.96 – 3.83 
2.89 
2.11 – 3.96 
3.84 
2.75 – 5.33 
3.71 
3.17 -4.35 
 0.5 – 0.79 g/l 0.39 
0.11 – 1.38 
0.51 
0.24 – 1.10 
0.70 
0.37 – 1.32 
0.01 
0.00 – 0.45 
0.44 
0.27 – 0.69 
 0.8 – 1.19 g/l 0.42 
0.12 – 1.43 
0.63 
0.32 – 1.26 
0.44 
0.20 – 0.97 
0.37 
0.13 – 1.04 
0.47 
0.30 – 0.74 
1.2+ 0.22 
0.04 – 1.12 
0.61 
0.30 – 1.23 
0.13 
0.03 – 0.52 
--- 0.31 
0.18 – 0.53 
In total 8.97 
6.83 – 11.70 
4.50 
3.46 – 5.82 
4.16 
3.19 – 5.39 
4.21 
3.07 – 5.75 
4.93 
4.29 – 5.64 
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Figure 13.8. Adjusted distribution of alcohol alone by BAC and gender 
 
According to the Portuguese Penal Code, a BAC value ≥ 1.2 g/l is considered a criminal offense. Only 
0.31% of drivers showed BAC ≥ 1.2 g/l. Among male drivers the prevalence of cases (0.45%) with 
BAC at or above criminal offense is about 10 times more than that seen in women (Table 13.16 and 
Figure 13.9). 
 
 
 
 
Figure 13.9. Adjusted distribution of alcohol alone by BAC and gender 
 
The highest prevalence of drivers with BAC ≥ 0.5 g/l was observed at weekend nights (1.74%). It was 
also in this time period that there was a higher prevalence of cases with a BAC value exceeding 1.2 g/l 
(1.17%) (Table 13.17 and Figure 13.10. Only 0.34% of drivers had values above ≥ 0.5 g/l on week 
nights. During the daytime the prevalence of cases with a value at or above 0.5 g/l was identical in 
week (1.27%) and weekend (1.03%) (table 13.17). 
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Table 13.17. Adjusted distribution of alcohol alone by day of the week and time of the day (n=3965) 
Period 
of the week 
Weekdays 
04:00 – 21:59 
Weeknights 
22:00 – 03:59 
Weekenddays 
04:00 – 21:59 
Weekendnight
s 
22:00 – 03:59 
In total 
Alcohol alone Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
Prevalence (%) 
95% C.I. 
 0.1 – 0.49 g/l 3.80 
3.17 – 4.56 
2.71 
0.74 – 9.39 
3.21 
2.25 – 4.57 
7.26 
3.24 – 15.45 
3.71 
3.17 – 4.35 
 0.5 – 0.79 g/l 0.48 
0.29 – 0.81 
0.34 
0.02  - 5.62 
0.29 
0.09 – 0.90 
0.50 
0.04 – 5.80 
0.44 
0.27- 0.69 
 0.8 – 1.19 g/l 0.48 
0.29 – 0.81 
--- 0.50 
0.21 – 1.22 
0.07 
0.00 – 5.01 
0.47 
0.30 – 0.74 
1.2+ 0.31 
0.16 – 0.59 
. 
--- 
0.24 
0.07 – 0.83 
1.17 
0.19 – 6.93 
0.31 
0.18 – 0.53 
In total 5.08 
4.34 – 5.94 
3.06 
0.90 – 9.90 
4.24 
3.11 – 5.76 
9.00 
4.37 – 17.64 
4.93 
4.29 – 5.64 
 
 
 
Figure 13.10. Adjusted distribution of alcohol alone by day of the week and time of the day 
 
13.5 Discussion 
 
13.5.1 Representativeness 
A comparative analysis of volunteer drivers with the whole Portuguese driving population is difficult as 
there are no previous studies available with aggregated data in accordance to the criteria used in this 
study. Nevertheless, a comparison between the distribution of the survey sample according to the 
eight DRUID time periods and the distribution of the driving population shows a good 
representativeness. Also the distributions of drivers by gender and by age group are identical to the 
official data regarding gender and age group of drivers in Portugal in 2006 [2].  
 
13.5.2 Effects of non-response 
The size of non response is so small (3%) that the effect of eventual non-response bias would be very 
small.  
 
13.5.3 Highlights 
This study was very important because it allowed, for the first time, to obtain relevant information 
about the situation in Portugal regarding prevalence of driving under the influence of alcohol and 
psychotropic substances among drivers not involved in accidents. The strong points of the designed 
study are the geographical distribution of road sites to ensure representativeness, the random 
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selection of drivers, the stratification in different time periods (month, days, and time of the day), the 
quality assurance of the analytical method used, the use of weights based on traffic volume and the 
comparability of the results between different European countries. 
 
It should be emphasized that this is a study addressed to prevalence and risk estimation, so the final 
established cut-offs reflect this objectives. Considering that the limit of detection (LOD) of the 
analytical method used for the core substances in oral fluid is lower than the concentration DRUID cut-
off (See Annex - Table 2), the prevalence of consumption among the Portuguese driver population is 
underestimate. Although the presence of a substance in oral fluid does not necessarily imply that the 
driver’s ability to operate a vehicle was impaired, it is important to our understanding of drugs and 
driving to know the extent of the use of certain drugs among driving population. To consume 
substances that have a potential detrimental impact on driving skills, is a risk of adverse 
consequences to themselves and other road users. 
 
In this study, analyses of the oral fluid were conducted to identify and quantify the twenty three core 
substances established in Deliverable 2.1.2. For the presentation of the results the substances were 
aggregated in ten categories: alcohol, amphetamines, cocaine, THC, illicit opiates, benzodiazepines, 
z-drugs, medicinal opiates and alcohol-drug and drug-drug combinations. 
 
The criteria used in selecting the geographical areas and the low refusal rate (3%) allow this study to 
be representative of the Portuguese drivers population. The refusal rate is lower than observed in 
other studies with random selection of voluntary drivers [3-5].  
 
Of the 3965 drivers included in the study, 30.8% were female. In fact  the number of female with 
driving licenses in Portugal is less than male [2]. The most prevalent age groups of the drivers tested 
were 25-34 and 35-49. This could be explain by the fact that the municipalities included in this study 
are part of large metropolitan areas where most of the active population lives. 
 
In overall drivers, the presence of at least one psychoactive substance was found in 10% of the 
drivers. Alcohol alone, benzodiazepines and THC, were the substances more time detected among 
drivers. With the exception of medicinal opioids, all substances showed a higher prevalence at night-
time (22:00 - 3:59), being alcohol, cocaine, THC and illicit opiates more prevalent on weekend, and 
benzodiazepines, alcohol-drugs and multiple drugs more prevalent during the week.  
 
Alcohol was the most prevalent substance among drivers with an occurrence of 4,93% alone and 
0,42% in association with drugs. About a quarter of drivers with alcohol alone had a BAC value at or 
above the legal limit (0.5 g/l) with special incidence on weekend nights. Alcohol prevalence with BAC 
over the legal limit in male was more than two times higher than in female. In both groups, male and 
female drivers, the higher prevalence of alcohol was observed among young drivers (18-24 years). A 
similar prevalence distribution by gender, age and time period was observed in equivalent studies [3,5-
8]. 
 
The most prevalent illicit drug was the THC alone (1.38%) with greater occurrence among male 
(2.08%) than female drivers (0.10%), especially in 18-24 and 25-34 age groups. THC was present in 
72% of the cases with alcohol-drug combination (results not shown).  
Cocaine or its metabolite (benzoylecgonine) was the illicit drug more detected after THC, mainly 
among multiple drug cases. The presence of cocaine was detected in 50% of those cases (results not 
shown). 
6-Acetylmorphine was detected in all cases of illicit opiates, 50% of witch in drug-drug combination 
(results not shown). The results demonstrate the importance of oral fluid for screening these substances 
among drivers, especially because 6-acetylmorphine is considered a definitive evidence of heroin use 
[9]. 
Depending if the study is performed among drivers selected randomly or among drivers suspected of 
driving under the influence of drugs, the prevalence of illicit drugs could be different. In our study 
prevalence of illicit drugs alone was lower (1.48%) than observed in equivalent studies [4,6,10-11] and 
higher than verified among Norwegian drivers [3]. The differences of prevalence observed could be 
partially explained by different cultural, social and legal issues.  
The prevalence of illicit drugs among drivers was higher in night time and weekend. THC in night time 
was always higher than in day time, whatever the day (week or weekend). Identical observation was 
registered by other authors [5-6]. 
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Benzodiazepines were the most prevalent substance after alcohol with an occurrence of 2.73%. The 
prevalence of these medicinal drugs was more common among older drivers (50+), especially among 
female with an occurrence above 10%, three times higher than in male. Our distribution by age and 
gender is consistent with other studies which also refer the use of benzodiazepines associated to older 
age groups and female population [6]. The prevalence of benzodiazepines in weekend nights (1.56%) 
was 3.4 times lower than during week nights (4.58%) and about half of the prevalence of 
benzodiazepines registered during day time period on week (2.73%) and weekend (2.71%) (Figures 
13.6 and 13.7). Similar distribution of prevalence by gender and time period was observed in other 
studies [6,12]. Nordiazepam, alprazolam and lorazepam were the substances more commonly 
detected in our study. Nordiazepam, the main active metabolite of diazepam, is a long action 
benzodiazepine with a t ½ > 24h while alprazolam and lorazepam are classified as intermediate action 
drugs with a t ½ 6-24h [13]. The presence of alprazolam and lorazepam is consistent with the 
Portuguese statistics of medicine use of the National Authority of Medicines and Health Products 
(INFARMED I.P.). The statistics show the psychodrugs as the second pharmacotherapeutic subgroup 
with more sales, and alprazolam and lorazepam as the 5th and 8th active substances with more sales 
in the Portuguese National Health Service in 2008 [14]. 
Methadone is a synthetic analgesic prescribed for the relief of moderate to severe pain, and used in 
detoxification treatment of opioid dependence and maintenance in narcotic addiction. This substance 
may impair mental and/or physical abilities required for the performance of potentially hazardous 
tasks, and its sedative effects may be enhanced by concurrent use of other CNS depressants, 
including alcohol. Methadone was present in 80% of the drivers that tested positive for medicinal 
opiates, and no association with other drugs was detected (results not shown).  
 
The evidence of this survey, based on a random sampling mechanism that allocates equal 
probabilities for selection to drink drivers and non-drinking, would be different if data had been based 
on the results of the usual enforcement actions. These actions are usually focused on road sites and 
time periods, whose probability of selection drinking drivers are higher than non-drinking. For this 
reason the information provided by this study is of particular relevance for planning drug-driving 
prevention and enforcement activities in the future.  
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Annex 13.1 - Toxicological Analysis of Oral Fluid Samples 
 
1. Sample preparation 
The samples were prepared by liquid-liquid extraction using Toxitubes®A. To a 5ml tube 0.6ml of 0.2 
mol/l ammonium carbonate buffer pH 9.3, 0.6ml of preserved oral fluid and 30 µl of the internal 
standard working solution were added. The samples were transferred to the Toxitubes®A and gently 
mixed for 25 min. After centrifugation at 3500 rpm for 15 min, the organic phase was transferred to 
glass conical tubes and evaporated to dryness at 30°C under a stream of nitrogen. The dried extract 
was reconstituted in 50 µl of methanol/water (1:1, v/v), transferred to a vial and analyzed by LC-
MS/MS. 
 
2. LC-MS/MS parameters 
A Waters Alliance 2795 separation module with a Waters Alliance series column heater (Waters, 
Milford, MA, USA) high-performance liquid chromatography (HPLC) system was used. The 
chromatographic separation was performed by a Waters Atlantis T3 (100x2.1mm, 3µm) column at 
35°C using gradient elution with acetonitrile/2mM ammonium formate buffer pH3.4 (95:5, v/v) (A) and 
2mM ammonium formate buffer pH3.4/acetonitrile (95:5, v/v) (B) at a flow rate of 0.3ml/min. The 
gradient was programmed as follows: 10% A for 0.1 min, linearly increased to 55% A in 1.9 min and to 
95% A in 5min, isocratic for 6min followed by a decrease to the initial conditions in 0.1min and 
equilibration time for 4.9min, which resulted in a total run time of 18min. An injection volume of 10µl 
was used. 
The HPLC system was combined with a Quattro Micro™ API ESCi triple quadrupole mass 
spectrometer (Micromass, Waters) fitted with a Z-spray ion interface. The equipment was operated in 
positive electrospray ionization (ESI+) mode and in the multiple reaction monitoring (MRM) mode. The 
source parameters were: capillary voltage, 3.0kV; source block temperature, 120°C; desolvation gas 
(nitrogen) heated to 450°C and delivered at a flow rate of 600L/h; no cone gas was used. The 
appropriate MRM transitions, cone voltages and collision energies for the individual analytes and 
internal standards were determined by direct infusion into the mass spectrometer. Collision gas 
(argon) pressure was maintained at 3.5x10-3mbar, the collision energy optimized and the two most 
abundant product ions from each substance were subsequently used for the MRM analysis. The MRM 
transitions with corresponding cone voltage, collision energy and retention time of the analytes and 
internal standards are presented in Table 1. 
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Table 1. MRM transitions, cone voltage, collision energy (Coll) and retention time (RT) of the analytes and 
internal standards (IS) 
 
Compound Transitions (m/z) Cone 
(V) 
Coll 
(eV) 
RT 
(min) 
IS 
Morphine-d3 289.3>201.3 35 25 1.4  
Morphine 286.2>201.2/165.2 35 25/35 1.4 Morphine-d3 
Codeine-d3 303.3>215.3 35 25 2.0  
Codeine 300.2>215.2/165.2 35 25/35 2.1 Codeine-d3 
Amphetamine-d6 142.1>125.1 15 8 2.6  
Amphetamine 136.0>90.8/119.0 15 12/8 2.7 Amphetamine-d6 
6-Acetylmorphine 328.2>165.2/211.3 35 35/25 2.8 Morphine-d3 
MDA 180.2>163.2/104.9 15 10/20 2.9 Methamphetamine-
d9 
Methamphetamine-d9 159.2>125.1 20 11 3.1  
Methamphetamine 150.1>90.8/119.0 15 15/10 3.1 Methamphetamine-
d9 
MDMA-d5 199.3>165.2 15 13 3.2  
MDMA 194.2>163.2/133.1 15 12/18 3.2 MDMA-d5 
MDEA-d5 213.4>163.2 20 13 3.5  
MDEA 208.2>163.2/133.1 15 12/18 3.5 MDEA-d5 
Benzoylecgonine-d3 293.3>171.2 25 18 3.6  
Benzoylecgonine 290.2>168.2/104.9 25 19/25 3.6 Benzoylecgonine-d3 
Zopiclone 389.1>245.2/345.2 15 14/18 3.7 Nordiazepam-d5 
Tramadol 264.3>264.4/57.5 15 5/14 3.8 Nordiazepam-d5 
Cocaine 304.2>182.3/81.8 25 19/26 3.9 Nordiazepam-d5 
Zolpidem 308.3>235.4/263.3 35 30/25 4.0 Nordiazepam-d5 
7-Aminoflunitrazepam 284.2>135.2/227.3 30 26/24 4.1 Nordiazepam-d5 
Amitriptyline 278.3>105.0/117.1 25 22/22 4.6 Nordiazepam-d5 
Methadone 310.3>265.4/105.0 20 14/26 4.7 Nordiazepam-d5 
Oxazepam 287.2>241.3/269.3 20 22/14 5.0 Nordiazepam-d5 
Alprazolam 309.2>205.3/281.3 35 40/26 5.0 Nordiazepam-d5 
Lorazepam 321.1>275.2/303.2 25 20/15 5.0 Nordiazepam-d5 
Clonazepam 316.1>270.3/214.3 35 26/34 5.1 Nordiazepam-d5 
Nordiazepam-d5 276.2>213.3 35 26 5.4  
Nordiazepam 271.2>140.1/165.1 35 30/30 5.4 Nordiazepam-d5 
Flunitrazepam 314.2>268.3/239.3 35 25/30 5.4 Nordiazepam-d5 
Diazepam 285.2>193.2/154.2 35 30/25 6.0 Nordiazepam-d5 
THC-d3 318.3>196.3 25 22 10.1  
THC 315.3>193.3/135.2 25 22/22 10.1 THC-d3 
 
 
 
 
 
3. Validation 
The method was fully validated in terms of specificity and capacity of identification, limit of detection 
and quantification, recovery, carryover, linearity, intra-assay precision and inter-assay accuracy and 
precision. Method validation data are summarized in Tables 2 and 3. 
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Table 2. Method validation data (limit of detection, limit of quantification, recovery and linearity) 
 
 LOQ test Recovery Linearity 
1 µg/l 5 µg/l   Intercept 
Interval 
Compound LOD (µg/l) 
LOQ 
(µg/l) 
CV 
(%) 
E 
(%) 
CV 
(%) 
E 
(%) 
20 
µg/l 
200 
µg/l R
2 Inf. 
95% 
Sup. 
95% 
Morphine 0.4 1.2 1.8 2.6 6.4 1.7 82 90 0.9987 -
0.0191 
0.05
41 
Codeine 0.4 1.4 5.1 10.
4 
4.0 2.4 84 90 0.9996 -
0.0144 
0.02
55 
Amphetamine 0.2 0.8 10.2 7.8 5.0 1.6 84 91 0.9986 -
0.0111 
0.04
80 
6-Acetylmorphine 0.5 1.4 11.2 2.6 3.9 3.7 79 86 0.9987 -
0.2910 
0.02
71 
MDA 0.5 1.6 6.3 3.0 3.6 5.0 82 83 0.9997 -
0.0341 
0.00
04 
Methamphetamin
e 
0.5 1.5 5.5 13.
4 
5.4 3.4 87 90 0.9987 -
0.0290 
0.03
58 
MDMA 1.2 3.7 5.2 10.
4 
4.2 2.3 78 75 0.9986 -
0.0077 
0.04
25 
Benzoylecgonine 0.9 2.6 4.2 8.0 7.7 11.7 34 34 0.9944 -
0.0851 
0.04
18 
MDEA 0.6 1.9 6.2 5.6 5.2 3.1 84 69 0.9948 -
0.0401 
0.10
76 
Zopiclone 1.4 4.1 19.7 5.2 18.
0 
13.4 65 88 0.9907 -
0.0286 
0.03
00 
Tramadol 0.4 1.3 14.8 8.4 5.4 14.7 76 54 0.9988 -
0.0281 
0.14
97 
Cocaine 0.5 1.6 8.7 5.4 2.7 10.2 75 95 0.9985 -
0.0729 
0.07
49 
Zolpidem 0.4 1.2 5.2 14.
4 
13.
0 
16.4 80 87 0.9955 -
0.0321 
0.13
14 
7-
Aminoflunitrazepa
m 
0.6 1.7 6.7 10.
6 
4.7 1.4 87 94 0.9995 -
0.0689 
0.01
84 
Amitriptyline 0.6 1.8 14.6 13.
0 
6.1 15.4 56 70 0.9958 -
0.0344 
0.30
50 
Methadone 0.4 1.4 14.7 0.2 7.8 13.5 69 77 0.9969 -
0.1370 
0.60
56 
Oxazepam 0.5 1.5 6.8 3.6 9.7 10.9 87 82 0.9986 -
0.0101 
0.07
44 
Alprazolam 0.3 1.0 9.9 10.
6 
6.1 0.5 87 98 0.9956 -
0.0308 
0.20
94 
Lorazepam 0.4 1.2 12.0 6.0 6.1 0.5 86 90 0.9993 -
0.0068 
0.04
42 
Clonazepam 0.3 0.8 8.4 14.
0 
4.2 8.0 87 88 0.9980 -
0.0101 
0.07
88 
Nordiazepam 0.4 1.2 4.9 13.
6 
4.1 0.7 84 91 0.9942 -
0.0504 
0.12
50 
Flunitrazepam 0.3 1.0 9.4 0.6 6.6 10.4 82 87 0.9938 -
0.0741 
0.17
48 
Diazepam 0.4 1.2 8.4 0.2 6.6 8.8 78 86 0.9959 -
0.0068 
0.30
04 
THC 0.4 1.1 9.3 0.8 2.6 8.6 40 47 0.9979 -
0.0242 
0.03
36 
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Table 3. Method validation data (intra-assay precision and inter-assay precision and  
accuracy (expressed as the bias)) 
 
 Intra-assay (CV 
%) 
Inter-assay 
A/API Precision (CV %) Bias (%) 
Compound 20 µg/l 100 µ/L 5 µg/l 50 µg/l 150 µ/L 5 µg/l 50 µg/l 150µ/L 
Morphine 4.5 7.4 12.1 5.8 9.0 2.3 4.7 6.7 
Codeine 1.7 6.0 18.4 6.5 6.6 -0.9 2.6 4.5 
Amphetamine 4.9 7.7 12.1 5.4 4.4 -6.7 4.6 2.3 
6-Acetylmorphine 5.5 6.3 15.8 5.2 3.2 -13.3 -2.5 -2.4 
MDA 5.9 9.8 12.2 9.0 11.2 -2.4 7.8 5.0 
Methamphetamine 7.4 5.7 17.0 8.4 9.4 3.1 -0.4 -2.1 
MDMA 3.8 6.5 11.2 10.3 7.7 4.1 4.9 5.1 
Benzoylecgonine 7.8 8.5 19.4 17.9 11.3 0.1 -0.2 1.1 
MDEA 14.2 7.1 14.1 10.3 10.0 4.1 1.5 -3.8 
Zopiclone 8.8 8.8 _ _ _ _ _ _ 
Tramadol 19.9 5.8 17.1 12.5 13.2 -1.7 -4.9 -1.0 
Cocaine 8.9 5.8 16.5 9.7 7.4 -0.9 -6.3 -1.9 
Zolpidem 7.4 5.1 13.1 9.2 7.7 -0.5 -1.9 -0.7 
7-Aminoflunitrazepam 7.1 6.4 16.4 8.2 9.5 -6.3 1.1 -8.2 
Amitriptyline 11.6 9.8 17.2 14.1 13.7 -2.5 0.4 -4.7 
Methadone 15.0 7.6 12.5 8.8 10.7 -7.3 8.4 -5.7 
Oxazepam 14.0 6.3 11.2 14.9 11.3 9.6 4.0 2.0 
Alprazolam 15.3 9.9 14.2 12.6 10.5 -9.1 7.4 -1.9 
Lorazepam 5.3 5.7 13.6 5.5 5.3 -11.1 -1.0 -1.0 
Clonazepam 5.7 4.4 12.0 6.2 7.4 -10.1 5.4 3.2 
Nordiazepam 8.5 9.2 8.5 9.3 5.9 2.9 2.0 2.9 
Flunitrazepam 8.6 6.2 13.8 9.5 8.7 -9.3 3.3 -2.3 
Diazepam 6.7 5.1 11.5 9.8 8.9 -1.3 7.6 -4.9 
THC 3.0 6.7 9.1 5.0 6.5 -4.5 -2.8 0.0 
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14 Country Report Sweden 
 
Authors: Åsa Forsman1, Robert Kronstrand², Gunnel Ceder², Linda Renner1, Magnus Hjälmdahl1. 
 
1 The Swedish National Road and Transport Research Institute (VTI) 
² The National Board of Forensic Medicine (RMV) 
 
14.1 Description of the roadside driver sample 
The Swedish roadside driver sample was collected during one year, from March 2008 to February 
2009. In all, 6372 drivers provided saliva samples. The survey design described below is a 
compromise between the DRUID recommended design (see Annex 1 of the Summary Report) and 
practical considerations. A main deviation from the recommended design is that only one geographic 
region is included in the study, the results may therefore not be representative for the whole country. 
The reason for this limitation is that Sweden is divided in 21 counties and each county is a separate 
police authority. It was not practically possible to include more than a few authorities and we finally 
choose three counties in which we have had previous collaboration with the police. These counties 
were Södermanland, Örebro, and Östergötland, situated in the mid-south of Sweden (see map in 
figure 14.1). We have no reason to believe that the use of drugs and medicines differ to any large 
extent between the three counties so the whole area is regarded as one region. 
 
 
Figure 14.1. The study region in Sweden 
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Another deviation is that drivers positive for alcohol (over 0.2 g/l) was excluded from the study. The 
procedure at the test sits was that the police first conducted a breath test and if the screening 
instrument showed a positive result, the driver were taken care of by the police and were not asked to 
participate in the study. 
 
Moreover, we did not collect all the recommended information about the refusers, such as gender, age 
and reason for refusal. However, we have information of the general age and gender distribution 
among the drivers in the study area from a previous study that can be used for comparison (Forsman 
et al., 2007). 
 
Within each county, 12-15 test sites on rural roads and 5 test sites on urban roads where selected. 
The sites were located along the major roads (motorways excluded) in order to ensure an effective 
sampling also during hours with low traffic flow. The police chose test sites that were large enough to 
accommodate the setup with both the police and the research staff with equipment. Moreover, the test 
sites were spread out over the whole county.  
 
Only drivers of personal cars and vans were included in the study. The tables below include all drivers 
who provided a saliva sample and were 18 years of age or older. 
 
The distribution between rural and urban road types was chosen to resemble the real distribution of 
traffic which is approximately 78% on rural roads and 22% on urban roads in the study region 
(Björketun and Eriksson, 2001). In the actual sample, two thirds came from rural roads and one third 
from urban roads (Table 14.1). 
 
Table 14.1. Distribution of drivers by road type 
Road type Distribution of 
sample 
Rural 67% 
Urban 33% 
 
The distribution of drivers by the quarter is shown in table 14.2. In our study design, the number of 
collected samples was spread out evenly between seasons. However, the seasons did not coincide 
with quarters and therefore the number of samples differs between the quarters.  
 
Table 14.2. Distribution of drivers by the quarter 
Season Distribution 
of sample  
Quarter 1 (Jan-Mar)  29% 
Quarter 2 (Apr-Jun) 32% 
Quarter 3 (Jul-Sep) 24% 
Quarter 4 (Oct-Dec) 15% 
 
The sampling scheme regarding time of the day and time of the week were worked out to fit 
requirements of the police. As a consequence, the data collection was concentrated to day time. 
Almost half of the samples were collected during 10-16 on weekdays (table 14.3). In comparison with 
actual traffic distribution, the number of sampled drivers was overrepresented during daytime and 
underrepresented during mornings and evenings in weekdays and evenings in weekends. Only slight 
deviations are found in the other periods. Also, the time periods have been fully covered, there were 
no systematic periods missing within the eight specified time periods. 
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Table 14.3. Distribution of drivers by time period 
Time period Distribution 
of sample 
1: Weekday 04-10 6% 
2: Weekday 10-16 49% 
3: Weekday 16-22 9% 
4: Weekday 22-04 4% 
5: Weekend 04-10 5% 
6: Weekend 10-16 22% 
7: Weekend 16-22 3% 
8: Weekend 22-04 2% 
 
 
At the sampling site, cars where stopped at random with no respect to the age or gender of the driver. 
Thus, the drivers stopped by the police should be representative of the driver population at the specific 
places and times. However, the distribution could be affected by non-response which will be discussed 
in chapter 3. The sampled distribution is shown in 14.4. 
 
Table 14.4. Distribution of drivers by age category and gender 
Age category Males Females All 
18-24 years   4%   2%   7% 
25-34 years   9%   5% 13% 
35-49 years 20% 10% 30% 
50- years 37% 13% 50% 
All ages 70% 30% 100% 
 
14.2 Roadside data collection and analysis 
The collection of data at the test sites was done in collaboration between the police and a team of civil 
test leaders. The civil team was recruited among students at the University of Linköping. At the test 
site, which typically was a parking space alongside the road, the police and the test team was parted 
by a certain distance. The reason for this was to protect the integrity of drivers that may be positive for 
alcohol in the police control and also to make sure that the drivers didn’t feel pressured by the police to 
participate in the study.  
 
The procedure at the test site was as follows: 
 
1.1. When there was free capacity at the test site, the police stopped the next possible driver 
and conducted a breath test. 
1.2. If the test was negative, the police informed the driver that VTI was performing a research 
study and that participation was voluntary and anonymous. 
1.3. If the driver wanted to participate, he or she drove a short distance to the test team. If they 
didn’t want to participate they simply drove pass the team. 
1.4. The team informed the driver about the study and asked for a saliva sample. The driver 
was informed again that participation was voluntary and anonymous. 
1.5. If the breath test was positive for alcohol, the driver was taken care of by the police, and 
was not asked to participate in the research study. 
 
The collection of data was organised in blocks, with three sampling sessions in each block. All test 
sites within a block were visited in a sequence and within the same time period. Only drivers of 
personal cars and vans were included. 
 
Participation in the study was completely anonymous. Afterwards, we could not trace the drivers who 
provided saliva samples.  
 
The study was approved by the Regional Ethical Review Board in Linköping. 
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14.2.1 Substances 
 
The substances included in the study and their classification are shown in table 14.5. Note that the 
groups are mutually exclusive, that is, a driver could only be included in one of the groups. For 
example, if Zoldipem is the only substance found in a driver, he or she will be included in the group of 
Z-drugs. However, if both Zoldipem and Morphine are found, he or she will be included in the multiple 
drugs group. 
 
As mentioned in the description of the roadside driver sample, drivers positive for alcohol in the breath 
test were excluded from the study. Therefore, Ethanol was not included in the analysis of the saliva 
samples. However, the screening instrument is set on 0.2 g/l (the legal limit in Sweden) and therefore, 
there might be drivers with a blood alcohol concentration below 0.2 g/l in the data set. 
Table 14.5. Classification of substances 
Type Group Analyticalfindings 
Alcohol* Alcohol Ethanol 
Illicit Amphetamines Amphetamine 
Drugs   methamphetamine or methamphetamine + amphetamine 
    MDMA or (MDMA + MDA) 
    MDEA or (MDEA + MDA) 
    MDA 
  Cocaine benzoylecgonine or (cocaine + benzoylecgonine) or cocaine  
  THCCOOH** THCCOOH 
  THC THC or THC+THCCOOH 
  illicitopiates 
6-acetylmorphine or 6-AM + codeine or 6-AM + morphine or 6-
AM + codeine + morphine or (morphine + codeine and 
morphine>= codeine) 
Medicinal benzodiazepines 
diazepam or (diazepam + nordiazepam) or (diaz + oxaz) or (diaz 
+ nordiaz + oxaz) 
Drugs   nordiaz or (nordiaz + oxaz) 
    Oxazepam 
    Lorazepam 
    Alprazolam 
    flunitrazepam or (flunitrazepam + 7-aminoflunitrazepam) 
    clonazepam or (clonazepam + 7-aminoclonazepam) 
  Z-drugs Zolpidem 
    Zopiclone 
  medicinal  Morphine 
  Opioids codeine or(codeine + morphine and codeine> morphine) 
    Methadone 
    Tramadol 
Various alcohol-drugs* all combinations except (ethanol+THCCOOH) 
combinations multipledrugs all combinations except(drug+THCCOOH) 
*Not included in the Swedish study. 
** Not analysed in saliva. 
 
14.2.2 Toxicological analysis 
 
The toxicological analysis was made at the forensic toxicology laboratory at the National Board of 
Forensic Medicine. 
 
The saliva samples were collected with the Statsure device. The analytical method is based on UPLC-
MS/MS and includes the DRUID core substances and some additional drugs and metabolites 
commonly used in Sweden. In total twenty-nine drugs and metabolites were included. Samples were 
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extracted on a Gilson ASPEC XL-4 robot. Aliquots of 0.4 ml saliva-buffer mixture (from the Statsure 
device) were loaded and extracted on 130 mg Bond Elute Certify columns. A Waters Quattro Premier 
XE tandem-quadruple MS combined with an Acquity UPLC was used for the analysis. High-resolution 
separation was performed by a linear gradient chromatography on a 50x2.1 mm i.d. HSS-T3 UPLC-
column with 1.8 µm particles using mobile phases consisting of 5 mM ammonium acetate buffer, pH 5 
(A) and methanol with 0.05% acetic acid (B). Two MRM-transitions were used for each compound and 
criteria for their relative area intensities were set for positive identification. The most intense transition 
was used for quantification. Nine deuterated internal standards with different chemical properties were 
selected for the quantification. Cut-off levels were set according to the common decision within DRUID 
(see Annex 2 of Summary Report for a list of applied cut-offs). 
 
14.2.3 Questionnaire 
A short questionnaire was filled out for each driver, the collected information was: 
− Gender 
− Age 
− Type of vehicle (personal car or van)  
− If the vehicle was registered in Sweden or not 
− Car ownership (private or supplied by the company) 
 
14.2.4 Statistical analysis 
The weighted prevalence was calculated by using descriptive statistics by means of the statistical 
software SAS version 9.2. Tables have been created by using the "proc freq statement", including a 
statement on the weight factors to be used. The weighted prevalence of the substance under scrutiny 
was calculated by dividing the weighted number of positives for this substance by the weighted total of 
samples. Because lower and upper confidence limits calculated using traditional approximations may 
result in limits outside the (0.1) interval, a more elaborate approximation was used. To the end, the 
Wilson confidence interval formula is used as it is supplied by SAS as one of the available options. 
 
More information on the method can be found in chapter 3 and annex 2 of the general report. 
 
14.3 Non-response 
The response rate at the roadside was 62% (6 372 out of 10 223). Five of these drivers were younger 
than 18 and therefore omitted from the analysis. The drivers could deny participation at two different 
occasions. Firstly after the police control when the police had informed them that VTI conducted a 
research study and secondly when they had been stopped by the research team and received more 
information about the study. Almost all of the non-respondents decided not to participate at the first 
occasion. 
 
We did not collect any information about the non-respondents. However, a similar study was 
conducted in the same three counties a few years ago (Forsman et al., 2007). That study was 
restricted to test for alcohol and therefore the drivers could not deny participation. All data in that study 
was collected by the police. In figure 14.2, the age and gender distribution of the DRUID sample and 
the sample from the previous study (control) is compared. As can be seen, there are no major 
differences between the data. There is a tendency that old drivers are more willing to participate than 
young drivers, but this effect is small. 
 
All drivers stopped by the police were asked to conduct a breath test to screen for alcohol and drivers 
who provided a positive test were not included in the study. In total, 0.18% (18 out of 10223) of the 
drivers tested positive for alcohol (≥ 0.2 g/l).  
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Figure 14.2. Age and gender distribution in the DRUID study (grey bars) and in a previous 
study used for control (black bars). The control study did not include nights so nighttime 
drivers are excluded from the DRUID data.  
 
Apart from the non response at the roadside, 168 of the 6367 saliva samples (2.6%) provided from 
drivers at least 18 years of age could not be analysed because of too little saliva or some other 
problem with the sample. Thus, we have toxicological results for 6199 drivers. 
 
 
14.4 Results 
 
The prevalence of the different substance categories are shown in table 14.6. The prevalence of the 
illicit drugs are very low, 0.07% for amphetamine and 0.03% for THC. Because of the wide confidence 
intervals it is not possible to conclude which is the most prevalent illicit drug. Moreover, there is no 
illicit drug included in the multiple drugs category. 
 
Medicinal drugs are more prevalent than illicit drugs and medicinal opioids is the most prevalent 
category. The most common substance of the medicinal opioids is Tramadol. 
 
Cocaine and illicit opiates were not found at all in the Swedish sample. 
 
Table 14.6. Adjusted general distribution of  substance categories (N=6199) 
Substance category Prevalence (%) Confidence interval (%) 
Negative 98.66 98.34 - 98.92 
Amphetamine 0.07 0.03 - 0.17 
Cocaine - - 
THC 0.03 0.01 - 0.12 
Illicit opiates - - 
Benzodiazepines 0.19 0.11 - 0.33 
Z-drugs 0.31 0.20 - 0.48 
Medicinal opioids 0.63 0.46 - 0.86 
Multiple drugs 0.12 0.06 - 0.25 
 
The prevalence of the different substance categories by gender and age and by time period are shown 
in table 14.7 and table 14.8. These results are highly uncertain due to the low prevalence and a low 
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number of subjects in several subgroups. Therefore, no certain conclusions can be drawn from the 
prevalences in table 14.7 and table 14.8. However, some interesting tendencies are found. 
The total prevalence of illegal and medicinal drugs increase with age category and the highest 
prevalence are found among those 50 years or older. No substance at all was found among the male 
drivers in the age category 18-24. Among the female drivers in the same age category, Tramadol was 
found in one driver resulting in the prevalence 0.39 for medicinal opioids. All illicit drugs were found 
among the male drivers but the prevalence of medicinal drugs was higher among the female drivers. 
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Table 14.7. Adjusted general distribution of substance categories by gender and age(N=6187) 
 Prevalence (%) (Confidence interval, %) 
Substance 
category 
18-24 25-34 35-49 50- Total 
Men N=278 N=541 N=1216 N=2308 N=4343 
Negative 100 99.48 (98.55-98.82) 
99.08 
(98.38–99.47) 
98.17 
(97.50-98.66) 
98.77 
(98.39-99.05) 
Amphetamine 
- 
0.13 
(0.02-0.85) 
0.22 
(0.07-0.67) 
0.03 
(0.00-0.23) 
0.09 
(0.04-0.24) 
Cocaine - - - - - 
THC 
- 
0.21 
(0.05-0.99) 
0.04 
(0.00-0.38) 
- 0.04 
(0.01-0.16) 
Illicit opiates - - - - - 
Benzodiazepines 
- 
0.08 
(0.01-0.76) 
0.30 
(0.12-0.79) 
0.08 
(0.02-0.32) 
0.14 
(0.06-0.30) 
Z-drugs 
- 
- 0.04 
(0.00-0.38) 
0.64 
(0.38-1.08) 
0.32 
(0.19-0.54) 
Medicinal opioids 
- 
0.09 
(0.01–0.77) 
0.28 
(0.10-0.75) 
0.89 
(0.57-1.39) 
0.53 
(0.35-0.79) 
Multiple drugs 
- 
- 0.04 
(0.00-0.38) 
0.20 
(0.08-0.49) 
0.11 
(0.04-0.26) 
Women N=142 N=288 N=632 N=782 N=1844 
Negative 99.61 
(99.72-99.96) 
98.52 
(96.44-99.39) 
99.00 
(97.93-99.52) 
97.50 
(96.06-98.42) 
98.39 
(97.71-98.88) 
Amphetamine - - - - - 
Cocaine - - - - - 
THC - - - - - 
Illicit opiates - - - - - 
Benzodiazepines 
- 
- 0.20 
(0.04-0.91) 
0.63 
(0.25-1.53) 
0.31 
(0.14-0.69) 
Z-drugs 
- 
0.17 
(0.02-1.56) 
0.08 
(0.01-0.71) 
0.55 
(0.21-1.43) 
0.27 
(0.11-0.63) 
Medicinal opioids 0.39 
(0.04-3.28) 
0.53 
(0.13-2.16) 
0.72 
(0.30-1.68) 
1.25 
(0.66-2.38) 
0.87 
(0.53-1.40) 
Multiple drugs 
- 
0.78 
(0.24-2.55) 
- 0.07 
(0.01-0.68) 
0.16 
(0.05-0.47) 
Total N=420 N=829 N=1848 N=3090 N=6187 
Negative 99.88 
(99.00-99.99) 
99.17 
(98.35-99.58) 
99.05 
(98.51-99.40) 
98.00 
(97.42-98.46) 
98.66 
(98.34-98.92) 
Amphetamine 
- 
0.09 
(0.01-0.57) 
0.14 
(0.05-0.43) 
0.02 
(0.00-0.17) 
0.07 
(0.03-0.17) 
Cocaine - - - - - 
THC 
- 
0.14 
(0.03-0.67) 
0.03 
(0.00-0.25) 
- 0.03 
(0.01-0.12) 
Illicit opiates - - - - - 
Benzodiazepines 
- 
0.06 
(0.01-0.51) 
0.27 
(0.12-0.61) 
0.21 
(0.10-0.46) 
0.19 
(0.11-0.33) 
Z-drugs 
- 
0.06 
(0.01-0.51) 
0.06 
(0.01-0.30) 
0.62 
(0.39-0.98) 
0.31 
(0.20-0.48) 
Medicinal opioids 0.12 
(0.01-1.00) 
0.23 
(0.07-0.81) 
0.43 
(0.22-0.83) 
0.98 
(0.68-1.42) 
0.63 
(0.46-0.86) 
Multiple drugs 
- 
0.25 
(0.08-0.84) 
0.03 
(0.00-0.25) 
0.17 
(0.07-0.40) 
0.12 
(0.06-0.25) 
 
Only 127 samples were collected during weekend nights and no substance was found in any of these 
(table 14.8). During weekday nights, 3 out of 225 drivers were found positive for amphetamine, THC 
and zopiclone respectively. 
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The distribution of substance categories is similar for weekdays and weekend days. The largest 
difference is found for Z-drugs were the estimated prevalence is higher during weekdays than during 
weekend days. 
 
Table 14.8. Adjusted general distribution of substance categories by time period (N=6199) 
 Prevalence (%) (Confidence interval, %) 
Substance 
category 
Weekday 
04-22 
(N=4024) 
Weekday 
22-04 
(N=225) 
Weekend 
04-22 
(N=1823) 
Weekend 
22-04 
(N=127) 
Total 
(N=6199) 
Negative 98.56 
(98.17-98.87) 
98.67 
(94.74-99.67) 
98.83 
(98.14-99.26) 
100 98.66 
(98.34-98.92) 
Amphetamine 0.06 
(0.02-0.19) 
0.44 
(0.05-3.82) 
0.06 
(0.01-0.36) 
- 0.07 
(0.03-0.17) 
Cocaine - - - - - 
THC 0.01 
(0.00-0.11) 
0.44 
(0.05-3.82) 
0.06 
(0.01-0.36) 
- 0.03 
(0.01-0.12) 
Illicit opiates - - - - - 
Benzodiazepines 0.19 
(0.10-0.37) 
- 0.21 
(0.07-0.60) 
- 0.19 
(0.11-0.33) 
Z-drugs 0.39 
(0.25-0.62) 
0.44 
(0.05-3.82) 
0.08 
(0.01-0.39) 
- 0.31 
(0.20-0.48) 
Medicinal opioids 0.68 
(0.48-0.97) 
- 0.56 
(0.29-1.08) 
- 0.63 
(0.46-0.86) 
Multiple drugs 0.10 
(0.04-0.24) 
- 0.22 
(0.08-0.61) 
- 0.12 
(0.06-0.25) 
 
 
14.5 Discussion 
 
The study was conducted in a relatively small area of Sweden which includes several medium sized 
cities. Since this is the first study of its kind in Sweden, it is difficult to know if the results are 
representative for other parts of the country. However, we found two studies of drug prevalence in 
general; one is a survey of drug use among young adults (mostly men) signing in for the Swedish 
army (CAN, 2009; table 19) and one is about cannabis use among the general population (age 16-84; 
FHI, 2011). Both studies showed that drug use varied between counties but there were no evidence 
that the DRUID study region differed substantially from other counties, at least not if the counties 
including the big cities Stockholm, Göteborg and Malmö were excluded. 
 
For practical reasons, the data collection outside the cities was conducted on the major roads (except 
motorways). Therefore, the results are not representative for minor rural roads. Moreover, the test 
sites were not selected randomly since there were a limited number of suitable test sites along the 
roads. It is therefore not possible to generalise the results to the entire network of major roads. 
However, the data collection was spread out on relatively many different test sites (42 sites on rural 
roads) and the sites were also spread out over the whole region. Therefore, it is after all reasonable to 
believe that the results fairly well represent the situation on all the major roads in the study region.  
 
The response rate at the roadside was 62%. One explanation for the relatively large non response has 
to do with the set up at the test sites. For integrity reasons, there was a distance between the police 
control and the research team. It was relatively easy to drive off after the police control if the driver 
didn’t want to participate in the study.  
 
When comparing the age and gender distribution with a control sample from a previous study, we did 
not find any large deviations. Thus, the driver sample should be representative of the age and gender 
distribution on the roads. 
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The results showed a total prevalence of 1.34% for medicinal and illicit drugs. The prevalence for illicit 
drugs alone was as low as 0.10%. The most prevalent substance category (0.63%) was medicinal 
opioids. 
 
When the results were divided by age and gender it was found that the total prevalence was higher for 
women and for older drivers. The results should be interpreted with care since there are large 
uncertainties in the results. However, the findings are realistic since mostly medicinal drugs were 
found and since, in the general public, the kind of substances included in the study is more often used 
by women than by men and the use increases with age (FHI, 2011). 
 
The prevalence was of the same size for all time periods except for weekend nights were no 
substance was found in any of the drivers. However, only a small number of samples were collected 
during weekend nights. 
 
The prevalence of alcohol was not included in this study. However, the police tested all drivers 
stopped at the test sites and 0.18% showed a positive result of alcohol in the breath test instruments 
(corresponding to ≥ 0.2 g/l). Moreover, a previous study conducted in the same region as the DRUID 
study during the period June 2006–May 2007 showed a prevalence of 0.24% (C.I.: 0.15%-0.32%) 
during daytime (7 am to 11 pm).In that study, the alcohol concentration was also measured by the 
breath test screening instruments. 
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List of abbreviations 
BAC: Blood Alcohol Concentration 
BE: Belgium 
CV: coefficient of variation 
CZ: Czech Republic 
DK: Denmark 
DRUID: Driving Under the Influence of Drugs, alcohol and medicines 
ES: Spain 
FIN: Finland 
GC: Gas Chromatography 
HPLC: High Performance Liquid Chromatography 
HU: Hungary 
IT: Italy 
LC: Liquid Chromatography 
LLE: Liquid Liquid Extraction 
LT: Lithuania 
MS: Mass Spectrometry 
N: Norway 
NA: Not Applicable 
NL: The Netherlands 
OF: Oral Fluid 
PL: Poland 
PT: Portugal 
PrT: proficiency testing 
SE: Sweden 
SDHOR: standard deviation according to Horwitz 
SPE: Solid Phase Extraction 
THC: delta-9-tetrahydrocannabinol 
THCCOOH: 11-nor-9-carboxy-Δ9-tetrahydrocannabinol 
UPLC: Ultra Performance Liquid Chromatography 
WB: Whole Blood 
WP2: DRUID - Work Package 2 
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